In pursuit of a novel UTI treatment strategy - an "in silico" study of the FimH adhesin by Zalewski, Adam
In pursuit of a novel UTI treatment
strategy – an in silico study of the
FimH adhesin
Inauguraldissertation
zur
Erlangung der Wu¨rde eines Doktors der Philosophie
vorgelegt der
Philosophisch-Naturwissenschaftlichen Fakulta¨t
der Universtita¨t Basel
von
Adam Zalewski
aus Gdan´sk, Polen
Referent: Prof. Dr. Angelo Vedani
Korreferent: Dr. Julie Bouckaert
Basel, 2013
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakulta¨t
Auf Antrag von:
Prof. Dr. A. Vedani, Institut fu¨r Molekulare Pharmazie, Universita¨t Basel
Dr. J. Bouckaert, UFR de Biologie, Universite´ des Sciences et Technolo-
gies de Lille 1, France
Basel, October 15, 2013
Prof. Dr. Jo¨rg Schibler
Dekan
“I may not have gone where I intended to go,
but I think I have ended up where I needed to be.”
Douglas Adams
3
Acknowledgments
First and foremost, I would like to express my heartfelt gratitude to Prof.
Angelo Vedani for the opportunity, supervision, and patience that enabled
me to conclude my PhD. I feel that the last three and a half years have made
me both a better person and scientist, neither of which would have been
possible without his support.
I would also like to thank Prof. Beat Ernst for providing both a scientific
challenge and the assistance I required to face it. I have no doubt that par-
ticipating in the FimH project has made my PhD all the more valuable.
A special “thank you” goes to Dr. Sameh Eid, for being an invaluable friend
and support through my PhD. It takes a very special kind of person to with-
stand me for over three years, let alone to keep on helping me for that long.
My kindest thanks go to Dr. Julie Bouckaert for her enormous contributions
towards the subject I worked on and for agreeing to be the co-referee of this
thesis. I wouldn’t prefer anyone else for this role.
Computational science isn’t always very exciting and my time at the Pharma-
center would have been far less enjoyable without my fellow “modelers”. Spe-
cial thanks go to Dr. Martin Smiesˇko, Dr. Gianluca Rossato, and Christoph
Sager for all the on- and off-topic discussions, during and after working hours.
Scientific challenges aside, what made my time with the IMP special were
the people that constituted it. To name just a few, I would like to thank
Jacqueline, Simon, Mirko, Meike, Giulio, Wojtek, Kathi, and Matthias for
always being the great people that they are.
Last but not least, I want to thank my family. What I owe you goes far
beyond this PhD and I only hope that I can someday repay at least a small
portion of it.
4
5
Abstract
Carbohydrate-binding proteins (particularly lectins) are frequent targets of
present pharmaceutical research. While of high priority due to their involve-
ment in an array of pathophysiological events, these systems (along with
their saccharidic ligands) present many challenges related, in part, to the
limited means of their in-depth structural exploration. A foothold towards
improving the design throughput of carbohydrate-based drugs is provided
by the state-of-the-art in silico technologies, offering both means of struc-
ture generation and refinement as well as rapid screening of putative ligands.
In this account, the application of some of these methods (docking, molec-
ular dynamics, and MM-GBSA/QSAR protocols), toward inhibiting FimH
– a virulence factor of urinary tract infections – is presented. The role of
this bacterial lectin involves the adhesion to highly-mannosylated urothelial
cell surfaces. This process is supported by the presence of urine flow, lead-
ing to the so-called catch-bonding characteristics. The presented work was
focused primarily on the rationalization and optimization of the binding of
mannosidic ligands with available crystallographic and in vitro data. As a re-
sult, several series of new promising compounds were designed, with selected
among them synthesized, assayed, and published. In addition, an array of
molecular dynamics simulation techniques was employed to probe the struc-
tural properties of the native, two-domain protein in presence and absence
of shear conditions. Through this, a receptor conformation was identified,
that differed (including the binding site) from ones previously employed in
structure-based design approaches. Given the wealth of data reporting the
existence of FimH variants with a broad range of affinities towards their nat-
ural ligands (further dependent on many endogenic and exogenic factors),
the reported discoveries may lead to versatile and potent inhibitors, superior
to currently applied antibiotic treatments.
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1. Aim of this work
The aim of this work is twofold. Firstly, it describes the support provided –
by means of several in silico techniques – to the design and study of small
molecular ligands aimed at inhibiting the FimH adhesin. This part focuses
on predicting and scoring the binding poses of prospective synthesis candi-
dates through flexible docking and molecular dynamics simulations. As my
work progressed, some of these tasks were eventually re-delegated to a fully
automated platform referred to as the VirtualDesignLab, offering superior
predictive power and accessibility to all researches involved in the project.
A final addition to the platform – that, given the potential of the underly-
ing VirtualToxLab technology, enables re-purposing toward other systems of
interest – is a module calculating the entropy change sustained by a given
system upon ligand binding.
The second part of the thesis describes the attempts of elucidating the dy-
namic structural properties of the full, two-domain FimH. The significance of
this work lies in the fact that the protein is reported to assume multiple con-
formational states depending on various conditions and resulting in a broad
spectrum of ligand binding affinities. In light of this, the determination of
whether the available crystal structures are an adequate physiological repre-
sentation of the system, is of utmost importance. These attempts were based
primarily on steered and accelerated molecular dynamics techniques, geared
toward exploring structural events inaccessible to the conventional protocols.
14
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2. Introduction
2.1 Properties and biological significance of
host-guest complexes
The formation of a complex between two or more molecular entities lies at
the heart of nearly every biochemical process. Be it enzymatic cleavage of a
substrate, allosteric regulation of a G protein-coupled receptor, or inhibition
of a virulence factor, numerous events taking place in living organisms rely
on mutual recognition between partner molecules. Among these, the very
specific binding of a small molecular ligand to a protein receptor, plays a
particularly special role, as already suggested more than a century ago by the
German Nobel Prize laureate Emil Fisher. Through his revolutionary work,1
that would guide scientists in decades to come (paving way for the structure-
based design we know today), he presented a model in which a receptor and
its ligand fitted each other like the proverbial “lock and key”. With this anal-
ogy in mind, researches could begin attempts of manufacturing customized
“keys” that could stimulate or inhibit the functions of biological receptors
involved in various physiological or pathophysiological processes. Eventually,
thanks to the advancements in X-ray crystallography, these attempts could
be transfered away from an imaginary or two-dimensional space, obtaining
insight into the three-dimensional structures of the macromolecular “locks”.
Though of great value, the concept of a rigid, perfectly complementary
pair of molecules could not explain certain aspects of biochemical recognition.
For instance, the binding of molecules smaller than their receptor site as well
as promiscuity of certain targets toward a vast array of structurally diverse
ligands could not be clarified.2 It was not until over half a century after the
introduction of Fisher’s theory, that it could be expanded – largely due to
the progress in the fields of crystallography and NMR spectroscopy – with
the concepts of flexibility. Henceforth, both the receptor and ligand would
no longer be treated as rigid, but rather capable – to an extent – of adapt-
ing their shape toward the partner. As a consequence, the design of small
16
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molecules began focusing not only on the conformation in which they would
bind to a given protein, but also on how much it deviated from the native
conformation in solution. Through this, the concepts of internal strain (i.e.
the cost of assuming the bioactive conformation by the ligand) and synthetic
structure preorganization (in order to avoid that very strain) could first be
introduced into the drug design and optimization attempts.3, 4 Nevertheless,
conformational properties of prospective macromolecular targets remained
more elusive. The first – and still broadly accepted – model explaining the
adaptation of a protein structure toward a small molecular ligand was pro-
posed in the form of the induced-fit (conformational induction) theory.5 In
the context of this model, it is only after the formation of an initial, weak
protein-ligand complex, that the former can be “induced” toward forming
a shape better accommodating the small molecule. While widely accepted
and convenient toward explaining the capability of receptors to adapt var-
ious conformations depending on the given ligand, the induction theory is
however difficult to validate in context of large – at times spanning multiple
protein domains – conformational changes. Also, based on stark differences
between the binding site regions of apo and holo receptors,6 the obligatory
initial ligand recognition – requiring a certain degree of complementarity be-
tween native protein and ligand conformations – is often used to undermine
the induced-fit hypothesis. Hence, alternatively to this mechanism, a confor-
mational selection (population shift, selected fit) model was derived.7 This
theory (ever since gaining increasing attention) postulates, that a vast ar-
ray of molecular receptors exist within an ensemble of conformational states,
separated by small energetical barriers. Between these an equilibrium is pro-
posed, in which only a single, distinct conformation can be “selected” by a
binding partner.
With experimental evidence provided to support both receptor adapta-
tion theories, distinctions between them had to be established. Hence, in
order to enable categorization of protein-ligand systems between the two
mechanisms, a simplified representation of their underlying energy landscapes
(referred as the double-basin Hamiltonian) was developed [Figure 2.1].8 Ac-
cording to the concept, induced-fit events are accompanied by relatively small
conformational changes, commonly limited to the side chains of residues di-
rectly involved in binding. Thanks to the energetical benefit of initial contact
with the ligand, these events can transgress significant energy barriers, often
leading to very stable final complex. On the other hand, conformational se-
lection preference is believed to be a trademark of systems with low (several
kT at most) transition barriers between the involved states.9 The strength
of ligand binding necessary to shift the underlying equilibrium toward the
binding-capable species is commonly comparably low. With the native pro-
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tein motion often involving the backbones of entire domains, conformational
selection events may however be associated with much greater structural re-
arrangements than induced-fit.10 Presently both modes are widely accepted,
with a vigorous discussion continuing with regard to their validity and bound-
aries.
Figure 2.1: Schematic representation of the induced-fit (blue) and conformational
selection (red) mechanisms in relation to the protein energy landscape, adapted
from the work introducing the double-basin Hamiltonian concept.8 Highlighted
are four distinct conformational states: unbound-open, unbound-closed, bound-
open, and bound-closed. Additional vertical arrows correspond to the key energy
thresholds likely to determine the preference of one mechanism over the other.
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2.2 Thermodynamics of host-guest binding
Although illustrated with simplistic models (e.g. “lock and key”, induced-
fit, or conformational selection), all binding events relate to the complex
theorems of equilibrium thermodynamics. These state that a spontaneous
formation of a protein-ligand complex
Paq. + Laq. ￿ P ￿L￿aq. (2.1)
may only take place if the accompanying Gibb’s free energy change within
the entire system (commonly referred to as the binding affinity) is negative.11
This change is most often described through the equation
∆G = −RTlnKb (2.2)
where R and Kb are the universal gas and binding constants and T is the
temperature. Reversible in nature and governed by non-bonded interactions,
ligand-target binding commonly falls into a Kb range of 10−2−10−12 M (sub-
millimolar to picomolar), corresponding to free energy changes between 2
and 15 kcal/mol at 298 K.12 Common drug-target complexes are found be-
tween 5 and 12 kcal/mol, with the remaining parts of the spectrum occupied
by weak, naturally-occurring organic complexes and very strong enzyme-
inhibitor pairs respectively. With regard to the strength and energetical
makeup of a specific binding event, the ∆G can also be dissected into en-
thalpic (∆H ) and entropic (∆S ) components
∆G = ∆H − T∆S (2.3)
Though strongly correlated, leading to the phenomenon of entropy-enthalpy
compensation (discussed later in this chapter),13 the free energy constituents
are commonly further decomposed and approached separately, to enable in-
sight into various factors guiding the protein-ligand binding.
2.2.1 Enthalpy
Enthalpy is the cumulative measure of the thermodynamic energy within a
system, reflected by the amount of heat produced or consumed by it. It
consists of the internal energies of all solute and solvent molecules (directly
related to the conformations they have to assume during binding events),
along with all favorable and unfavorable non-bonded interactions between
them.14 While often non-specific and overlapping (making them difficult to
target and optimize), some of these energetical components fall into distinct
categories relevant from the viewpoint of structural design.
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Electrostatic interactions
Electrostatics arise from non-uniform charge distributions common in molec-
ular interfaces. Given their substantial reach (exceeding 10 A˚) along with
the omnipresence of charges in biomolecules, these forces also encompass vir-
tually all atoms in a system.15 At shorter ranges, electrostatics lead to strong
repulsive (attractive) interactions between entities with the same (opposite)
charges, determining the complementarity of polar and ionized groups, suc-
cessfully utilized in numerous scientific endeavors.16
Commonly, electrostatic forces are represented using the coulombic rela-
tionship between the point charges of two atoms
Eel. =
q1q2
4πε0R
(2.4)
where q1 and q2 are the partial charges of each atom, R is the distance between
them, and ε0 – the dielectric constant of the surrounding medium (approxi-
mately 80 in the case of water but around 2–6 inside buried protein cavities).
It also bears mentioning, that electrostatic-based interactions dominate the
overall free energy and specificity of carbohydrate-protein binding, due to
the abundance of polar hydroxyl groups at the corresponding interfaces.17
Hydrogen bonds
While still electrostatic in nature, hydrogen bonds reveal several distinct
properties that lead toward treating them as a separate group of interac-
tions. These highly specific forces form on the basis of attraction between
a hydrogen atom and a pair of electronegative moieties, referred to as the
donor and acceptor. They are also characterized by rigorous geometrical
preferences, resulting in distances of 2.5–3.2 A˚ between donor and acceptor
atoms, donor–hydrogen–acceptor angles around 130–180°,18 and a direction-
ality dictated by the positions of lone acceptor electron pairs.19 The majority
of hydrogen-bond donors and acceptors constitutes of nitrogen- and oxygen-
centric groups (e.g. amines, carbonyls or esters) though other polar moieties
such as π systems may also be involved. Whenever formally-charged entities
(deprotonated carboxylic acids, protonated amines, guanidyl groups) partake
in the interaction, charge-assisted hydrogen bonds (one ionized partner) or
salt bridges (formal charges on both donor and acceptor) are formed. Fi-
nally – and of special importance for surface-exposed, solvated binding sites
–, partially-buried solvent molecules may also partake in forming these in-
teractions, leading to a common phenomenon of water-mediated hydrogen
bonds.20 Given the abundance of these groups in biomolecules and a net
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beneficial effect of 0.5–3.0 kcal/mol (after deducting the desolvation and en-
tropy costs with the gain increasing up to 5.0 kcal/mol whenever ionized
partners are involved), hydrogen bonds are of immense importance. This is
all the more so, given their impact on the specificity in various protein-ligand
complexes, exerted through the rigorous conditions of satisfying desolvated
donor/acceptor groups.21
Van der Waals interactions
Named after the Dutch physicist Johannes Diderik van der Waals, these
interactions, comprise a class of relationships formed between permanent or
induced dipoles of non-polar atoms. Although only weakly attractive for opti-
mal arrangements of a singular atom pairs (around 0.5 kcal/mol resulting pri-
marily from dispersive forces rapidly diminishing with increasing distance),22
they often dominate short-range relationships. This is due to imposing harsh
energetic penalties for lack of spacial complementarity within a system – re-
sulting from Pauli’s exclusion principle –,23 sufficient to altogether void the
possibility of forming an interface between biomolecules, independently from
other energy constituents.
The dualistic, attractive–repulsive nature of van der Waals interactions
requires unique mathematical models to be described and quantified. One of
the most commonly employed of these models is the Lennard-Jones poten-
tial (also referred to as the 6-12 potential), illustrating a generally accepted
distance-energy relationship for a pair of atoms [Figure 2.2].24
Interactions involving π systems
Around 60% of all phenylalanine, tyrosine, and tryptophan side chains, are
found involved in parallel or perpendicular (referred to as T-shaped or edge-
to-face) aromatic stacking.25 The source of this phenomenon lies in the unique
distribution and properties of the π electrons, resulting in the formation
of polarized areas that can favorably interact with one another as well as
other groups. The abundance of aromatic rings within protein binding sites
has also made “arming” prospective ligands with complementary groups,
a common practice in the design and optimization of drug-like molecules.
Through numerous studies, primarily based on high-level computational ab
initio methods, it could be derived, that the energetical benefit of forming
these interactions is similar to weak hydrogen bonds, with a free energy de-
crease between 1.0 and 2.5 kcal/mol, depending on the interaction geometry
and properties of both partners.26 The stacking between unsaturated ring sys-
tems is however not the only interaction involving π systems. A substantially
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Figure 2.2: Schematic representation of the relationship between the van der
Waals potential energy of two atoms and their respective distance. The highlighted
optimal distance is typically 0.3-0.5 A˚ greater than the sum of the so-called atomic
van der Waals radii defined from distances observed in crystal structures.
stronger – rivaling the energetical benefit of salt bridges – interaction may
also be formed between π electrons of various moieties and groups bearing
a formal positive charge. As with the π-π stackings, these so-called cation-
π interactions have been successfully utilized in many design approaches,
often targeting exposed side chains of arginine residues.27 Attempts of in-
tegrating positively-charged groups into the structures of drugs remain less
common however, due to the reported high promiscuity of such molecules.28
It should also be mentioned that CH-π interactions may also benefit the bind-
ing affinities of various molecular entities, due to the attraction between the
aliphatic groups and the π systems. While abundant in many complexes –
including carbohydrate-protein pairings –, these interactions are however still
challenging to quantify and optimize, with arguments supporting their dis-
persive, charge-transfer, or hydrogen bond-like nature constantly exchanged.
Hence, a commonly utilized trait of π-electron related interactions, is that
their strength increases along with the acidic/positive character of the part-
ner group, leading to positioning various electron-withdrawing groups in their
vicinity.
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2.2.2 Entropy
Entropy is perhaps the single most elusive aspect of biomolecular binding.
According to its statistical interpretation, it relates to the tendency of a
given system to distribute the available energy between a number of confor-
mational states. This definition dates back to the fundamental 19th century
work of Ludwig Boltzmann and relates to the probability of finding a given
microscopical system in a distinct conformation.29 Another, earlier defini-
tion, describes entropy as the overall energy related to all equilibrium and
non-reversible motion within a system. This form – referred to as the ther-
modynamic interpretation of entropy – relies heavily on the works of Rudolf
Clausius and often proves the more useful of the two with respect to under-
stating the formation and stability of host-guest complexes.30 In accordance
with this theory, entropy is a state function determined by a set of parame-
ters (e.g. temperature, volume, pressure), and not by the way a given state
is acquired. The impact of temperature is perhaps the most profound, often
determining entropy- or enthalpy-driven binding, or voiding the association
altogether, with an “overheated” system “preferring” to stay decomposed.
Although, not uniformly defined – due to lack of means of its direct
measurement –, the change in entropy is commonly described as consisting
of three primary components
∆Stot. = ∆Ssolv. +∆Sconf. +∆Sr/t (2.5)
where ∆Ssolv. corresponds to the solvent release and motion upon binding,
∆Sconf. relates to the loss of conformational flexibility with respect to the
free solute molecules, and ∆Sr/t describes the loss of rigid body rotation and
translation. Solvation entropy is commonly the largest constituent, given
the significant interface surface areas stripped (desolvated) of water during
all binding events. With the return of these molecules into the so-called bulk
solvent commonly increasing their disorder, this component is also normally
the only one favorably impacting the overall binding, providing as much as
40 kcal/mol of energy in 298 K.31 The conformational entropy on the other
hand is virtually always unfavorable, relating to the loss of rotational motion
around the torsion angles of the protein and ligand. Still, the initial concepts
of complete bond restriction upon binding – resulting in employing arbitrary
“per-bond” penalties of 0.5–0.7 kcal/mol –, have ever since been proven in-
accurate, with weak and surface-exposed interfaces retaining a significant
degree of their free-state motion.32 The entropy related to the rigid body
movement, while significant, is commonly assigned arbitrary 2–5 kcal/mol
constants (or ignored altogether) for the purposes of comparing various lig-
ands of a receptor,31 as long as their relative shape and size remain similar.
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Taken together, the entropy constituents tend to follow the principle of “large
numbers amounting to small changes”, as often observed through Isothermal
Titration Calorimetry (ITC) measurements. It also bears mentioning that a
fourth constituent – the so-called vibrational entropy – is at times mentioned
throughout literature. This quantity may however be merged with the other
three, based on the theory that loss of translational and rotational motion
results in the formation of additional vibrational degrees of freedom.33
2.2.3 Hydrophobic and solvation-related effects
Binding occurs in an aqueous environment. This obvious fact is at times
easily overlooked, given too much focus on the already complex nature of
protein-ligand interactions. In truth however, the thermodynamical events
related to the water surrounding a host-guest complex – comprised of both
enthalpic and entropic components –, are often determinant to the overall
binding energy.
One reason for the importance of water – aside from the above–mentioned
ability of forming bridged-hydrogen bonds – is its impact on the enthalpy of
binding. Due to its small molecular size and high polarity, water molecules
occupy virtually all receptor (and ligand) cavities, leading to the formation
of the so-called first solvation shell. This also holds true for all binding sites,
that require to be stripped of the surrounding solvent upon ligand approach.
Depending on the character, shape, and size of these cavities – and as a
consequence, the strength with which they interact with the solvent –, their
desolvation may result in varying costs. Those are then further modulated,
once the released water molecules rejoin the hydrogen-bond network of the
bulk solvent. Due to such, the overall binding enthalpy can in fact be defined
as the extent by which the protein-ligand interaction overcompensates the
net cost of the solvent displacement.34
The water displacement itself is also closely related to the possibly most
powerful factor determining all molecular rearrangement events (be it protein
folding or a change of a single torsion angle), mainly the so-called “hydropho-
bic effect”. Its origin – while still under discussion – is commonly related
to the change in entropy accompanying the solvation/desolvation of vari-
ous molecular surfaces. Specifically, upon surrounding a given solute, water
molecules become more localized – the more so the more non-polar the solute
–, leading to a substantial entropic penalty for loss of their inherent motion.
This in turn pushes all solute molecules toward diminishing this cost through
aggregating and minimizing the solvent-excluded volume. When looked at
from the opposite direction, the hydrophobic effect may lead to substantial
free energy benefits of returning waters to the bulk. Indeed, a common cor-
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relation between the hydrophobic surface area buried upon ligand binding
and the affinity toward a given receptor, has for a long time served as basis
of many optimization approaches. Directly proportional to the heat capacity
change within the system, this value is in fact one of the most crucial struc-
tural parameters employed in the design of various computational scoring
functions.35
2.2.4 Entropy-enthalpy balance and compensation
Improving molecules through enabling more/stronger interactions is often
met with little to no increase of the overall binding energy. This phenomenon
arises from a very obvious fact that tighter binding inevitably leads to a
decrease of the intrinsic motion within the system, and hence its overall
entropy, resulting in a semi-linear relationship referred to as entropy-enthalpy
compensation. While widely researched and accepted, this trend continues
to pose difficulty to the field of medicinal chemistry, relating to the fact that
various energy constituents (e.g. electrostatic interactions) rarely correlate
with the binding affinity and cannot be optimized separately.36
Were it truly the case that entropy and enthalpy were perfectly synchro-
nized, the overall binding energy would prove independent from the changes
of either (caused for example by an increase of temperature), resulting in an
impossible task of designing interactions without imposing restriction. While
a trend is still observable in many cases, it does not hold true in general
however, as proven by the numerous successful drug optimization attempts.
Hence, a revised model of the enthalpy-entropy relationship is currently gain-
ing attention [Figure 2.3], accounting for both the entropy importance in
weak organic complexes (sub-micromolar affinities) and the enthalpy-driven
association of “best in class” synthetic molecules.37
The accumulated knowledge regarding the entropy-enthalpy relationship,
has also helped in establishing various efficiency metrics – with the most basic
one being the result of dividing an estimated free enthalpy by the number
of ligand atoms – that have proven valuable in biological and computational
screening approaches.38
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Figure 2.3: Idealized representation of the binding enthalpy-entropy relation-
ship, illustrating a limit of the sustained entropy loss approached for very strong
(possibly covalent) interactions. Figure adapted from37.
2.3 Relevant computational methods
Experimental approaches probing aspects of host-guest association are often
met with limitations regarding their cost and efficiency. Furthermore, a de-
tailed energetic makeup of various systems can rarely be obtained outside of
ITC experiments that consume precious amounts of substance and require
interpretation in context of the specific measurement conditions.39 To this
end, the multitude of in silico tools developed and refined over the last few
decades along with the gradual increase in machine processing power are of
immense benefit. Below follows a short overview of computational methods
geared toward predicting specific properties – hence the term “modeling” –
relevant for structural drug design and optimization. A common practice in
present-day research is employing multiple of these techniques alongside each
other or coupling them with actual experimental procedures.
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2.3.1 Structure generation
In silico methods of predicting protein folding and large-scale rearrange-
ments (commonly centered around template-based homology modeling and
extensive molecular dynamics simulations) have made tremendous progress
in recent years.40 Even so, obtaining a purely-computationally derived struc-
ture composed of dozens or hundreds of residues remains a formidable chal-
lenge. On the other hand X-ray crystallography still struggles with express-
ing certain proteins and resolving their structures with sufficient resolutions
– preferably below 1.2 A˚ to provide an atomic level of detail.41 Luckily, for
the purposes of exploring ligand binding to a known receptor structure (e.g.
resolved with a different ligand), the vast array of computational docking
software often provides all that is necessary.
Computational docking consists of two basic components, sampling and
scoring (the latter discussed in the next section). The first part corresponds
to the generation of multiple putative ligand poses that fit a given receptor
binding site. These poses are commonly generated by means of an exhaus-
tive, automated conformational search, guided by either shape-matching or
energetical criteria.42 As did the entire field of structure-based design, the
fully automated docking algorithms have throughout the years evolved away
from the rigid “lock and key” concepts and now offer state-of-the-art flexi-
ble treatment of the ligand (Glide) or the entire binding interface (Induced
Fit Docking, Cheetah).43, 44 The validity of these methods could be proven
by means of various benchmarks, in which Root-Mean-Square Deviations
(RMSD) below 1-2 A˚ from corresponding crystal structures could often be
obtained.45 If need be, the so called “manual” docking may also be em-
ployed, in which the user – taking advantage of his knowledge about the
given system – adjusts the conformation of the small molecule or even the
receptor. Finally, intermediate solutions like template-based (guided by an
experimentally-derived ligand pose) or ensemble docking (generating bind-
ing poses to multiple configurations of the receptor) may also be employed.46
Given this vast diversity and rapid processing speeds, docking methods are
the starting point of most molecular modeling endeavors.
2.3.2 Energy calculation and ligand scoring
Obtaining a realistic representation of a protein-ligand configuration – while
valuable – is often not sufficient to proceed with compound design or analy-
sis. To this end, relative or absolute estimates of the binding energy (prefer-
ably decomposed into its various constituents) are required to interpret the
structural data. For this purpose, an array of mathematical means of pre-
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diction, referred to as scoring functions may be employed. Based on their
origin and functional form, scoring functions are normally categorized be-
tween different groups, with force-field and empirical types being of primary
interest in context of this work, along with the closely related Quantitative
Structure-Activity Relationships (QSAR).47 Given the varying case to case
performance, approaches of employing multiple methods to yield a single,
composite score are gaining increasing attention. These are referred to as
consensus scoring.48
Force-field scoring functions
The underlying energetics of molecules may be obtained directly from the
potential energy function present in most computational methods (including
docking, in which they allow selection of the top poses within an ensem-
ble). Along with sets of parameters derived by either means of high level
ab initio calculations (themselves being inappropriate for scoring tasks due
to tremendous computational requirements) or fitting to sets of experimental
data, these functions are referred to as force fields.49 Throughout the decades
of intense improvement, force fields have become the basis of most molecular
modeling, relied on by both academia as well as industry.
A common conceptual approach applied toward designing all potential
energy functions may be presented using one of the most established among
them – AMBER. In its basic, somewhat historical form,50 the AMBER force-
field (standing for “Assisted Model Building with Energy Refinement”) con-
sists of the following components
Etotal =
￿
bonds
kr(r − req)2 +
￿
angles
kθ(θ − θeq)2 +
￿
dihedrals
Vn
2
[1 + cos(nφ− γ)]
+
￿
non−bond.
￿
Aij
R12ij
− Bij
R6ij
+
qiqj
￿Rij
￿
+
￿
H−bonds
￿
Cij
R12ij
− Dij
R10ij
￿
with their meaning as follows:
First and second term represent the bond and valence angle energies of
covalently-bonded atoms, using a harmonic approximation, with k a
respective force constant parameter and r/θ – current and equilibrium
bond/angle values.
Third term represents the torsional (φ) energies, with Vn a force constant,
n the periodicity, and γ the equilibrium angle value.
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Fourth term represents the non-bonded energy for i -j atom pairs sepa-
rated by a distance R. Consists of van der Waals (Lenard Jones poten-
tial with A and B corresponding to specific atom types) and electro-
static (coulombic) energies.
Fifth term represents hydrogen-bonding, with R being the distance be-
tween donor and acceptor (i and j ), and C/D – parameters corre-
sponding to their atom types.
Although commonly enhanced with additional or improved terms (polariz-
ability in CHARMM, angular hydrogen bond geometry and metal interac-
tion terms in Yeti), force-field based methods display certain limitations.51, 52
Firstly, the distance-dependent dielectric treatment prevents accounting for
various solvation effects. One way for remedying this limitation is an explicit
(atomistic) representation of the solvent molecules. Still, the corresponding
methods such as Free Energy Perturbation (FEP) or Thermodynamic Inte-
gration (TI),53 commonly require coupling with molecular dynamics (MD)
protocols along with extensive computation times. A compromise between
accuracy and speed may be obtained through the employment of implicit sol-
vation models. Among these, the Poisson-Boltzmann Surface Area (PBSA)
and Generalized Born Surface Area (GBSA) models are especially popu-
lar and often integrated into standalone post-processing modules, such as
MM/PBSA (software Amber) and MM/GBSA (software Prime).54, 55 Nev-
ertheless, while proven to correlate well with various sets of experimental
results,56 the implicit solvation models do not remedy all the limitations of
force-field based approaches. Specifically, the previously-mentioned corre-
lation between various energy components (making them in principle non-
additive), is often a source of severely overestimated in silico predictions.
Also, the persisting lack of atomistic solvent properties may lead to inac-
curate treatment (no hydrogen-bonding with the solvent) and prevents ac-
counting for its entropic components.
Empirical scoring functions
While also relying on a summation of various energy terms, empirical scor-
ing functions (e.g. GlideScore) boast certain advantages over their force-field
counterparts.57 Firstly – and as already implied by their name –, these func-
tions consist of empirical energy components, weighted to fit so-called train-
ing sets of experimental data and allowing (in principle) higher predictive
accuracy. Secondly, due to a very simple mathematical form
Etotal =
￿
i
WiEi
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where E is a specific energy term andW its weighting coefficient, these func-
tions prove highly efficient.58 Lastly, given the not necessarily computational
sources of parametrization, empirical scoring functions enable incorporation
of solvation and entropy terms, difficult to account for outside of an exper-
iment. Still, the effective performance of the corresponding methods, relies
heavily on the quality and robustness of their underlying training sets. Due
to retaining the energy decomposition scheme, double-counting (overestima-
tion) errors may also persist.
Quantitative structure-activity relationships
Structure-Activity Relationships (SAR) comprise concepts driven by the
idea that structural features of a system are related to its various proper-
ties.59 Given the unique predisposition of computers in handling SAR-related
data, design approaches are common to employ the so-called Quantitative
Structure-Activity Relationships (QSAR) as a means of rapid and accurate
affinity prediction.60 Although not scoring functions per se, the connections
between the QSAR methodologies and force-field/empirical concepts become
apparent, with both common to employ the same basis of predictions (force
fields, experimental data fitting, structural data mining). Nevertheless, it
should be emphasized, that these methods are by far more specialized and
diverse. Commonly QSAR methodologies are classified based on so-called
dimensionality [Table 2.1], ranging from one-dimensional relationships be-
tween affinity and an experimental observable (pKa, logP), to multidimen-
sional (mQSAR) concepts, employing three-dimensional structural ensembles
alongside multiple receptor models (VirtualToxLab platform).61
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Table 2.1: Dimensionality of QSAR techniques in relation to the prediction of a
given property (commonly ligand affinity).
Dimensionality Concept
1D Relationship between an observable and the prop-
erty
2D Relationship between a structural pattern (pharma-
cophore) and the property
3D Relationship between the three-dimensional struc-
ture and the property
4D Incorporation of multiple representations of each
molecule (conformations, protonation states, iso-
mers)
5D Incorporation of receptor-related events such as
induced-fit (flexible and/or multiple binding site
models)
6D Incorporation of multiple solvation representations
As with the empirical scoring functions, QSAR models are commonly
established based on biological and structural data of a training set. How-
ever, while retaining the underlying benefits of accuracy and accounting for
elusive entropy and solvation properties, QSAR techniques often venture fur-
ther with respect to their usefulness. Specifically, the higher dimensionality
approaches (4D+), enable eliminating the human bias of selecting the re-
ceptor/ligand conformation from an ensemble of poses.62 Furthermore, at
the pinnacle of their sophistication, the models may even shed the molecu-
lar mechanics “ball and spring” representation altogether, resulting in flex-
ible receptor surrogates (“envelopes”) with various properties mapped on
their surface.63 On the downside, the technical complexity of mQSAR meth-
ods along with the strong relation to the underlying experimental data,
often makes them laborious to employ and inappropriate toward handling
molecules strongly deviating from their initial training sets.
2.3.3 Insight into structural dynamics
The value of molecular docking and scoring cannot be denied, having served
numerous applications throughout the last three decades. Nevertheless, while
commonly coupled with state-of-the-art sampling and energy minimization
algorithms, these methods cannot alone account for all effects of the motion
accompanying binding events. On the other hand, the experimentally-derived
structures carry a strong relation to the conditions in which they are procured
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(involving low temperature and presence of crystallization additives), leading
to the occurrence of crystal packing effects. These techniques also preclude
insight into the inherent motion of biomolecules (whenever it transcends the
boundaries of vibrational movement or rotation around unrestricted bonds),
given the employed averaging of time and space.64 Due to such, molecular
dynamics (MD) simulations are perhaps the single most important in sil-
ico contribution toward the field of structure generation, refinement, and
analysis.
Conventional molecular dynamics
From a theoretical viewpoint, molecular dynamics rely on the iterative nu-
merical solution of Newton’s equation of movement
￿F = m￿a (2.7)
where F is the force exerted on an atom, m its mass, and a the acceleration.65
Based on a relation with the potential energy of the system, the force may
also be expressed as follows
￿F = −dEP
dr
(2.8)
where r corresponds to displacement (e.g. change in the Cartesian coor-
dinates). Using the two equations, a relationship between the change in
position, the energy, and the time (t) may be established
−dEP
dr
= m
d2￿r
dt2
(2.9)
enabling calculating the configuration of a system at any point in time, based
only on an initial set of coordinates (commonly obtained from crystal struc-
tures) and velocities (generated by the algorithm).66
In practice, it is common for MD simulations to retain the same molec-
ular mechanics principles as the docking protocols, including deriving the
underlying energetics by means of force fields. Alongside the exploration
of various structural events, this enables energy quantification (albeit as an
average over an ensemble of poses referred to as the trajectory) with most
of the “static” methods presented earlier (such as MM/GBSA). If need be,
more precise calculations (FEP, TI or even quantum-level simulations, known
to achieve experimental-level precision) may also be coupled with the algo-
rithms.67 Given the tremendous increase of computational power, simulations
using an explicit representation of the surrounding water molecules have also
become standard, enabling insight into both their enthalpic and entropic
CHAPTER 2. INTRODUCTION 33
contributions. Finally, techniques such as normal mode analysis (NMA) or
quasi-harmonic/harmonic approximations may be applied to the ensembles
of MD frames, yielding estimates of translational, rotational and conforma-
tional entropy.68, 69
Taken together, the multitude of MD techniques makes them a robust and
multi-purpose means of structural prediction, refinement, and scoring, well
worth the additional time devoted to their preparation and running. Still, the
applicability of these techniques relies heavily on the time scale of the event
we wish to observe [Table 2.2]. Due to such, while local reorientation of side
chains accompanying ligand binding (commonly ns-scale) may be simulated
using relatively inexpensive desktop machines, events such as conformational
selection or allosteric transition (µs to ms), remain inaccessible without access
to multi-million dollar supercomputers.70
Table 2.2: Approximate ranges and time scales of various structural events.71
Event Extent of atomic
motion [nm]
Time scale [s]
bond vibration 0.001–0.01 < 10−12
rotation of exposed side chains 0.5–1.0 ∼ 10−9
rotation of buried side chains ∼ 0.5 ∼ 10−6
allosteric transitions 0.5–4.0 10−6 − 10−3
loop motions 1.0–5.0 10−9 − 10−6
domain motion/association ￿ 1.0 > 10−6
Advanced sampling techniques
An alternative and far more feasible foothold toward exploring rare/large-
scale conformational events may be offered by several specialized (at the
expense of detailedness and scoring capabilities) MD algorithms developed
primarily within the last decade. These techniques may be assigned between
two major classes:
− Methods prioritizing sampling of specific degrees of freedom (e.g. re-
spective protein domain motion), while rigidifying or ignoring the oth-
ers.
− Methods modifying the sampled potential energy landscape, allowing
“escaping” the local minima in which the systems spend most of the
time.
A common example of the first type of techniques is the SHAKE algorithm,72
imposing constraints on either all or only hydrogen-related covalent bonds
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within the system. Through this, the necessity of accounting for bond mo-
tion is eliminated, allowing the simulation to progress in larger time steps.
A further case are the various “coarse-grained” methods, in which groups
of atoms (residues, domains, etc) are treated as single rigid “beads”, with
the simulation sampling only their relative motion.73 Finally, a class of inter-
mediate methods employing strong forces driving the simulations, also exist
(umbrella sampling, metadynamics, steered molecular dynamics), proving
very beneficial toward cases when the endpoints of a given conformational
change or its direction (definable by means of so-called collective variables)
are already known.74, 75, 76 Regarding the second type of techniques, they cor-
respond to a family focused on generating conformations at the expense of
their realistic distribution. A concept employed in simulated annealing and
replica exchange techniques for example,77 is increasing the simulation tem-
perature resulting in higher residual motion. Alternatively, methods based
on biasing potentials (applying “boost” levels inversely proportional to the
potential energy) also exist, with accelerated molecular dynamics (AMD) be-
ing of primary importance for this work and described in the Materials and
Methods section.78
2.4 The FimH adhesin
2.4.1 Specifics of carbohydrate-protein binding
Carbohydrates are among the most abundant biomolecules (alongside nucleic
acids and proteins), constituting the external cell surfaces of every living or-
ganism. Although consisting of a relatively narrow set of base molecules
(monosaccharides), they form a diverse array of complex structures, allow-
ing them to conduct numerous structural, recognition, and metabolic func-
tions. This broad functionality is enabled through the formation of variously-
positioned glycosidic linkages between the monosaccharide building blocks,
leading to the formation of extensive branched biomolecules. In addition, the
base components themselves may exist in open, “chair”, or “boat” confor-
mations (with the latter two displaying α and β isomerism on their anomeric
center), further extending the structural and functional diversity of carbohy-
drates.
In terms of interaction with other biomolecules, poly- or oligosaccharides
(commonly referred to as glycans) tend to bind to highly-specific protein
receptors, such as lectins and sulfated glycosaminoglycan binding proteins
(SGAGs).79 The formation of these complexes is also often involved in vari-
ous pathophysiological events like bacterial and viral infections, inflammatory
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cascades or cancer metastasis.80 Due to such, and in no small part thanks to
the insight provided by the various experimental and computational meth-
ods presented in the previous sections, various carbohydrate receptors have
become a vital target of pharmaceutical research.
Although relatively simple in terms of chemical composition, small natu-
ral carbohydrates are not a suitable basis for drug design. This is largely due
to their high polarity preventing passive permeation through lipid layers and,
as a consequence, oral bioavailability. When administered through alterna-
tive means (e.g. injected), the compounds also suffer from rapid renal excre-
tion. In order to address these drawbacks, a novel, largely untapped class
of small molecules, known as glycomimetics is more commonly the center of
attention. Still, the design and optimization of drug-like molecules targeting
a given carbohydrate receptor remains all but simple. For instance, while
the issue of high polarity is theoretically circumventable by the elimination
of non-essential hydroxyl groups, many of the carbohydrate receptors display
an extreme degree of specificity toward their natural binders, preventing even
the slightest deviation form the original structure. Despite progress in the
field, the synthesis of these substances is also challenging and lengthy. Hence
till date, the tremendous effort on both academic and industrial fronts could
only yield a limited number of market-approved carbohydrate-based drugs
[Figure 2.4].81
From a viewpoint of computational design, carbohydrate-protein binding
presents no less of a challenge [Figure 2.5]. Firstly, the high content of polar
and non-polar groups alike, requires force fields to correctly account for an
interplay of inter- and intra-molecular interactions. Of particular priority
is the treatment of all hydroxyl groups that (both in bulk solvent and the
carbohydrate binding pockets) participate in the formation of a geometri-
cally rigorous network of hydrogen bonds. Equally important are the non-
specific electrostatic interactions formed by these polar groups, that have to
be modeled in context of long range and shielding (i.e. partially diminish-
ing) effects of binding site residues. While commonly of lower magnitude,
van der Waals/hydrophobic contacts enabled by the non-polar elements of
the carbohydrate rings have also be taken into account. This includes CH-π
interactions formed with – primarily – phenylalanine and tyrosine side chains,
commonly exposed into the binding sites.82 In addition, the distinct geome-
tries of glycosidic linkages between the carbohydrate subunits are rarely cov-
ered by the base parameter sets, calling for the employment of specialized
force fields such as GLYCAM.83 Finally, and perhaps presenting the greatest
challenge yet, the high inherent conformational motion of carbohydrate struc-
tures (hydroxyl groups and glycosidic linkages, “chair flips”, hydrogen-bond
exchange), requires state-of-the-art conformational searching algorithms or
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molecular dynamics simulations to be accounted for. This necessity is pro-
nounced by the commonness of forming highly-flexible interfaces on protein
surfaces, that cannot be appropriately described without accounting for en-
tropic and solvation contributions.
Figure 2.4: Examples of carbohydrate-based drugs along with their market brand
names.
Taken together, while still uniquely predisposed toward handling the
above-mentioned hurdles, modeling methods aimed at carbohydrate-protein
binding require utmost attention and knowledge about a given system to
prove of benefit. Due to such, a general carbohydrate scoring function (if at
all obtainable) has yet to be introduced.84
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Figure 2.5: Scheme of a carbohydrate-protein interface, based on a structure of
the FimH adhesin with its natural ligand (specifics discussed later in this work).
Depicted are the following interactions: hydrogen bonds (violet), charge-assisted
interactions (red), polar interactions (blue), non-polar interactions (green with
arrows corresponding to CH-π contacts), solvent exposure (gray), and covalent
glycosidic linkages (dashed ovals).
2.4.2 FimH: context and role
Urinary tract infections (UTI), caused primarily (70–95% of cases) by uro-
pathogenic Escherichia coli (UPEC), are a common health issue affecting
millions of people each year and accounting for extensive medical costs. Al-
though normally non-severe (with developments of kidney or prostate dis-
eases mostly related to untreated cases), symptomatic UTIs still result in a
substantial decrease of life quality. Particularly affected are women, out of
which approximately 40–50% experience at least one UTI in their lifetime,
with a high chance of relapse.85 While the commonly employed β-lactam (e.g.
amoxicillin) and fluoroqiniolone (e.g. ciprofloxacin) antibiotic treatments of-
ten prove effective in short-term countering the UTI symptoms, they are more
and more often met with the development of bacterial resistance upon pro-
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longed/repeated application. As a consequence an efficient, non-antibiotic,
and orally-available treatment strategy is of high demand.86
A potential foothold toward countering UTIs, relates to the initial stage
of UPEC host invasion – the adhesion to the urinary bladder. This step is
mediated through the prevalent fimbriae expressed on the bacterial surface,
the multimeric type 1 pili [Figure 2.6]. A dominating structural feature of
these adhesive organelle is the presence of up to several thousands of non-
covalently bound, repeated FimA subunits, resulting in pilus rod lengths
in the µm scale. A further characteristic is the presence of singular FimF,
FimG, and FimH subunits on the tip of the pili. The assembly of the rod
is handled in participation of the FimC chaperone protein, responsible for
temporarily stabilizing the respective subunits through donation of a missing
C-terminal β-strand. Upon assembly completion, this subunit is detached,
with the donor strands provided instead by each preceding domain.87
Among the pili subunits, the terminal FimH protein has proven to be the
primary UTI virulence factor, directly responsible for bladder cell adhesion
and resistance to natural clearance mechanisms.88 This makes it a promising
target of inhibition by means of molecules mimicking its natural ligands –
the α-mannosidic epitopes expressed on the host cell surfaces. Given the
lack of selective pressure imposed on the invading bacteria, such inhibition
(preventing the entire infection cycle) would pave the way to a novel UTI
treatment method, unlikely to encounter resistance phenomena.
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Figure 2.6: (left) Schematic representation of a type 1 pili and its assembly, on
the E.coli surface (right). Images adapted from 89 and 90.
2.4.3 FimH structure
Nearly three decades ago, Sharon and co-workers explored various mannosidic
antagonists for FimH-mediated bacterial adhesion, obtaining affinities in the
milli- and micromolar ranges.91 The first crystal structure of FimH was solved
in 1999,92 followed by a first holo (containing a bound D-mannose) structure
in 2002.93 Since then, an impressive amount of FimH structural data has
become available in the Protein Data Bank (PDB) [Table 2.3]. Through
these, it could be revealed that the 29 kDa FimH protein was constituted
of 279 amino acid residues forming – unlike the remaining pili subunits –
two domains. These were the N-terminal lectin domain (LD; residues 1-
156 including the ligand binding site) and the C-terminal pilin domain (PD;
residues 160-279), connected by a short linker strand (residues 157-159). In
addition, a donor strand necessary to stabilize the PD, would commonly be
provided by a FimC protein wedged between the FimH domains. Later on,
structures of stable, detached LDs were also procured with various ligands.94
A striking feature of all but one of the structures – independent from the
presence of the PD and FimC –, are the nearly identical conformations of
the LD, its binding site, and (if present) the mannose moiety of the bound
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ligand. The sole structure deviating from this trend, contains the entire
pili tip (including domains FimG and FimF in addition to FimH and a re-
positioned FimC), and provides an entirely new context for discussing FimH-
ligand binding, tackled in Section 4.3.95
Table 2.3: Overview of solved FimH crystal structures. Initial five entries cor-
respond to structures referenced in this work but not yet published nor deposited
in the Protein Data Bank. Structure resolutions are given in A˚. Unless stated
otherwise, all ligands (if present) were co-crystallized with the proteins.
Code Ligand Resolution Remarks
4BUQ 2.2 –
– 1.4 pending deposition/Y137A mutation
– 2.5 pending deposition
– 2.8 pending deposition/Y48A mutation
– 1.2 pending deposition
4AUU – 1.6 apo
4AUY 2.1 –
4AV0 2.1 –
4AV4 1.9 –
4AV5 1.4 –
4AVH 2.1 soaked structure
4AVI 2.4 soaked structure
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Continued from previous page . . .
Code Ligand Resolution Remarks
4AVJ 2.1 soaked structure
4AVK 2.4 soaked structure
3JWN – 2.7 apo/two domains/low-affinity protein
2VCO oligommannose-3 2.1 –
1TR7 2.1 –
1UWF 1.7 –
3MCY 2.9 –
1KLF 2.8 two domains/high-affinity protein
1QUN – 2.8 apo/two domains
The dominant crystal conformation of FimH is convenient to present us-
ing the work of Wellens et al. from 2008. The corresponding structure con-
tains an oligomannose-3 ligand, bearing a Manα1-3Manβ1-4GlcNAc motif,
proven determinant for natural FimH adhesion [Figure 2.7].96 As with the
other structures, the isolated LD of this structure, consists primarily of an
ensemble of anti-parallel β-sheets connected by loops on both domain ends.
A solvent-accessible, surface binding site is formed at an interface of three of
these loops (identifiable by the presence of residues Ile13, Tyr48, and Tyr137
respectively). A closer inspection of the site reveals a terminal mannose
moiety of the oligomannose-3, tightly anchored in the pocket by an exten-
sive network of hydrogen bonds. The remaining sections of the motif adapt a
relatively planar conformation, inserting between the two parallel-aligned ty-
rosine residues lining the pocket’s periphery. This structural element of FimH
is commonly referred as the tyrosine gate or – upon inclusion of additional
neighboring residues – the hydrophobic rim. Analyses of further structures
complexed with monovalent α-D-mannoside mimics, present a very similar
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picture, with various aglycones attached to the carbohydrate taking over
the tyrosine-stacking role of the central oligomannose-3 moiety. The parallel
alignment of the tyrosines is also maintained in all but one apo structures
(aside from the effects of crystal packing). This unique complex, obtained by
Han and co-workers in 2010, presents a rigid, biphenyl α-D-mannoside enforc-
ing a perpendicular Tyr48-Tyr137 alignment.97 It is thus assumed that the
Tyr48 residue is prone toward taking on different conformations depending
on the specifics of a ligand.
Figure 2.7: FimH lectin domain complexed with part of the natural high-mannose
epitope – oligomannose-3 (PDB structure 2VCO with 2.1 A˚ resolution and added
hydrogen atoms). A terminal mannose moiety is rigidly anchored by a tight net-
work of hydrogen bonds, whereas the remaining units form a planar conformation,
partially inserted between two tyrosine gate residues.
Based on the abundance of structural and biological data, two primary
strategies could be established toward further improvement of mannosidic
ligand affinity. The first one corresponds to employment of multivalent α-
mannosidic structures, resembling the natural high-mannose epitopes and
aimed at taking advantage of either secondary binding sites (not identified
till date) or multiple pili expressed in close proximity.98 The second approach
CHAPTER 2. INTRODUCTION 43
relies on rational design based the paradigm of further optimizing the con-
tacts between the aglycones of monovalent α-D-mannosides and the tyrosine
gate (necessary given the low affinity and selectivity of the mannose alone).
This concept relates to one of the central points of this thesis and is discussed
starting from Section 4.1.
2.4.4 Further FimH properties
Before proceeding with the discussion concerning mannosidic ligand opti-
mization, certain unique properties pertaining to the structure of the entire
FimH protein need to be highlighted.
Firstly, owing the non-rigid connection of its subunits resulting in the
existence of at least two distinct conformations, FimH may exhibit either
slip- or catch-bonding characteristics. This property, has been confirmed
by flow chamber assay experiments,99 and attributed to increased/decreased
protein-ligand complex lifetimes under various conditions. The first, native
conformation, is assumed under lack of urine flow and stabilized by a contact
between the PD and LD. The second, visibly extended conformation exists
primarily under flow conditions, with the LD firmly attached to the manno-
sylated cell surface. In this case, the shear force imposed on the bacterium
causes the two FimH domains to separate (aside from the short strand of
residues 157-159). As a consequence, several LD loops natively involved in
interactions with the PD are liberated, leading to an untwisting of a cen-
tral β-sandwich fold and elongation of the entire domain.95 With this effect
also allosterically transmitted to the mannose binding site on the tip of the
LD – causing it to significantly tighten upon shear application –, the two
conformations of FimH are commonly referred to as low- and high-affinity
states. The reassumption of the compressed structure upon loss of shear or
dissociation from the cell surface, is commonly known as self-inhibition. In
general, the catch-bonding property – observed also for other systems such
as selectins – is considered to be a natural evolutionary mechanism, enabling
UPEC mobility within a host environment while at the same time preventing
clearance by natural processes (i.e. urine flow).100
A second characteristic of FimH, is an array of natural mutations, in-
volving at least 15% of all residues.101 This feature, related to maintaining
maximum pathogenicity in various conditions, results in the existence of E.
coli strains expressing FimH variants with differing mannose-binding capabil-
ities. While structural data on the various variants are scarce, it is commonly
argued, that their properties relate to the ease with which they may transit
between respective affinity states, i.e. a balance of a pre-existing conforma-
tional equilibrium. In extreme cases (such as mutation of residue 62) the
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Figure 2.8: Two domain structure of the F18 FimH variant (native compressed
state; PDB structure code 3JWN, 2.7 A˚ resolution). Residues commonly suscep-
tible to point mutations marked with red beads.
shift of this equilibrium may lead to a permanently “locked” high-affinity
state. This theory is well supported by the concentration of most mutations
around the PD-LD interface (where they can disrupt the domain interac-
tion), with none found within the conserved binding pocket [Figure 2.8].
Although strongly related to prospective inhibition attempts, the only so far
documented method of efficiently assessing the FimH domain conformation,
is the binding of a selective LIBS antibody to an epitope in the domain inter-
face (residues 29 and 152 to 157), accessible upon domain separation. Due
to such, alternative means of determining the FimH state and properties for
a given bacterial strain – especially related to no-flow conditions expected
for inhibitor binding –, are of utmost necessity.
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3. Materials and methods
3.1 Structure preparation
All of the presented work was based on either one or several of the following
FimH crystal structures retrieved from the Protein Data Bank (PDB):
− 1UWF structure, 1.7 A˚ resolution. All protein residues retained. Used
for the majority of all docking.
− 3MCY structure, 2.9 A˚ resolution. All residues of chain A retained.
− 3JWN structure, 2.7 A˚ resolution. Chain H along with 13 residues of
chain G (FimG donor strand) retained.
− 1KLF structure, 2.8 A˚ resolution. Chain B along with 13 residues of
the FimC chaperone (chain A) retained.
− 2VCO structure, 2.1 A˚ resolution. Chain A only.
Unless stated otherwise, only the above-mentioned protein residues, the co-
crystallized ligands, and a single structural water molecule were used. All
systems were pre-processed using an identical protocol that included addi-
tion of missing side chains (if necessary), calculation of hydrogen atom posi-
tions, hydrogen-bond network optimization, and energy minimization (with
backbone constraints) with the Protein Preparation Wizard.102 Protonation
states were assigned using PROPKA for a slightly acidic pH of 6.5, reflecting
urine.103 Whenever modification of a specific side chain was necessary, the
new orientations were assigned based on the most common rotamer found in
the Schro¨dinger software library,104 that did not clash with any other atom
of the solute.
In addition, structures co-crystallized with heptyl (wild type, Y48A, and
Y137A FimH), indolyl, and squaric acid derivatives are mentioned. These
have not yet been published or deposited in the PDB and were only used as
reference. For details regarding them please refer to Dr. Julie Bouckaert and
Dr. Roland Preston.
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3.2 Docking
Outside of the VirtualDesignLab (discussed below), all ligand docking was
performed using the Induced Fit Docking (IFD) protocol,105 employing flexi-
ble treatment of the ligand and all residues within its 8 A˚ vicinity. The initial
compound geometries were constructed using theMaestro interface (Maestro,
version 9.3, Schro¨dinger, LLC, New York, NY, 2012) and optimized (min-
imization and protonation state assignment for a pH of 6.5) using LigPrep
(LigPrep, version 2.5, Schro¨dinger, LLC, New York, NY, 2012) and Epik.106
The IFD protocol consisted of an initial phase of docking to the rigid binding
site (designated using residues Phe1, Tyr48, Asp54, and Tyr137), followed by
protein side-chain optimization, and re-docking to the optimized grids. Lig-
and scores were obtained from the underlying Glide SP function employing
GScore 107
GScore = 0.05 vdW + 0.15 Coul.+ Lipo+Hbond
+ Metal +Rewards+RotB + Site
where vdW and Coul. are the van der Waals and electrostatic energy com-
ponents, Lipo the contribution of the non-polar solvation, and Hbond – the
hydrogen-bond energy. The remaining terms correspond to (in order): solute-
metal interactions (if present), rewards and penalties for features such as
buried polar groups or hydrophobic enclosure, penalties for freezing rotat-
able bonds, and non-directional polar interactions in the binding site. In
addition the IFD protocol applied a score correction based on the extent of
receptor reorientation necessary to obtain a given pose (i.e. the induced-fit).
In each case, up to eight docking poses (if found within a 15 kcal/mol win-
dow from the top-scored one) were retained for interactive inspection. From
these, the result with the highest score that also reproduced the hydrogen-
bond network around the mannose moiety was used.
3.3 Molecular dynamics
Depending on the system (all originating from crystal structures or docking),
molecular dynamics simulations were carried out either with Desmond (using
the OPLS 2005 force-field as implemented in the Schro¨dinger 2012 suite) or
Amber12 (employing the AMBER 99SB force-field).108, 109 In either case, the
systems were solvated using an orthorhombic, TIP3P water box with periodic
boundary conditions at a minimum distance of 10 A˚ from the solute.110
Na+ and Cl− ions were added to neutralize the charges and account for
physiological salt concentration (0.15 M). The systems were then equilibrated
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using the default Desmond relaxation routine or – for Amber – a self-prepared
protocol consisting of constrained and unconstrained energy minimization
followed by a gradual temperature increase from 100 to 300 K over a period
of 25 picoseconds (ps). Long-range electrostatic interactions (cut at 8.0 A˚)
were handled using the particle mesh Ewald summation.111 The SHAKE
algorithm was applied to all hydrogen atoms.72 Production runs were carried
out using the Martyna-Tobias-Klein isothermal-isobaric ensemble (NPT) and
the Nose-Hoover (Langevin for Amber) thermostat, maintaining a constant
temperature of 300 K.112, 113 Unless stated otherwise, these runs covered the
span of either 2 or 30 nanoseconds (ns; referred to as “short” and “long”
respectively). Energetic and structural data were recorded in 4.8 ps intervals
for a simulation time step of 2.0 femtoseconds (fs).
3.4 Steered molecular dynamics
The steered molecular dynamics (SMD) simulations apply an external phys-
ical force on a system, driving its conformational changes in a designated
direction.76 For the purposes of this work, the SMD protocol implemented in
the Amber12 software suite was used to increase the distance between the end
of the FimH PD donor strand and the anomeric oxygen of the bound ligand
from 81 to 116 A˚. All simulations were based on the 3JWN structure with
a manually-docked methyl α-D-mannoside. The donor strand stabilizing the
PD was obtained by retaining the first 13 residues of the FimG domain also
resolved as part of the structure. The simulations were performed over the
span of 10 ns, at a constant velocity of 3.5 A˚/ns, offering a compromise be-
tween CPU time and sampling detail. The effective driving force (F ) at any
given time point – exerted by pulling a dummy atom attached to the anomeric
oxygen via a virtual spring – was determined according to the relation
F = −k∆x
where k is a defined force constant and∆x the spring extension. The selection
of the former parameter was crucial towards the validity of the simulations
and guided by the so-called stiff-spring approximation.114 In light of it, the
spring should be rigid enough to maintain a linear change of the reaction
coordinate (distance between designated atoms) but still sensitive to the
responses of the system. Based on multiple trial runs with various settings, a
force constant of 10.0 kcal/molA˚2 was selected. Aside from these parameters,
all simulation settings were identical to the Amber MDs described above.
In order to probe the free energy changes accompanying the pulling (re-
ferred to as the potential of mean force or PMF), a total of 10 SMD simu-
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lations were performed. Their starting points were extracted from a short,
constrained MD with the initial docking pose. The underlying energy changes
(∆G) could then be derived by employing the Jarzynski relationship115
exp(−∆G/kbT ) = ￿exp(−W/kbT )￿
where kb is the Boltzmann constant, T the temperature, W the work (equal
to F∆x), and the angle brackets – an indication of a mean over multiple
simulations. The resulting PMF was plotted in a global (reaction coordinate
vs. accumulated work) and a local form (using the work accumulated within
arbitrarily-defined 1 A˚ intervals).116
3.5 Accelerated molecular dynamics
Accelerated molecular dynamics (AMD) are a representative of the so-called
enhanced sampling MD techniques. Their aim is the simulation of rare struc-
tural events (loop/domain motion, ligand unbinding), inaccessible to conven-
tional methods.117 This functionality is obtained by modifying the potential
energy (V (r)) surface sampled during a simulation, by raising the meta-stable
minima (consuming most of the sampling time) while retaining its general
shape
V (r)∗ = V (r) +∆V (r)
where V (r)∗ is the recalculated energy and ∆V (r) – the so-called bias po-
tential determining the extent by which the original surface is raised. As
implemented in the Amber12 software suite, this quantity is defined as
∆V (r) =
(Ep − V (r))
(αP + EP − V (r)) +
(ED − VD(r))
(αD + ED − VD(r))
with VD(r) being the dihedral component of the potential energy at a given
simulation step. The parameters E and α are unique to the AMD sim-
ulations and obtainable from short conventional MDs. The first variable
determines the threshold of total/dihedral energy above which no boost is
applied and should be set up with caution not to destabilize the system.
The second parameter defines (inversely) the strength with which the accel-
eration is applied. The presented form of the bias potential is referred to
as “dual-boosted” and enables accelerating the movement in the entire sys-
tem (facilitating e.g. the slow diffusive motions due to including the solvent
molecules) while additionally “encouraging” the solute to explore different
conformations (related to dihedral angle changes).118 Given the non-specific
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nature of the added potential, no prior knowledge regarding the conforma-
tional behavior of the system is required prior to employing the AMD pro-
tocol.
The simulated systems, were obtained based on the 1KLF and 3JWN
FimH crystal structures, representing its known conformational states. As
with all other two-domain simulations described in this work, these systems
retained short sections of the accompanying FimC/FimG domains to stabi-
lize the PDs. The acceleration parameters were derived based on multiple
trial runs with different settings. Given the extent of conformational mo-
tion implied by the experimental structures, relatively large “boost” levels
were selected, presumed to rank among the highest reported till date [Table
3.1].119
Table 3.1: AMD parameters used in the presented work. All values in kcal/mol
and determined based on the energetics of short conventional MD simulations
performed for each system.
System αD ED αP EP
3JWN (apo) 234 4107 8351 -122352
3JWN (holo) 234 4130 7698 -111365
1KLF (apo) 229 4051 7664 -112107
1KLF (holo) 230 4082 7681 -112221
3.6 MM/GBSA post-processing
The Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) me-
thod of free energy estimation presents a compromise between the processing
speed native to docking and the accuracy of FEP/TI techniques, and has been
extensively used in various design and screening approaches.120, 121 It relies
on comparing the energetics of free and bound solute molecules as illustrated
on the following scheme for the FimH adhesin
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where the total binding free energy equals
∆Gbinding solv. = ∆Gcomplex solv. − (∆Greceptor solv. +∆Gligand solv.)
and (for receptor, ligand, and complex alike)
∆Gsolv. = ∆Ggas +∆Gsolv. − T∆S
The so-called gas phase energetics (corresponding to the intra- and inter-
molecular interactions in the solute) are obtained from an underlying force
field. The computation of the solvation energy changes relies on an implicit
model and comprises polar (using the generalized Born model) and non-polar
components (proportional to the solvent-accessible surface area changes ac-
companying the binding and calculated by the LCPO algorithm).122, 123 Aside
from the GB model, other solvent representations are often employed, such
as the Poisson-Boltzmann (underlying the MM/PBSA method) or Reference
Integration Site model (RISM).124, 125 Finally, the (optional) entropy term
is commonly provided by normal mode analyses (NMA) or harmonic/quasi-
harmonic approximations.126
Given that each calculation requires only a single protein-ligand complex
(with its components assumed to be valid representations of the unbound
molecule conformations), the MM/GBSA protocols may be used to process
structures originating from various experimental and in silico sources. In this
work, either the Prime software implementation (using the OPLS 2005 force-
field) or the MMPBSA.py module of the Amber12 suite (using the AMBER
99SB force-field) were used.127, 54 With regard to the former, it was mainly
employed toward post-processing of docking poses, improving the accuracy
of their scoring. Residues within 8.0 A˚ from the ligand were treated as
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flexible, providing (through a subsequent energy minimization) additional
terms for protein and ligand strains. This method also employed the variable
dielectric VSGB2.0 model to account for polarization effects.128. The Amber
MM/GBSA employed the GB model developed by Onufriev et al,129 and was
used to obtain mean values over ensembles of MD snapshots (between 50 and
250 depending on the simulation length and purpose), diminishing the bias of
single representations. These calculations also enabled decomposition of the
resulting energy into per-residue contributions. For either software, explicit
solvent molecules and ions were stripped to facilitate the computation.
3.7 Geometry analysis and clustering
The geometrical analyses of singular docking structures and Desmond MD
simulations discussed in this thesis (distance and angle measurements, sta-
bility of hydrogen bonds) were performed using the in-build tools of theMae-
stro interface. For Amber simulations (MDs, SMDs, and AMDs), the ptraj
module was used.130 Hydrogen bonds were recognized for donor-acceptor dis-
tances below 3.0 A˚ and donor-hydrogen-acceptor angles above 135 degrees.
Whenever necessary, trajectory frame clustering was performed based on
the positions of protein Cα atoms or all heavy atoms of the ligand and the
surrounding binding site (residues Phe1, Ile13, Asp47, Ile52, Asp54, Gln133,
Asn135, and Asp140). The clustered snapshots were extracted every 10th MD
frame and grouped – using a hierarchical average-linkage algorithm – based
on an RMSD cutoff of 2.0 A˚ between the clusters.131 Volume measurements
were performed using the phase volCalc routine of the Phase software,132
employing a spherical probe with a radius of 1.4 A˚.
3.8 The VirtualDesignLab
The VirtualDesignLab is an in silico tool developed at our institute (based
on the VirtualToxLab framework,133 kindly shared by the Biographics Lab-
oratory 3R) simulating and quantifying the binding of small molecules to a
macromolecular target. Though initially developed for automating modeling
tasks related to the FimH protein, it now allows re-orientation toward other
targets. Its technology employs automated, flexible docking combined with
multidimensional Quantitative Structure-Activity Relationships (mQSAR).
Controlled over an easy-to-use graphical user interface and model-building
tools, the VirtualDesignLab allows medicinal chemists for quick and straight-
forward design, screening and structural inspection of any compound of in-
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terest.134
In order to provide a reliable in silico affinity estimate for a given sys-
tem, it is necessary to account for protein-ligand interactions, solvation and
entropic phenomena. With respect to the FimH adhesin, we utilized a set
of 108 compounds along with their experimental affinity data, to develop
and validate a corresponding mQSAR model (Appendix Table 7.1). When
generating the model, the initial compound structures were constructed us-
ing the integrated model-building tool and then optimized with MacroModel
(MacroModel, version 9.9, Schro¨dinger, LLC, New York, NY, 2012). Atomic
partial charges were computed using the AMSOL package.135 All structures
were subjected to the conformational-searching algorithm ConfGen,136 re-
sulting in sets of low-energy conformations for each molecule in aqueous
solution. Energetically feasible binding poses (within 10 kcal/mol from the
lowest-energy structure) were identified by means of automated docking to
two three-dimensional structures (in and out modes, cf. below) of the FimH
carbohydrate-binding domain. The employed alignment (Alignator) and
docking (Cheetah) protocols allowed for flexibility of both ligand and the
protein (induced-fit) as well as dynamic solvation.137, 44 Several templates
were used for the prealignment in order to account for distinct modes of bind-
ing reported previously. The underlying protein grids were obtained from the
1UWF and 3MCY crystal structures and pre-processed as described above. A
total of 282 docking poses (allowing for multiple poses per ligand) comprising
a 4D data set were then used as input (84 training and 24 test substances) for
the mQSAR software Quasar to generate a series of quasi-atomistic binding-
site models.63 The underlying model families (comprising 200 members) were
evaluated in consensus-scoring mode – along with a direct force-field scoring
in Cheetah and the comparison of a molecule’s interaction energy in a box of
pre-equilibrated water and in the binding site. For validation, we addition-
ally employed an alternative receptor-modeling concept Raptor,138 featuring
a substantially different scoring function (dual-shell induced-fit representa-
tion and introduction of a hydrophobicity term).
CHAPTER 3. MATERIALS AND METHODS 54
Figure 3.1: Example of a VirtualDesignLab workflow (bottom) and its flowchart
(top). A compound of interest is designed within the framework or imported from
an external source. Its initial conformation then undergoes an exhaustive confor-
mational search, yielding feasible poses for subsequent docking and mQSAR. The
entire workflow may be followed and controlled from a central interface window.
Figures adapted from139.
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Every compound submitted to the VirtualDesignLab server (by means of
imported PDB files or the integrated model builder) is subjected to identical
protocols as those employed to train and validate the underlying mQSAR
model(s) [Figure 3.1]. The affinity is calculated based on multiple compo-
nents of the binding energy [Figure 3.2]. Protein-ligand interaction and inter-
nal strain energies (Cheetah and Quasar) are obtained using a force field with
terms for polarization as well as hydrogen bond linearity and directionality.52
The desolvation costs are calculated for the global minimum obtained from
the conformational search, using a continuum solvation model. Loss of en-
tropy is approximated from the number of rotatable bonds constrained upon
binding to the protein. Induced-fit energy calculation is an inherent func-
tion of the Quasar algorithm. The affinity predictions are based on (up to)
eight docking poses as obtained from Alignator/Cheetah (4D) and evaluate
(up to) six induced-fit mechanisms (5D) and two solvation (6D) scenarios
in order to account for the unique properties of certain binding sites (e.g.
the surface-exposed FimH pocket). Protein-ligand structures may be viewed
and/or downloaded (in PDB format) upon job completion. The files may also
serve as input for other software including the MD Client also developed at
our institute.
Figure 3.2: (top) Equation for calculating the binding energy used in the Vir-
tualDesignLab and (bottom) the directional force field employed in Cheetah and
Quasar. The individual terms (quantifying the bond lengths, bond angles, torsion
angles, van der Waals contacts, geometries of hydrogen bonds, electrostatic/metal-
ligand interactions, and ligand-protein polarization) are described in detail in a
related publication.52
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3.9 Entropy treatment
Given the lack of suitable methods of rapid binding entropy prediction, a
custom-made program was written as part of the presented work. Its aim
was to correct a constant energetic penalty applied per each rotatable lig-
and bond, by probing the extent of motion still accessible to it upon com-
plex formation. The conceived technology accepts the input of standard
and extended (in-house developed format additionally storing atomic partial
charges) PDB files, containing a protein-ligand structure. The underlying
parameters were either derived from the Cheetah software (atom types, van
der Waals radii, potential well depths), or fitted based on processing a diverse
set of 317 protein-carbohydrate complexes discussed in the PhD dissertation
of Sameh Eid.140 In addition, various sources of input files were tested (In-
duced Fit Docking and VirtualDesignLab poses, extracted MD frames), to
account for inconsistencies within the PDB file standard.
Upon recognizing the ligand and protein, the software maps their atom
types, connectivity, bond orders as well as various elements that are not
to be violated by later processing (4, 5, and 6-membered rings, inter- and
intra-molecular hydrogen bonds and amide linkages). From there, non-rigid
ligand torsions are identified and rotated (in 1 degree intervals) around their
starting positions, using the Euler-Rodrigues formula [Figure 3.3].141 The ro-
tation is handled in four stages (180 degrees clockwise and counterclockwise
on both sides of the bond), ensuring sampling of the entire conformational
space. During each stage, the van der Waals energies of all atoms are checked
(using the 6–12 potential model) to avoid steric clashes. Upon atom overlap,
the program determines whether a rigid protein backbone, a proline or a cys-
teine residue (only when forming a disulfide bond) are involved, and either
terminates the motion immediately (“hard” clash) or attempts to continue
for a few additional degrees (“soft” clash). The distinguishing between the
contact types enables accounting for protein side chain flexibility, often main-
tained upon binding.142 An identical scan is then repeated for the ligand alone
(starting from the bound conformation or a separately provided “global mini-
mum”), to analyze intra-molecular restrictions. Overly-compressed poses are
filtered out from the pool of found “virtual conformers”, given the tendency
of small molecular ligands to bind in extended geometries.143 The number of
remaining conformers is then used to scale down the cost of 0.7 kcal/mol per
a fully frozen torsion at 298 K.144
T∆SConf. = 0.7 ∗No. of rotatable bonds ∗ (free conf.− bound conf.)
free conf.
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The resulting conformational penalty for all bonds is added to an estimate of
entropy loss for rigid body translation, rotation, and vibration, obtained from
an external RRHO (stands for Rigid-Rotor Harmonic-Oscillator) module of
the MacroModel software.
Figure 3.3: Result of the bond scanning procedure for heptyl α-D-mannoside
binding to the FimH LD. The horizontal axis corresponds to the identified rotatable
bonds (red labels), with their respective penalties [kcal/mol] given on top of each
bar. The vertical axis corresponds to the rotation – in degrees – accessible to each
bond.
4. Results and discussion
Layout
The following chapter summarizes the design and evaluation of selected
groups of FimH inhibitors, performed based on the published biological and
structural knowledge regarding the protein’s lectin domain. The various parts
of this work were done in collaboration with Prof. Beat Ernst, Dr. Said
Rabbani (competitive binding assay measurements), Dr. Roland Preston
(ITC measurements), Dr. Katharina Mayer, Dr. Katrin Lemme, Dr. Oliver
Schwardt, Lijuan Pang, and Wojciech Scho¨nemann. Next, the chapter pro-
ceeds to the development of the VirtualDesignLab framework, that automates
and simplifies the design tasks for the convenience of medicinal chemists.
This work was done with the help of Prof. Angelo Vedani, Dr. Martin
Smiesˇko, and Dr. Sameh Eid. Finally, attempts to model microsecond-scale
behavior of the complete, two-domain FimH protein – based on advanced
molecular dynamics protocols – are discussed, in the attempt of elucidat-
ing the conformational characteristics of the system under flow and static
conditions. This part of the work was carried out entirely by me.
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4.1 FimH inhibitor design and optimization
4.1.1 Analysis of known structures
Owing to the effort of our and other groups,97, 145 the past two decades of re-
search resulted in the discovery of various mannosidic compounds displaying
a high affinity toward the FimH protein. These studies revealed, that excel-
lent potencies for the lectin domain (LD) of this target could be achieved by
means of monovalent α-D mannosides mimicking the natural high-mannose
epitopes expressed on the urothelial cells. More recently, further improve-
ments could be accomplished by focusing on interactions between the agly-
cones of these carbohydrate derivatives and the so-called FimH tyrosine gate
lined by protein residues Tyr48 and Tyr137 [Figure 4.1]. These findings are
illustrated by several crystal structures of the FimH protein with various
ligands, including a natural, tri-mannosidic motif [Table 2.3]. Inspection
of these structures showed that all but one (corresponding to a compressed
conformation discussed in Section 4.2.4) maintained a remarkably conserved
LD and binding pocket, with the position of Tyr48 (responding to a specific
ligand) proving the only significant variable. Depending on the respective
arrangements of the aglycone and tyrosine residues, the so-called in and out
binding modes (at times referred to as open and closed) are commonly ad-
dressed throughout literature146. In order to build on these findings, the
characteristics of in- and out-binding needed to be assessed. To this end,
two FimH LD crystal structures – with ligands bearing an in-bound butyl
(PDB code 1UWF; resolution 1.7 A˚) and an out-bound biphenyl aglycone
(PDB code 3MCY; resolution 2.9 A˚) – were processed and analyzed based
on MD simulations and subsequent free-energy calculations.
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Figure 4.1: Stereo representations of butyl (top) and biphenyl (bottom) α-D-
mannoside binding poses as obtained from computationally-refined 1UWF and
3MCY crystal structures. In the case of 1UWF, the refinement process led to
changing the tyrosine gate alignment from closed to open.
Following structure preparation and refinement, interactive inspection of
the complexes showed the presence of multiple hydrogen bonds around the
mannose moiety along with hydrophobic interactions between the aglycones
and the tyrosine gate [Figure 4.1]. The respective ligand poses have also
proven to be stable throughout 2 ns MD simulations, confirming the pref-
erences of either in- or out-binding depending on aglycone shape, size, and
rigidity. MM/GBSA free-energy decomposition [Table 4.1] performed on the
two trajectories revealed the particularly important role of residues Phe1,
Asp47, Asp54, Gln133, Asn135, and Asp140 within the mannose-binding
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pocket. As also previously reported,147 these residues (along with Ile13 and
Ile52 engaged in hydrophobic interactions) were likely responsible for the
bulk of affinity and specificity toward mannose-bearing ligands due to the
formation of a tight hydrogen-bond network. Among them, Phe1 and Asp54
were the strongest contributors to the binding energy (around 5 kcal/mol
each), due to each forming two very stable (present in the majority of all
simulation frames), charge-assisted hydrogen bonds. It is assumed, that a
lack of interaction with either one of these residues (i.e. caused by modi-
fication of the mannose hydroxyl groups) would lead to a complete loss of
affinity. Altogether, a total of 8 stable hydrogen bonds (as opposed to pre-
viously reported 10) could be identified around the mannose moiety [Figure
4.2],93 with a potential 9th mediated by a conserved water molecule deep
within the binding pocket (discussed in Section 4.1.4). An additional bond,
reported to form between the meta-positioned methyl-ester substituent of the
biphenyl aglycone and the residue Arg98 outside of the pocket,97 could only
be observed in a fraction of the MD frames (around 30%) and was consid-
ered of low significance. The discrepancy between modeling and experiment
regarding the number of hydrogen bonds could be attributed to the flash-
cooling procedures accompanying the latter. Specifically, the introduction of
very low temperature (commonly 100 K), was likely to diminish some of the
residual motion, allowing interactions that would, under physiological condi-
tions (over 300 K), prove entropically unfavorable. Furthermore, as already
highlighted in the case of the 1UWF structure,94 the exposure of the binding
interface on the protein surface could have led to crystal packing stabiliza-
tion of less favorable arrangements. These assumptions could be validated by
subjecting the 3MCY structure to an MD simulation in 100 K, that showed
minimal amount of motion within the binding interface and excellent stability
of all interactions, including the hydrogen bond with Arg98.
Upon ligand removal, 300 K MD simulations of the apo proteins were
also performed in order to observe the behavior of the unoccupied binding
pockets and their vicinity. Subsequent inspection indicated that while the
site interior was preorganized and did not experience change upon mannose
binding, the residues Tyr48 and Tyr137 maintained constant motion with
the former sampling both in and out conformations. The prevalent Tyr48
side chain conformations were found in good agreement with the two most
common tyrosine rotamers (corresponding to χ1 angles of 66 and 180 degrees)
found in the Schro¨dinger software library,104 indicating that the mode pref-
erences were influenced by the internal energy of this amino acid. Finally,
clustering of the trajectory snapshots, shoved the in arrangement more often
populated (both simulations), as also indicated by the available apo protein
structures.92
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Table 4.1: Selected per-residue contributions to the binding free energy of
butyl- and biphenyl α-D-mannosides, obtained as average values from MD-based
MM/GBSA (software Amber) calculations based on the respective crystal struc-
tures. Due to the employed implicit solvent model, the results are likely to be
overestimated and serve only to highlight the most important residues. All values
are given in kcal/mol.
Residue Butyl
mannoside
Biphenyl
mannoside
Asp54 −5.7 −6.2
Phe1 −5.8 −4.3
Tyr48 −1.4 −3.3
Asn135 −2.4 −2.6
Asp47 −1.9 −2.1
Ile52 −1.5 −2.0
Gln133 −2.7 −1.9
Arg98 0.0 −1.8
Asn46 −1.4 −1.4
Asp140 −0.4 −1.1
Ile13 −1.5 −0.8
Phe142 −0.5 −0.5
Tyr137 −0.4 −0.3
His45 −0.3 −0.3
Thr51 0.0 −0.2
Asn138 −0.3 −0.2
Thr53 −0.1 −0.1
Phe144 −0.1 −0.1
Cys44 −0.1 −0.1
Based on these findings, it was concluded that further affinity improve-
ments for monovalent mannosidic ligands could be obtained either via 1) agly-
cone alterations maximizing the favorable contacts with the tyrosine gate or,
2) modifications of the mannose moiety introducing new interactions while
retaining the existing ones.
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Figure 4.2: (top) Two-dimensional representation of all hydrogen bonds identi-
fied around the biphenyl ligand of the 3MCY crystal structure, along with (bottom)
their frequencies and geometries throughout a MD simulation. Unless stated oth-
erwise, the strongest among these bonds were also found for all other compounds
presented in this work.
4.1.2 Evaluation protocols
Due to the substantial number of screened structures (close to 150), MD
simulations and post-processing analyses for all of them could not be accom-
plished within the scope of this thesis. Hence, the majority of evaluations was
performed based on interactive inspection (focusing on aglycone orientation
and hydrogen bonding) and scoring of single docking structures, with only
selected cases subjected to a more through MD-based analysis. To this end,
unified and reliable means of ligand evaluation had to be established. For the
purposes of this work, scoring using the well-established Glide SP function
implemented in the Induced Fit Docking protocol along with MM/GBSA
post-processing methods (software Prime for docking and Amber for MD
analyses, unless stated otherwise) were selected. Given the possibility of bias
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toward larger ligands,148 an additional efficiency metric defined by dividing
the MM/GBSA scores by the number of heavy ligand atoms was also estab-
lished. In addition, representative compounds in each group were subjected
to the Cheetah and Aquarius technologies,44, 134 employing an explicit solvent
representation and the directional Yeti force-field.52 Applying these proto-
cols toward re-docking the two compounds discussed in the previous section
to their corresponding protein grids (i.e. refined experimental conforma-
tions), resulted in top-scored poses within an RMSD of 1 A˚ from the crystal
structures, with all crucial interactions reproduced and the biphenyl ligand
correctly ranked above the alkyl derivative. Cross-docking (i.e. switching the
protein grids) of the molecules was also successful, with the correct Tyr48
rotamers re-assigned in both cases. Subsequent MD simulations with the
docked poses could prove them stable, showing no deviation from the ex-
perimental structures. Altogether, the chosen computational protocols were
deemed capable of reliably docking and ranking prospective compounds and
accounting for the necessary protein flexibility. Still, it should be empha-
sized that the properties of the underling implicit solvent models and lack
of entropy account, have likely led to an overestimation of the MM/GBSA
scores.149 Thus, the presented work was primarily meant to diminish the pool
of synthesis candidates, rather than yield accurate predictions. Later on, a
larger set of compounds was used to derive approximate scaling coefficients
for the MM/GBSA results – 1/10 for Prime and 1/7 for Amber [Appendix
Figure 7.1] –, and to establish a vastly more accurate QSAR model (discussed
in Section 4.2).
Further discussion in this chapter will focus on a selected subset of promis-
ing compounds, with special emphasis on those presented in already pub-
lished work. For every group discussed, a single representative compound
is highlighted along with its detailed interaction profile obtained from an
MD simulation. The entire sets of tested derivatives are listed in Tables 7.1
and 7.2 of the Appendix along with their docking, MM/GBSA, and ligand
efficiency scores.
4.1.3 Aglycone modifications
Various biphenyl derivatives introduced around the time this work began,
have proven among the most potent FimH LD binders.150 Based on available
crystal structure knowledge, it could be derived that their excellent affinities
were related to π-π stacking interactions between the residue Tyr48 and the
second (“outer”) phenyl ring of the their aglycones. In addition, the free-
energy decomposition of the biphenyl compound presented in section 4.1.1,
indicated a significantly weaker interaction with the second “gate” residue
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– Tyr137. This was attributed to a too high rigidity and bulkiness of the
aglycone, preventing positioning between the tyrosine side chains and forcing
them into a non-native, perpendicular orientation (a general characteristic
of the out-binding mode). Hence, attempts were made to either insert larger
aglycones between the parallel-aligned tyrosine gate residues (while retain-
ing the favorable stacking interactions), or modify the biphenyl scaffold to
optimize the out-binding pattern. To this end, series of compounds contain-
ing various aglycone modifications were screened in silico against the LD
structure. In each case, multiple residue/ligand conformations – generated
by the flexible docking protocol – were tested in order to account for individ-
ual mode preferences. In summary, the majority of the screened compounds
could be classified between the following groups (cf. Appendix Table 7.1):
− Biphenyl compounds with various substitution patterns on one or both
rings
− Structures introducing linkers before and/or between the aromatic moi-
eties
− Squaric acid derivatives and similar compounds, altering the shape of
the biphenyl aglycone by introducing a unique ring system
− Triazole and aminocyclobutanol derivatives, exploring the potential of
replacing the first (“inner”) phenyl ring
− Indolyl, indolinyl, and pyrrolopyridine derivatives replacing the outer
phenyl ring with a larger system
− Derivatives with saturated or heteroaromatic ring systems
− Compounds bearing alkyl aglycones, primarily used for reference pur-
poses
Optimization of the biphenyl substitution pattern
Following the discovery of the inhibitors based on a rigid biphenyl scaffold,
it could also be observed that the introduction of aromatic ring substituents
could lead to further gains in potency. Initial work in this direction,145 re-
vealed ligands with ortho-chloro and para-carboxyl groups on inner and outer
rings respectively, to reach in vitro affinities in the low-nanomolar ranges.
Thus, further optimization attempts in this direction were undertaken [Ap-
pendix Table 7.1: 1–21].
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Flexible docking of a representative compound bearing the both above-
mentioned substituents, resulted in a higher scored out-binding pose, closely
resembling the one of the previously discussed co-crystallized 3MCY ligand
[Figure 4.3]. Subsequent MD simulations indicated a high stability of this
pose, allowing excellent stacking interactions with Tyr48 (2.4 kcal/mol). This
further confirmed that the modest resolution (2.9 A˚) of the experimental
structure and the crystallization conditions did not lead to an invalid rep-
resentation of biphenyl ligand binding. Still, a somewhat higher residual
mobility of our compound could be noted (likely to the benefit of conforma-
tional entropy), owing to the outer-ring substituent not forming directional
interactions with the protein. It could thus be stated, that the out-binding
mode was related to the large size, linear shape, and rigidity of the aglycones
rather than the presence of specific interactions or conditions. With respect
to the halogen substituent, it occupied a niche between the Tyr137 side
chain and the mannose binding pocket. Given the predominately hydropho-
bic character of this cavity and lack of suitable acceptor groups, a possibility
of a chlorine-specific interaction (e.g. a halogen bond) was excluded and the
increased affinity attributed to van der Waals contacts of the atom. Subse-
quent synthesis and evaluation of compounds with the chlorine replaced by
other moieties have validated this, showing potency improvements with in-
creasing substituent van der Waals volumes. Nevertheless, deviating from a
symmetric character of the groups (introduction of a metoxy and cyclopropyl
substituents) resulted in the deterioration of the in vitro potencies [Figure
4.3]. Based on the analysis of docking structures it could be concluded, that
the niche preferred groups of spherical shape and/or that the entropic compo-
nent related to restricting the rotatable, non-symmetric groups, diminished
the benefit of the added interactions. As a result, a compound with a trifluo-
romethyl group replacing the chlorine atom was synthesized and has proven
the most potent in the series [Table 4.2]. It is likely that this moiety corre-
sponds to the maximum substituent size that can be accommodated without
distorting the optimal position of the scaffold atoms. This work has been
reported as part of a recent publication.151
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Figure 4.3: (left) Binding pose of a representative biphenyl α-D-mannoside,
bearing an ortho-chloro substitution on its inner phenyl ring. Surface coloring cor-
responds to hydrophobic (gray), positively-charged (blue), and negatively-charged
(red) regions. (right) Relationship between experimental binding enthalpies and
van der Waals volumes of various ortho aglycone substituents. Figure adapted
from151.
MD simulations for various compounds aimed at optimizing the substi-
tution pattern of the outer phenyl ring were also performed. Up till date
however, the para-positioned carboxyl/methyl-ester groups remain among
the most beneficial. In all likelihood, the presence of these moieties (with
their strong electron-withdrawing properties) favorably influences the π-π
stacking with the electron-rich Tyr48 side chain, while increased desolvation
costs are avoided through a high solvent-exposure of the aglycone. This, in
turn, has led to a conclusion that groups with stronger electron-withdrawing
properties could prove even more advantageous.
Various other biphenyl compounds – introducing linker groups or altering
the linear phenyl ring arrangement – screened as part of this study, have
proven inferior to the above-discussed derivatives. Given the good in silico
scores for some of them, the weaker affinities were attributed to entropy and
solvation-related components of their binding – aspects difficult to properly
address with the employed methods.
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Table 4.2: Binding characteristics of a reference biphenyl derivative, including
constituents of the binding free energy (top; scaling coefficient 1/7), per-residue
free energy contributions (right), and most stable hydrogen bonds (bottom). All
results obtained either using Amber (averages over MD trajectories) or Cheetah
and Aquarius software (docking pose; values in brackets) and given in kcal/mol
and A˚. The relatively small desolvation costs are a consequence of a high solvent-
exposure of the bound ligand (applies also for further results).
Energy Contribution Residue Contribution
van der Waals −24.1 (−20.9) Phe1 −4.8
electrostatic −59.5 (−41.9) Ile13 −1.0
solvation +25.2 (+32.1) Cys44 −0.1
H-bond n/a (−24.1) His45 −0.3
total −58.4 (−54.8) Asn46 −1.5
Asp47 −2.4
Exp. affinity 8.9 nM Tyr48 −2.4
Thr51 −0.2
Ile52 −2.0
Thr53 −0.1
Acceptor atom Donor atom % frames Distance Angle Asp54 −5.9
Ligand: O4 Asn135: ND2 60 2.9 156 Arg98 −0.1
Ligand: O5 Asp47: N 60 2.9 161 Gln133 −2.2
Ligand: O3 Gln133: NE2 40 2.9 162 Asn135 −2.6
Ligand: O5 Phe1: N 70 2.9 151 Tyr137 −0.4
Ligand: O2 Phe1: N 60 2.9 152 Asn138 −0.2
Asp54: OD2 Ligand: O5 100 2.6 168 Asp140 −0.6
Asp54: OD1 Ligand: O4 100 2.6 168 Phe142 −0.2
Asp140: OD2 Ligand: O3 100 2.7 165 Phe144 −0.1
Squaric acid derivatives
Given the vicinity of polar groups (including the side chains of residues Tyr48,
Tyr137, and Thr51), enhancing the ligands with complementary moieties re-
mained a vital design approach. Still, previous biphenyl derivatives have
proven incapable of taking advantage of these groups, owing to the rigidity
and linearity of their molecular scaffolds. Thus, a subset of compounds [Ap-
pendix Table 7.1: 22–27] with a squaric acid moiety altering both the shape
and the flexibility of the aglycones was screened in silico. A secondary ob-
jective regarding these compounds was exploring the possibility of stacking
between the tyrosine gate and alternative, non-phenyl ring systems. Ac-
cording to previous reports,152 compounds of this type could also potentially
form covalent bonds between the squaric acid and the charged N-terminus
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of residue Phe1 in the mannose-binding pocket. These considerations were
however discarded based on a more recent publication as well as experimental
affinities below of what one would expect form the formation of a covalent
linkage.153
In line with our intentions, docking poses obtained for the compounds
were often accompanied by hydrogen-bond formation between the oxygen
atoms of the added cycle and the tyrosine residues. Countering these indica-
tions though, further analyses based on MD simulations, did not confirm the
stability of the interactions [Table 4.3]. This was – yet again – likely due to
an entropic penalty that would have to be paid for restraining the aglycone
upon forming the bonds. Nevertheless, the unique, curved shape enforced
by the added group – itself successfully taking over the role of stacking with
Tyr48, as apparent from the energy decomposition – enabled the distal ends
of the aglycones to form additional contacts with the vicinity of the previously
mentioned Arg98. Interestingly, while the subsequent biological evaluation of
the synthesized compounds did not prove them superior to the most potent
LD binders (affinities in the mid- to low-nanomolar ranges), some of them
exhibited similar potencies across a variety of assays and FimH variants.154
This gave reason to conclude that the compounds could either bind equally
well to multiple FimH conformational states (discussed elsewhere in this the-
sis) or enforce one of these states independently from the conditions. Work
on this subject is currently undergoing and has recently resulted in a crystal
structure of one such compound with the FimH LD (personal communica-
tion – Dr. Roland Preston). The corresponding binding mode was found in
good agreement with the computationally-derived pose [Figure 4.4] and has
also confirmed (through the presence of multiple ligand conformations) that
the previously assumed high residual mobility of the aglycone was indeed
present.
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Table 4.3: Binding characteristics of a representative squaric acid derivative, in-
cluding constituents of the free energy (top; scaling coefficient 1/7), per-residue en-
ergy contributions (right), and most stable hydrogen bonds (bottom). Results ob-
tained either using Amber (averages over MD trajectories) or Cheetah and Aquar-
ius software (docking pose; values in brackets) and given in kcal/mol and A˚.
Energy Contribution Residue Contribution
van der Waals −29.8 (−16.7) Phe1 −5.6
electrostatic −91.7 (−43.5) Ile13 −1.4
solvation +54.2 (+25.7) Cys44 −0.1
H-bond n/a (−26.0) His45 −0.4
total −67.3 (−60.5) Asn46 −1.5
Asp47 −2.9
Exp. affinity 21.1 nM Tyr48 −3.9
Thr51 −0.2
Ile52 −1.9
Thr53 −0.1
Acceptor atom Donor atom % frames Distance Angle Asp54 −6.1
Ligand: O4 Asn135: ND2 60 2.9 158 Arg98 −0.3
Ligand: O5 Asp47: N 60 2.9 161 Gln133 −2.4
Ligand: O3 Gln133: NE2 50 2.9 162 Asn135 −2.6
Ligand: O5 Phe1: N 80 2.9 153 Tyr137 −0.4
Ligand: O2 Phe1: N 70 2.9 152 Asn138 −0.2
Asp54: OD2 Ligand: O5 100 2.6 168 Asp140 −0.7
Asp54: OD1 Ligand: O4 100 2.6 168 Phe142 −0.3
Asp140: OD2 Ligand: O3 100 2.7 166 Phe144 −0.1
On a separate note, some of the compounds in this series showed that
aglycones substantially longer than the biphenylic ones, yielded little to no
affinity improvement. A limitation like this has already been indicated for the
previously introduced alkyl α-D-mannosides,94 with ligands longer than the
heptyl derivative not showing improved potencies due to exposing hydropho-
bic parts of the aglycone to the solvent without gaining further interactions.
Regarding the compounds discussed in this work, it could be derived that
aglycone lengths exceeding 10-11 A˚ (measured as the distance between the
anomeric oxygen and the furthest aglycone atom) were unlikely to benefit
potency. Attaching specific groups beyond this point could however favor-
ably affect PK properties at a acceptable expense of affinity. It should also be
noted that, both the initial docking and subsequent MD simulations for some
of the compounds, hinted on their ability to adapt/switch between poses that
were often difficult to classify in terms of in/out binding. This suggests that
categorizing between two arbitrary docking modes, could prove misleading.
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Figure 4.4: Docking pose of a representative squaric acid derivative. Yellow
arrow illustrates an approximate aglycone length beyond which no interactions
with the protein may be formed. Surface coloring corresponds to hydrophobic
(gray), positively-charged (blue), and negatively-charged (red) regions.
Triazole derivatives
Based on the assumption, that positioning the ligand aglycone between the
two parallel-aligned tyrosine residues should benefit the affinities – as already
proven for inhibitors with alkyl moieties –,155 a series of triazole derivatives
was screened in silico, synthesized, and tested in-vitro.146 The design of these
derivatives was also related to the observation that the direction in which
the biphenyl aglycone was oriented (as seen in the 3MCY crystal structure),
differed from that of alkyl α-D-mannosides [Figure 4.1]. This in turn could
be attributed to the geometry imposed by the tightly bound, inner phenyl
ring, lacking rotatable bonds around it. This cycle was thus substituted with
a smaller triazole system preceded by a flexible linker group [Appendix Table
7.1: 28–37].
Docking and MD simulations performed for compounds in this group,
indicated successful reorientation of the aglycones into an open tyrosine gate
[Figure 4.6]. Later on this could be – to an extent – confirmed by the emer-
gence of crystal structures with similar compounds bearing flexible linker
groups alongside bulky ring systems.147 Opposing the initial assumptions
(though in line with the generally weaker docking scores), the in vitro affini-
ties for the series, have proven inferior to the most potent biphenyl and alkyl
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inhibitors. A more detailed inspection of the corresponding MD trajectories
hinted on diminished mobility of the protein-ligand interfaces with respect to
alkyl α-D-mannosides. This suggested that the entropic penalty imposed on
the natively mobile but also bulky triazole-bearing aglycone and the tyrosine
gate, overcompensated the already modest enthalpic gains. [Table 4.4]. As
such, it could be concluded, that only compounds with slim, flexible agly-
cones (e.g. heptyl α-D-mannoside that perfectly complements the shape and
capacity of the tyrosine gate) could fully benefit from an in-binding mode,
whereas larger scaffolds should be kept rigid and prioritize interactions with
residues accessible within the out mode. Still, this class of inhibitors remains
noteworthy due to their excellent aqueous solubilities – a prerequisite toward
oral bioavailability.
Table 4.4: Binding characteristics of a representative triazole derivative, including
constituents of the binding free energy (top; scaling coefficient 1/7), per-residue
free energy contributions (right), and most stable hydrogen bonds (bottom). All
results obtained either using Amber (averages over MD trajectories) or Cheetah
and Aquarius software (docking pose; values in brackets) and given in kcal/mol
and A˚.
Energy Contribution Residue Contribution
van der Waals −25.3 (−18.1) Phe1 −3.5
electrostatic −76.9 (−41.9) Ile13 −0.9
solvation +46.5 (+22.0) Cys44 −0.1
H-bond n/a (−27.7) His45 −0.3
total −55.8 (−65.7) Asn46 −1.4
Asp47 −1.9
Exp. affinity 70.0 nM Tyr48 −3.0
Thr51 −0.5
Ile52 −2.2
Thr53 −0.1
Asp54 −6.2
Acceptor atom Donor atom % frames Distance Angle Arg98 0.0
Ligand: O5 Phe1: N 70 2.8 150 Gln133 −1.6
Ligand: O4 Asn135: ND2 70 2.9 158 Asn135 −2.6
Ligand: O2 Phe1: N 60 2.9 150 Tyr137 −1.0
Ligand: O5 Asp47: N 40 2.9 159 Asn138 0.0
Ligand: O3 Gln133: NE2 30 2.9 161 Asp140 −0.1
Asp54: OD2 Ligand: O5 100 2.6 168 Phe142 −0.6
Asp54: OD1 Ligand: O4 100 2.6 168 Phe144 −0.1
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On a side note, NMR experiments performed as part of our published
study, revealed that the removal of the anomeric oxygen and attachment of
the aglycones directly to their mannose moieties, could result in an unusual
1C4 chair conformation of the latter [Figure 4.5]. Due to substantial loss of
compound affinities, this structural element is thus considered crucial and
should not be tampered with.
Figure 4.5: Illustration of the unfavorable 1C4 mannose flip discovered – by
means of 1H NMR experiments – for some for the presented (right) and additional
compounds in the triazole series.
Indolyl, indolinyl and pyrrolopiridine derivatives
As indicated with the squaric acid derivatives, the outer phenyl ring of the
biphenyl scaffold could be substituted without overly diminishing the po-
tencies of the compounds. A further attempt in this direction, involved the
replacement of the ring with indolyl and indolinyl moieties [Appendix Table
7.1: 38–54]. Here, a secondary goal was the improvement of the generally
poor aqueous solubility of previous compounds, by means of distorting the
symmetry and planarity of the aglycone. Strategies like this, have been
previously successfully applied toward optimizing the properties of various
compounds.156
In silico evaluation of representative compounds, indicated some of them
as excellent LD binders (though their scores were possibly biased by the
larger size of the aglycones as indicated by the ligand efficiency data). The
primary reason for this, was the increased contact surface offered by the
fused-ring systems, enabling more interactions while otherwise replicating
all the favorable contacts of the biphenyl ligands [Table 4.5]. Furthermore,
these compounds could fully benefit form the ring substitution effects (i.e.
ortho substitution on the inner ring along with an electron withdrawing moi-
ety on the outer) discovered for the biphenyl series. Still, the most soluble
derivatives (generally bearing the least planar aglycones) proved incapable of
equally good interactions, resulting in lower scores. These observations were
found in good agreement with a later biological evaluation in which indolyl
compounds with 30-45 degree angles between respective ring systems, were
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found most potent.157 These derivatives are in fact among the most potent
FimH inhibitors till date, rivaling the in vivo efficacy of the standard UTI
antibiotic treatment – ciprofloxacin. Also, an additional confirmation toward
the validity of the modeling could be gained through a recently resolved crys-
tal structure (personal communication – Dr. Roland Preston), showing an
orientation of an indolyl derivative that was nearly indistinguishable form its
docking pose [Figure 4.6].
Figure 4.6: (left) Predicted binding pose of the most potent and best-scored
of the triazole inhibitor series. (right) Docking pose of a representative indolyl
derivative. The yellow number corresponds to the dihedral angle between respec-
tive ring systems of the compound. Surface coloring corresponds to hydrophobic
(gray), positively-charged (blue), and negatively-charged (red) regions.
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Table 4.5: Binding characteristics of a representative indole derivative, including
constituents of the binding free energy (top; scaling coefficient 1/7), per-residue
free energy contributions (right), and most stable hydrogen bonds (bottom). All
results obtained either using Amber (averages over MD trajectories) or Cheetah
and Aquarius software (docking pose; values in brackets) and given in kcal/mol
and A˚.
Energy Contribution Residue Contribution
van der Waals −26.2 (−16.0) Phe1 −4.3
electrostatic −83.4 (−35.9) Ile13 −1.3
solvation +48.8 (+20.2) Cys44 −0.1
H-bond n/a (−16.2) His45 −0.4
total −60.7 (−47.9) Asn46 −1.1
Asp47 −2.2
Exp. affinity 7.7 nM Tyr48 −2.5
Thr51 −0.3
Ile52 −2.2
Thr53 −0.1
Acceptor atom Donor atom % frames Distance Angle Asp54 −7.1
Ligand: O5 Phe1: N 90 2.9 154 Arg98 0.0
Ligand: O4 Asn135: ND2 70 2.9 160 Gln133 −2.0
Ligand: O2 Phe1: N 70 2.9 153 Asn135 −2.1
Ligand: O3 Gln133: NE2 60 2.9 163 Tyr137 −0.6
Ligand: O5 Asp47: N 30 2.9 163 Asn138 −0.1
Asp54: OD2 Ligand: O5 100 2.6 167 Asp140 −0.8
Asp54: OD1 Ligand: O4 100 2.6 168 Phe142 −0.4
Asp140: OD1 Ligand: O3 70 2.7 165 Phe144 −0.2
Other compounds of interest
Two additional groups of compounds were screened in silico but await syn-
thesis and biological evaluation [Table 7.1: 55-62].
The first was a small set of derivatives bearing carboxyl and hydroxyl
groups flexibly-linked to the distal end of their aglycones [Figure 4.7]. The
primary aim of these compounds was the improvement of potential bioavail-
ability by enabling them to form lactones when not bound to their protein
target.158, 159 Through the span of the analysis, it could additionally be re-
vealed that two of the tested structures, bearing carboxyl groups linked to
the meta-phenyl positions, formed stable salt bridges to the Arg98, resulting
in in silico scores superior to previous biphenyl compounds [Table 4.6]. It
is likely that the long, flexible linkers introduced as part of the substituents,
enabled an interaction that could not be maintained by the ligand of the
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3MCY crystal structure. Also, though tested with a biphenyl scaffold, the
favorable properties of the added groups could likely be retained with other
aglycones, as long as they preserved a similar shape and size.
Table 4.6: Binding characteristics of a representative lactone-forming derivative,
including constituents of the binding free energy (top; scaling coefficient 1/7), per-
residue free energy contributions (right), and most stable hydrogen bonds (bot-
tom). All results obtained either using Amber (averages over MD trajectories) or
Cheetah and Aquarius software (docking pose; values in brackets) and given in
kcal/mol and A˚.
Energy Contribution Residue Contribution
van der Waals −25.8 (−19.8) Phe1 −5.9
electrostatic −70.6 (−39.2) Ile13 −1.1
solvation +31.9 (+23.4) Cys44 −0.1
H-bond n/a (−12.9) His45 −0.4
total −64.5 (−47.5) Asn46 −1.6
Asp47 −2.5
Exp. affinity no data Tyr48 −3.1
Thr51 −0.2
Ile52 −1.9
Thr53 −0.1
Acceptor atom Donor atom % frames Distance Angle Asp54 −6.0
Ligand: O5 Phe1: N 80 2.9 153 Arg98 −1.9
Ligand: O2 Phe1: N 70 2.9 152 Gln133 −2.4
Ligand: O4 Asn135: ND2 60 2.9 156 Asn135 −2.7
Ligand: O5 Asp47: N 60 2.9 162 Tyr137 −0.4
Ligand: O3 Gln133: NE2 50 2.9 163 Asn138 −0.2
Asp54: OD1 Ligand: O4 100 2.6 168 Asp140 −0.7
Asp54: OD2 Ligand: O5 100 2.6 168 Phe142 −0.2
Asp140: OD2 Ligand: O3 100 2.7 165 Phe144 −0.1
The second inhibitor group consisted of “bifurcated” compounds with two
aromatic rings connected to a shared CH/phenyl core [Figure 4.7]. The idea
here was to enable interactions common for both binding modes, by position-
ing one of the rings between the tyrosine residues and the other within the
vicinity of Arg98. Molecular dynamics simulations showed the compounds
designed around the phenyl core as capable of sustaining their excellent ini-
tial docking poses. The same could not be said for the remaining structures
due to a too high scaffold flexibility. Energy calculations performed on the
antagonists, indicated improvement of their affinities [Table 4.7] (though,
given the compound sizes, the ligand efficiency scores have to be kept in
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mind). If proven even comparably potent to previously-tested derivatives,
further improvement of these scaffolds could easily be obtained by means of
various aromatic substituents.
Table 4.7: Binding characteristics of a representative bifurcated derivative, in-
cluding constituents of the binding free energy (top; scaling coefficient 1/7), per-
residue free energy contributions (right), and most stable hydrogen bonds (bot-
tom). All results obtained either using Amber (averages over MD trajectories) or
Cheetah and Aquarius software (docking pose; values in brackets) and given in
kcal/mol and A˚.
Energy Contribution Residue Contribution
vdW −27.0 (−18.1) Phe1 −5.3
electrostatic −88.6 (−41.8) Ile13 −1.3
solvation +51.3 (+11.9) Cys44 −0.1
H-bond n/a (−24.9) His45 −0.4
total −64.2 (−72.9) Asn46 −1.4
Asp47 −2.8
Exp. affinity no data Tyr48 −3.1
Thr51 −0.2
Ile52 −1.9
Thr53 −0.1
Acceptor atom Donor atom % frames Distance Angle Asp54 −6.9
Ligand: O5 Phe1: N 80 2.9 152 Arg98 −0.3
Ligand: O2 Phe1: N 70 2.9 152 Gln133 −2.2
Ligand: O4 Asn135: ND2 60 2.9 158 Asn135 −2.4
Ligand: O5 Asp47: N 50 2.9 162 Tyr137 −0.4
Ligand: O3 Gln133: NE2 50 2.9 163 Asn138 −0.4
Asp54: OD1 Ligand: O4 100 2.6 168 Asp140 −0.5
Asp54: OD2 Ligand: O5 100 2.6 168 Phe142 −0.3
Asp140: OD2 Ligand: O3 100 2.7 164 Phe144 −0.1
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Figure 4.7: (left) Proposed binding pose of a representative lactone-forming com-
pound, establishing a salt bridge with residue Arg98. (right) Docking pose of the
top-scored “bifurcated” antagonist. Surface coloring corresponds to hydrophobic
(gray), positively-charged (blue), and negatively-charged (red) regions.
Mutation study
The work on prospective FimH inhibitors revealed different residual contri-
butions toward coordinating the various aglycone types. Attempts of elu-
cidating these relationships however, have met with several inconsistencies
between modeling and experiment. Furthermore, the native flexibility dis-
covered for the tyrosine gate called for assessing its role in greater detail.
Hence, an approach was devised to selectively mutate the two tyrosines into
alanines. This way the impact of respective side chains would be negated,
allowing subsequent biological evaluation to reveal the consequences on lig-
and binding. Following expression and purification of the mutated proteins,
competitive binding assay and ITC measurements (with the latter providing
valuable insight into the entropy changes) were employed to probe the po-
tency of ligands representing the in and out binding modes. The obtained
results however, proved difficult to interpret. Specifically, the data showed a
significant loss of affinity upon Tyr137 mutation, with the lack of Tyr48 being
of much lesser consequence (for in and out binding compounds alike). What
made this discovery surprising, was the fact that stacking with Tyr48 (much
more so than interactions with Tyr137) were already confirmed responsible
for the improved potencies of biphenyl ligands (Section 4.1.1). Furthermore,
no indication could previously be found as to this residue holding any less sig-
nificance toward the in-mode binding of alkyl α-D-mannosides than Tyr137.
To elucidate the structural consequences of the Y48A and Y137A mutations,
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protein grids based on modified FimH LD structures were constructed, MD-
refined, and employed alongside the wild type models.
Table 4.8: Experimental (ITC) end computational (Prime MM/GBSA scores
averaged over MD trajectories) results obtained for selected protein-ligand systems.
All values in kcal/mol.
MM/GBSA binding free energy calculations performed on respective en-
sembles of ligand-bound MD snapshots confirmed that the mutation Y48A
resulted in diminished protein-ligand interaction energies [Table 4.8]. At the
same time however, visual inspection and clustering analyses of the simula-
tions indicated that the removal of the bulky phenyl ring allowed for increased
ligand aglycone flexibility (heptyl α-D-mannoside) or rotation (biphenyl α-D-
mannoside) [Figure 4.8]. Furthermore, given that the Tyr48 side chain was,
in the case of wild type binding, forced to adapt a single, mode-dependent ro-
tamer, a corresponding entropic cost was also to be expected. Consequently,
the interplay of all these factors has likely resulted in a near-perfect entropy-
enthalpy compensation for the Y48A mutation – a fact also apparent form
the ITC data. As such, the Tyr48 residue should still be treated with utmost
attention given the interactions it participates in for the wild type FimH.
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Figure 4.8: MD snapshots showing the binding of heptyl (left) and biphenyl
(right) α-D-mannosides to the FimH LD wild type and the Y48A mutant. In
both cases, the mutation resulted in increased ligand freedom (i.e. flexibility of
the heptyl moiety and rotation of the outer biphenyl ring). Surface coloring cor-
responds to hydrophobic (gray), positively-charged (blue), and negatively-charged
(red) regions.
With respect to the Y137A mutation, no satisfactory explanation could
be obtained from MM/GBSA post-processing of holo MD simulations. Fur-
thermore, employing the state-of-the art Free Energy Perturbation (FEP)
methodology also only served to confirm the lesser importance of the 137
residue, especially for the biphenyl ligand (∆∆GY 137A of 0.9 and 0.6 kcal/mol
for heptyl and biphenyl derivatives respectively), leading to assume that the
necessary answers could not be derived form the protein-ligand complexes.
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Hence, additional MD simulations for the apo wild type and mutant pro-
teins, coupled with a detailed geometric and energetic analysis were per-
formed (work done by Dr. Sameh Eid). As a result, a significant deforma-
tion of the apo binding site (side chains only) of the mutant was revealed,
as demonstrated by the evident distortion of residues Tyr48, Gln133, and
Asp135 [Figure 4.9]. Thus, upon ligand approach, the original binding site
conformation needed to be re-assumed, with certain residues (e.g. Asp135)
not capable of fully reorienting. As a consequence, an additional cost for a
protein induced-fit had to be paid for the Y137A mutation, as reflected by
the experimental data.
To confirm our findings, we were provided with crystal structures of heptyl
α-D-mannoside in complex with wild type, Y48A, and Y137A FimH (struc-
tures solved by Dr. Julie Bouckaert). The three complexes supported our
expectations regarding protein stability and a retained carbohydrate-binding
pattern, showing identical orientations of the mannose moieties. The heptyl
aglycones were also found similarly oriented between respective structures,
though for the Y48A mutation four distinct conformers could be observed.
As with the modeling data, this indicated a pronounced increase of aglycone
mobility with respect to the wild type binding, leading to a more benefi-
cial ligand conformational entropy. Lastly, the Tyr48 side chains were found
perpendicular to Tyr137, opposing the results of molecular modeling. As
already discussed in section 4.1.1, this was likely caused by crystal packing
effects and unrelated to ligand binding. Short MD simulations for each struc-
ture, allowed the Tyr48 side chain to reorient, enclosing the ligand aglycone
between the tyrosine gate residues.
During our study, additional FimH protein mutants were also investi-
gated. Firstly, a set of serine mutants (Y48S and Y137S) was expressed and
tested but did not reveal anything conflicting with the alanine-mutant based
conclusions. Given the different properties of the respective hydroxyl and
methyl groups, this confirmed that the side-chains of the mutated amino
acids no longer had any impact on the binding. Secondly, an R98A mutation
was also explored, but yielded affinities virtually no-different from the wild
type FimH. While of no relation to the tyrosine gate, this confirmed that
the previously disputed (Section 4.1.1) interaction between Arg98 and the
biphenyl aglycone, was indeed absent under physiological conditions.
In summary, the performed study confirmed the vital importance of the
FimH tyrosine gate toward binding – in multiple modes – of mannosidic
ligands. It also provided direct evidence of the previously-assumed signifi-
cant entropy differences between various compounds. A more detailed insight
could not be gained however, due to mutation-induced distortions of thermo-
dynamical and conformational equilibria within the native binding interface.
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Figure 4.9: Snapshots from MD simulations of apo and holo FimH LD bound to
the biphenyl α-D-mannoside. The bottom-left image shows the mutation-induced
deformation of the wild type binding site (top-left). Upon ligand approach (hori-
zontal arrows), the Y137A pocket needs to be rearranged (through an induced-fit)
to accommodate the mannoside. The resulting interface conformation (bottom-
right) still retains some difference from the wild type holo arrangement (top-right).
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4.1.4 Mannose modifications
The substantial effort devoted into optimizing the aglycone portion of α-
D-mannosides, has met with multiple limitations related to its maximum
size, entropy-enthalpy compensation phenomena, and scarceness of interac-
tion partners located outside of the mannose-binding pocket. At the same
time, previous attempts of substituting or modifying the mannose moiety
(including amino- and fluoro-substituted compounds synthesized and tested
in our group),160 resulted in substantially diminished affinities – a testament
to the very high specificity of the FimH binding site. Nevertheless (as high-
lighted in Section 4.1.1), with roughly 60-70% of the binding enthalpy related
to interactions with the carbohydrate moiety (likely over-compensating the
entropy loss of the hydroxyl groups), modifying it, while challenging, held
too much promise to be given up. In a renewed attempt to tackle the man-
nose specificity of FimH, additional compounds [Appendix Table 7.2] were
designed and screened using the methods described in Section 4.1.1. Some
of these attempts are discussed below.
Expanding the mannose ring
Given the failed attempts in substituting the mannose with other carbohy-
drates,161 a conclusion was drawn that this moiety should be modified rather
than replaced. In a first attempt, a heptose-like cyclic derivative was evalu-
ated [Appendix Table 7.2: 1]. During the initial modeling, the bulky (with
respect to mannose) structure could be docked into the binding pocket, form-
ing eight hydrogen bonds. A subsequent MD simulation (2 ns) showed the
docking pose to be stable, excluding the possibility of a too-high internal
strain of the modified ring system. Finally, an in vitro evaluation performed
competitively against the heptyl α-D-mannoside, yielded affinities in the low-
micromolar ranges, providing a qualitative agreement with a modest but still
clearly-favorable MM/GBSA score [Table 4.9]. Thus, while inferior to the
previously discussed compounds, this derivative offered (to our best knowl-
edge) the highest non-mannosidic ligand potency obtained at the time. As
such, it served as proof of concept that the carbohydrate moiety could be,
to an extent, modified. An additional observation gained from the modeling
study, was a somewhat different orientation of the anomeric oxygen of the
derivatives [Figure 4.10] that, through the addition of aglycones, could be
exploited for further compound optimization.
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Table 4.9: Binding characteristics of a derivative with an expanded carbohydrate
ring, including constituents of the binding free energy (top; scaling coefficient 1/7),
per-residue free energy contributions (right), and most stable hydrogen bonds (bot-
tom). All results obtained either using Amber (averages over MD trajectories) or
Cheetah and Aquarius software (docking; values in brackets) and given in kcal/mol
and A˚.
Energy Contribution Residue Contribution
van der Waals −18.1 (−12.0) Phe1 −4.6
electrostatic −70.9 (−28.7) Ile13 −1.4
solvation +41.0 (+13.5) Cys44 −0.1
H-bond n/a (−17.8) His45 −0.3
total −48.1 (−45.0) Asn46 −0.8
Asp47 −2.3
Exp. affinity low-µM Tyr48 −1.2
Thr51 −0.1
Ile52 −1.5
Thr53 0.0
Acceptor atom Donor atom % frames Distance Angle Asp54 −7.9
Ligand: O5 Phe1: N 70 2.9 156 Arg98 −0.1
Ligand: O5 Asp47: N 50 2.9 163 Gln133 0.0
Ligand: O3 Phe1: N 40 2.9 150 Asn135 −0.9
Ligand: O4 Asn135: ND2 30 2.9 164 Tyr137 −0.1
Ligand: O3 Phe1: N 10 2.9 152 Asn138 0.0
Asp54: OD1 Ligand: O4 100 2.6 165 Asp140 0.0
Asp54: OD2 Ligand: O5 100 2.6 169 Phe142 −0.5
Asp140: OD2 Ligand: O2 30 2.7 165 Phe144 −0.2
On a separate note, prolonged MD simulations performed for various
FimH-ligand complexes indicated – as opposed to the image presented by
the static crystal structures and docking – occasional reorientation of certain
binding-pocket elements:
− Residue Asp140, interacting with the 3-OH group of the bound man-
nose in all crystal structures
− The so-called “clamp loop”,162 containing residue Ile13 positioned close
to the C-2 of the carbohydrate moiety
While the first observation could be attributed to insufficient stabilization
of the underlying force field and was circumvented by employing different
software, the loop motion persisted under various setups under room temper-
ature. The finding became even more intriguing in context of a compressed
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Figure 4.10: MD-refined docking poses obtained for the heptose-like (left) and
a C-2 substituted (right) mannosidic derivatives. In both cases all crucial compo-
nents of the hydrogen bond network could successfully be retained.Surface color-
ing corresponds to hydrophobic (gray), positively-charged (blue), and negatively-
charged (red) regions.
FimH crystal structure (discussed in section 4.3), also showing a different
position of the “clamp loop”, leaving the C-2 mannose vicinity practically
devoid of interactions. Spurred by this, an effort was made to expand the
mannose in the direction of the potentially absent/flexible loop. For them to
be successful, the new derivatives had to maintain an intact hydrogen-bond
network. Thus, a series of derivatives with equatorial C-2 attachments pre-
serving all initial hydroxyl groups, was docked and scored in silico [Table
4.10; Appendix Table 7.2: 2–6].
While this sub-project is still in an early stage (personal communica-
tion – Wojciech Scho¨nemann), initial modeling indicated that the modified
compounds could indeed maintain all discussed mannose and aglycone inter-
actions while orienting the attached groups toward a previously not targeted
region of the protein [Figure 4.10]. Subsequent evaluation by means of the
competitive polymer binding assay, yielded potencies in the mid- to low-
nanomolar ranges – best till date for non-mannosidic binders.163 Thus, this
attempt presents yet another successful modification of the mannose moi-
ety, that could furthermore enable inhibition of both known conformational
states of FimH.
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Table 4.10: Binding characteristics of a derivative with an equatorial C-2 ad-
dition, including constituents of the binding free energy (top; scaling coefficient
1/7), per-residue free energy contributions (right), and most stable hydrogen bonds
(bottom). All results obtained either using Amber (averages over MD trajecto-
ries) or Cheetah and Aquarius software (docking; values in brackets) and given in
kcal/mol and A˚.
Energy Contribution Residue Contribution
van der Waals −29.4 (−19.5) Phe1 −3.4
electrostatic −77.3 (−39.1) Ile13 −2.8
solvation +44.4 (+29.3) Cys44 −0.1
H-bond n/a (−16.5) His45 −0.4
total −62.3 (−45.8) Asn46 −1.0
Asp47 −2.1
Exp. affinity 147.3 nM Tyr48 −2.3
Thr51 −0.3
Ile52 −2.1
Thr53 0.0
Acceptor atom Donor atom % frames Distance Angle Asp54 −7.7
Ligand: O3 Phe1: N 90 2.9 154 Arg98 0.0
Ligand: OH Phe1: N 70 2.9 154 Gln133 −1.5
Ligand: O1 Gln133: NE2 50 2.9 164 Asn135 −1.6
Ligand: O2 Asn135: ND2 50 2.9 161 Tyr137 −0.6
Ligand: O3 Asp47: N 30 2.9 163 Asn138 0.0
Asp54: OD1 Ligand: O2 100 2.6 168 Asp140 −0.5
Asp54: OD2 Ligand: O3 100 2.6 167 Phe142 −1.1
Asp140: OD2 Ligand: O1 60 2.7 163 Phe144 −0.2
Replacement of a conserved water molecule
The highly selective conformation of the FimH binding pocket (in its high-
affinity state) impaired modification of the carbohydrate hydroxyl groups. A
potential foothold toward overcoming these drawbacks related to a conserved
water molecule present at the deep end of the pocket in multiple apo and holo
crystal structures (16 out of 35 analyzed protein chains belonging to 8 sepa-
rate PDB entries). The displacement of such a molecule would be expected
to result in enthalpic and entropic (up to 2 kcal/mol) rewards alike,164 while
offering a structurally new antagonist species, with possibly altered drug-like
properties. Hence, an attempt was made to design ligand extensions at the
C-2 mannose position, capable of displacing the water while mimicking its
interactions with the protein.
Before proceeding with compound design, the importance of a hydro-
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gen bond between the water molecule and the mannose 2-OH group had to
be determined [Figure 4.11]. To this end, molecular dynamics simulations
performed on various previously-discussed systems were “re-visited”. A re-
sulting statistical analysis of the distances between the donor and acceptor
oxygens, yielded a mean value of 3.1 A˚ as opposed to 2.7–2.8 A˚ distances
found through a search in the Relibase crystal structure database.165 Addi-
tionally, simulations of the apo protein showed a frequent exchange of the
water molecule with the bulk solvent. Hence, as long as all other mannose
interactions would be retained, this bond – if at all present – was deemed an
acceptable loss. As a result, a compound with the 2-OH group replaced with
a 2-hydroxyethoxy moiety was selected for synthesis (personal communica-
tion – Dr. Katharina Mayer) and evaluation.
Figure 4.11: Top-scored docking poses for heptyl α-D-mannoside (left) and its
derivative extended with the hydroxyethoxy moiety (right). Blue circles indicate
the regions occupied by the conserved water molecule/ligand extension.
Flexible docking and subsequent MD simulations for the new ligand – per-
formed in absence of the water justified by the above-mentioned observations
–, confirmed it capable of maintaining a stable pose that could mimic most of
the solvent molecule’s interactions [Figure 4.11]. Binding free energy calcula-
tions, coupled with an RRHO entropy estimate [Table 4.11; Appendix Table
7.2: 7] showed equal promise. In fact, the calculated energy improvement to-
ward heptyl mannoside was large enough (∆∆G of 12.8 kcal/mol) to almost
insure superiority of the modified compound independently from method
inaccuracies (incomplete entropy and desolvation treatment discussed previ-
ously). Still, a subsequent evaluation by means of the competitive polymer
binding assay and ITC, indicated an affinity several hundred times worse
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than that of heptyl mannoside (difficult to determine more precisely given
the assay discrepancies and detection limits).
Table 4.11: Ligand properties and MM/GBSA results obtained from respective
simulations of heptyl α-D-mannoside and its extended derivative (in its most fa-
vorable pose). As opposed to other MD-based results, these were obtained using
the Desmond (simulation), Prime (MM/GBSA), and MacroModel (RRHO en-
tropy) software, enabling more insight into the energetic components of binding.
All values in kcal/mol and A˚3. Energy components rounded to the first decimal
digit.
Heptyl α-D-mannoside Modified derivative
Ligand volume 264 306
Number of heavy atoms 19 22
Hydrogen-bond donors 4 4
Hydrogen-bond acceptors 6 7
MM/GBSA ∆GCoulomb -31.9 -37.5
MM/GBSA ∆GLipophilic -30.6 -37.8
MM/GBSA ∆GSolvation 18.8 19.0
MM/GBSA ∆GvdW -23.7 -28.9
MM/GBSA ∆Gtotal -67.1 -81.8
Ligand strain 4.5 6.5
Protein strain 11.1 12.4
RRHO entropy 17.8 19.7
∆Gtotal -49.3 -62.1
Given that the obtained in silico data strongly indicated that the ligand
– in its favorable conformation – should benefit from a substantial increase in
binding energy, we concluded that it failed in displacing the water molecule.
In order to account for this scenario, docking to a protein grid retaining
the molecule was performed. As a result, a pose with an inferior score and
a noticeable distortion of the hydrogen-bond network was obtained [Figure
4.12]. A subsequent MD simulation resulted in further pose deterioration,
with more crucial interactions with the protein being lost (e.g. with residue
Phe1). Interactive inspection of the simulation revealed that the buried water
molecule remained immobilized by the added group and impaired optimal
binding. The origin of the unfavorable initial geometry could be discovered
by means of ligand-only molecular dynamics, in which conformations close to
the one required for favorable binding were scarcely populated [Figure 4.12].
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Based on the performed study, we concluded that the modified ligand
could neither approach the receptor in a favorable conformation nor adapt
a water-displacing shape within the binding site due to steric clashes. It re-
mains possible that more pre-organized carbohydrate extensions could prove
more successful, all the more so since the results reported in Section 4.1.4
confirmed the relatively limited significance of the mannose C-2 vicinity. A
crucial factor to be kept in mind however, is the once again encountered
significance of entropy toward the overall ligand binding. At the present the
synthesized compound is also pending evaluation using the full, two-domain
FimH protein that could yield a different result.
Figure 4.12: (left) Binding pose of the hydroxyethoxy-extended derivative, as-
sumed upon failing to displace the conserved water molecule (position indicated
by the blue circle). (right) Free state conformer distribution of the extended com-
pound (black lines) in comparison with the conformation necessary to displace and
mimic the binding site solvent (ball and stick).
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4.2 The VirtualDesignLab
During the course of modeling the various compounds presented in the previ-
ous sections, several limitations of the employed computational methods be-
came apparent with respect to their precision. Firstly, given the discovery of
multiple FimH binding modes, selection of single structures representing each
ligand could have led to errors. Furthermore, the implicit solvation treatment
implemented in the Induced Fit Docking and MM/GBSA protocols, could
have proven inappropriate for simulating the highly solvent-exposed FimH
binding site. Finally, given the inherent flexibility of the protein-ligand inter-
face, the employed treatment was disregarding the vital role of the binding
entropy. It was also concluded that the tedious and repetitive procedures
involved in the evaluation of various compound series were too inefficient
and prone to human error. In order to circumvent all of these limitations,
an automated framework – the VirtualDesignLab – was developed, consist-
ing of design, docking, and scoring modules derived from technologies of the
VirtualToxLab platform. Due to its original purpose as well as consistency of
this work, the framework will be presented as applied toward design of FimH
ligands, focusing on training/test compound selection and validation of the
resulting QSAR model (responsible for affinity predictions), along with later
attempts of more accurate entropy calculation. Still, it bears mentioning
that the underlying technology enables re-orientation toward other targets
as discussed at the end of this section. Also, a more general description of
the framework is presented as a part of a recently published article.139
4.2.1 Docking module and base compound selection
Although the state-of-the-art Induced Fit Docking protocol has proven suffi-
cient for screening purposes, it still showed limitations toward handling the
structurally-diverse FimH inhibitors. Hence, a decision to replace it in fa-
vor of the Alignator and Cheetah software (performing pre-alignment and
docking tasks respectively) was reached, due the following benefits:
− Explicit solvent treatment, enabling more precise assessment of related
properties and incorporation of structural water molecules
− Employment of a directional force field, improving the treatment of
hydrogen bonds
− A feature of using multiple templates to guide the flexible alignment
and docking toward specific, crystal-structure based binding modes
CHAPTER 4. RESULTS AND DISCUSSION 91
− Both programs being integral and thoroughly validated components of
the parent VirtualToxLab technology
Before employment, the new protocols were evaluated with respect to
handling mannose-based ligands. A secondary objective here was to confirm
the necessity of later employing the mQSAR-based scoring and – if so – ob-
taining test and training substance sets for the development of the FimH
model. To both ends, a set of 108 FimH inhibitors with known experimental
affinities was docked [Appendix Table 7.3]. These compounds were carefully
selected in order to represent maximum diversity in terms of structure and
potency (spanning nearly five orders of magnitude from 220 µM to 2.4 nM)
and contained representatives of all structural classes presented in Sections
4.1.3 and 4.1.4. The generated ligand geometries confirmed that the newly
employed software was capable of correctly docking the mannose moieties and
reproducing the surrounding hydrogen-bond network. Sampling of multiple
Tyr48 conformations could also be observed, indicating that different binding
modes were being accounted for. Nevertheless, pair-wise comparison with the
top-scored poses generated by Induced Fit Docking protocol yielded RMSD
values between 0.2 A˚ and 6.1 A˚, with a mean of 2.0 A˚. This clearly indicated
that the two methods were at times favoring significantly different confor-
mations, none of which could be discarded given the pronounced aglycone
motions discovered previously. Also, between the singular docking scores
and the experimental affinities, coefficients of determination (r2) of 0.202
and 0.232 could be obtained for Induced Fit Docking and Alignator/Cheetah
respectively. Given that docking protocols are commonly known to generate
reliable geometries while suffering from inaccurate scoring/ranking,166 this
confirmed the necessity of using multiple ligand poses along with a more ac-
curate affinity estimation method. As such, up to eight geometries per-ligand
were used for the FimH mQSAR model development and all later predictions.
4.2.2 QSAR model
The FimH QSAR model currently employed for the VirtualDesignLab was
selected from a series established based on structural and biological data of
the above-mentioned 108 mannosidic inhibitors displaying diverse PK/PD
profiles. Compound synthesis, biological assays, and model development
were performed in-house, ensuring consistency of all results. Table 7.3 of the
Appendix shows the structures and experimental/predicted affinities of com-
pounds used for the development. The model based on a genetic algorithm
implemented in the Quasar software,167, 168 converged at a cross-validated r2
of 0.805 and yielded a predictive r2 of 0.596 [Figure 4.13]. The only modest
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value of the predictive r2 was a consequence of the relatively narrow range
of test compound affinities, with some substances necessary for the training
set due to their structural uniqueness. The performance of the model was
therefore better reflected by the individual predictions, with 23 out of 24
test substances found within a factor of 10 from their experimental affin-
ity. Thus, it could be stated that the method displayed predictive power
vastly superior to the previous attempts. The FimH model was then further
challenged by using Y-scrambling and consensus scoring with the software
Raptor (dual-shell 5D-QSAR; Figure 4.13).138 All tests, including the pro-
cessing of additional compounds, further confirmed the predictive power of
the mQSAR model and the framework established around it.
Figure 4.13: Comparison between experimental (horizontal axis) and predicted
pK values (vertical axis) for the Quasar (left) and Raptor model (right). Black
and red points represent compounds of the training and test set, respectively. Ver-
tical bars indicate the estimated standard deviations of the prediction. Dashed
lines are drawn at factors of 10 from the experimental value. The difference be-
tween the two methods relates to the latter lacking terms for electrostatics and
polarization (replaced with a hydrophobicity term) and incorporating a dual-shell
representation of the induced-fit.
4.2.3 Entropy treatment
The entropy change related to various association events is an often impor-
tant and at times crucial – due to serving as the driving force – component
of the binding energy. Nevertheless, experimental means of measuring these
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changes are still limited to complex and costly ITC and NMR techniques,169
impairing many drug design and optimization attempts. This holds equally
true for in silico approaches that – despite decades of research – are still
primarily centered around extremely computationally expensive Thermody-
namic Integration and Normal Mode Analysis [NMA] techniques.170 Thus,
within the scope of higher throughput evaluation, simple attempts of ap-
proximating ligand binding entropies are employed, commonly based on a
constant penalty per a rotatable bond (around 0.5–0.7 kcal/mol). While the
addition of this term has at times proven beneficial,171 this was likely not to
hold true with respect to modeling of prospective FimH ligands. Specifically,
the previously-discussed inherent flexibility of the protein-ligand interface
was likely to be treated with a too high penalty that assumed full rigidifica-
tion of all rotatable bonds. Due to such, a method for individually scaling
the per-bond penalties – based on probing the rotation accessible to each
bond in the bound and free ligand states – was developed for the purposes
of the VirtualDesignLab. The conceived technology additionally enabled –
by employing the RRHO approximation – calculating the entropy compo-
nents related to the loss of rigid body translation, rotation, and vibration,
commonly neglected in computational and experimental approaches alike.
Following development and testing (see Section 3.9), the method was em-
ployed toward establishing a new QSAR model for the FimH adhesin. The
resulting receptor surrogate – developed otherwise identically to the one pre-
sented in the previous section – converged at a cross-validated r2 of 0.830
yielding, a predictive r2 of 0.640 [Figure 4.14], with all test set compounds
within a factor of 10.0 from their experimental affinities. Given the identical
settings and set compositions (along with their discussed limitations), this
was considered a clear improvement over all previously tested models. In
order to exclude the possibility of the calculated values coincidentally ben-
efiting the Quasar technology, the new software was also coupled with the
MM/GBSA protocol, by means of multiple linear regression (necessary given
the heterogeneous origin of the data). To this end, a separate set of com-
pounds was used [Table 4.12], offering a good correlation with experimental
ITC data (r2 of 0.804) and a large variation of binding entropy changes (T∆S
values spanning a range 3.5 kcal/mol). As a result, a coefficient of determi-
nation of 0.846 could be obtained, with the entropy results differing by up
to 3.8 kcal/mol from one another. All in all, a satisfactory performance
of the developed method could be obtained along with indications toward
its general applicability outside the VirtualDesignLab framework. With the
software also employed toward establishing a carbohydrate scoring function
(personal communication – Dr. Sameh Eid), this applicability can hopefully
soon be shown in a dedicated publication.
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On a side note, it should be mentioned that when using only parts of
the calculated entropies (conformational, vibrational, rotational, or trans-
lational), the prediction quality rarely surpassed the constant/no penalty
approaches – a likely testament toward the highly correlated nature of the
state function’s components. This led to think, that accounting for the third
primary entropy constituent – solvation – could further improve the quality
of the results. Regrettably though, the complex nature of the calculations
related the explicit solvent along with the necessity of its dynamic repre-
sentation, impaired developing a suitable method within the scope of this
work. As it stands, the conceived technology is best employed toward series
of congeneric ligands such as the FimH binders, where the bulk of solvation
changes concerns the fully desolvated, identically bound mannose.
Figure 4.14: Comparison between experimental (horizontal axis) and predicted
pK values (vertical axis) for the Quasar model employing the improved entropy
estimation. Black and red points represent compounds of the training and test
set, respectively. Vertical bars indicate the estimated standard deviations of the
prediction. Dashed lines are drawn at factors of 10 from the experimental value.
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Table 4.12: Experimental and calculated free energies (MM-GBSA; software
Prime; scaling coefficient 1/10) for a small set of ITC-tested compounds, with and
without the calculated entropy estimate. All values in kcal/mol and rounded to
the first decimal digit. Entropies given as –T∆S values for 298 K.
Structure Exp. free
energy
Predicted
free energy
Trans./rot.
entropy
Conform.
entropy
Corrected
prediction
1 −8.1 −68.6 16.7 2.5 −49.4
2 −10.3 −98.8 19.7 4.6 −74.5
3 −9.1 −90.2 18.4 3.9 −67.9
4 −8.9 −71.2 16.4 2.7 −52.1
5 −11.4 −100.6 19.6 3.7 −77.3
6 −11.6 −102.3 20.1 3.5 −78.7
7 −11.9 −106.8 20.3 3.3 −83.2
8 −10.9 −92.8 18.3 3.0 −71.5
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Continued from previous page . . .
Structure Exp. free
energy
Predicted
free energy
Trans./rot.
entropy
Conform.
entropy
Corrected
prediction
9 −11.1 −100.3 18.2 5.0 −77.1
10 −11.5 −94.0 18.2 3.0 −72.8
11 −9.4 −82.2 17.3 3.1 −61.8
12 −10.7 −89.7 17.9 2.9 −68.9
13 −11.4 −98.9 18.3 4.7 −75.9
4.2.4 Performance, limitations, and re-purposing
The VirtualDesignLab is aimed at predicting the binding affinity for a given
compound within a factor of 10.0 from the experimental value. Currently,
the prediction for a single candidate requires approximately one hour of CPU
time (with additional 3–5 minutes needed when employing the improved
entropy estimation), offering a good balance between accuracy and processing
time. Nevertheless, as can be seen in the Appendix Table 7.3, the precision
of the underlying models tends to weaken for highly flexible structures. In
such cases, a non-static approach offered by MD simulations is often still
helpful.
It should also be emphasized, that the framework, while initially devel-
oped for the purposes of FimH inhibitor design and evaluation, is independent
of the FimH mQSAR model. As such – assuming that a satisfactory amount
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of ligands with experimental affinity data is available –, it only requires the
generation and validation of a new model to enable re-orientation toward any
target of interest. Furthermore, as long as an experimental structure or a
homology model of the target exist, the corresponding docking and scoring
tasks may be accomplished through numerous, freely accessible computa-
tional tools, making the framework intendant form any particular piece of
software. Still with respect to the QSAR model development and validation,
the procedures are best handled using the originally employed Quasar soft-
ware to ensure satisfactory performance.
CHAPTER 4. RESULTS AND DISCUSSION 98
4.3 Modeling on the complete FimH protein
As highlighted in Section 2.4.3, the majority of research performed on FimH
was, until recently, based on its detached lectin domain, rather than the
complete structure. While mostly dictated by the difficulty of expressing
the full protein in its native state (instability of the PD in absence of the
FimG/FimC donor strand), this approach could be justified by a general
correlation between in vivo and in vitro results (with the latter obtained
using single-domain constructs).145 Still, given the limited success in further
improving the affinities of alkyl and biphenyl mannosidic derivatives, insight
into the full structure of the receptor along with its dynamics (especially
under no-flow conditions) remained imperative. In pursuit of this, several
studies were performed during the last decade,172 revealing that the protein
could assume multiple conformations (resulting in varying ligand affinities)
depending on several conditions:
− Presence of sheer force exerted by the physiological urine flow (affinity
dependent on the sheer level, resulting in slip/catch-bonding charac-
teristics)
− Insertion of the FimC chaperone between the respective domains (high
affinity)
− Absence of the pilin domain (high affinity)
− None of the above (low affinity; refereed to as self-inhibition)
− Natural mutations (ligand affinity dependent on the specific mutation)
Based on these findings, the crystal structures available up until a few years
ago – given the FimC-stabilization or lack of the PD – were associated with
a high (most likely maximum) affinity FimH state, leaving the native apo
protein conformation unknown. More recently though, it could be argued
that a high-affinity conformation was also assumed under static conditions
in presence of soluble mannose,173 implying an induced-fit mechanism and
supporting the validity of single-domain based work. Specifically, the study
stated that the presence of the carbohydrate ligand enabled the binding of se-
lective antibodies (expected to attach to an interface within the inter-domain
region in a manner similar to the FimC chaperone) that would otherwise show
no affinity toward the whole protein. Even more recently however, a crystal
structure of the type-1 pili tip (with the common F18 variant of the FimH
lectin) could be solved,95 for the first time enabling analysis of the receptor
CHAPTER 4. RESULTS AND DISCUSSION 99
in its native apo state. As a consequence, a drastically different protein con-
formation could be observed with respect to ones previously obtained. In
the context of the previous findings and assumptions, this discovery would
have meant that the FimH protein could undergo an unprecedentedly-large
conformational change under flow and static conditions alike. Given the
up to 200-fold affinity variations reported for different protein variants and
experimental conditions,174 this made the determination of the underlying
mechanism all the more crucial. Furthermore, it was still necessary to con-
firm whether one, both, or neither of the known structure types offered a
valid physiological representation of FimH and whether this representation
differed between flow and static conditions (the latter relevant for inhibition
attempts due to the compounds not being attached to the bladder surface).
4.3.1 Structure preparation and analysis
In order to obtain representative structures of the two FimH states and en-
able their energetical comparison, constructs based on the 3JWN and 1KLF
crystal structures (with 2.7 A˚ and 2.8 A˚ resolution respectively) were gen-
erated. Specifically, the 1KLF structure was modified to comply with the
F18 amino acid sequence of the 3JWN counterpart (mutations V28A, S70N,
and N78S). It was also stripped of its accompanying FimC chaperone (na-
tively detached once the pilus rod assembly process is concluded), aside from
a short strand of residues stabilizing the pilin domain. Similarly, the other
conformer was separated from the remaining pili tip domains, with the excep-
tion of the FimG donor strand. Following preparation, the conformers were
subjected to 10 ns MD simulations, given the previously noted possibility of
crystal packing distortions and the necessity of relaxing the modified amino
acid sequence of the 1KLF construct in absence of FimC.
While the performed simulations did not reveal significant changes within
the domains of either state, a shortening of the distance between the 1KLF
subunits could be seen. This was due to a “hydrophobic collapse” follow-
ing the FimC removal, and gave reason to believe that this fully extended
FimH conformation could not exist without shear flow or another stabilizing
element. As such, structures representing the most stable parts of each MD
trajectory were selected for further work [Figure 4.15]. Geometrical analyses
of these representatives confirmed the retained structural differences initially
observed with the crystal structures. Specifically, the 1KLF construct was
found nearly 20 A˚ longer, with the LD and PD only weakly connected. The
native apo structure on the other hand, presented a tighter contact between
the subunits enabling multiple – primarily hydrophobic – interactions, as
described in a publication released alongside the crystal structure.95 RMSD
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Figure 4.15: Stereo representation of MD-refined structures of the native apo
(green; PDB code 3JWN) and FimC-stabilized (red; PDB code 1KLF) FimH
protein structures, superimposed on the Cα atoms of the lectin domains. Upon
closer inspection, one may observe that the dihedral angle between the domains
differs by nearly 180 degrees.
calculations revealed that aside from the domain separation/compression,
the most pronounced structural differences were focused in the LD (3.6 A˚ for
116 Cα atoms outside of the domain interface, with the 1KLF LD longer by
approximately 10 A˚), whereas the PD was much more conserved between the
states (1.8 A˚ for all 121 Cα atoms). Focusing on the mannose-binding region
– defined using the heavy atoms of residues Phe1, Ile13, Asp47, Ile52, Asp54,
Gln133, Asn135, and Asp140 – yielded an RMSD of 3.5 A˚, with the 3JWN
residues partaking in forming a large, nearly-flat surface, hardly resembling
the well-defined 1KLF mannose-binding pocket and unlikely to prove mono-
mannose selective [Figure 4.16]. While potentially related to the lack of a
ligand in the 3JWN structure, the overall scale of the differences substantially
surpassed those commonly related to induced-fit events,175 contradicting the
theory that binding of mannosidic ligands imposed a conformational transi-
tion between the two crystal structure conformations. Also, no explanation
could be found as to how rearrangements of this magnitude (commonly re-
lated to µs or ms time scales) could occur quickly enough to accompany
sub-µ
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Figure 4.16: Binding site regions of the 3JWN (left), and 1KLF (right) crys-
tal structures assumed to correspond to the low- and high-affinity FimH confor-
mational states. Surface coloring corresponds to hydrophobic (gray), positively-
charged (blue), and negatively-charged (red) regions.
An alternative explanation for the FimH binding characteristics, could
be conceived in the form of a conformational selection mechanism. In light
of this theory, large-scale changes of the target receptor were less unlikely as
long as the relevant conformations could maintain an equilibrium. In order
for the selection not to result in a kinetic bottleneck (with the concentration
of the binding-capable species directly proportional to the kon rates),176 the
underlying energy difference along with the size of the barrier between the
states would have to be moderate however. To determine whether this sce-
nario was more likely than the large-scale induced-fit mechanism, attempts
were made to probe the behavior and energetics of relevant apo and holo
conformations by means of MD simulations and MM/GBSA calculations
employing the well-established AMBER-99SB force field (see Section 4.1).177
Also, to avoid an incomplete free energy assessment, the calculations were
coupled with the normal mode analysis (NMA) entropy estimation.
4.3.2 Protein energy calculations
The likelihood of preferring either the induced-fit or conformational selection
mechanism by a protein may be derived from the underlying energy land-
scape formed by its relevant conformers. Specifically, surmounting a large
energy barrier between the states requires a catalyst in the form of initial
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ligand binding occurring as part of an induced-fit. A smaller barrier coupled
with larger structural changes (rare for induced-fit due to the time neces-
sary for them to occur) are commonly related to inherent protein motion
enabling conformational selection. In light of this, probing whether the na-
tive “compressed” FimH form was capable of binding mannosidic ligands
(without undergoing a large-scale change), was first required. If proven oth-
erwise, a selection mechanism in which only one conformation could bind
the ligands, would have became likely. To this end, the previously discussed
Induced Fit Docking protocol – allowing residual motion necessary to escape
the unfavorable planar binding site arrangement – was employed to dock
a methyl α-D-mannoside (MM; chosen to focus conformational sampling of
the docking protocol on the mannose binding) to the 3JWN-based grid. As
a result, several complexes could be obtained, none of which reflected the
binding pattern observed in the 1KLF structure. Furthermore, subsequent
MD simulations would commonly lead to a complete ligand unbinding due
to insufficient amount of favorable interactions with the protein (commonly
2–3 hydrogen bonds formed for the initial poses). Hence, assuming that the
same residues were involved in mannoside binding to all FimH states, the
ligand was docked manually to the 3JWN structure, with priority placed on
reproducing as many 1KLF hydrogen bonds as possible. A resulting pose was
then subjected to a short MD simulation while keeping the obtained inter-
actions constrained. Finally, the constraints were removed and the system
relaxed during an extensive, 100 ns simulation. As a result, the protein-
ligand interface could be maintained, enabling reproduction of seven 1KLF
hydrogen bonds (though lacking the charge-assisted bond with Asp140 as
well as the hydrophobic interactions with the Ile13 “clamp loop”). Further-
more, a formation of a clearly defined pocket could be observed around the
methyl mannoside [Figure 4.17], indicating that while the site was not na-
tively preorganized, the compressed FimH state was still capable of ligand
binding.
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Figure 4.17: Cartoon (left) and surface (right) representations of the MD-refined
MM binding pose with the native FimH protein. The resulting interface shares
a lot of resemblance to its highest affinity counterpart but lacks – resulting in
a somewhat larger binding site – a charge-assisted hydrogen bond with Asp140
and hydrophobic interactions with the “clamp loop” containing the residue Ile13.
Surface coloring corresponds to hydrophobic (gray), positively-charged (blue), and
negatively-charged (red) regions.
Obtaining the alternative binding pose, enabled probing the energetics
of the apo and holo conformers with the MM/GBSA method [Table 4.13].
As an expected result, a more favorable ligand binding free energy could be
obtained for the elongated system (–26.5 and –12.5 kcal/mol for 1KLF and
3JWN constructs respectively). Still, while likely prone to overestimation,
the protocol also revealed an approximately 21 kcal/mol more favorable total
free energy of the holo 3JWN complex over the 1KLF. Furthermore, sum-
ming up the energies of the free ligand and the native apo protein, yielded
a 6 kcal/mol lower value to that of the 1KLF complex. Taken together this
indicated that the formation of a complex with the extended protein was not
a thermodynamically favorable process (when started from the compressed
FimH) and required an external force – physiologically provided through
shear stress – to counter a strong hydrophobic effect “collapsing” the do-
mains. Additionally it could also be shown that the native apo protein had a
significantly lower energy than its higher affinity counterpart (∆∆G = −32
kcal/mol), undermining the theory that these two states could maintain an
equilibrium.
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Table 4.13: MD-based results of MM/GBSA (software Amber) free energy mea-
surements performed for holo and apo FimH systems. Values may be compared
due to imposing a 100% sequence identity between the systems. Entropy estimates
obtained from normal mode analyses (NMA) at 298 K. All values in kcal/mol and
rounded to the first decimal digit.
Compressed state Elongated state Residual
Receptor MM/GBSA -23000.5 -22958.1 -42.3
Receptor NMA 2959.6 2969.8 -10.2
Receptor total -25960.0 -25927.9 -32.1
Ligand MM/GBSA -112.2 -115.3 3.0
Ligand NMA 34.7 34.8 -0.1
Ligand total -146.9 -150.0 3.1
Complex MM/GBSA -23147.4 -23113.0 -34.4
Complex NMA 2975.2 2988.3 -13.1
Complex total -26122.6 -26101.3 -21.3
∆G MM/GBSA -31.6 -42.6 11.0
T∆S NMA -19.1 -16.1 -3.0
∆G total -12.5 -26.5 14.0
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Figure 4.18: Graphical representation of the energy values obtained for com-
pressed and elongated states of the FimH protein (blue) and the FimH-MM com-
plex (red). Even though the ligand binding lowers the energy of both states and
the difference between them, the native protein arrangement is favored in both
cases.
4.3.3 Steered molecular dynamics
The obtained results strongly opposed the possibility of FimH transiting be-
tween its two crystal structure conformations without the influence of exter-
nal forces. Nevertheless, it could not be excluded that the employed energy
scoring methods were too inaccurate to compare the states. Furthermore,
given lack of structural data regarding mannosidic ligand binding to the
compressed protein form, the validity of the obtained docking pose could not
be confirmed. Thus, a concept was devised to support the MM/GBSA re-
sults with steered molecular dynamics (SMD) simulations applying a pulling
force on the system in a manner similar to atomic force microscopy exper-
iments. Through this, the stability of the obtained ligand pose could be
probed under flow conditions, reflecting the naturally occurring cell adhesion
events in which the bacteria attach themselves to the highly-mannosylated
cell surfaces. While of little relation to static inhibition attempts, an in-
ability of simulating the accompanying domain separation or loss of ligand
binding (preceding subunit detachment), would undermine the validity of
the obtained pose and the derived conclusions. An additional benefit of the
SMD simulations – if performed multiple times from closely-related struc-
tural starting points – was the possibility to plot the free energy changes
along the pulling path (referred to as the potential of mean force or PMF).
Through this, binding and barrier energies along with intermediate states
involved in the transition could be highlighted, possibly delivering evidence
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toward induced-fit/conformational selection preferences. This type of simula-
tions was already previously employed toward studying the FimH protein.178
The past work however, was based on the apo protein structure and limited
to a single, constant-force run, without deriving the underlying energetics.
Hence the study presented here remains – to my knowledge – unprecedented.
The performed simulations (run under a constant pulling velocity of 3.5
A˚/ns up to a distance of 35 A˚ between the end of the donor strand and the
anomeric oxygen of the ligand) resulted in the MM pose surviving the ap-
plied force – until the point of domain separation – in eight out of ten runs.
A ninth simulation actually failed to unbind the molecule before the maxi-
mum allowed extension was reached. Given that the applied pulling forces
(120 pN on average) were substantially greater to those common to atomic
force microscopy experiments or exerted by the urine flow,179 this indicated
excellent stability of the MD-refined docking pose. Interestingly, during the
pulling runs the LD did not show deviation toward a tighter conformation
(that could further support the binding), indicating that either longer sam-
pling times were required or that the domain separation and LD reorientation
did not occur simultaneously but rather in sequence. Also, a closer analysis
of the subunit movement, revealed that the extended conformations of the
FimH protein (obtained toward the end of all pulling runs) did not reflect
the 1KLF domain arrangement. Specifically, while a similar extent of sepa-
ration could be obtained (increase of the defined distance by around 20 A˚),
the dihedral angle between the domains did not twist in a manner implied
by the experimental structures [Figure 4.19]. While possibly caused by lack
of additional domains transmitting the pulling force along the pilus rod, this
could once again be interpreted through the conformational uniqueness of
the FimC-stabilized constructs.
Finally, based on eight of ten simulations showing similar system behav-
ior, a “global” PMF along the pulling path could be constructed [Figure
4.20]. As a result a steep energy increase was observed, reaching a maximum
around 53 kcal/mol. Given the estimated native MM binding free energy of
close to 13 kcal/mol (as obtained from MM/GBSA calculations), this value
along with the shape of the curve, clearly indicated a substantial cost (around
40 kcal/mol) of the domain separation preceding ligand unbinding. In order
to explore this further, a so-called “local” PMF was also plotted,116 corre-
sponding to free energy changes within 1 A˚ bins defined along the pulling
path [Figure 4.20]. As a result, an upwards slope littered with multiple local
minima and maxima could be observed, followed by a steep energy decrease
related to loss of binding. The presence of these small barriers separating
meta-stable conformations, illustrated why the relatively weakly bound lig-
and – and not the native inter-domain interaction – was able to withstand
CHAPTER 4. RESULTS AND DISCUSSION 107
the applied pulling force, and was found in good agreement with a previously
proposed sequential “unzipping” model for FimH.180 Still it should be noted,
that due to an arbitrary definition of the bin size, the corresponding en-
ergy values hold little significance, making the local PMF only a qualitative
illustration of the underlying free energy landscape.
Figure 4.19: Stereo representation of the extended SMD FimH conformation
(red) and the FimC-stabilized 1KLF crystal structure (gray). Purple spheres rep-
resent the atoms that were being pulled away from each other (starting distance: 81
A˚). Noticeable are the differences in the LD conformations and the PD positions.
Taken together, the employed SMD protocols succeeded in simulating key
stages of the bacterial cell adhesion process and confirmed the validity of the
obtained MM docking pose. Still, while likely having yielded overestimated
values due to high pulling velocities, they also confirmed the presence of
a substantial energetical barrier related to shifting the FimH conformation
between its two crystal structure states, undermining the possibility of this
transition taking place under static conditions. Finally, it could be argued,
that given no trace of LD conformational changes, the closure of this domain
was the final stage of the catch-bonding mechanism that could only occur
with the subunit separation concluded and stabilized by shear forces.
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Figure 4.20: (left) Global potential of mean force, corresponding to pulling the
ligand anomeric oxygen and the furtherest donor strand atom away from each
other. (right) Local potential of mean force, illustrating the free energy changes
within arbitrarily defined 1 A˚ bins. Distances given in A˚ and energies in kcal/mol.
4.3.4 Accelerated molecular dynamics
While the binding to the native FimH conformation – albeit requiring re-
arrangement within the binding pocket region – was confirmed, arguments
against both discussed mechanisms of transition between known states could
be raised. Particularly, the induced-fit scenario was undermined by the very
large extent of the structural change – involving virtually every FimH residue
– and the instability of the extended conformation. A selection mechanism
on the other hand was put in doubt based on the significant energetic barriers
discovered between the conformers. These findings indicated that the FimH
structure presented by the majority of available crystal structures – with the
LD separated from the PD, rearranged, and tightly locked around the man-
nosidic ligands – could not be assumed under no-flow conditions. From a
computational viewpoint, definitive evidence toward/against these assump-
tions could be obtained from sufficiently long MD simulations of apo and holo
systems. In practice however, approaching the relevant timescales (likely in
the µs or ms ranges) would require months of extensive computation (100 ns
MD simulations were nonetheless run for both FimH conformers, but yielded
minimal change within the domains). In order to circumvent this limitation,
the accelerated molecular dynamics (AMD) protocol was employed. Through
this technique, we could raise the local energy minima in which the systems
spend most of their time, reducing the required sampling times by a factor
of 500 to 2000,181 and enabling observation of rare events.
Due to the large and non-selective boost (strongly enhancing the motion
of the natively flexible, surface-exposed moieties), initial holo simulation at-
tempts resulted in loss of ligand binding. With the previously confirmed
stability of the MM poses, this could however be safely remedied by weakly
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constraining the ligand to the vicinity of the binding pockets. Following this,
four 50 ns AMD simulations (theoretically corresponding to 25–100 µs of
conventional MD) were run for the 1KLF- and 3JWN-based holo and apo
systems discussed in previous sections. To enable analysis (beyond the level
of visual inspection) focused on relevant protein backbone motion, the fol-
lowing metrics were employed:
− RMSD from the position of all 279 Cα 3JWN atoms, reflecting the
changes in the respective domain position (difference between initial
compressed and elongated conformers: 15.0 A˚).
− RMSD from the position of 116 Cα 1KLF atoms outside of the domain
interface, illustrating closeness to the tighter LD arrangement (differ-
ence between initial compressed and elongated conformers: 3.6 A˚).
− RMSD from the position of Phe1, Ile13, Asp47, Ile52, Asp54, Gln133,
Asn135, and Asp140 1KLF heavy atoms, reflecting resemblance to the
rigid interior of the high-affinity pocket (difference between initial com-
pressed and elongated conformers: 3.5 A˚).
As a result, both extended FimH conformations could be seen collapsing
toward a compressed 3JWN-like state, with the bound ligand proving of no
observable consequence. Its presence however, could be seen to somewhat
support the LD conformation, which – while still affected – would stabilize
around 2 A˚ from the initial 1KLF arrangement. The same could be stated
for the holo 1KLF binding pocket that, aside from displacement of residues
Ile13 and Asp140, retained close resemblance to the starting arrangement.
Interestingly, the pockets and LDs alike could also be seen populating sim-
ilar conformations when both 3JWN-based simulations were run, with the
RMSDs often close to 2 A˚ from the 1KLF template. Lastly, and perhaps most
surprisingly, the collapsed 3JWN domain conformation has only proven sta-
ble in absence of the small molecular binder, suggesting an allosteric effect of
the protein-ligand interface formation. Specifically, while the domains never
separated in presence of MM, they could be seen moving in a scissor-like
fashion, constantly decreasing or increasing the angle between them [Figure
4.21]. Given the possibility of under-sampling a larger conformational event,
the two holo simulations were prolonged to 100 ns (theoretically worth up to
200 µs of conventional MD). However nothing significant could be observed,
beyond the trends of collapsing the 1KLF- and retaining – albeit through an
ensemble of conformations – the 3JWN-domain conformations. The above-
mentioned trends are illustrated in Figures 4.22 and 4.23.
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Figure 4.21: Representative structures of dominant trajectory clusters obtained
from the holo 3JWN AMD simulation, superimposed on the LD Cα atoms. While a
1KLF-like domain separation was never obtained, conformations varying between
a bent (blue) and nearly-linear (brown) were commonly sampled.
In summary, the AMD simulations have proven the preference of the
3JWN-like FimH conformation under static conditions, independently from
the MD starting point and ligand presence. Still it bears mentioning, that
the binding-site region of the native structure, was found capable of accessing
a large variety of conformations. Given that this could be observed for both
apo an holo simulations and that some of these conformations resembled the
1KLF arrangement, it could be hypothesized that the binding of manno-
sidic ligands to the F18 FimH protein was governed by a local – i.e. not
involving the rest of the protein – conformational selection mechanism. Nev-
ertheless, while strong resemblances between the sites of both states could
be found – explaining the good in vivo potencies of ligands designed using
LD-constructs –, certain residues were unable to participate in ligand bind-
ing prior to domain separation, diminishing interactions of the 2- and 3-OH
mannose groups (as indicated in Figure 4.17 and reflected by the RMSD
data). Specifically the previously-mentioned Ile13 residue, positioned at the
tip of the “clamp loop” was never observed to near the ligand while the two
FimH domains remained connected. Similarly Asp140 (expected to form a
charge-assisted hydrogen bond with the 3-OH group of the mannose), would
commonly maintain a distance of several a˚ngstro¨m away from the ligand
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bound to the native protein. It is assumed that the lack of these pocket ele-
ments or the cost of re-orienting them (along with their closely-neighboring
residues) is primarily responsible for the differing mannosidic ligand affinities
between specific protein variants and binding conditions. Finally, the previ-
ously mentioned affinity of the selective antibodies toward FimH in presence
of mannose could be explained by the increased inter-domain motion likely
to occasionally expose the relevant attachment region.
Figure 4.22: RMSDs (in A˚; vertical axis) from the native compressed protein
(blue), the high-affinity LD (red), and the high-affinity binding site (green). Re-
sults obtained from 50 ns apo and holo AMD simulations (horizontal axes represent
the time) started from the extended FimH conformation. In both cases large do-
main movement could be observed, with the protein conformation slowly collapsing
into the compressed arrangement. For the holo simulation, the bound ligand man-
aged to stabilize the LD and pocket, allowing them to retain conformations close
to the initial ones.
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Figure 4.23: RMSDs (in A˚; vertical axis) from the native compressed protein
(blue), the high-affinity LD (red), and the high-affinity binding site (green). Re-
sults obtained from 50 ns apo and holo AMD simulations (horizontal axes represent
the time) started from the compressed FimH conformation. While the apo protein
was found relatively stable through the simulation, the inter-domain interface of
the holo system was much more flexible.
4.3.5 Effects of natural mutations
Given the reported evolutionary predominance of the modeled F18 FimH
variant, its compressed conformation was expected to be a valid basis for gen-
eral structure-based inhibitor design. This could further be ensured through
a very recent emergence of a nearly-identical K12 crystal structure,182 (279
Cα atom RMSD of 1.2 A˚ between respective 3JWN and 4J3O structures).
Still, the impact of the FimH sequence variations called for further probing
of the relation between the naturally-occurring mutations and the affinity of
mannosidic ligands. According to reported data,88 the K12 FimH variant
mediated approximately two times stronger binding of mannosidic ligands
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than the F18 counterpart, while only differing by three, non-binding site
residues (mutations A27V, N70S, and S78N). In light of previous observa-
tions, affinity variations such as these could relate to local movement around
the compressed protein state rather than extensive structural changes. In
order to confirm this and following residue modification and MD equilibra-
tion (using the 3JWN construct as basis given that the 4J3O structure was
not yet available at the time), 50 ns AMD simulations were also run on apo
and holo FimH systems representing the K12 variant. As a result, different
microstate preferences could indeed be observed, still strongly modulated by
the mannosidic ligand presence [Figure 4.24]. Nevertheless, while the K12
holo system also revealed increased inter-domain motion, its extent as well as
the general resemblance to the 1KLF high-affinity pocket/LD conformation
actually decreased. Even so, applying the MM/GBSA protocol on ensembles
of holo AMD frames, yielded an approximately 1 kcal/mol lower energy with
respect to F18, related primarily to desolvation costs. While difficult to con-
firm given the amount of “noise” introduced by the simulation boosts, this
hinted that binding to this FimH variant either favored a different pocket
conformation or required lesser desolvation and rearrangement costs to form
the binding interface. With the AMD protocol indicating sensitivity to al-
losteric ligand and mutation effects, a systematic study introducing further
FimH variants and multiple simulations per system would likely reveal more
of the underlying structural characteristics.
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Figure 4.24: RMSDs (in A˚; vertical axis) from the native compressed protein
(blue), the high-affinity LD (red), and the high-affinity binding site (green). Re-
sults obtained from 50 ns apo and holo AMD simulations (horizontal axes repre-
sent the time) started from the compressed conformation of the K12 FimH variant.
While the ligand presence could be seen to increase the inter-domain movement,
its effect was less pronounced than for F18 FimH.
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5. Conclusions and summary
While the nearly three decades of intensive research devoted to inhibiting the
bacterial FimH adhesin yielded an array of compounds with excellent proper-
ties, certain structural aspects of the target itself remained elusive, impairing
further progress. These involved primarily the relationships between the pro-
tein and various parts of its ligands as well as factors inducing the catch/slip-
bonding behavior. Regarding the former, work described here and based on
a variety of state-of-the-art in silico technologies, yielded a detailed descrip-
tion of the forces stabilizing the interface between FimH and its mannosidic
ligands. While the bulk of these findings reflected the already published data,
the presented optimization strategies and level of quantitative detail were – to
the authors best knowledge – unprecedented. Furthermore between the mod-
eling and previously published crystallographic studies, certain discrepancies
were found, likely owing the different conditions imposed by both approaches.
Of special significance, was the discovery of distinctively different character-
istics of two amino acid groups partaking in the ligand binding. On one hand,
the polar residues Phe1, Asp47, Asp54, Gln133, Asn135, and Asp140 within
the mannose-binding pocket were confirmed responsible – through the forma-
tion of a tight hydrogen-bond network – for the bulk of ligand potency and
specificity. Among these, Phe1 and Asp54 were of utmost importance, given
the charge-assisted nature and excellent stability of their interactions. With
the pocket perfectly pre-arranged to receive its ligands (in the case of the de-
tached LD or FimC-stabilized complexes), this part of the interface offered
an example of “traditional” binding, dominated by enthalpic components.
On the other hand, a group of amino acids forming the hydrophobic rim at
the periphery of the pocket (especially the residues Tyr48 and Tyr137 of the
FimH tyrosine gate), defied the classical paradigms of structure-based design.
Although exploring the underlying characteristics has proven challenging (as
illustrated by the mutation study discussed in Section 4.1.3), evidence could
be collected toward a highly-flexible and non-specifically interacting nature
of this region, voiding the distinction of rigid and mutually-exclusive docking
modes. Between these two “faces” of the binding site, the optimization of
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interactions with the interior pocket presents – in the opinion of the author
– a greater appeal. This conclusion could be reached based on the limited
reach of the tyrosine gate and the persisting entropic phenomena preventing
directional interaction with the aglycones. The mannose pocket on the other
hand, was shown to tolerate modifications of the carbohydrate at the C-2
position that extended towards previously untapped regions of the protein.
If hypothetical interactions with additional residues were the sole argu-
ment for the synthetically-challenging modification of the mannose moiety,
this direction would not be worth perusing. However, a further argument was
presented through the advanced MD protocols employed towards studying
the full, two-domain FimH. These unprecedented studies, revealed a differ-
ence between the structure and properties of the protein attached to the
highly-mannosylated urothelial surface and its “inhibitor-binding” form, not
subjected to shear stress. Specifically, energy scoring and SMD/AMD simula-
tions highlighted a substantial energetical barrier separating the known crys-
tal conformations of FimH (previously referred to as high- and low-affinity
states), unlikely to be crossed without the influence of an external force. Due
to such, an alternative arrangement of the ligand-binding site was proposed
for the native protein conformation, in which some of the previously-assumed
interactions of the 2- and 3-OH carbohydrate groups were not present or re-
quired additional residue re-orientation costs to be formed. Compounds sat-
isfying both pocket arrangements (possibly already at our disposal thanks
to the efforts discussed in Section 4.1.4), present a more versatile means of
targeting the vast array of naturally-occurring FimH variants. In addition,
given that favorable site arrangements were also observed during apo MD
simulations with the native protein (as indicated by RMSD measurements
reported in Section 4.3.4), a local conformational selection mechanism (i.e.
not involving rearrangement of the rest of the protein) is proposed for FimH-
mannoside binding under static conditions.
Finally, the broad range of in silico techniques presented in this work has
proven beneficial toward the design, screening, optimization, and rationaliza-
tion of FimH-mannoside binding. Nevertheless, it could also be shown that
several commonly-employed technologies failed to accurately reproduce the
in vitro affinities of the tested compound sets. The reason for that, was the
importance of solvation and entropic phenomena – aspects still difficult to
address with the standard methods – for the surface-exposed protein-ligand
interface. Thus, with the indispensable support of experimental data, more
suitable technologies could be used toward establishing the VirtualDesignLab
platform (Section 4.2), that demonstrated significantly improved predictive
capabilities. In addition, the employment of MD protocols has proven in-
valuable for further studying the FimH-ligand interfaces. With the bacterial
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adhesin having proven in equal part fascinating and challenging, these and
other powerful and inexpensive tools, stand ready to assist the work of medic-
inal chemists.
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7. Appendix
7.1 Additional results (Section 4.1.3)
Table 7.1: Structures, docking scores (Induced Fit Docking), free energy estimates
(MM-GBSA; software Prime), and ligand efficiencies of screened compounds with
various aglycone modifications. All values in kcal/mol and rounded to the first
decimal digit.
Structure Docking
score
Binding
energy
Ligand
efficiency
1 −7.3 −92.2 −3.3
2 −6.6 −91.4 −3.3
3 −6.5 −94.3 −3.4
4 −6.8 −101.1 −3.4
5 −6.7 −93.6 −3.2
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Structure Docking
score
Binding
energy
Ligand
efficiency
6 −7.1 −95.6 −3.3
7 −6.9 −92.9 −3.3
8 −7.0 −97.3 −3.1
9 −7.3 −97.0 −3.5
10 −7.0 −97.3 −3.5
11 −7.1 −100.2 −3.5
12 −7.0 −99.7 −3.4
13 −6.9 −99.2 −3.3
14 −7.1 −98.7 −3.5
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Structure Docking
score
Binding
energy
Ligand
efficiency
15 −6.8 −95.7 −3.3
16 −6.9 −99.8 −3.3
17 −7.0 −91.3 −3.1
18 −6.8 −96.4 −3.3
19 −6.7 −93.5 −3.2
20 −7.5 −102.6 −3.5
21 −6.5 −93.9 −3.1
22 −6.7 −98.1 −3.4
23 −6.5 −106.9 −3.2
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Structure Docking
score
Binding
energy
Ligand
efficiency
24 −6.8 −104.7 −3.1
25 −6.4 −102.4 −3.1
26 −6.4 −103.7 −2.9
27 −6.3 −96.9 −3.0
28 −6.6 −82.0 −3.4
29 −5.6 −59.1 −2.2
30 −6.4 −87.7 −3.2
31 −6.4 −87.2 −3.2
32 −6.5 −88.2 −3.3
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Structure Docking
score
Binding
energy
Ligand
efficiency
33 −6.7 −88.9 −3.3
34 −6.3 −73.8 −2.7
35 −6.9 −92.6 −3.4
36 −6.4 −82.9 −3.1
37 −6.9 −89.3 −3.7
38 −6.6 −101.3 −3.2
39 −6.5 −101.1 −3.2
40 −6.3 −102.3 −3.2
41 −6.5 −95.1 −3.0
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Structure Docking
score
Binding
energy
Ligand
efficiency
42 −6.5 −94.7 −3.0
43 −7.2 −96.0 −3.0
44 −6.9 −104.4 −3.5
45 −7.1 −105.7 −3.3
46 −6.2 −102.4 −3.1
47 −7.8 −103.1 −3.3
48 −6.4 −93.2 −3.3
49 −7.5 −99.1 −3.2
50 −7.2 −101.9 −3.6
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Structure Docking
score
Binding
energy
Ligand
efficiency
51 −7.1 −97.5 −3.2
52 −7.2 −95.0 −3.5
53 −6.9 −103.2 −3.3
54 −7.1 −100.6 −3.6
55 −6.4 −98.9 −2.7
56 −6.6 −102.7 −3.0
57 −5.9 −112.2 −3.2
58 −6.1 −98.0 −3.0
59 −7.1 −98.3 −3.3
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Structure Docking
score
Binding
energy
Ligand
efficiency
60 −7.4 −114.8 −3.7
61 −6.7 −99.0 −3.3
62 −6.9 −100.6 −3.2
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7.2 Additional results (Section 4.1.4)
Table 7.2: Structures, docking scores (Induced Fit Docking), free energy estimates
(MM-GBSA; software Prime), and ligand efficiencies of screened compounds with
various mannose modifications. All values in kcal/mol and rounded to the first
decimal digit.
Structure Docking
score
Binding
energy
Ligand
efficiency
1 −7.0 −59.0 −3.9
2 −6.5 −83.3 −4.0
3 −7.0 −92.9 −3.4
4 −6.5 −94.3 −4.5
5 −6.8 −79.8 −3.5
6 −7.1 −92.9 −4.2
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7.3 Additional results (Section 4.2.2)
Table 7.3: Structures, docking scores (Cheetah), experimental free energies, and
predicted free energies (Quasar of compounds composing the FimH QSAR model.
All values in kcal/mol and rounded to the first decimal digit.
Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
1 −95.1 −10.3 −10.6 0.2
2 −92.0 −8.8 −9.3 0.5
3 −82.0 −7.3 −6.7 0.6
4 −97.1 −10.1 −9.8 0.4
5 −92.9 −9.9 −9.4 0.5
6 −98.9 −10.0 −10.1 0.1
7 −92.9 −10.2 −10.0 0.2
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
8 −98.9 −10.7 −9.9 0.8
9 −92.3 −9.5 −9.9 0.4
10 −91.2 −8.7 −9.0 0.2
11 −96.6 −10.1 −10.9 0.8
12 −91.4 −10.3 −10.7 0.4
13 −100.8 −9.2 −10.0 0.8
14 −96.7 −9.9 −10.4 0.5
15 −91.8 −9.8 −11.0 1.1
16 −103.5 −10.1 −10.4 0.4
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
17 −96.6 −10.8 −10.6 0.2
18 −93.6 −10.3 −11.3 1.1
19 −103.6 −10.4 −10.3 0.1
20 −101.5 −10.3 −9.7 0.6
21 −95.1 −9.6 −10.3 0.7
22 −98.8 −10.8 −10.6 0.2
23 −89.8 −10.4 −11.5 1.1
24 −113.9 −9.0 −8.3 0.6
25 −88.0 −7.8 −7.5 0.3
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
26 −81.0 −9.3 −10.5 1.2
27 −92.9 −6.4 −5.7 0.7
28 −101.5 −9.9 −10.7 0.7
29 −92.2 −9.7 −10.0 0.3
30 −75.8 −5.1 −4.9 0.2
31 −91.5 −9.7 −9.9 0.2
32 −77.1 −6.1 −5.1 1.0
33 −95.9 −9.8 −10.2 0.4
34 −90.3 −9.8 −10.5 0.7
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
35 −75.8 −7.0 −6.7 0.4
36 −90.7 −9.3 −10.9 1.5
37 −74.6 −5.1 −5.2 0.1
38 −77.7 −6.4 −6.0 0.5
39 −73.8 −7.1 −6.0 1.1
40 −80.5 −7.4 −8.7 1.3
41 −76.3 −7.8 −8.8 1.0
42 −74.9 −7.6 −8.0 0.4
43 −104.7 −5.8 −5.4 0.4
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
44 −94.6 −10.0 −10.5 0.4
45 −93.3 −10.6 −9.9 0.7
46 −92.3 −9.4 −8.8 0.5
47 −87.5 −8.9 −9.1 0.3
48 −88.4 −8.3 −8.6 0.3
49 −88.2 −8.0 −7.4 0.6
50 −92.2 −9.3 −9.7 0.4
51 −95.9 −9.5 −8.3 1.2
52 −94.1 −8.9 −8.5 0.4
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
53 −92.9 −9.5 −9.2 0.2
54 −92.0 −9.5 −8.6 1.0
55 −96.9 −9.5 −8.4 1.0
56 −96.0 −9.4 −8.5 0.9
57 −94.6 −9.9 −9.1 0.8
58 −91.6 −9.0 −8.7 0.4
59 −90.8 −9.2 −9.6 0.4
60 −92.6 −9.4 −9.8 0.4
61 −93.7 −10.7 −11.6 0.9
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
62 −102.3 −9.1 −9.0 0.1
63 −94.9 −9.1 −8.2 0.9
64 −94.0 −9.8 −8.9 0.9
65 −94.4 −9.2 −9.1 0.0
66 −93.2 −9.7 −9.3 0.4
67 −96.6 −9.3 −9.0 0.3
68 −108.8 −10.0 −10.4 0.4
69 −88.2 −10.7 −10.3 0.4
70 −87.8 −7.6 −8.8 1.2
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
71 −90.8 −8.0 −8.9 0.9
72 −87.8 −7.9 −8.6 0.7
73 −90.5 −8.0 −8.8 0.8
74 −93.5 −8.6 −9.4 0.8
75 −100.4 −9.1 −9.1 0.1
76 −96.0 −8.9 −9.0 0.1
77 −89.2 −8.5 −8.7 0.2
78 −98.8 −10.4 −10.5 0.1
79 −94.3 −10.6 −9.8 0.8
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
80 −110.4 −9.5 −9.6 0.1
81 −104.9 −9.8 −9.7 0.1
82 −94.2 −10.3 −10.3 0.0
83 −102.0 −10.1 −10.2 0.1
84 −102.6 −9.7 −10.4 0.7
85 −89.3 −9.1 −8.9 0.2
86 −85.3 −8.8 −8.9 0.0
87 −85.6 −9.0 −8.7 0.3
88 −89.0 −9.8 −9.2 0.6
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
89 −92.1 −8.8 −8.9 0.2
90 −89.0 −8.7 −8.5 0.3
91 −94.9 −10.4 −10.7 0.4
92 −97.3 −9.6 −9.4 0.1
93 −95.2 −9.8 −9.4 0.4
94 −99.5 −9.4 −9.8 0.4
95 −99.5 −9.1 −9.8 0.7
96 −101.0 −10.0 −11.0 0.9
97 −89.4 −10.2 −10.3 0.0
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
98 −102.3 −10.0 −10.1 0.1
99 −94.9 −10.5 −11.2 0.7
100 −92.0 −9.9 −10.3 0.4
101 −93.4 −9.8 −9.9 0.2
102 −77.8 −9.8 −10.1 0.3
103 −97.0 −9.9 −10.5 0.5
104 −90.2 −10.6 −11.1 0.5
105 −101.0 −9.9 −10.7 0.8
106 −97.4 −10.5 −10.8 0.3
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Structure Docking
score
Exp. free
energy
Predicted
free energy
Residual
107 −94.5 −10.5 −9.8 0.7
108 −92.6 −10.1 −9.5 0.7
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7.4 Method performance and scaling
Figure 7.1: Comparison between predicted and experimental results for the 108
compounds used for developing the FimH mQSAR model. The derived scaling
coefficients were 1/10, 1/7, and 1/10 for Prime, Amber, and Cheetah respectively.
All values in kcal/mol.
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a b s t r a c t
Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) is one of the most prevalent
infectious diseases. Particularly affected are women, who have a 40–50% risk to experience at least one
symptomatic UTI episode at some time during their life. In the initial step of the infection, the lectin
FimH, located at the tip of bacterial pili, interacts with the high-mannosylated uroplakin Ia glycoprotein
on the urinary bladder mucosa. This interaction is critical for the ability of UPEC to colonize and invade
the bladder epithelium. X-ray structures of FimH co-crystallized with two different ligands, the physio-
logical binding epitope oligomannose-3 and the antagonist biphenyl a-D-mannoside 4a revealed different
binding modes, an in-docking-mode and an out-docking-mode, respectively. To accomplish the in-docking-
mode, that is the docking mode where the ligand is hosted by the so-called tyrosine gate, FimH antago-
nists with increased flexibility were designed and synthesized. All derivatives 5–8 showed nanomolar
affinities, but only one representative, the 4-pyridiyl derivative 5j, was as potent as the reference com-
pound n-heptyl a-D-mannoside (1b). Furthermore, a loss of affinity was observed for C-glycosides and
derivatives where the triazole aglycone is directly N-linked to the anomeric center. A conformational
analysis by NMR revealed that the triazolyl-methyl-C-mannosides 8 adopt an unusual 1C4 chair confor-
mation, explaining the comparably lower affinity of these compounds. Furthermore, to address the drug-
likeness of this new class of FimH antagonists, selected pharmacokinetic parameters, which are critical
for oral bioavailability (lipophilicity, solubility, and membrane permeation), were determined.
! 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Urinary tract infections (UTIs) are among the most common
infections, affecting millions of people each year. Although UTIs
rarely cause severe diseases such as pyelonephritis or urosepsis,
they are associated with extensive morbidity and generate consid-
erable medical expenses.1 Uropathogenic Escherichia coli (UPEC)
are the primary cause of UTIs accounting for 70–95% of the re-
ported cases. Particularly affected are women, who have a 40–
50% risk to suffer from a symptomatic UTI episode at some time
during their life.2,3 Symptomatic UTIs require antimicrobial treat-
ment, resulting in selection and development of bacterial resis-
tance. Consequently, treatment of consecutive infections becomes
increasingly difficult. Especially patients with diabetes, urinary
tract anomaly, paraplegia and those with permanent urinary cath-
eter experience repeated UTIs with resistant strains. Therefore, a
new approach for the treatment and prevention of UTI with non-
antibiotic and orally applicable therapeutics with a low potential
for resistance would have a great impact on patient care, public
healthcare, and medical expenses.
UPEC express a number of well-studied virulence factors for
successful colonization of and survival within the host.1,4,5 One
important virulence factor, the mannose-specific FimH adhesin, is
located at the tip of bacterial type 1 pili.6 Type 1 pili are the most
prevalent fimbriae encoded by UPEC, consisting of the four sub-
units FimA, FimF, FimG and FimH. The FimH lectin enables UPEC
to attach to high-mannosylated uroplakin Ia glycoproteins on the
urinary bladder mucosa, thus enabling adherence and invasion of
host cells and at the same time preventing the rapid clearance of
0968-0896/$ - see front matter ! 2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2011.08.057
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E. coli from the UTI by the bulk flow of urine.1,7 As a part of the
FimH subunit, a carbohydrate-recognition domain (CRD) is
responsible for bacterial interactions with the host cells within
the urinary tract.7 The crystal structure of methyl a-D-mannopy-
ranoside bound to the FimH-CRD was solved8 and the structures
of the corresponding complexes with n-butyl a-D-mannopyrano-
side,9 Mana(1-3)-[Mana(1-6)]-Manb(1-4)-GlcNAcb-(1-4)GlcNAc
(oligomannose-3)10 and biphenyl a-D-mannopyranoside11 recently
became available.
Previous studies showed that colonization and subsequent
E. coli infection of the human urothelium can be prevented by vac-
cination with FimH adhesin.12,13 Furthermore, adherence and inva-
sion of host cells by E. coli can also be inhibited by oligomannosides
representing the glycosylation of uroplakin 1a.14 For some a-D-
mannosides it was shown that they prevent type 1 pili mediated
adhesion, that is, they do not act by killing or arresting the growth
of the pathogen as antibiotics do. Therefore, the spread of strains
resistant to such agents are expected to be significantly delayed
as compared to that of strains resistant to antibiotics.15 In addition,
environmental contamination is less problematic compared to
antibiotics.15a
More than two decades ago, various oligomannosides and aro-
matic a-D-mannosides that antagonize type 1 fimbriae-mediated
bacterial adhesion were identified.15,16 However, for these manno-
sides only weak interactions in the milli- to micromolar range were
observed. To improve their affinity, the multivalent presentation of
the a-mannoside epitope,17 and the rational design of ligands
guided by structural information were explored.9–11 Recently, var-
ious reports on high affinity monovalent FimH antagonists were
published.11,18,19
The CRD of the FimH protein consists of amino acids with
hydrophilic side chains and can therefore establish a perfect
network of hydrogen bonds with the hydroxyl groups at the 2-,
3-, 4- and 6-positions of D-mannose. The entrance to this man-
nose-binding pocket, the so-called ‘tyrosine gate’, is shaped by
two tyrosines (Tyr48 and Tyr137), and one isoleucine (Ile52) which
support hydrophobic contacts.20 Generally, long chain alkyl and
aryl mannosides (for selected examples see Fig. 1) displayed the
highest affinities.8,9,11,16–21
Recently, we reported the synthesis, the critical pharmacoki-
netic properties and affinity data of low molecular weight a-D-
mannosides with the ability to block the FimH-mediated bacterial
adhesion in a mouse infection model.19 The orally available, nano-
molar FimH antagonist 4b (Fig. 1) exhibited the potential to reduce
the colony forming units (CFU) in the urine and in the bladder by
two and four orders of magnitude, respectively, demonstrating
the therapeutic potential of this new class of anti-infectives for
the effective treatment of urinary tract infections.
However, a potential drawback of FimH antagonists with agly-
cons consisting of biphenyls directly linked to the carbohydrate
moiety is their limited conformational flexibility, which could
hamper an optimal fit with the tyrosine gate.11 To increase the con-
formational flexibility, the spacers between the mannose moiety
and the first aromatic ring of the biphenyl moiety in i (Fig. 2) as
well as between the aromatic rings was extended. Furthermore,
the rotational barrier of the biphenyl25 was reduced by replacing
one of the rings by a triazole (for the torsion profile see Fig. 2).
Overall, these modifications should lead to a reduction of the con-
formational restraints and therefore an optimized spatial arrange-
ment of the aglycone in the tyrosine gate.
Oligomannose-3 is present on the high-mannosylated uroplakin
Ia located on urothelial cells and is supposed to interact with UPEC.
The crystal structure of the FimH-CRD10 complexed with oligo-
mannose-3 (PDB code 2VCO, Fig. 3A) clearly shows the important
role of the tyrosine gate hosting this physiological ligand in the
so-called in-docking-mode. Interestingly, for 4a complexed with
FimH-CRD a different binding mode outside of the tyrosine gate
was reported (out-docking-mode, see Fig. 3B).11 In analogy to oligo-
mannose-3, docking of triazole derivative 5b to the crystal struc-
ture of the FimH lectin domain (PDB code 3MCY)11 led - as a
result of the increased flexibility of the aglycone - to the in-dock-
ing-mode. Thus, in contrast to the biphenyl aglycone present in
4a, the phenyl-triazole 5b is expected to be hosted by the tyrosine
gate. The three-dimensional structure 5b was generated using
Glide 5.526 and the kinetic stability of the protein–ligand complex
was then assessed with a 2 ns molecular-dynamics simulation
using Desmond.27
A comparison of the docking modes of oligomannose-3, 4a and
5b reveals that the interaction of the mannose moiety is highly
conserved for all three compounds. However, in contrast to oligo-
mannose-3 and 5b, the biphenyl moiety in 4a is not able to reach
the tyrosine gate due to its rigid structure. Instead, a p-p-stacking
interaction of the second aromatic ring of the biphenyl aglycone
with Tyr48 outside of the tyrosine gate11 (out-docking-mode,
Fig. 3B) is achieved by induced fit, that is, a substantial move of
Tyr48. In addition, a further stabilization of the protein–ligand
complex by a hydrogen bond between the ester in the meta-posi-
tion of 4a and the side-chain of Arg98 was assumed.11
Based on these evidences, a library of derivatives according to
the criteria summarized in Figure 2 was designed. Here, we de-
scribe synthesis, biological evaluation, and determination of phar-
macokinetic parameters of triazole derivatives.
2. Results and discussion
2.1. Synthesis of triazolyl-methyl and -ethyl a-D-
mannopyranosides
In a first approach, the phenyl ring adjacent to the anomeric
center (see Fig. 2) was replaced by a triazolyl-methyl moiety to in-
crease the conformational flexibility. To avoid solubility problems
as well as to take advantage of additional polar interactions, for
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Figure 1. Known alkyl (1) and aryl (2–4) a-D-mannosides exhibiting micro- to nanomolar affinities.
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example, H-bonds with the hydroxyl-groups of Thr51 or Tyr137
(Fig. 3C), the second aromatic ring was substituted with a carbox-
ylate in para- or meta-position (?5a–c, Scheme 1).
For the synthesis of mannosyl triazoles 5a–c, alkyne 1029 read-
ily available from peracetylated D-mannose (9) was reacted with
the known aryl azides 11a,30 11b,31 and 11c32 in a copper(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition33,34 using tert-buta-
nol/water/THF (1:1:1) as solvent.35 The saponification of the
anti-substituted triazoles 12a–c yielded the test compounds 5a–c
(Table 1).
Figure 3. (A) & (B) Crystal structures of oligomannose-3 (A, PDB code 2VCO)10 and biphenyl 4a (B, PDB code 3MCY)11 bound to the FimH-CRD. C) Automated docking of
triazole 5b into the lectin domain of FimH (PDB code 3MCY).11 The images have been generated using VMD.28 The ligands are depicted colored by atom (C: dark grey, H:
white, O: red, N: blue); the tyrosine gate (residues Tyr48, Tyr137 and Ile52) is shown in yellow, residue Thr51 in green and residue Arg98 in red. While 4a binds in the out-
docking-mode, compound 5b, like oligomannose-3, is inserted into the tyrosine gate (in-docking-mode).
Figure 2. Design of FimH antagonists with aglycons of increased flexibility. Spacer elongations and replacement of one phenyl ring by a triazole should reduce the
conformational restraints and lead to an improved fit in the tyrosine gate. The torsion profiles for biphenyl and 1-phenyl-1,2,3-triazole were calculated at the B3LYP level of
theory22,23 with 6-31G(d,p) basis set in the gas phase using Gaussian 03.24
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In a second approach, the terminal aromatic ring was replaced
by various substituents like (hetero)aryl, benzyl, and adamantyl
groups (?5d–i & 5j–m). Furthermore, in compounds 6h–k the
spacer between the carbohydrate moiety and the triazole ring
was elongated from methyl to ethyl allowing for a higher confor-
mational flexibility (Scheme 2).
The mannosyl triazoles 5d–m and 6h–k were obtained by
reacting the known mannosyl alkynes 10,29 1336 and 1437 with
the azides 15d–m. Whereas the azides 15d–f are commercially
available, 15g,38 15h,39 15i,40 15j–l,41 and 15m40 were obtained
by known procedures.
The cycloaddition of alkyne 14 and azides 15d–i under Cu(I)-
catalyzed click conditions33,34 yielded directly the anti-substituted
triazoles 5d–i in 27–77% (Table 1). However, due to the cumber-
some purification of the unprotected mannosyl triazoles, test com-
pounds 5j–m were obtained by an alternative sequence starting
from the protected alkyne 10 and azides 15j–m followed by sapon-
ification of the intermediates 16j–m. The analogous cycloaddition
of butinyl mannoside 13 with azides 15h–k yielded the protected
triazoles 17h–k in 83–96%. Final deacetylation under Zemplén
conditions gave the test compounds 6h–k, which contain a linker
extended by an additional carbon between mannose and aglycone
(Table 1).
2.2. Synthesis of FimH antagonists modified at the anomeric
center
To avoid the low metabolic stability of O-mannosides like com-
pounds 5 and 6 due to potential cleavage by mannosidases, the
corresponding N-linked mannosyl triazoles 7 and C-mannosides 8
were prepared (Scheme 3). Mannosyl azide 18 was obtained
according to published procedures.42 The Cu(I)-catalyzed click
reaction of 18 with the commercially available acetylenes 19n–s
gave exclusively the anomerically pure anti-substituted a-D-man-
nosyl-triazoles 20n–s in 84–98% yield and after deacetylation the
test compounds 7n–s (Table 1).
Finally, the synthesis of triazolyl-methyl-C-mannosides 8n–s
(Scheme 3) started frommannosyl cyanide 21, which was obtained
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Scheme 1. Reagents and conditions: (a) CuSO4!5H2O, Na-ascorbate, t-BuOH/H2O/THF (1:1:1), rt, 24 h, 73–97%; (b) (i) NaOMe, MeOH, rt, 3 h; (ii) 1 M NaOH, H2O/dioxane (1:1),
16 h, 78–91%.
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Scheme 2. Reagents and conditions: (a) CuSO4!5H2O, Na-ascorbate, t-BuOH/H2O (1:1), rt, 24 h, (5d–i: 27–77%); (b) CuSO4!5H2O, Na-ascorbate, t-BuOH/H2O/THF (1:1:1), rt,
24 h (16j–m: 85–94%, 17h–k: 83–96%); (c) NaOMe, MeOH, rt, 2–6 h, (5j–m: 75–85%, 6h–k: 73–90%).
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Table 1
Pharmacodynamic and pharmacokinetic parameters of mannosylated triazoles 5–8
(continued on next page)
6458 O. Schwardt et al. / Bioorg. Med. Chem. 19 (2011) 6454–6473
The IC50sweredeterminedwitha cell-free competitivebinding assay.45Relative IC50s (rIC50)werecalculatedbydividing the IC50 of the substance of interest
by the IC50 of the reference compound 1b (entry 2). Passive permeation through an artificial membrane and retention therein was determined by PAMPA
(parallel artificial membrane permeation assay).50 Distribution coefficients (logD7.4 values) were measured by a miniaturized shake flask procedure.51
Thermodynamic solubility was measured by an equilibrium shake flask approach.52 Pe effective permeation; n.p. not permeable; n.d. not determined.
Table 1. (continued)
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from 9 as reported earlier.43 Catalytic hydrogenation in the pres-
ence of Boc2O (?22) followed by deacetylation led to the Boc-pro-
tected amine 23. Cleavage of the Boc-group, amine-azide
exchange44 and subsequent re-acetylation yielded azide 24 in
81% over three steps. The cycloaddition of 24 and the acetylenes
19n–s gave the anti-substituted triazoles 25n–s in excellent yields.
Final deprotection afforded the test compounds 8n–s (Table 1).
2.3. Biological evaluation
For an initial biological in vitro characterization, a cell-free com-
petitive binding assay45 and later on, a cell-based aggregation as-
say46 were applied. Whereas for the cell-free competitive binding
assay only the CRD of the pili was expressed, the complete pili
are present in the cell-based assay format. Furthermore, both for-
mats are competitive assays, that is, the analyzed antagonists com-
pete with mannosides for the binding site. In the cell-free
competitive binding assay, the competitors are polymer-bound
trimannosides, whereas in the aggregation assay the antagonist
competes with more potent oligo- and polysaccharide chains14
present on the surface of erythrocytes.47 The interaction is further
complicated by the existence of a high- and a low-affinity state of
the CRD of FimH. Aprikian et al. experimentally demonstrated that
in full-length fimbriae the pilin domain stabilizes the CRD domain
in the low-affinity state, whereas the CRD domain alone adopts the
high-affinity state.48 Furthermore, it was recently shown that shear
stress can induce a conformational switch (twist in the b-sandwich
fold of the CRD domain) resulting in improved affinity.49 Therefore,
different affinities are expected when - as in the cell-based aggre-
gometry assay - full-length fimbriae are present, when compared
to the CRD domain alone.
2.4. Cell-free competitive binding assay
The cell-free inhibition assay is based on the interaction of a
biotinylated polyacrylamide glycopolymer with the carbohydrate
recognition domain (CRD) of FimH as previously reported.45 A sol-
uble recombinant protein consisting of the FimH-CRD (amino acid
residues 1–156), a C-terminal thrombin cleavage site and a 6His-
tag (FimH-CRD-Th-6His) was expressed in E. coli strain HM125
and purified by affinity chromatography on a Ni-NTA column. For
the determination of IC50 values, a microtiter plate coated with
FimH-CRD-Th-6His was incubated with biotinylated Mana(1-3)-
[Mana(1-6)]-Manb(1-4)-GlcNAcb(1-4)-GlcNAcb-polyacrylamide
(TM-PAA) polymer conjugated to streptavidin-horseradish peroxi-
dase and the FimH antagonist in fourfold serial dilution (Fig. 4).
The assay was performed in duplicates and repeated twice for each
compound. To ensure comparability of different antagonists, the
reference compound n-heptyl a-D-mannopyranoside (1b)9,46 was
tested in parallel on each individual microtiter plate. The affinities
are reported relative to 1b as rIC50 in Table 1. The relative IC50
(rIC50) is the ratio of the IC50 of the test compound to the IC50 of
1b (entry 2).
Interestingly, all antagonists in Table 1 except methyl a-D-man-
noside (1a) exhibit nanomolar affinities. When compared to 1a, an
up to 30-fold improvement was obtained. In the first series, con-
taining a triazolyl-methyl moiety (5a–m, entries 3–15), 5j (entry
12) exhibits the highest affinity with an IC50 of 70 nM. This is in
the range of n-heptyl a-D-mannoside (1b), however, compared to
the biphenyl derivative 4b19 (Fig. 1), this in fact represents a
18-fold reduction of affinity (rIC50 0.0619 for 4b vs. rIC50 1.1 for
5j). At this point, we should recollect that 4b and 5j address differ-
ent docking modes (out- and in-docking-mode) and therefore also
different structural environments.
Antagonists where the linker between the anomeric center and
the triazole is extended by an additional carbon (?6h–k, entries
16–19) show affinities in the range of 200 nM and therefore - with
the exception of 4-pyridyl derivative 6j (entry 18) - two- to four-
fold higher affinity compared to their counterparts with the shorter
linker. When the triazole is directly linked to the anomeric center
(?7n–s, entries 20–25) affinities are 2- to 8-fold reduced, probably
as a consequence of the reduced flexibility preventing an optimal
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Scheme 3. Reagents and conditions: (a) CuSO4!5H2O, Na-ascorbate, t-BuOH/H2O/THF (1:1:1), rt, 1–2 d (20n–s: 84–98%, 25n–s: 93–98%); (b) NaOMe, MeOH, rt, 3–6 h, (7n–s:
65–92%, 8n–s: 83–87%, 23: 95%); (c) H2 (4 bar), cat. Pd/C, Boc2O, EtOAc, 1 d (72%); d) (i) concd HCl, dioxane/H2O (2:1), 4 h; (ii) TfN3, NaHCO3, cat. CuSO4!5H2O, PhMe/H2O/
MeOH, rt, 20 h; (iii) Ac2O, pyridine, rt, 4 h (81%).
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interaction of the aglycone with the tyrosine gate. Finally, the
C-mannosides 8n–s (entries 26–31), which do not exhibit the exo-
anomeric effect of the O-mannosides and therefore can more easily
adopt the optimal orientation within the tyrosine gate, surprisingly
show a twofold reduction in affinity.
2.5. Aggregometry assay
The potential to disaggregate E. coli from guinea pig erythrocytes
(GPE) was determined for a variety of themannosylated triazoles in
a function-based aggregometry assay.46 The measurements were
performed in triplicates and the corresponding IC50 valueswere cal-
culated by plotting the area under the curve (AUC) of disaggregation
against the concentration of the antagonists. n-Heptyl a-D-manno-
pyranoside (1b) was again used as reference compound with an
IC50 of 77.1 lM (Table 2, entry 1). While the antagonists 5e, 6j, 6k,
7o and 7q showed IC50 values in the range of 200–300 lM, surpris-
ingly no activities could be determined for compounds 5j, 8q and 8r
up to a concentration of 700 lM. As earlier observed,46 the activities
obtained from the aggregometry assay are approximately 1000-fold
lower than the affinities determined in the target-based competi-
tive assay.
2.6. Conformational analysis of mannosyl triazoles
Compared to their counterparts 7, where the triazole is directly
linked to the anomeric center, most of the C-mannosides 8 exhibit
a lower affinity. By applying NMR techniques, it was investigated
whether this loss of affinity originates fromdistorted ring conforma-
tions. Due to signal overlap, the unprotected mannosides 7 and 8
were not suited for the conformational analysis. However, for the
peracetylated derivatives 20n and 25n the ring conformation could
be assigned based on coupling constants and NOESY experiments.
First, the observed 3J coupling constants for their ring protons were
strikingly different. In 20n, they were in agreement with those ex-
pected for a regular 4C1 chair conformation of an a-D-mannopyran-
osyl ring,with small J1,2 and J2,3 couplings and largevalues for J3,4 and
J4,5 (Fig. 5A). In contrast, the large J1,2 coupling constant (8.4 Hz) and
small to medium values for J2,3, J3,4 and J4,5 found for 25n, are in
agreement with a ring flip of the a-D-mannopyranosyl chair from
the common 4C1 to the unusual 1C4 conformation (Fig. 5B). A similar
conformational switch has also been observed for a-CF2-manno-
sides.53 As a consequence, the triazolyl-methyl group now is ori-
ented equatorially in C-mannoside 25n, while in 20n the triazole
moiety adopts an axial position.
Subsequent 2D-NOESY measurements (Fig. 5C and D) con-
firmed this analysis. For both compounds a sequence of seven
2D-NOESY experiments with increasing mixing times from 0.5 s
to 2.0 s in steps of 0.25 s was recorded. The intensity of the positive
signals grows with increasing mixing time and indicates the rela-
tive spatial proximity of a particular proton to that of the source
proton. The NOEs of the proton of interest (intcross) were normal-
ized to the intensity of the diagonal peak of the source proton
(intdiag). Plotting these normalized intensities against the mixing
time results in a straight line for each pair of protons. The distances
rij were then calculated from the slopes r of the linear regression
according to rij = rref (rref /rij)1/6, were rref is the average distance
of the geminal protons H-6a and H-6b, which was chosen as refer-
ence (rref = 1.78 Å).54,55
Typically, in the chair conformation of carbohydrates the vicinal
proton–proton distances are approx. 2.95 ± 0.15 Å for a diaxial,
2.45 ± 0.15 Å for an axial-equatorial and 2.50 ± 0.20 Å for a diequa-
torial orientation.56 As shown in Figure 5A and B, the distances of
the ring protons in 20n and 25n determined from NOE experi-
ments correlate well with the theoretical values and support the
results obtained from the analysis of the coupling constants. In
summary, NMR spectroscopic data indicate that the mannopyran-
osyl chairs in these compounds adopt different conformations,
depending on the substituent at C-1.
This conformational analysis offers an explanation for the two-
fold reduction of affinity found for most of the C-mannosides 8
compared to the corresponding N-linked triazoles 7. Due to the
inversion of the ring conformation in 8 (1C4 vs 4C1), the optimal
fit into the hydrophilic mannose-binding pocket of FimH is
disturbed.
2.7. Pharmacokinetic properties of mannosyl triazoles
Finally, the druglikeness of this new class of FimH antagonists
was addressed. For a successful po application in our UTI mouse
model,19 FimH antagonists have to exhibit oral bioavailability,
metabolic stability and fast renal elimination to the urinary tract,
their place of action. For the evaluation of oral absorption and renal
excretion of the triazoles 5–8 physicochemical parameters such as
solubility, lipophilicity (distribution coefficients, log D7.4) and per-
meability were determined (Table 1). The mannosides of all four
compound families (5–8) are all highly soluble (159 lg/mL to >
3 mg/mL) and therefore fulfill a first prerequisite for absorption
in the gastrointestinal tract (GIT). All compounds showed low to
moderate log D7.4 values in the range of < -1.5 to 1.45. While these
parameters are beneficial for renal excretion,57 oral absorption by
passive diffusion can only be expected to a minor extent. Indeed,
for none of the tested compounds a significant permeation through
an artificial membrane (PAMPA,50 log Pe, Pe: effective permeation)
nor membrane retention could be detected. Whereas for a success-
ful oral absorption a log Pe >"5.7 and/or a membrane retention
%Mm > 80 % are required,58 the corresponding values for all tria-
zoles are far from being in this range. Overall, only poor absorption
from the GIT can be therefore expected.
3. Conclusions
Crystal structures indicate that the natural ligand oligoman-
nose-310 inserts into the tyrosine gate formed by Tyr48, Tyr137
and Ile52 of the carbohydrate recognition domain of FimH
(in-docking-mode). In contrast, the recently reported high-affinity
Figure 4. Examples of inhibition curves obtained from the cell-free competitive
binding assay.45 Each assay was run in duplicate and was repeated at least twice.
For antagonists 5h, 6i and the reference compound 1b IC50 values in the nM range
were obtained.
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biphenyl mannoside 4c was shown to bind in the out-docking-
mode, that is, it establishes a p-p-stacking interaction with Tyr48
from the outside of the tyrosine gate.11 Based on docking studies,
we designed a series of low molecular weight mannosyl triazoles,
which exhibit an increased conformational flexibility of the agly-
cone and therefore should allow for binding to the tyrosine gate
in the in-docking-mode. For their pharmacodynamical evaluation
two assay formats, a target-based binding assay45 and a function-
based aggregation assay,46 were applied. In general, all triazoles
5–8 showed nanomolar affinities, but only one representative,
the 4-pyridyl derivative 5j, was as potent as the reference
compound n-heptyl mannoside (1b). Obviously, the high flexibility
of the n-heptyl aglycone in 1b optimally fulfills the spatial require-
ments of the tyrosine gate. In addition, the hydrophobic contacts
established by the substituted triazole aglycone within the tyro-
sine gate in the in-docking-mode are less favorable than the p-p-
stacking interaction of biphenyl derivatives11,19 with Tyr48 in the
out-docking-mode.
Furthermore, the reduced affinities of the triazolyl-methyl-C-
mannosides 8 can be rationalized by a disturbed interaction of
the mannose moiety. A conformational analysis by 1H NMR and
NOESY NMR revealed that in contrast to the other three classes
of mannosyl triazoles (compounds 5, 6 and 7), the C-mannosides
8 do not adopt the common 4C1 but an unusual 1C4 chair conforma-
tion, thus preventing an optimal fit of the mannosyl moiety into
the hydrophilic mannose-binding pocket of FimH.
Finally, for a successful therapeutic application, FimH antago-
nists have to exhibit appropriate pharmacokinetic properties,
that is, oral bioavailability and fast renal elimination to the uri-
nary tract, their place of action. One prerequisite for absorption
in the GIT is sufficient solubility, a property, which is fulfilled
by all synthesized antagonists. However, according to their lipo-
philicity and membrane permeation properties, the mannosyl tri-
azoles are not expected to be orally absorbed. Possible
improvements of the pharmacokinetic profiles of mannosyl tria-
zoles are currently studied.
4. Experimental part
4.1. Chemistry
General. NMR spectra were recorded on a Bruker Avance
DMX-500 (500 MHz) spectrometer. Assignment of 1H and 13C
NMR spectra was achieved using 2D methods (COSY, HSQC).
Chemical shifts are expressed in ppm using residual CHCl3 and
CD2HOD as references. Optical rotations were measured using a
Perkin-Elmer Polarimeter 341. Electron spray ionization mass
Table 2
IC50 values of mannosylated triazoles determined in the aggregometry assay46
The relative IC50 (rIC50) was calculated by dividing the IC50 of the substance of interest by the IC50 of the
reference compound 1b. n.a., not active.
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spectra (ESI-MS) were obtained on a Waters micromass ZQ. The
HRMS analyses were carried out using a Bruker QTOF. Reactions
were monitored by TLC using glass plates coated with silica gel
60 F254 (Merck) and visualized by using UV light and/or by charring
with a molybdate solution (a 0.02 M solution of ammonium cerium
sulfate dihydrate and ammonium molybdate tetrahydrate in aque-
ous 10% H2SO4). MPLC separations were carried out on a Combi-
Flash Companion from Teledyne Isco equipped with RediSep
normal-phase or C18 reversed-phase flash columns. Tetrahydrofu-
rane (THF) was freshly distilled under argon over sodium and ben-
zophenone. Methanol (MeOH) was dried by refluxing with sodium
methoxide and distilled immediately before use. Dichloromethane
(DCM), ethyl acetate (EtOAc), and toluene were dried by filtration
over Al2O3 (Fluka, type 5016 A basic).
4.1.1. General procedure A for the synthesis of mannosyl
triazoles 5d–i
A mixture of acetylene 1437 (1.0 eq), azide 15d–i (1.5 eq), Cu-
SO4!5H2O (0.25 eq) and sodium ascorbate (0.5 eq) was dissolved
in degassed tert-BuOH/H2O (1:1, 2 mL/0.1 mmol 14) under argon.
After stirring for 1 d the solvents were removed in vacuo and the
crude product was first purified by MPLC on silica (DCM/MeOH)
and then by reversed-phase chromatography (RP-18, H2O/MeOH)
to yield 5d–i as colorless solids.
4.1.2. General procedure B for the synthesis of mannosyl
triazoles 12a–c, 16j–m and 17h–k
Acetylene 1029 or 1336 (1.0 eq) and azide 11a–c or 15h–m
(1.5–2 eq) were dissolved in THF/tert-BuOH/H2O (1:1:1, 1.5 mL/
0.1 mmol 10 or 11). The mixture was degassed in an ultrasound
bath under a flow of argon for 20 min. Then 0.5 M aq CuSO4!5H2O
(0.25 eq) and 1 M aq sodium ascorbate (0.5 eq) were added under
argon at rt. After stirring overnight the solvents were removed in
vacuo and the crude product was purified by MPLC on silica (petrol
ether/EtOAc) to yield 12a–c, 16j–m and 17h–k as colorless oils.
4.1.3. General procedure C for the synthesis of mannosyl
triazoles 20n–s and 25n–s
Azide 1842 or 24 (1.0 eq) and acetylene 19n–s (2.0 eq) were dis-
solved in THF/tert-BuOH/H2O (1:1:1, 3 mL/0.1 mmol 18 or 24). The
mixture was degassed in an ultrasound bath under a flow of argon
for 20 min. Then 0.2 M aq CuSO4!5H2O (0.2 eq) and 1 M aq sodium
ascorbate (0.4 eq) were added under argon at rt. After stirring for
1–2 d the solvents were removed in vacuo and the crude product
was purified by MPLC on silica (petrol ether/EtOAc) to yield 20n–
s and 25n–s as colorless oils.
4.1.4. General procedure D for deacetylation
To a solution of the acetylated compound (38–50 mg) in MeOH
(3 mL) was added 1 M NaOMe/MeOH (0.3 mL). The mixture was
stirred at rt for 3–6 h. The solution was concentrated and the res-
idue was purified by MPLC on reversed phase (RP-18 column, H2O/
MeOH) and P2 size-exclusion chromatography to afford the target
molecule as a colorless solid after a final lyophilization from water/
dioxane.
4.1.5. Synthesis of azide 24
4.1.5.1. (2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-N-tert-
butoxycarbonyl-methylamine (22). Cyanide 2143 (1.63 g,
4.57 mmol), Boc2O (1.49 g, 6.86 mmol) and Pd/C (10%, 250 mg)
were suspended in EtOAc (25 mL) and hydrogenated (4 bar H2) at
rt for 4 h. After filtration over Celite, fresh Pd/C (10%, 750 mg)
Figure 5. Coupling constants and proton-proton distances for peracetylated triazoles 20n (A) and 25n (B) determined by 1H NMR and 2D-NOESY experiments; 2D-NOESY
spectra of 20n (C) and 25n (D) in CDCl3 with mixing times of 1.5 s (C) and 750 ms (D).
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was added and the mixture was hydrogenated (4 bar H2) for addi-
tional 17 h. The suspension was filtered over Celite and concen-
trated. The residue was purified by MPLC on silica (petrol ether/
EtOAc) to give 22 (1.51 g, 72%) as a colorless solid.
1H NMR (500 MHz, CDCl3): d 1.44 (s, 9H, C(CH3)3), 2.07, 2.10,
2.10 (3 s, 12H, 4 COCH3), 3.38 (m, 2H, H-10), 3.99–4.05 (m, 2H, H-
1, H-5), 4.07 (dd, J = 3.8, 11.8 Hz, 1H, H-6a), 4.54 (dd, J = 6.9,
11.7 Hz, 1H, H-6b), 4.79 (m, 1H, NH), 5.07 (dd, J = 5.3, 6.4 Hz, 1H,
H-4), 5.10 (dd, J = 3.3, 6.0 Hz, 1H, H-2), 5.26 (dd, J = 3.3, 6.5 Hz,
1H, H-3); 13C NMR (125 MHz, CDCl3): d 20.70, 20.73, 20.76, 20.81
(4 COCH3), 28.3 (C(CH3)3), 39.7 (C-10), 61.2 (C-6), 67.50, 67.51 (C-
2, C-4), 68.0 (C-3), 71.1 (C-1), 72.2 (C-5), 79.7 (C(CH3)3), 155.8
(NCO), 169.5, 169.6, 169.9, 170.7 (4 COCH3); ESI-MS Calcd for
C20H31NNaO11 [M+Na]+: 484.18, Found: 484.11.
4.1.5.2. N-tert-Butoxycarbonyl-(a-D-mannopyranosyl)methyl-
amine (23). A solution of 22 (1.47 g, 3.19 mmol) in MeOH
(20 mL) was treated with 1 M methanolic NaOMe (2 mL) under ar-
gon at rt for 3 h. The reaction mixture was neutralized with acetic
acid and concentrated. The residue was purified by MPLC on silica
(DCM/MeOH) to give 23 (925 mg, 99%) as a colorless solid.
1H NMR (500 MHz, CD3OD): d 1.44 (s, 9H, C(CH3)3), 3.32 (m, 2H,
H-10), 3.54 (m, 1H, H-5), 3.63 (t, J = 7.6 Hz, 1H, H-4), 3.68 (dd,
J = 3.1, 7.8 Hz, 1H, H-3), 3.74 (dd, J = 2.8, 11.8 Hz, 1H, H-6a), 3.77
(m, 1H, H-2), 3.79 (dd, J = 6.4, 11.8 Hz, 1H, H-6b), 3.86 (m, 1H, H-
1), 6.72 (m, 1H, NH); 13C NMR (125 MHz, CD3OD): d 28.8
(C(CH3)3), 40.6 (C-10), 62.7 (C-6), 69.6 (C-4), 70.2 (C-2), 72.7 (C-3),
76.9 (C-1), 77.4 (C-5), 80.2 (C(CH3)3), 158.6 (NCO); ESI-MS Calcd
for C12H23NNaO7 [M+Na]+: 316.14, Found: 316.03.
4.1.5.3. (2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methylaz-
ide (24). Triflyl azide stock solution preparation:44 Sodium
azide (796 mg, 12.2 mmol) was dissolved in water (2 mL). Toluene
(2 mL) was added, and the mixture was cooled to 0 "C with stirring.
Then triflic anhydride (1.31 mL, 6.12 mmol) was added dropwise.
The biphasic reaction mixture was stirred vigorously at 0 "C for
30 min and at 10 "C for another 2 h. The reaction mixture was neu-
tralized with satd aq NaHCO3. The phases were separated, and the
aqueous phase extracted with toluene (2 # 2 mL). The organic
layers were combined to give the triflyl azide stock solution.
Amine-azide exchange: A solution of 23 (430 mg, 1.47 mmol) in
dioxane/water (2:1, 15 mL) was treated with concentrated HCl
(5 mL) under argon at rt for 4 h. The mixture was concentrated
and the residue was dried in high vacuo. Then, the crude amine
hydrochloride (341 mg), NaHCO3 (492 mg, 5.86 mmol) and Cu-
SO4!5H2O (14.1 mg, 61 lmol) were dissolved in water (1.91 mL).
The triflyl azide stock solution (3.25 mL, 3.3 mmol) was added
and the biphasic reaction mixture was made homogenous by the
addition of MeOH (12.6 mL). The mixture was stirred at rt for
20 h. The solvents were removed in vacuo and the residue was ta-
ken up in dry pyridine (10 mL), and acetic anhydride (4 mL) was
added. The reaction mixture was stirred at rt under argon for 4 h.
The solvents were removed in vacuo and the crude product was
purified by MPLC on silica (petrol ether/EtOAc) to yield 24
(459 mg, 81%) as a colorless oil.
IR (film) 2102 (vs, N3), 1747 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 2.04, 2.07, 2.08, 2.10 (4 s, 12H, 4 COCH3),
3.29 (dd, J = 3.3, 13.4 Hz, 1H, H-10a), 3.49 (dd, J = 7.3, 13.4 Hz,
1H, H-10b), 4.05–4.09 (m, 2H, H-5, H-6a), 4.15 (dt, J = 3.2,
7.1 Hz, 1H, H-1), 4.60 (m, 1H, H-6b), 5.01 (dd, J = 4.4, 6.0 Hz,
1H, H-4), 5.14 (dd, J = 3.4, 6.9 Hz, 1H, H-2), 5.27 (dd, J = 3.4,
6.0 Hz, 1H, H-3); 13C NMR (125 MHz, CDCl3): d 20.61, 20.63,
20.65, 20.74 (4 COCH3), 50.1 (C-10), 60.8 (C-6), 67.0 (C-2), 67.5
(C-3), 67.6 (C-4), 70.5 (C-1), 72.9 (C-5), 169.3, 169.5, 169.6,
170.6 (4 COCH3); ESI-MS Calcd for C15H21N3NaO9
[M+Na]+: 410.12, Found: 410.04.
4.1.6. Synthesis of peracetylated mannosyl triazoles
4.1.6.1. Methyl 4-[4-((2,3,4,6-tetra-O-acetyl-a-D-mannopyrano-
syloxy)methyl)-1H-1,2,3-triazol-1-yl]-benzoate (12a). Fol-
lowing general procedure B, 10 (40.0 mg, 0.103 mmol) was
reacted with methyl 4-azidobenzoate (11a,30 36.5 mg,
0.206 mmol), 0.5 M CuSO4 (52 lL, 26 lmol) and 1 M sodium ascor-
bate (52 lL, 52 lmol) to yield 12a (55.8 mg, 96%).
[a]D +45.0 (c 1.03, CHCl3); IR (film) 1747 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.99, 2.04, 2.12, 2.16 (4 s, 12H, 4 COCH3), 3.97
(s, 3H, OMe), 4.10 (ddd, J = 2.2, 5.1, 9.5 Hz, 1H, H-5), 4.14 (dd,
J = 2.3, 12.2 Hz, 1H, H-6a), 4.32 (dd, J = 5.2, 12.2 Hz, 1H, H-6b),
4.79, 4.95 (A, B of AB, J = 12.6 Hz, 2H, H-10), 5.01 (d, J = 1.1 Hz,
1H, H-1), 5.28 (dd, J = 1.7, 3.1 Hz, 1H, H-2), 5.32 (t, J = 9.8 Hz, 1H,
H-4), 5.36 (dd, J = 3.2, 10.0 Hz, 1H, H-3), 7.88 (AA0 of AA0BB0,
J = 8.7 Hz, 2H, C6H4), 8.11 (s, 1H, C2N3H), 8.23 (BB0 of AA0BB0,
J = 8.7 Hz, 2H, C6H4); 13C NMR (125 MHz, CDCl3): d 20.7, 20.8,
20.9 (4C, 4 COCH3), 52.5 (OMe), 61.0 (C-10), 62.4 (C-6), 66.0 (C-4),
68.8, 69.0, 69.4 (C-2, C-3, C-5), 97.0 (C-1), 120.0 (2C, C6H4), 121.0
(C2N3H–C5), 130.4 (C6H4–C1), 131.4 (2C, C6H4), 139.9 (C6H4–C4),
144.7 (C2N3H–C4), 169.7, 170.0, 170.1, 170.7 (5C, 5 CO); ESI-MS
Calcd for C25H29N3NaO12 [M+Na]+: 586.02, Found: 586.16.
4.1.6.2. Ethyl 3-[4-((2,3,4,6-tetra-O-acetyl-a-D-mannopyranosyl-
oxy)methyl)-1H-1,2,3-triazol-1-yl]-benzoate (12b). Follow-
ing general procedure B, 10 (50.0 mg, 0.129 mmol) was reacted
with ethyl 3-azidobenzoate (11b,31 49.3 mg, 0.258 mmol), 0.5 M
CuSO4 (64 lL, 32 lmol) and 1 M sodium ascorbate (64 lL,
64 lmol) to yield 12b (72.7 mg, 97%).
[a]D +40.2 (c 1.04, CHCl3); IR (film) 1749 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.43 (t, J = 7.2 Hz, 1H, CH3), 1.99, 2.04, 2.12,
2.16 (4 s, 12H, 4 COCH3), 4.09–4.15 (m, 2H, H-5, H-6a), 4.32 (dd,
J = 5.0, 12.1 Hz, 1H, H-6b), 4.44 (q, J = 7.2 Hz, 2H, OCH2), 4.79,
4.95 (A, B of AB, J = 12.4 Hz, 2H, H-10), 5.02 (d, J = 1.4 Hz, 1H, H-
1), 5.28 (dd, J = 1.7, 3.2 Hz, 1H, H-2), 5.31 (m, 1H, H-4), 5.36 (dd,
J = 3.3, 9.9 Hz, 1H, H-3), 7.64 (t, J = 8.0 Hz, 1H, C6H4–H5), 8.02
(ddd, J = 0.9, 2.1, 8.0 Hz, 1H, C6H4–H4), 8.11 (s, 1H, C2N3H), 8.14
(d, J = 7.9 Hz, 1H, C6H4-H6), 8.38 (t, J = 1.7 Hz, 1H, C6H4-H2); 13C
NMR (125 MHz, CDCl3): d 14.3 (CH3), 20.67, 20.69, 20.78, 20.88
(4 COCH3), 60.9 (C-10), 61.7 (OCH2), 62.4 (C-6), 66.0 (C-4), 68.8
(C-3), 69.0 (C-5), 69.4 (C-2), 96.9 (C-1), 121.2 (C6H4), 121.3
(C2N3H–C5), 124.8, 129.9, 130.0, 132.3, 137.0 (C6H4), 144.5
(C2N3H–C4), 165.2, 169.7, 169.9, 170.1, 170.7 (5 CO); ESI-MS Calcd
for C26H32N3O12 [M+H]+: 578.20, Found: 578.19.
4.1.6.3. Methyl 5-[4-((2,3,4,6-tetra-O-acetyl-a-D-mannopyrano-
syloxy)methyl)-1H-1,2,3-triazol-1-yl]-nicotinate (12c). Fol-
lowing general procedure B, 10 (40.0 mg, 0.103 mmol) was
reacted with methyl 5-azidonicotinate (11c,32 32.5 mg,
0.182 mmol), 0.5 M CuSO4 (52 lL, 26 lmol) and 1 M sodium ascor-
bate (52 lL, 52 lmol). The crude product was dissolved in DCM
(10 mL) and washed with 0.1 M aq EDTA (5 mL). The aqueous
phase was extracted with DCM (2 # 10 mL) and the combined or-
ganic layers were dried with Na2SO4 and evaporated to dryness.
The residue was purified by MPLC on silica (petrol ether/EtOAc)
to give 12c (42.4 mg, 73%).
[a]D +39.7 (c 1.06, CHCl3); IR (film) 1733 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.98, 2.03, 2.11, 2.15 (4 s, 12H, 4 COCH3), 4.01
(s, 3H, OCH3), 4.09 (m, 1H, H-5), 4.14 (dd, J = 2.4, 12.2 Hz, 1H, H-6a),
4.31 (dd, J = 5.2, 12.3 Hz, 1H, H-6b), 4.79, 4.96 (A, B of AB,
J = 12.5 Hz, 2H, H-10), 5.01 (d, J = 1.4 Hz, 1H, H-1), 5.27 (dd,
J = 1.7, 3.0 Hz, 1H, H-2), 5.30 (t, J = 9.8 Hz, 1H, H-4), 5.34 (dd,
J = 3.3, 9.9 Hz, 1H, H-3), 8.17 (s, 1H, C2N3H), 8.69 (t, J = 2.0 Hz, 1H,
C5H3N-H2), 9.27, 9.30 (2 s, 2H, C5H3N-H4, H6); 13C NMR
(125 MHz, CDCl3): d 20.63, 20.65, 20.75, 20.84 (4 COCH3), 52.9
(OMe), 60.8 (C-10), 62.4 (C-6), 66.0 (C-4), 68.8, 68.9 (C-3, C-5),
69.3 (C-2), 97.0 (C-1), 121.2 (C2N3H–C5), 126.9, 128.6, 133.3
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(C5H3N), 145.1 (2C, C5H3N, (C2N3H–C4), 150.7 (C5H3N), 164.4,
169.7, 169.9, 170.1, 170.7 (5 CO); ESI-MS Calcd for C24H29N4O12
[M+H]+: 565.18, Found: 565.15.
4.1.6.4. [1-(Pyridin-4-yl)-1,2,3-triazol-4-yl]methyl 2,3,4,6-tetra-
O-acetyl-a-D-mannopyranoside (16j). Following general
procedure B, 10 (100 mg, 0.26 mmol) was reacted with 4-azido-
pyridine (15j,41 47 mg, 0.39 mmol), 0.5 M CuSO4 (130 lL, 65 lmol)
and 1 M sodium ascorbate (130 lL, 130 lmol). The crude product
was dissolved in DCM (20 mL) and washed with 0.1 M aq EDTA
(10 mL). The aqueous phase was extracted with DCM (2 # 20 mL)
and the combined organic layers were dried with Na2SO4 and
evaporated to dryness. The residue was purified by MPLC on silica
(DCM/MeOH) to give 16j (114 mg, 87%).
[a]D +52.1 (c 2.26, DCM); IR (film) 1748 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.92, 1.97, 2.05, 2.09 (4s, 12H, 4 COCH3), 3.96–
4.14 (m, 2H, H-5, H-6a), 4.24 (dd, J = 4.8, 12.1 Hz, 1H, H-6b), 4.73,
4.89 (A, B of AB, J = 12.5 Hz, 2H, H-10), 4.94 (s, 1H, H-1), 5.14–
5.33 (m, 3H, H-2, H-3, H-4), 7.70 (m, 2H, C5H4N), 8.15 (s, 1H,
C2N3H), 8.73 (m, 2H, C5H4N); 13C NMR (125 MHz, CDCl3): d
20.77, 20.78, 20.88, 20.96 (4 COCH3), 61.0 (C-10), 62.5 (C-6), 66.1,
68.9, 69.0, 69.5 (C-2, C-3, C-4, C-5), 97.1 (C-1), 113.9 (2C, C5H4N),
120.7 (C2N3H–C5), 143.0 (C5H4N–C1), 145.2 (C2N3H–C4), 151.9
(2C, C5H4N), 169.8, 170.1, 170.2, 170.8 (4 COCH3); ESI-MS Calcd
for C22H26 N4NaO10 [M+Na]+: 529.16, Found: 529.07.
4.1.6.5. [1-(40-Fluorophenyl)-1,2,3-triazol-4-yl]methyl 2,3,4,6-
tetra-O-acetyl-a-D-mannopyranoside (16k). Following
general procedure B, 10 (100 mg, 0.26 mmol) was reacted with
1-azido-4-fluorobenzene (15k,41 53 mg, 0.39 mmol), 0.5 M CuSO4
(130 lL, 65 lmol) and 1 M sodium ascorbate (130 lL, 130 lmol)
to yield 16k (127 mg, 94%).
[a]D +42.0 (c 1.00, DCM); IR (film) 1749 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.96, 2.01, 2.09, 2.13 (4s, 12H, 4 COCH3), 4.07
(m, 1H, H-5), 4.11 (dd, J = 2.4, 12.2 Hz, 1H, H-6a), 4.28 (dd, J = 5.2,
12.2 Hz, 1H, H-6b), 4.75, 4.91 (A, B of AB, J = 12.4 Hz, 2H, H-10),
4.98 (d, J = 1.6 Hz, 1H, H-1), 5.24–5.31 (m, 2H, H-2, H-4), 5.33
(dd, J = 3.3, 10.0 Hz, 1H, H-3), 7.21 (m, 2H, C6H4), 7.71 (m, 2H,
C6H4), 7.97 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.87,
20.88, 20.98, 21.07 (4 COCH3), 61.3 (C-10), 62.6 (C-6), 66.3, 69.0,
69.2, 69.7 (C-2, C-3, C-4, C-5), 97.2 (C-1), 117.0 (d, J = 22.5 Hz, 2C,
C6H4), 121.6 (C2N3H–C5), 122.9 (d, J = 8.8 Hz, 2C, C6H4), 133.4 (d,
J = 3.8 Hz, C6H4–C1), 145.0 (C2N3H–C4), 163.8 (d, J = 247.5 Hz,
C6H4–C4), 169.9, 170.2, 170.3, 170.9 (4 COCH3); ESI-MS Calcd for
C23H26FN3NaO10 [M+Na]+: 546.16, Found: 546.15.
4.1.6.6. [1-(30-Fluorophenyl)-1,2,3-triazol-4-yl]methyl 2,3,4,6-
tetra-O-acetyl-a-D-mannopyranoside (16l). Following
general procedure B, 10 (100 mg, 0.26 mmol) was reacted with
1-azido-3-fluorobenzene (15l,41 53 mg, 0.39 mmol), 0.5 M CuSO4
(130 lL, 65 lmol) and 1 M sodium ascorbate (130 lL, 130 lmol)
to yield 16l (115 mg, 85%).
[a]D +47.5 (c 2.14, DCM); IR (film) 1748 (vs, CO) cm"1; 1H
NMR (500 MHz, CDCl3): d 1.96, 2.01, 2.09, 2.13 (4s, 12H, 4
COCH3), 4.02–4.15 (m, 2H, H-5, H-6a), 4.29 (dd, J = 5.1, 12.2 Hz,
1H, H-6b), 4.75, 4.91 (A, B of AB, J = 12.5 Hz, 2H, H-10), 4.98 (s,
1H, H-1), 5.22–5.36 (m, 3H, H-2, H-3, H-4), 7.14 (m, 1H, C6H4),
7.44–7.59 (m, 3H, C6H4), 8.02 (s, 1H, C2N3H); 13C NMR
(125 MHz, CDCl3): d 20.86, 20.88, 20.97, 21.07 (4 COCH3), 61.2
(C-10), 62.6 (C-6), 66.2, 69.0, 69.2, 69.6 (C-2, C-3, C-4, C-5),
97.2 (C-1), 108.6 (d, J = 26.3 Hz, C6H4), 116.0 (d, J = 17.5 Hz,
C6H4), 116.1 (m, C6H4), 121.3 (C2N3H–C5), 131.5 (d, J = 8.8 Hz,
C6H4), 138.2 (d, J = 10.0 Hz, C6H4–C1), 144.7 (C2N3H–C4), 163.3
(d, J = 247.5 Hz, C6H4–C4), 169.9, 170.1, 170.3, 170.9 (4 COCH3);
ESI-MS Calcd for C23H26FN3NaO10 [M+Na]+: 546.16, Found:
546.15.
4.1.6.7. [1-(40-Methoxyphenyl)-1,2,3-triazol-4-yl]methyl 2,3,4,6-
tetra-O-acetyl-a-D-mannopyranoside (16m). Following
general procedure B, 10 (100 mg, 0.26 mmol) was reacted with
1-azido-4-methoxybenzene (15m,40 58 mg, 0.39 mmol), 0.5 M
CuSO4 (130 lL, 65 lmol) and 1 M sodium ascorbate (130 lL,
130 lmol) to yield 16m (128 mg, 92%).
[a]D +45.0 (c 2.26, DCM); IR (film) 1749 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.93, 1.98, 2.06, 2.10 (4s, 12H, 4 COCH3), 3.81
(s, 3H, OCH3), 3.99–4.12 (m, 2H, H-5, H-6a), 4.26 (dd, J = 5.3,
12.4 Hz, 1H, H-6b), 4.71, 4.87 (A, B of AB, J = 12.4 Hz, 2H, H-10),
4.95 (d, J = 1.4 Hz, 1H, H-1), 5.20–5.28 (m, 2H, H-2, H-4), 5.30
(dd, J = 3.2, 10.0 Hz, 1H, H-3), 6.97 (m, 2H, C6H4), 7.58 (m, 2H,
C6H4), 7.91 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.78,
20.80, 20.89, 20.98 (4 COCH3), 55.7 (OCH3), 61.2 (C-10), 62.5 (C-
6), 66.1, 68.9, 69.1, 69.5 (C-2, C-3, C-4, C-5), 97.0 (C-1), 114.9 (2C,
C6H4), 121.5 (C2N3H–C5), 122.4 (2C, C6H4), 130.4 (C6H4–C1),
144.1 (C2N3H–C4), 160.0 (C6H4–C4), 169.8, 170.0, 170.2, 170.8 (4
COCH3); ESI-MS Calcd for C24H29N3NaO11 [M+Na]+: 558.18, Found:
558.18.
4.1.6.8. [1-(30-Methoxybenzyl)-1,2,3-triazol-4-yl]ethyl 2,3,4,6-
tetra-O-acetyl-a-D-mannopyranoside (17h). Following
general procedure B, 13 (55 mg, 0.14 mmol) was reacted with 3-
methoxybenzylazide (15h,39 34 mg, 0.21 mmol), 0.5 M CuSO4
(70 lL, 35 lmol) and 1 M sodium ascorbate (70 lL, 70 lmol) to
yield 17h (65 mg, 83%).
[a]D +36.5 (c 1.00, DCM); IR (film) 1748 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.85, 1.88, 1.93, 1.99 (4s, 12H, 4 COCH3), 2.86
(tt, J = 4.8, 9.9 Hz, 2H, H-20), 3.56 (dt, J = 6.6, 9.5 Hz, 1H, H-10a), 3.63
(s, 3H, OCH3), 3.69 (m, 1H, H-5), 3.83 (dt, J = 6.6, 9.5 Hz, 1H, H-10b),
3.91 (dd, J = 2.4, 12.3 Hz, 1H, H-6a), 4.09 (dd, J = 5.2, 12.3 Hz, 1H, H-
6b), 4.65 (d, J = 1.7 Hz, 1H, H-1), 5.03 (dd, J = 1.8, 3.0 Hz, 1H, H-2),
5.07–5.16 (m, 2H, H-3, H-4), 5.33 (s, 2H, CH2Ar), 6.68, 6.72, 7.13
(m, 4H, C6H4), 7.68 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d
20.85, 20.88, 21.02 (4C, 4 COCH3), 26.4 (C-20), 54.1 (CH2Ar), 55.4
(OCH3), 62.5 (C-6), 66.2 (C-4), 67.2 (C-10), 68.9, 69.2, 69.7 (C-2, C-
3, C-5), 97.6 (C-1), 113.9, 114.2, 120.4, 130.3 (C6H4, C2N3H–C5),
136.5 (C6H4–C1), 144.8 (C2N3H–C4), 160.2 (C6H4–C3), 169.8,
170.1, 170.2, 170.8 (4 COCH3); ESI-MS Calcd for C26H33N3NaO11
[M+Na]+: 586.21, Found 586.29.
4.1.6.9. [1-(40-Nitrophenyl)-1,2,3-triazol-4-yl]ethyl 2,3,4,6-tetra-
O-acetyl-a-D-mannopyranoside (17i). Following general
procedure B, 13 (55 mg, 0.14 mmol) was reacted with 1-azido-4-
nitrobenzene (15i,40 34 mg, 0.21 mmol), 0.5 M CuSO4 (70 lL,
35 lmol) and 1 M sodium ascorbate (70 lL, 70 lmol) to yield 17i
(74 mg, 94%).
[a]D +28.1 (c 1.00, DCM); IR (film) 1748 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.92, 1.99, 2.06, 2.11 (4s, 12H, 4 COCH3), 3.12
(m, 2H, H-20), 3.69–3.82 (m, 2H, H-5, H-10a), 3.99–4.09 (m, 2H, H-
6a, H-10b), 4.19 (dd, J = 5.3, 12.3 Hz, 1H, H-6b), 4.84 (d, J = 1.6 Hz,
1H, H-1), 5.17–5.27 (m, 2H, H-2, H-4), 5.30 (dd, J = 3.3, 10.2 Hz,
1H, H-3), 8.03 (s, 1H, C2N3H), 8.06, 8.37 (m, 4H, C6H4); 13C NMR
(125 MHz, CDCl3): d 20.75, 20.89, 20.91, 21.02 (4 COCH3), 26.3
(C-20), 62.5 (C-6), 66.1 (C-4), 66.6 (C-10), 69.1, 69.2, 69.6 (C-2, C-3,
C-5), 97.5 (C-1), 120.6 (C2N3H–C5), 120.6 (2C, C6H4), 125.6 (2C,
C6H4), 141.5 (C6H4–C1), 146.2 (C2N3H–C4), 147.2 (C6H4–C4),
169.7, 170.3, 170.4, 170.8 (4 COCH3); ESI-MS Calcd for
C26H33N3NaO11 [M+Na]+: 587.17, Found 587.25.
4.1.6.10. [1-(Pyridin-40-yl)-1,2,3-triazol-4-yl]ethyl 2,3,4,6-tetra-
O-acetyl-a-D-mannopyranoside (17j). Following general
procedure B, 13 (60 mg, 0.15 mmol) was reacted with 4-azidopyri-
dine (15j,41 28 mg, 0.23 mmol), 0.5 M CuSO4 (75 lL, 38 lmol) and
1 M sodium ascorbate (75 lL, 75 lmol). The crude product was
dissolved in DCM (20 mL) and washed with 0.1 M aq EDTA
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(10 mL). The aqueous phase was extracted with DCM (2 # 20 mL)
and the combined organic layers were dried with Na2SO4 and
evaporated to dryness. The residue was purified by MPLC on silica
(petrol ether/EtOAc) to give 17j (74 mg, 94%).
[a]D +32.6 (c 0.99, DCM); IR (film) 1748 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.88, 1.97, 2.05, 2.10 (4s, 12H, 4 COCH3), 3.10
(m, 2H, H-20), 3.64–3.79 (m, 2H, H-5, H-10a), 3.96–4.06 (m, 2H, H-
6a, H-10b), 4.17 (dd, J = 5.3, 12.3 Hz, 1H, H-6b), 4.83 (d, J = 1.6 Hz,
1H, H-1), 5.16–5.26 (m, 2H, H-2, H-4), 5.28 (dd, J = 3.4, 10.1 Hz,
1H, H-3), 7.78 (dd, J = 1.6, 4.7 Hz, 2H, C5H4N), 8.04 (s, 1H, C2N3H),
8.72 (dd, J = 1.4, 4.9 Hz, 2H, C5H4N); 13C NMR (125 MHz, CDCl3):
d 20.68, 20.88, 21.0 (4C, 4 COCH3), 26.3 (C-20), 62.5 (C-6), 66.0 (C-
4), 66.5 (C-10), 69.0, 69.2, 69.7 (C-2, C-3, C-5), 97.4 (C-1), 113.9
(2C, C5H4N), 120.0 (C2N3H–C5), 143.3 (C5H4N–C1), 146.1 (C2N3H–
C4), 151.8 (2C, C5H4N), 169.7, 170.3, 170.4, 170.8 (4 COCH3); ESI-
MS Calcd for C26H33N3 NaO11 [M+Na]+: 543.18, Found: 543.14.
4.1.6.11. [1-(40-Fluorophenyl)-1,2,3-triazol-4-yl]ethyl 2,3,4,6-
tetra-O-acetyl-a-D-mannopyranoside (17k). Following gen-
eral procedure B, 13 (60 mg, 0.15 mmol) was reacted with 1-azi-
do-4-fluorobenzene (15k,41 32 mg, 0.23 mmol), 0.5 M CuSO4
(77 lL, 38 lmol) and 1 M sodium ascorbate (75 lL, 75 lmol) to
yield 17k (77 mg, 96%).
[a]D +32.0 (c 1.01, DCM); IR (film) 1751 (vs, CO) cm"1; 1H NMR
(500 MHz, CDCl3): d 1.90, 1.96, 2.05, 2.10 (4s, 12H, 4 COCH3), 3.07
(m, 2H, H-20), 3.67–3.79 (m, 2H, H-5, H-10a), 3.96–4.06 (m, 2H, H-
6a, H-10b), 4.18 (dd, J = 5.2, 12.3 Hz, 1H, H-6b), 4.82 (d, J = 1.6 Hz,
1H, H-1), 5.16–5.24 (m, 2H, H-2, H-4), 5.28 (dd, J = 3.4, 10.1 Hz,
1H, H-3), 7.16, 7.73 (m, 4H, C6H4), 7.85 (s, 1H, C2N3H); 13C NMR
(125 MHz, CDCl3): d 20.71, 20.85, 20.88, 21.01 (4 COCH3), 26.3
(C-20), 62.5 (C-6), 66.1 (C-4), 66.8 (C-10), 68.9, 69.2, 69.7 (C-2, C-3,
C-5), 97.4 (C-1), 116.8 (d, J = 22.5 Hz, 2C, C6H4), 120.7 (C2N3H–
C5), 122.6 (d, J = 8.8 Hz, 2C, C6H4), 133.6 (d, J = 2.5 Hz, C6H4–C1),
145.4 (C2N3H–C4), 162.5 (d, J = 247.5 Hz, C6H4–C4), 169.7, 170.2,
170.3, 170.8 (4 COCH3); ESI-MS Calcd for C26H33N3NaO11
[M+Na]+: 560.18, Found 560.17.
4.1.6.12. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-phe-
nyl-1,2,3-triazole (20n). Following general procedure C, 18
(102 mg, 0.273 mmol) was reacted with phenylacetylene (19n,
60 lL, 0.55 mmol), 0.2 M CuSO4 (273 lL, 54.6 lmol) and 1 M so-
dium ascorbate (109 lL, 109 lmol) to yield 20n (110 mg, 84%).
[a]D +65.5 (c 1.01, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.07,
2.07, 2.09, 2.20 (4 s, 12H, 4 COCH3), 3.94 (ddd, J = 2.5, 5.4, 9.0 Hz,
1H, H-5), 4.08 (dd, J = 2.5, 12.5 Hz, 1H, H-6a), 4.39 (dd, J = 5.4,
12.5 Hz, 1H, H-6b), 5.39 (t, J = 8.9 Hz, 1H, H-4), 5.98 (dd, J = 3.7,
8.8 Hz, 1H, H-3), 6.02 (dd, J = 2.7, 3.7 Hz, 1H, H-2), 6.07 (d,
J = 2.6 Hz, 1H, H-1), 7.32–7.39, 7.44–7.47, 7.85–7.87 (m, 5H,
C6H5), 7.96 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.5,
20.6, 20.6, 20.7 (4 COCH3), 61.5 (C-6), 66.0 (C-4), 68.2 (C-2), 68.7
(C-3), 72.1 (C-5), 83.5 (C-1), 119.7 (C2N3H–C5), 125.8, 128.6,
128.9, 129.6 (6C, C6H5), 148.2 (C2N3H–C4), 169.2, 169.6, 169.6,
170.4 (4 COCH3); ESI-MS Calcd for C22H25N3NaO9 [M+Na]+:
498.15, Found: 498.20.
4.1.6.13. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-(4-
methylphenyl)-1,2,3-triazole (20o). Following general pro-
cedure C, 18 (50 mg, 0.13 mmol) was reacted with p-tolylacetylene
(19o, 34 lL, 0.27 mmol), 0.2 M CuSO4 (134 lL, 27 lmol) and 1 M
sodium ascorbate (54 lL, 54 lmol) to yield 20o (64 mg, 98%).
[a]D +62.4 (c 1.09, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.06,
2.07, 2.09, 2.19 (4 s, 12H, 4 COCH3), 2.39 (s, 3H, PhCH3), 3.94
(ddd, J = 2.4, 5.3, 9.0 Hz, 1H, H-5), 4.07 (dd, J = 2.4, 12.5 Hz, 1H,
H-6a), 4.38 (dd, J = 5.4, 12.5 Hz, 1H, H-6b), 5.39 (t, J = 8.9 Hz, 1H,
H-4), 5.98 (dd, J = 3.7, 8.7 Hz, 1H, H-3), 6.01 (dd, J = 2.6, 3.7 Hz,
1H, H-2), 6.05 (d, J = 2.4 Hz, 1H, H-1), 7.26, 7.74 (AA0, BB0 of AA0BB0,
J = 7.9 Hz, 4H, C6H4), 7.90 (s, 1H, C2N3H); 13C NMR (125 MHz,
CDCl3): d 20.6, 20.7, 20.8 (4C, 4 COCH3), 21.3 (PhCH3), 61.6 (C-6),
66.1 (C-4), 68.3 (C-2), 68.8 (C-3), 72.1 (C-5), 83.6 (C-1), 119.3
(C2N3H–C5), 125.8, 126.8, 129.6, 138.6 (6C, C6H4), 148.4 (C2N3H–
C4), 169.3, 169.7, 169.7, 170.5 (4 COCH3); ESI-MS Calcd for
C23H27N3NaO9 [M+Na]+: 512.16, Found: 512.15.
4.1.6.14. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-(3-
chlorophenyl)-1,2,3-triazole (20p). Following general proce-
dure C, 18 (50 mg, 0.13 mmol) was reacted with 3-chloro-1-ethi-
nylbenzene (19p, 33 lL, 0.27 mmol), 0.2 M CuSO4 (134 lL,
27 lmol) and 1 M sodium ascorbate (54 lL, 54 lmol) to yield
20p (59 mg, 86%).
[a]D +56.3 (c 1.03, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.07,
2.08, 2.09, 2.19 (4 s, 12H, 4 COCH3), 3.95 (m, 1H, H-5), 4.08 (dd,
J = 2.1, 12.5 Hz, 1H, H-6a), 4.41 (dd, J = 5.4, 12.5 Hz, 1H, H-6b),
5.38 (t, J = 8.7 Hz, 1H, H-4), 5.95 (dd, J = 3.6, 8.6 Hz, 1H, H-3), 6.00
(m, 1H, H-2), 6.07 (d, J = 2.4 Hz, 1H, H-1), 7.34–7.40 (m, 2H,
C6H4–H5, H6), 7.75 (d, J = 7.4 Hz, 1H, C6H4–H4), 7.85 (s, 1H, C6H4-
H2), 7.98 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.6, 20.7,
20.7, 20.8 (4 COCH3), 61.5 (C-6), 66.1 (C-4), 68.2 (C-2), 68.7 (C-3),
72.4 (C-5), 83.5 (C-1), 120.1 (C2N3H–C5), 124.0 (C6H4–C4), 126.0
(C6H4–C2), 128.7, 130.3 (C6H4–C5, C6), 131.5 (C6H4–C3), 134.9
(C6H4–C1), 147.2 (C2N3H–C4), 169.3, 169.6, 169.7, 170.5 (4
COCH3); ESI-MS Calcd for C22H24ClN3NaO9 [M+Na]+: 532.11,
Found: 532.13.
4.1.6.15. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-(4-
trifluoromethylphenyl)-1,2,3-triazole (20q). Following gen-
eral procedure C, 18 (50 mg, 0.13 mmol) was reacted with 1-ethi-
nyl-4-trifluoromethylbenzene (19q, 44 lL, 0.27 mmol), 0.2 M
CuSO4 (134 lL, 27 lmol) and 1 M sodium ascorbate (54 lL,
54 lmol) to yield 20q (62 mg, 85%).
[a]D +54.5 (c 0.95, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.08,
2.09, 2.19 (3 s, 12H, 4 COCH3), 3.97 (ddd, J = 2.5, 5.4, 8.7 Hz, 1H,
H-5), 4.09 (dd, J = 2.5, 12.5 Hz, 1H, H-6a), 4.41 (dd, J = 5.5,
12.5 Hz, 1H, H-6b), 5.39 (t, J = 8.8 Hz, 1H, H-4), 5.95 (dd, J = 3.7,
8.7 Hz, 1H, H-3), 6.00 (dd, J = 3.1, 3.4 Hz, 1H, H-2), 6.09 (d,
J = 2.8 Hz, 1H, H-1), 7.71, 7.98 (AA0, BB0 of AA0BB0, J = 8.1 Hz, 4H,
C6H4), 8.05 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.60,
20.69, 20.70, 20.73 (4 COCH3), 61.4 (C-6), 66.0 (C-4), 68.2 (C-2),
68.7 (C-3), 72.5 (C-5), 83.5 (C-1), 120.6 (C2N3H–C5), 124.0 (q,
J = 272 Hz, CF3), 126.0 (q, J = 3.8 Hz, 2C, C6H4–C3, C5), 126.1 (2C,
C6H4–C2, C6), 130.5 (d, J = 32.6 Hz, C6H4–C4), 133.1 (C6H4–C1),
147.0 (C2N3H–C4), 169.3, 169.6, 169.7, 170.5 (4 COCH3); ESI-MS
Calcd for C23H24F3N3NaO9 [M+Na]+: 566.14, Found: 566.10.
4.1.6.16. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-(3-
pyridyl)-1,2,3-triazole (20r). Following general procedure C,
18 (50 mg, 0.13 mmol) was reacted with 3-ethinylpyridine (19r,
27.6 mg, 0.27 mmol), 0.2 M CuSO4 (134 lL, 27 lmol) and 1 M so-
dium ascorbate (54 lL, 54 lmol). Then the reaction mixture was
diluted with DCM (20 mL) and extracted with 25 mM aq EDTA
(10 mL). The organic layer was dried (Na2SO4), concentrated and
the residue was purified by MPLC on silica (petrol ether/EtOAc)
to yield 20r (61 mg, 96%).
[a]D +56.0 (c 0.70, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.06,
2.06, 2.07, 2.17 (4 s, 12H, 4 COCH3), 3.95 (ddd, J = 2.6, 5.5, 8.8 Hz,
1H, H-5), 4.07 (dd, J = 2.6, 12.5 Hz, 1H, H-6a), 4.40 (dd, J = 5.6,
12.5 Hz, 1H, H-6b), 5.38 (t, J = 8.8 Hz, 1H, H-4), 5.92 (dd, J = 3.7,
8.8 Hz, 1H, H-3), 6.00 (dd, J = 3.2, 3.5 Hz, 1H, H-2), 6.11 (d,
J = 2.9 Hz, 1H, H-1), 7.45 (dd, J = 4.9, 7.2 Hz, 1H, C5H4N-H5), 8.11
(s, 1H, C2N3H), 8.28 (d, J = 7.9 Hz, 1H, C5H4N-H6), 8.62 (m, 1H,
C5H4N-H4), 9.06 (br s, 1H, C5H4N–H2); 13C NMR (125 MHz, CDCl3):
d 20.56, 20.66, 20.68, 20.70 (4 COCH3), 61.4 (C-6), 66.0 (C-4), 68.1
(C-2), 68.6 (C-3), 72.5 (C-5), 83.6 (C-1), 120.4 (C2N3H–C5), 124.1
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(C5H4N–C5), 126.3 (C5H4N–C1), 133.7 (C5H4N–C6), 145.0 (C2N3H–
C4), 146.5 (C5H4N–C2), 148.9 (C5H4N–C4), 169.3, 169.6, 169.6,
170.5 (4 COCH3); ESI-MS Calcd for C21H24N4NaO9 [M+Na]+:
477.16, Found: 477.08.
4.1.6.17. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)-4-
phenoxymethyl-1,2,3-triazole (20s). Following general pro-
cedure C, 18 (50 mg, 0.13 mmol) was reacted with phenylpropargyl
ether (19s, 34 lL, 0.27 mmol), 0.2 M CuSO4 (134 lL, 27 lmol) and
1 M sodium ascorbate (54 lL, 54 lmol) to yield 20s (58 mg, 85%).
[a]D +38.8 (c 0.61, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.06,
2.07, 2.09, 2.18 (4 s, 12H, 4 COCH3), 3.90 (m, 1H, H-5), 4.05 (dd,
J = 2.0, 12.5 Hz, 1H, H-6a), 4.37 (dd, J = 5.4, 12.5 Hz, 1H, H-6b),
5.26 (s, 2H, CH2OPh), 5.37 (t, J = 8.9 Hz, 1H, H-4), 5.93 (dd, J = 3.6,
8.8 Hz, 1H, H-3), 5.97 (dd, J = 2.7, 3.3 Hz, 1H, H-2), 6.00 (d,
J = 2.3 Hz, 1H, H-1), 6.98–7.00, 7.30–7.32 (m, 5H, C6H5), 7.81 (s,
1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.59, 20.67, 20.69,
20.73 (4 COCH3), 61.5 (C-6), 61.8 (CH2OPh), 66.0 (C-4), 68.2 (C-2),
68.7 (C-3), 72.2 (C-5), 83.6 (C-1), 114.7 (2C, C6H5–C2, C6), 121.4
(C6H5–C4), 123.0 (C2N3H–C5), 129.6 (2C, C6H5–C3, C5), 145.2
(C2N3H–C4), 158.0 (C6H5–C1), 169.3, 169.6, 169.7, 170.5 (4 COCH3);
ESI-MS Calcd for C23H27N3NaO10 [M+Na]+: 528.16, Found: 528.14.
4.1.6.18. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-phenyl-1,2,3-triazole (25n). Following general procedure
C, 24 (40 mg, 0.10 mmol) was reacted with phenylacetylene
(19n, 23 lL, 0.21 mmol), 0.2 M CuSO4 (103 lL, 21 lmol) and 1 M
sodium ascorbate (41 lL, 41 lmol) to yield 25n (47 mg, 93%).
[a]D -1.76 (c 1.50, CHCl3); 1H NMR (500 MHz, CDCl3): d 1.83,
2.08, 2.11, 2.12 (4 s, 12H, 4 COCH3), 4.00 (dd, J = 3.9, 12.2 Hz, 1H,
H-6a), 4.16 (dt, J = 3.5, 9.0 Hz, 1H, H-5), 4.39 (dt, J = 2.6, 8.6 Hz,
1H, H-1), 4.50 (dd, J = 8.8, 14.3 Hz, 1H, H-10a), 4.59 (dd, J = 9.2,
12.1 Hz, 1H, H-6b), 4.66 (dd, J = 2.4, 14.3 Hz, 1H, H-10b), 4.94 (dd,
J = 3.0, 4.9 Hz, 1H, H-4), 5.06 (dd, J = 3.2, 8.4 Hz, 1H, H-2), 5.35 (t,
J = 4.0 Hz, 1H, H-3), 7.32 (t, J = 7.4 Hz, 1H, C6H5-H4), 7.41 (t,
J = 7.4 Hz, 2H, C6H5-H3, H5), 7.83 (d, J = 8.0 Hz, 2H, C6H5-H2, H6),
7.92 (s, 1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.4, 20.6,
20.7, 20.8 (4 COCH3), 50.3 (C-10), 60.0 (C-6), 66.8 (C-2), 66.9 (C-
3), 68.0 (C-4), 68.4 (C-1), 73.4 (C-5), 120.9 (C2N3H–C5), 125.6,
128.2, 128.8, 130.5 (6C, C6H5), 148.0 (C2N3H–C4), 169.1, 169.4,
169.6, 170.4 (4 COCH3); ESI-MS Calcd for C23H28N3O9 [M+H]+:
490.18, Found: 490.17.
4.1.6.19. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-(4-methylphenyl)-1,2,3-triazole (25o). Following general
procedure C, 24 (40 mg, 0.10 mmol) was reacted with p-tolylacet-
ylene (19o, 26 lL, 0.21 mmol), 0.2 M CuSO4 (103 lL, 21 lmol) and
1 M sodium ascorbate (41 lL, 41 lmol) to yield 25o (50 mg, 97%).
[a]D -1.57 (c 1.26, CHCl3); 1H NMR (500 MHz, CDCl3): d 1.83,
2.07, 2.10, 2.11 (4 s, 12H, 4 COCH3), 2.36 (s, 3H, PhCH3), 3.99 (dd,
J = 4.0, 12.2 Hz, 1H, H-6a), 4.15 (dt, J = 3.5, 9.0 Hz, 1H, H-5), 4.38
(dt, J = 2.7, 8.6 Hz, 1H, H-1), 4.50 (dd, J = 8.8, 14.4 Hz, 1H, H-10a),
4.58 (dd, J = 9.1, 12.2 Hz, 1H, H-6b), 4.64 (dd, J = 2.8, 14.4 Hz, 1H,
H-10b), 4.94 (dd, J = 3.1, 5.0 Hz, 1H, H-4), 5.06 (dd, J = 3.3, 8.3 Hz,
1H, H-2), 5.34 (dd, J = 3.5, 4.8 Hz, 1H, H-3), 7.21, 7.70 (AA0, BB0 of
AA0BB0, J = 8.0 Hz, 4H, C6H4), 7.87 (s, 1H, C2N3H); 13C NMR
(125 MHz, CDCl3): d 20.41, 20.62, 20.64, 20.74 (4 COCH3), 21.2
(PhCH3), 50.2 (C-10), 60.0 (C-6), 66.8 (C-2), 66.9 (C-3), 68.0 (C-4),
68.5 (C-1), 73.3 (C-5), 120.5 (C2N3H–C5), 125.5, 127.6, 129.5,
138.0 (6C, C6H4), 147.8 (C2N3H–C4), 169.1, 169.4, 169.6, 170.4 (4
COCH3); ESI-MS Calcd for C24H30N3O9 [M+H]+: 504.20, Found:
504.20.
4.1.6.20. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-(3-chlorophenyl)-1,2,3-triazole (25p). Following general
procedure C, 24 (40 mg, 0.10 mmol) was reacted with 3-chloro-1-
ethinylbenzene (19p, 25 lL, 0.21 mmol), 0.2 M CuSO4 (103 lL,
21 lmol) and 1 M sodium ascorbate (41 lL, 41 lmol) to yield
25p (51 mg, 94%).
[a]D -2.55 (c 1.27, CHCl3); 1H NMR (500 MHz, CDCl3): d 1.84,
2.07, 2.10, 2.11 (4 s, 12H, 4 COCH3), 3.99 (dd, J = 4.0, 12.2 Hz, 1H,
H-6a), 4.15 (dt, J = 3.4, 9.0 Hz, 1H, H-5), 4.38 (dt, J = 2.7, 8.6 Hz,
1H, H-1), 4.51 (dd, J = 8.7, 14.4 Hz, 1H, H-10a), 4.60 (dd, J = 9.2,
12.2 Hz, 1H, H-6b), 4.65 (dd, J = 2.7, 14.4 Hz, 1H, H-10b), 4.93 (dd,
J = 2.9, 4.9 Hz, 1H, H-4), 5.03 (dd, J = 3.3, 8.5 Hz, 1H, H-2), 5.34
(dd, J = 3.6, 4.6 Hz, 1H, H-3), 7.27 (m, 1H, C6H4-H6), 7.33 (t,
J = 7.8 Hz, 1H, C6H4–H5), 7.72 (d, J = 7.7 Hz, 1H, C6H4–H4), 7.81 (t,
J = 1.7 Hz, 1H, C6H4-H2), 7.94 (s, 1H, C2N3H); 13C NMR (125 MHz,
CDCl3): d 20.41, 20.60, 20.64, 20.73 (4 COCH3), 50.4 (C-10), 59.9
(C-6), 66.7 (C-2), 66.8 (C-3), 68.0 (C-4), 68.3 (C-1), 73.5 (C-5),
121.3 (C2N3H–C5), 123.6, 125.6, 128.1, 130.1, 132.3, 134.8 (C6H4),
146.5 (C2N3H–C4), 169.1, 169.3, 169.5, 170.3 (4 COCH3); ESI-MS
Calcd for C23H27ClN3O9 [M+H]+: 524.14, Found: 524.04.
4.1.6.21. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-(4-trifluoromethylphenyl)-1,2,3-triazole (25q). Following
general procedure C, 24 (40 mg, 0.10 mmol) was reacted with 1-
ethinyl-4-trifluoromethylbenzene (19q, 34 lL, 0.21 mmol), 0.2 M
CuSO4 (103 lL, 21 lmol) and 1 M sodium ascorbate (41 lL,
41 lmol) to yield 25q (56 mg, 98%).
[a]D +0.47 (c 1.19, CHCl3); 1HNMR (500 MHz, CDCl3): d 1.82, 2.08,
2.10, 2.12 (4 s, 12H, 4 COCH3), 3.97 (dd, J = 4.0, 12.2 Hz, 1H, H-6a),
4.15 (dt, J = 3.4, 9.0 Hz, 1H, H-5), 4.40 (dt, J = 2.5, 8.6 Hz, 1H, H-1),
4.53 (dd, J = 8.7, 14.4 Hz, 1H, H-10a), 4.63 (dd, J = 9.2, 12.2 Hz, 1H,
H-6b), 4.67 (dd, J = 2.7, 14.4 Hz, 1H, H-10b), 4.93 (dd, J = 2.9, 4.7 Hz,
1H, H-4), 5.04 (dd, J = 3.2, 8.6 Hz, 1H, H-2), 5.34 (t, J = 4.0 Hz, 1H,
H-3), 7.66, 7.95 (AA0, BB0 of AA0BB0, J = 8.2 Hz, 4H, C6H4), 8.00 (s,
1H, C2N3H); 13C NMR (125 MHz, CDCl3): d 20.42, 20.63, 20.67,
20.76 (4 COCH3), 50.4 (C-10), 59.9 (C-6), 66.7 (C-2), 66.8 (C-3), 68.0
(C-4), 68.2 (C-1), 73.5 (C-5), 121.7 (C2N3H–C5), 124.0 (q,
J = 272 Hz, CF3), 125.7 (2C, C6H4–C2, C6), 125.8 (q, J = 3.8 Hz, 2C,
C6H4–C3, C5), 129.9 (q, J = 32.5 Hz, C6H4–C4), 133.9 (C6H4–C1),
146.4 (C2N3H–C4), 169.1, 169.4, 169.6, 170.3 (4 COCH3); ESI-MS
Calcd for C24H27F3N3O9 [M+H]+: 558.17, Found: 558.22.
4.1.6.22. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-(3-pyridyl)-1,2,3-triazole (25r). Following general proce-
dure C, 24 (40 mg, 0.10 mmol) was reacted with 3-ethinylpyridine
(19r, 21.2 mg, 0.206 mmol), 0.2 M CuSO4 (103 lL, 21 lmol) and
1 M sodium ascorbate (41 lL, 41 lmol) to yield 25r (50 mg, 98%).
[a]D -0.08 (c 1.04, CHCl3); 1H NMR (500 MHz, CDCl3): d 1.83,
2.07, 2.09, 2.10 (4 s, 12H, 4 COCH3), 3.97 (dd, J = 4.0, 12.2 Hz, 1H,
H-6a), 4.14 (dt, J = 3.4, 8.9 Hz, 1H, H-5), 4.39 (dt, J = 2.6, 8.6 Hz,
1H, H-1), 4.54 (dd, J = 8.6, 14.4 Hz, 1H, H-10a), 4.60 (dd, J = 9.1,
12.2 Hz, 1H, H-6b), 4.66 (dd, J = 2.7, 14.4 Hz, 1H, H-10b), 4.92 (dd,
J = 2.9, 4.8 Hz, 1H, H-4), 5.02 (dd, J = 3.3, 8.5 Hz, 1H, H-2), 5.33
(m, 1H, H-3), 7.37 (m, 1H, C5H4N-H5), 8.02 (s, 1H, C2N3H), 8.21
(d, J = 7.9 Hz, 1H, C5H4N-H6), 8.56 (s, 1H, C5H4N–H2), 9.00 (m,
1H, C5H4N-H4); 13C NMR (125 MHz, CDCl3): d 20.44, 20.61, 20.65,
20.74 (4 COCH3), 50.4 (C-10), 59.9 (C-6), 66.6 (C-2), 66.8 (C-3),
67.9 (C-4), 68.3 (C-1), 73.5 (C-5), 121.3 (C2N3H–C5), 123.8
(C5H4N–C5), 126.8 (C5H4N–C1), 133.0 (C5H4N–C6), 144.6
(C2N3H–C4), 146.7 (C5H4N–C2), 149.0 (C5H4N–C4), 169.1, 169.3,
169.5, 170.3 (4 COCH3); ESI-MS Calcd for C22H27N4O9 [M+H]+:
491.18, Found: 491.17.
4.1.6.23. 1-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyl)methyl-
4-phenoxymethyl-1,2,3-triazole (25s). Following general
procedure C, 24 (40 mg, 0.10 mmol) was reacted with phenylprop-
argyl ether (19s, 26 lL, 0.21 mmol), 0.2 M CuSO4 (103 lL, 21 lmol)
and 1 M sodium ascorbate (41 lL, 41 lmol) to yield 25s (51 mg,
96%).
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[a]D +2.34 (c 1.03, CHCl3); 1H NMR (500 MHz, CDCl3): d 2.00,
2.08, 2.12, 2.13 (4 s, 12H, 4 COCH3), 4.04 (dd, J = 4.1, 12.1 Hz, 1H,
H-6a), 4.15 (m, 1H, H-5), 4.37 (dt, J = 2.4, 8.6 Hz, 1H, H-1), 4.50
(dd, J = 8.7, 14.4 Hz, 1H, H-10a), 4.55 (dd, J = 9.0, 12.1 Hz, 1H, H-
6b), 4.63 (dd, J = 2.5, 14.4 Hz, 1H, H-10b), 4.96 (dd, J = 3.2, 4.9 Hz,
1H, H-4), 5.04 (dd, J = 3.3, 8.3 Hz, 1H, H-2), 5.34 (m, 1H, H-3),
6.96–6.99, 7.29–7.31 (m, 5H, C6H5), 7.80 (s, 1H, C2N3H); 13C NMR
(125 MHz, CDCl3): d 20.49, 20.62, 20.66, 20.74 (4 COCH3), 50.2
(C-10), 60.0 (C-6), 61.9 (CH2OPh), 66.7 (C-2), 66.9 (C-3), 67.8
(C-4), 68.5 (C-1), 73.3 (C-5), 114.6, 121.2 (3C, C6H5), 123.8
(C2N3H–C5), 129.5 (2C, C6H5), 144.3 (C2N3H–C4), 158.1 (C6H4–
C1), 169.1, 169.4, 169.6, 170.4 (4 COCH3); ESI-MS Calcd for
C24H30N3O9 [M+H]+: 520.19, Found: 520.16.
4.1.7. Synthesis of mannosyl triazoles
4.1.7.1. Sodium 4-[4-((a-D-mannopyranosyloxy)methyl)-1H-
1,2,3-triazol-1-yl]-benzoate (5a). To a solution of 12a
(48.0 mg, 85.2 lmol) in MeOH (4 mL) was added freshly prepared
1 M NaOMe in MeOH (0.4 mL) under argon. The mixture was stir-
red at rt for 3 h and then evaporated to dryness. The remains were
dissolved in H2O/dioxane (1:1, 5 mL) and treated with 1 M aq.
NaOH (0.5 mL) for 16 h. The solution was concentrated and the res-
idue purified by MPLC on RP-18 (H2O/MeOH) and P2 size exclusion
chromatography to give 5a (31.2 mg, 91%) as white powder after a
final lyophilization from water.
[a]D +41.7 (c 0.60, H2O); IR (KBr) 3413 (vs b, OH), 1607 (vs,
CO) cm"1; 1H NMR (500 MHz, D2O): d 3.60–3.66 (m, 2H, H-4, H-
5), 3.72 (dd, J = 5.5, 12.1 Hz, 1H, H-6a), 3.78 (dd, J = 3.4, 9.4 Hz,
1H, H-3), 3.82 (dd, J = 1.4, 12.2 Hz, 1H, H-6b), 3.93 (dd, J = 1.7,
3.4 Hz, 1H, H-2), 4.71 (m, 1H, H-10a), 4.82 (m, 1H, H-10b), 4.97 (s,
1H, H-1), 7.68 (m, 2H, C6H4), 7.94 (m, 2H, C6H4), 8.41 (m, 1H,
C2N3H); 13C NMR (125 MHz, D2O): d 59.7 (C-10), 60.8 (C-6), 66.6
(C-4), 69.9 (C-2), 70.4 (C-3), 72.9 (C-5), 99.5 (C-1), 120.2 (2C,
C6H4), 123.3 (C2N3H–C5), 130.3, 137.0, 137.7 (4C, C6H4), 144.2
(C2N3H–C4), 174.1 (CO); HR-MS Calcd for C16H19N3NaO8 [M+H]+:
404.1070, Found: 404.1071.
4.1.7.2. Sodium 3-[4-((a-D-mannopyranosyloxy)methyl)-1H-
1,2,3-triazol-1-yl]-benzoate (5b). According to the proce-
dure described for 5a, 12b (67.0 mg, 0.116 mmol) was subse-
quently treated with 1 M methanolic NaOMe (0.5 mL) in MeOH
(5 mL) and 1 M aq. NaOH (0.5 mL) in H2O/dioxane (1:1, 6 mL) to
yield 5b (37.7 mg, 81%).
[a]D +44.4 (c 0.89, H2O); IR (KBr) 3401 (vs b, OH), 1610 (vs,
CO) cm"1; 1H NMR (500 MHz, D2O): d 3.61–3.66 (m, 2H, H-4,
H-5), 3.72 (dd, J = 5.4, 12.2 Hz, 1H, H-6a), 3.78 (dd, J = 3.5, 9.5 Hz,
1H, H-3), 3.82 (dd, J = 1.5, 12.2 Hz, 1H, H-6b), 3.92 (dd, J = 1.7,
3.3 Hz, 1H, H-2), 4.69 (A of AB, J = 12.8 Hz, 1H, H-10a), 4.80 (m,
1H, H-10b), 4.96 (s, 1H, H-1), 7.51 (m, 1H, C6H4–H5), 7.69 (d,
J = 7.0 Hz, 1H, C6H4–H4), 7.87 (d, J = 7.7 Hz, 1H, C6H4-H6), 8.01 (s,
1H, C6H4-H2), 8.36 (m, 1H, C2N3H); 13C NMR (125 MHz, D2O): d
59.7 (C-10), 60.8 (C-6), 66.7 (C-4), 69.9 (C-2), 70.4 (C-3), 72.9 (C-
5), 99.5 (C-1), 120.8 (C6H4), 123.0 (C2N3H–C5), 123.3, 129.5,
129.8, 135.9, 138.1 (C6H4), 144.1 (C2N3H–C4), 173.6 (CO); HR-MS
Calcd for C16H19N3NaO8 [M+H]+: 404.1070, Found: 404.1068.
4.1.7.3. Sodium 5-[4-((a-D-mannopyranosyloxy)methyl)-1H-
1,2,3-triazol-1-yl]-nicotinate (5c). According to the proce-
dure described for 5a, 12c (41.0 mg, 72.6 lmol) was subsequently
treated with 1 M methanolic NaOMe (0.4 mL) in MeOH (4 mL) and
1 M aq. NaOH (0.4 mL) in H2O/dioxane (1:1, 4 mL) to yield 5c
(23.0 mg, 78%).
[a]D +36.0 (c 0.69, H2O); IR (KBr) 3413 (vs b, OH), 1616 (vs,
CO) cm"1; 1H NMR (500 MHz, D2O): d 3.61–3.66 (m, 2H, H-4, H-
5), 3.73 (dd, J = 5.4, 12.1 Hz, 1H, H-6a), 3.79 (dd, J = 3.5, 9.4 Hz,
1H, H-3), 3.83 (d, J = 12.0 Hz, 1H, H-6b), 3.94 (dd, J = 1.7, 3.2 Hz,
1H, H-2), 4.76, 4.87 (A, B of AB, J = 12.6 Hz, 1H, H-10), 4.99 (d,
J = 0.7 Hz, 1H, H-1), 8.47 (t, J = 2.0 Hz, 1H, C5H3N-H2), 8.56 (m,
1H, C2N3H), 8.96 (d, J = 2.1 Hz, 1H, C5H3N-H6), 8.97 (d, J = 1.4 Hz,
1H, C5H3N-H4); 13C NMR (125 MHz, D2O): d 59.7 (C-10), 60.8 (C-
6), 66.7 (C-4), 69.9 (C-2), 70.4 (C-3), 73.0 (C-5), 99.5 (C-1), 123.6
(C2N3H–C5), 129.5, 133.1, 133.4, 142.6 (C5H3N), 144.6
(C2N3H–C4), 149.7 (C5H3N), 171.1 (CO); HR-MS Calcd for
C15H17N4Na2O8 [M+Na]+: 427.0842, Found: 427.0844.
4.1.7.4. (1-Benzyl-1,2,3-triazol-4-yl)methyl a-D-mannopyrano-
side (5d). Following general procedure A, 14 (40 mg,
0.18 mmol) was reacted with benzyl azide (15d, 34 lL, 0.27 mmol),
CuSO4 (11 mg, 45 lmol) and sodium ascorbate (18 mg, 90 lmol) to
yield 5d (57 mg, 71%).
[a]D +53.3 (c 1.03, MeOH); 1H NMR (500 MHz, CD3OD): d 3.50
(m, 1H, H-5), 3.56 (t, J = 9.4 Hz, 1H, H-4), 3.60–3.68 (m, 2H, H-3,
H-6a), 3.73 (m, 1H, H-2), 3.79 (dd, J = 1.7, 11.7 Hz, 1H, H-6b),
4.60, 4.75 (A, B of AB, J = 12.4 Hz, 2H, H-10), 4.80 (d, J = 1.6 Hz,
1H, H-1), 5.56 (s, 2H, CH2Ph), 7.24–7.41 (m, 5H, C6H5), 7.97 (s,
1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 55.1 (CH2Ph), 60.8 (C-
10), 63.1 (C-6), 68.7 (C-4), 72.1 (C-2), 72.6 (C-3), 75.1 (C-5), 100.9
(C-1), 125.5 (C2N3H–C5), 129.3, 129.8, 130.2, 136.9 (6C, C6H5),
145.9 (C2N3H–C4); HR-MS Calcd for C16H21N3NaO6 [M+Na]+:
374.1328, Found: 374.1334.
4.1.7.5. [1-(40-Aminophenyl)-1,2,3-triazol-4-yl]methyl a-D-man-
nopyranoside hydrochloride (5e). Following general proce-
dure A, 14 (40 mg, 0.18 mmol) was reacted with 4-azidoaniline
hydrochloride (15e, 46 mg, 0.27 mmol), CuSO4 (11 mg, 45 lmol)
and sodium ascorbate (18 mg, 90 lmol) to yield 5e (19 mg, 27%).
[a]D +55.2 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.55–
3.60 (m, 2H, H-4, H-5), 3.64–3.72 (m, 2H, H-3, H-6a), 3.78 (m, 1H,
H-2), 3.83 (m, 1H, H-6b), 4.68, 4.82 (A, B of AB, J = 12.4 Hz, 2H, H-
10), 4.86 (m, 1H, H-1), 6.78, 7.45 (AA0, BB0 of AA0BB0, J = 8.7 Hz, 4H,
C6H4), 8.33 (s, 1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 60.8
(C-10), 63.2 (C-6), 68.8 (C-4), 72.2 (C-2), 72.6 (C-3), 75.2 (C-5),
100.9 (C-1), 116.2 (2C, C6H4), 123.3 (2C, C6H4), 123.7 (C2N3H–C5),
128.8 (C6H4–C1), 145.8 (C2N3H–C4), 150.8 (C6H4–C4); HR-MS Calcd
for C15H21N4O6 [M+H]+: 353.1461, Found: 353.1463.
4.1.7.6. (1-Adamantyl-1,2,3-triazol-4-yl)methyl a-D-mannopy-
ranoside (5f). Following general procedure A, 14 (40 mg,
0.18 mmol) was reacted with 1-azidoadamantane (15f, 48 mg,
0.27 mmol), CuSO4 (11 mg, 45 lmol) and sodium ascorbate
(18 mg, 90 lmol) to yield 5f (20 mg, 28%).
[a]D +50.5 (c 1.04, MeOH); 1H NMR (500 MHz, CD3OD): d 1.76–
1.88 (m, 6H, Ad), 2.24 (s, 9H, Ad), 3.50–3.60 (m, 2H, H-4, H-5),
3.61–3.70 (m, 2H, H-3, H-6a), 3.75 (dd, J = 1.7, 3.3 Hz, 1H, H-2),
3.82 (m, 1H, H-6b), 4.60, 4.76 (A, B of AB, J = 12.3 Hz, 2H, H-10),
4.80 (d, J = 1.4 Hz, 1H, H-1), 8.09 (s, 1H, C2N3H); 13C NMR
(125 MHz, CD3OD): d 31.1, 37.1, 44.0 (10 C, Ad), 60.9 (C-10), 63.2
(C-6), 68.8 (C-4), 72.2 (C-2), 72.6 (C-3), 75.1 (C-5), 100.9 (C-1),
122.2 (C2N3H–C5), 144.6 (C2N3H–C4); HR-MS Calcd for
C19H29N3NaO6 [M+Na]+: 418.1954, Found: 418.1951.
4.1.7.7. [1-(40-Methoxybenzyl)-1,2,3-triazol-4-yl]methyl a-D-
mannopyranoside (5g). Following general procedure A, 14
(50 mg, 0.23 mmol) was reacted with 4-methoxybenzylazide
(15g,38 57 mg, 0.35 mmol), CuSO4 (15 mg, 60 lmol) and sodium
ascorbate (24 mg, 120 lmol) to yield 5g (64 mg, 73%).
[a]D +66.6 (c 1.01, MeOH); 1H NMR (500 MHz, CD3OD): d 3.50
(m, 1H, H-5), 3.57 (t, J = 9.4 Hz, 1H, H-4), 3.61–3.69 (m, 2H, H-3,
H-6a), 3.74 (m, 4H, H-2, OCH3), 3.78 (dd, J = 1.7, 11.7 Hz, 1H, H-
6b), 4.58, 4.73 (A, B of AB, J = 12.4 Hz, 2H, H-10), 4.79 (m, 1H, H-
1), 5.46 (s, 2H, CH2Ar), 6.88, 7.25 (AA0, BB0 of AA0BB0, J = 8.6 Hz,
4H, C6H4), 7.91 (s, 1H, C2N3H);
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13C NMR (125 MHz, CD3OD): d 54.6 (CH2Ar), 55.8 (OCH3), 60.7
(C-10), 63.0 (C-6), 68.6 (C-4), 72.0 (C-2), 72.5 (C-3), 75.0 (C-5),
100.8 (C-1), 115.4 (2C, C6H4), 125.1 (C2N3H–C5), 128.6 (2C, C6H4),
130.8 (C6H4–C1), 145.6 (C2N3H–C4), 161.4 (C6H4–C4); HR-MS Calcd
for C17H23N3NaO7 [M+Na]+: 404.1434, Found: 404.1431.
4.1.7.8. [1-(30-Methoxybenzyl)-1,2,3-triazol-4-yl]methyl a-D-
mannopyranoside (5h). Following general procedure A, 14
(50 mg, 0.23 mmol) was reacted with 3-methoxybenzylazide
(15h,39 57 mg, 0.35 mmol), CuSO4 (15 mg, 60 lmol) and sodium
ascorbate (24 mg, 120 lmol) to yield 5h (68 mg, 77%).
[a]D +62.2 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.52
(m, 1H, H-5), 3.58 (t, J = 9.4 Hz, 1H, H-4), 3.61–3.70 (m, 2H, H-3,
H-6a), 3.70–3.84 (m, 5H, H-2, H-6b, OCH3), 4.60, 4.75 (A, B of AB,
J = 12.3 Hz, 2H, H-10), 4.81 (m, 1H, H-1), 5.52 (s, 2H, CH2Ar), 6.85
(s, 3H, C6H4), 7.24 (t, J = 7.9 Hz, 1H, C6H4), 7.98 (s, 1H, C2N3H);
13C NMR (125 MHz, CD3OD): d 55.5 (CH2Ar), 55.9 (OCH3), 60.8
(C-10), 63.0 (C-6), 68.7 (C-4), 72.1 (C-2), 72.6 (C-3), 75.1 (C-5),
100.9 (C-1), 114.9, 115.2, 121.4 (3C, C6H4), 125.6 (C2N3H–C5),
131.3 (C6H4), 138.2 (C6H4–C1), 145.8 (C2N3H–C4), 161.7 (C6H4–
C3); HR-MS Calcd for C17H23N3NaO7 [M+Na]+: 404.1434, Found:
404.1435.
4.1.7.9. [1-(40-Nitrophenyl)-1,2,3-triazol-4-yl]methyl a-D-man-
nopyranoside (5i). Following general procedure A, 14 (40 mg,
0.18 mmol) was reacted with 1-azido-4-nitrobenzene (15i,40
44 mg, 0.27 mmol), CuSO4 (11 mg, 45 lmol) and sodium ascorbate
(18 mg, 90 lmol) to yield 5i (31 mg, 44%).
[a]D +50.4 (c 1.02, MeOH); 1H NMR (500 MHz, CD3OD): d 3.56–
3.60 (m, 2H, H-4, H-5), 3.64–3.72 (m, 2H, H-3, H-6a), 3.80 (dd,
J = 1.7, 3.3 Hz, 1H, H-2), 3.84 (dd, J = 1.0, 11.7 Hz, 1H, H-66), 4.75
(A of AB, J = 12.5 Hz, 1H, H-10a), 4.88–4.91 (m, 2H, H-1, H-10b),
8.16 (m, 2H, C6H4), 8.44 (m, 2H, C6H4), 8.75 (s, 1H, C2N3H); 13C
NMR (125 MHz, CD3OD): d 60.9 (C-10), 63.2 (C-6), 68.8 (C-4), 72.1
(C-2), 72.6 (C-3), 75.3 (C-5), 101.2 (C-1), 122.0 (2C, C6H4), 123.9
(C2N3H–C5), 126.7 (2C, C6H4), 142.7 (C6H4–C1), 147.1 (C2N3H–
C4), 148.9 (C6H4–C4); HR-MS Calcd for C15H18N4NaO8 [M+Na]+:
405.1022, Found: 405.1020.
4.1.7.10. [1-(Pyridin-40-yl)-1,2,3-triazol-4-yl]methyl a-D-manno-
pyranoside (5j). Prepared from 16j (102 mg, 0.20 mmol)
according to general procedure D. Yield: 58 mg, 85%.
[a]D +70.3 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.53–
3.63 (m, 2H, H-4, H-5), 3.64–3.74 (m, 2H, H-3, H-6a), 3.77–3.87 (m,
2H, H-2, H-6b), 4.73 (A of AB, J = 12.6 Hz, 1H, H-10a), 4.84–4.92 (m,
2H, H-1, H-10b), 7.96, 8.67 (m, 4H, C5H4N), 8.77 (s, 1H, C2N3H); 13C
NMR (125 MHz, CD3OD): d 60.9 (C-10), 63.1 (C-6), 68.7 (C-4), 72.1
(C-2), 72.6 (C-3), 75.2 (C-5), 101.2 (C-1), 115.5 (2C, C5H4N), 123.5
(C2N3H–C5), 145.2 (C2N3H–C4), 147.2 (C5H4N–C1), 152.5 (2C,
C5H4N); HR-MS Calcd for C14H19N4O6 [M+H]+: 339.1305, Found:
339.1302.
4.1.7.11. [1-(40-Fluorophenyl)-1,2,3-triazol-4-yl]methyl a-D-man
nopyranoside (5k). Prepared from 16k (106 mg, 0.20 mmol)
according to general procedure D. Yield: 56 mg, 78%.
[a]D +78.5 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.60–
3.69 (m, 2H, H-4, H-5), 3.71–3.78 (m, 2H, H-3, H-6a), 3.86 (dd,
J = 1.7, 3.4 Hz, 1H, H-2), 3.89 (dd, J = 1.8, 11.8 Hz, 1H, H-6b), 4.77,
4.91 (A, B of AB, J = 12.5 Hz, 2H, H-10), 4.94 (d, J = 1.6 Hz, 1H, H-
1), 7.34, 7.89 (m, 4H, C6H4), 8.56 (s, 1H, C2N3H); 13C NMR
(125 MHz, CD3OD): d 60.9 (C-10), 63.2 (C-6), 68.8 (C-4), 72.2 (C-
2), 72.6 (C-3), 75.2 (C-5), 101.1 (C-1), 117.8 (d, J = 23.8 Hz, 2C,
C6H4), 124.0 (2C, C6H4), 124.0 (C2N3H–C5), 134.9 (d, J = 3.8 Hz,
C6H4–C1), 146.5 (C2N3H–C4), 164.1 (d, J = 246.3 Hz, C6H4–C4);
HR-MS Calcd for C15H18FN3NaO6 [M+Na]+: 378.1077, Found:
378.1079.
4.1.7.12. [1-(30-Fluorophenyl)-1,2,3-triazol-4-yl]methyl a-D-
mannopyranoside (5l). Prepared from 16l (105 mg, 0.20
mmol) according to general procedure D. Yield: 58 mg, 81%.
[a]D +73.8 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.51–
3.62 (m, 2H, H-4, H-5), 3.62–3.73 (m, 2H, H-3, H-6a), 3.78 (dd,
J = 1.6, 3.1 Hz, 1H, H-2), 3.84 (m, 1H, H-6b), 4.71 (A of AB,
J = 12.4 Hz, 1H, H-10a), 4.82–4.89 (m, 2H, H-1, H-10b), 7.23 (m,
1H, C6H4), 7.57 (m, 1H, C6H4), 7.64–7.74 (m, 2H, C6H4), 8.61 (s,
1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 60.8 (C-10), 63.1 (C-
6), 68.8 (C-4), 72.1 (C-2), 72.6 (C-3), 75.2 (C-5), 101.1 (C-1), 109.1
(d, J = 26.3 Hz, C6H4), 116.9 (d, J = 21.3 Hz, C6H4), 117.3 (d,
J = 3.8 Hz, C6H4), 123.8 (C2N3H–C5), 132.9 (d, J = 10.0 Hz, C6H4),
139.7 (d, J = 10.0 Hz, C6H4–C1), 146.6 (C2N3H–C4), 161.7 (d,
J = 245.0 Hz, C6H4–C3); HR-MS Calcd for C15H18FN3NaO6 [M+Na]+:
378.1077, Found: 378.1081.
4.1.7.13. [1-(40-Methoxyphenyl)-1,2,3-triazol-4-yl]methyl a-D-
mannopyranoside (5m). Prepared from 16m (113 mg,
0.21 mmol) according to general procedure D. Yield: 58 mg, 75%.
[a]D +37.4 (c 1.01, MeOH); 1H NMR (500 MHz, CD3OD): d
3.54–3.64 (m, 2H, H-4, H-5), 3.65–3.74 (m, 2H, H-3, H-6a),
3.80 (dd, J = 1.6, 3.2 Hz, 1H, H-2), 3.81–3.87 (m, 4H, H-6b,
OCH3), 4.69, 4.83 (A, B of AB, J = 12.4 Hz, 2H, H-10), 4.87 (m,
1H, H-1), 7.05, 7.68 (AA0, BB0 of AA0BB0, J = 9.0 Hz, 4H, C6H4),
8.42 (s, 1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 56.3
(OCH3), 60.8 (C-10), 63.1 (C-6), 68.8 (C-4), 72.2 (C-2), 72.6 (C-
3), 75.2 (C-5), 101.0 (C-1), 116.0 (2C, C6H4), 123.4 (2C, C6H4),
123.8 (C2N3H–C5), 131.7 (C6H4–C1), 146.1 (C2N3H–C4), 161.7
(C6H4–C4); HR-MS Calcd for C16H21N3NaO7 [M+Na]+: 390.1277,
Found: 390.1279.
4.1.7.14. [1-(30-Methoxybenzyl)-1,2,3-triazol-4-yl]ethyl a-D-man
nopyranoside (6h). Prepared from 17h (53 mg, 94 lmol)
according to general procedure D. Yield: 30 mg, 81%.
[a]D +45.9 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 2.99 (t,
J = 6.6 Hz, 2H, H-20), 3.41 (m, 1H, H-5), 3.57–3.75 (m, 4H, H-3, H-4,
H-6a, H-10a), 3.71 (dd, J = 1.7, 3.1 Hz, 1H, H-2), 3.78–3.83 (m, 4H, H-
6b, OCH3), 3.97 (dt, J = 6.7, 9.7 Hz, 1H, H-10b), 4.77 (d, J = 1.6 Hz, 1H,
H-1), 5.54 (s, 2H, CH2Ar), 6.80–6.96, 7.29 (m, 4H, C6H4), 7.79 (s, 1H,
C2N3H); 13C NMR (125 MHz, CD3OD): d 27.2 (C-20), 54.9 (CH2Ar),
55.9 (OCH3), 63.0 (C-6), 67.6 (C-10), 68.7 (C-4), 72.2 (C-2), 72.7
(C-3), 74.9 (C-5), 101.7 (C-1), 114.8, 115.1, 121.2 (3C, C6H4),
124.2 (C2N3H–C5), 131.3 (C6H4), 138.4 (C6H4–C1), 146.7 (C2N3H–
C4), 161.7 (C6H4–C3); HR-MS Calcd for C18H25N3NaO7 [M+Na]+:
418.1590, Found: 418.1591.
4.1.7.15. [1-(40-Nitrophenyl)-1,2,3-triazol-4-yl]ethyl a-D-manno-
pyranoside (6i). Prepared from 17i (61 mg, 0.11 mmol)
according to general procedure D. Yield: 37 mg, 86%.
[a]D +44.4 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.13 (t,
J = 6.5 Hz, 2H, H-20), 3.42 (m, 1H, H-5), 3.60 (t, J = 9.5 Hz, 1H, H-4),
3.64–3.73 (m, 2H, H-3, H-6a), 3.78–3.88 (m, 3H, H-2, H-6b, H-10a),
4.09 (dt, J = 6.6, 9.8 Hz, 1H, H-10b), 4.83 (d, J = 1.5 Hz, 1H, H-1), 8.18,
8.48 (m, 4H, C6H4), 8.55 (s, 1H, C2N3H); 13C NMR (125 MHz,
CD3OD): d 27.3 (C-20), 63.1 (C-6), 67.4 (C-10), 68.7 (C-4), 72.2 (C-
2), 72.8 (C-3), 75.0 (C-5), 101.8 (C-1), 122.0 (2C, C6H4), 122.5
(C2N3H–C5), 126.6 (2C, C6H4), 142.8 (C6H4–C1), 148.1 (C2N3H–
C4), 148.9 (C6H4–C4); HR-MS Calcd for C16H20N4NaO8 [M+Na]+:
419.1179, Found: 419.1177.
4.1.7.16. [1-(Pyridin-40-yl)-1,2,3-triazol-4-yl]ethyl a-D-manno-
pyranoside (6j). Prepared from 17j (63 mg, 0.12 mmol)
according to general procedure D. Yield: 31 mg, 73%.
[a]D +48.3 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.12 (t,
J = 6.5 Hz, 2H, H-20), 3.43 (m, 1H, H-5), 3.61 (t, J = 9.5 Hz, 1H, H-4),
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3.64–3.73 (m, 2H, H-3, H-6a), 3.77–3.87 (m, 3H, H-2, H-6b, H-10a),
4.08 (dt, J = 6.6, 9.8 Hz, 1H, H-10b), 4.83 (d, J = 1.5 Hz, 1H, H-1), 7.99
(dd, J = 1.6, 4.8 Hz, 2H, C5H4N), 8.58 (s, 1H, C2N3H), 8.74 (m, 2H,
C5H4N); 13C NMR (125 MHz, CD3OD): d 27.2 (C-20), 63.1 (C-6),
67.3 (C-10), 68.7 (C-4), 72.2 (C-2), 72.7 (C-3), 75.0 (C-5), 101.8 (C-
1), 115.5 (2C, C5H4N), 122.0 (C2N3H–C5), 145.3 (C5H4N–C1),
148.1 (C2N3H–C4), 152.4 (2C, C5H4N); HR-MS Calcd for
C15H21N4O6 [M+H]+: 353.1461, Found: 353.1460.
4.1.7.17. [1-(40-Fluorophenyl)-1,2,3-triazol-4-yl]ethyl a-D-man-
nopyranoside (6k). Prepared from 17k (65 mg, 0.12 mmol)
according to general procedure D. Yield: 40 mg, 90%.
[a]D +50.7 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): d 3.10 (t,
J = 6.5 Hz, 2H, H-20), 3.43 (m, 1H, H-5), 3.61 (t, J = 9.5 Hz, 1H, H-4),
3.65–3.74 (m, 2H, H-3, H-6a), 3.77–3.87 (m, 3H, H-2, H-6b, H-10a),
4.07 (dt, J = 6.6, 9.8 Hz, 1H, H-10b), 4.82 (d, J = 1.6 Hz, 1H, H-1), 7.34,
7.88 (m, 4H, C6H4), 8.33 (s, 1H, C2N3H); 13C NMR (125 MHz,
CD3OD): d 27.2 (C-20), 63.1 (C-6), 67.5 (C-10), 68.7 (C-4), 72.2 (C-
2), 72.8 (C-3), 75.0 (C-5), 101.8 (C-1), 117.8 (d, J = 23.8 Hz, 2C,
C6H4), 122.6 (C2N3H–C5), 124.0 (d, J = 8.8 Hz, 2C, C6H4), 135.0 (d,
J = 2.5 Hz, C6H4–C1), 147.4 (C2N3H–C4), 164.1 (d, J = 246.3 Hz,
C6H4–C4); HR-MS Calcd for C16H20FN3NaO6 [M+Na]+: 392.1234,
Found: 392.1238.
4.1.7.18. 1-(a-D-Mannopyranosyl)-4-phenyl-1,2,3-triazole
(7n). Prepared from 20n (50 mg, 0.11 mmol) according to
general procedure D. Yield: 29 mg, 89%.
[a]D +98.0 (c 1.34, MeOH); 1H NMR (500 MHz, CD3OD): d 3.38
(ddd, J = 2.5, 6.6, 8.9 Hz, 1H, H-5), 3.76–3.80 (m, 2H, H-4, H-6a),
3.85 (dd, J = 2.5, 12.1 Hz, 1H, H-6b), 4.12 (dd, J = 3.5, 8.5 Hz, 1H, H-
3), 4.76 (t, J = 3.1 Hz, 1H, H-2), 6.08 (d, J = 2.7 Hz, 1H, H-1), 7.34–
7.38, 7.43–7.46, 7.84–7.85 (m, 5H, C6H5), 8.51 (s, 1H, C2N3H); 13C
NMR (125 MHz, CD3OD): d 62.6 (C-6), 68.7 (C-4), 70.1 (C-2), 72.6
(C-3), 78.7 (C-5), 88.5 (C-1), 122.1 (C2N3H–C5), 126.8, 129.5, 130.0,
131.4 (6C, C6H5), 149.0 (C2N3H–C4); HR-MS Calcd for C14H17N3NaO5
[M+Na]+: 330.1066, Found: 330.1060.
4.1.7.19. 1-(a-D-Mannopyranosyl)-4-(4-methylphenyl)-1,2,3-tri-
azole (7o). Prepared from 20o (46 mg, 94 lmol) according to
general procedure D. Yield: 20 mg, 65%.
[a]D +84.6 (c 0.63, MeOH); 1H NMR (500 MHz, CD3OD): d 2.36 (s,
3H, PhCH3), 3.36 (ddd, J = 2.3, 6.7, 8.9 Hz, 1H, H-5), 3.74–3.78 (m,
2H, H-4, H-6a), 3.84 (dd, J = 2.4, 12.1 Hz, 1H, H-6b), 4.10 (dd,
J = 3.5, 8.5 Hz, 1H, H-3), 4.74 (t, J = 3.0 Hz, 1H, H-2), 6.05 (d,
J = 2.6 Hz, 1H, H-1), 7.25, 7.72 (AA0, BB0 of AA0BB0, J = 8.0 Hz, 4H,
C6H4), 8.45 (s, 1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 21.3
(PhCH3), 62.6 (C-6), 68.7 (C-4), 70.1 (C-2), 72.6 (C-3), 78.7 (C-5),
88.5 (C-1), 121.7 (C2N3H–C5), 126.7, 128.6, 130.6, 139.6 (6C,
C6H5), 149.2 (C2N3H–C4); HR-MS Calcd for C15H18N3NaO5
[M+Na]+: 344.1222, Found: 344.1215.
4.1.7.20. 4-(3-Chlorophenyl)-1-(a-D-mannopyranosyl)-1,2,3-tri-
azole (7p). Prepared from 20p (43 mg, 84 lmol) according to
general procedure D. Yield: 25 mg, 87%.
[a]D +89.2 (c 0.50, MeOH); 1H NMR (500 MHz, CD3OD): d 3.37
(ddd, J = 2.4, 6.7, 8.7 Hz, 1H, H-5), 3.77 (dd, J = 6.6, 12.2 Hz, 1H,
H-6a), 3.78 (t, J = 8.6 Hz, 1H, H-4), 3.87 (dd, J = 2.4, 12.1 Hz, 1H,
H-6b), 4.11 (dd, J = 3.5, 8.3 Hz, 1H, H-3), 4.75 (t, J = 3.1 Hz, 1H,
H-2), 6.07 (d, J = 2.6 Hz, 1H, H-1), 7.37 (d, J = 8.1 Hz, 1H, C6H4-
H6), 7.44 (t, J = 7.9 Hz, 1H, C6H4–H5), 7.79 (d, J = 7.7 Hz, 1H,
C6H4–H4), 7.90 (s, 1H, C6H4-H2), 8.58 (s, 1H, C2N3H); 13C NMR
(125 MHz, CD3OD): d 62.6 (C-6), 68.7 (C-4), 70.1 (C-2), 72.6 (C-
3), 78.7 (C-5), 88.6 (C-1), 122.7 (C2N3H–C5), 125.0, 126.6, 129.4,
131.6, 133.5, 136.0 (C6H4), 147.7 (C2N3H–C4); HR-MS Calcd for
C14H16ClN3NaO5 [M+Na]+: 364.0676, Found: 364.0676.
4.1.7.21. 4-(4-Trifluoromethylphenyl)-1-(a-D-mannopyranosyl)-
1,2,3-triazole (7q). Prepared from 20q (46 mg, 85 lmol)
according to general procedure D. Yield: 27 mg, 86%.
[a]D +83.4 (c 0.34, MeOH); 1H NMR (500 MHz, CD3OD): d 3.38
(m, 1H, H-5), 3.77–3.81 (m, 2H, H-4, H-6a), 3.85 (dd, J = 1.9,
12.0 Hz, 1H, H-6b), 4.11 (dd, J = 3.3, 8.4 Hz, 1H, H-3), 4.76 (t,
J = 2.7 Hz, 1H, H-2), 6.10 (d, J = 2.3 Hz, 1H, H-1), 7.76, 8.06 (AA0,
BB0 of AA0BB0, J = 8.0 Hz, 4H, C6H4), 8.66 (s, 1H, C2N3H); 13C NMR
(125 MHz, CD3OD): d 62.6 (C-6), 68.7 (C-4), 70.1 (C-2), 72.6 (C-3),
78.8 (C-5), 88.6 (C-1), 123.2 (C2N3H–C5), 125.6 (q, J = 272 Hz,
CF3), 127.0 (q, J = 3.7 Hz, 2C, C6H4–C3, C5), 127.2 (2C, C6H4–C2,
C6), 131.2 (d, J = 32.4 Hz, C6H4–C4), 135.5 (C6H4–C1), 147.6
(C2N3H–C4); HR-MS Calcd for C15H16F3N3NaO5 [M+Na]+:
398.0940, Found: 398.0942.
4.1.7.22. 1-(a-D-Mannopyranosyl)-4-(3-pyridyl)-1,2,3-triazole
(7r). Prepared from 20r (47 mg, 98 lmol) according to gen-
eral procedure D. Yield: 28 mg, 92%.
[a]D +86.7 (c 0.93, MeOH); 1H NMR (500 MHz, CD3OD): d 3.40
(ddd, J = 2.3, 6.6, 8.6 Hz, 1H, H-5), 3.77–3.82 (m, 2H, H-4, H-6a),
3.86 (dd, J = 2.4, 12.1 Hz, 1H, H-6b), 4.11 (dd, J = 3.5, 8.4 Hz, 1H,
H-3), 4.76 (t, J = 3.1 Hz, 1H, H-2), 6.11 (d, J = 2.7 Hz, 1H, H-1),
7.54 (dd, J = 5.0, 7.8 Hz, 1H, C5H4N-H5), 8.31 (m, 1H, C5H4N-H6),
8.53 (dd, J = 1.4, 4.9 Hz, 1H, C5H4N-H4), 8.68 (s, 1H, C2N3H), 9.04
(d, J = 1.5, 1H, C5H4N–H2); 13C NMR (125 MHz, CD3OD): d 62.6
(C-6), 68.7 (C-4), 70.1 (C-2), 72.6 (C-3), 78.8 (C-5), 88.6 (C-1),
123.1 (C2N3H–C5), 125.6 (C5H4N–C5), 128.5 (C5H4N–C1), 135.0
(C5H4N–C6), 145.6 (C2N3H–C4), 147.3 (C5H4N–C2), 149.7 (C5H4N–
C4); HR-MS Calcd for C13H16N4NaO5 [M+Na]+: 331.1018, Found:
331.1013.
4.1.7.23. 1-(a-D-Mannopyranosyl)-4-phenoxymethyl-1,2,3-tria-
zole (7s). Prepared from 20s (46 mg, 90 lmol) according to
general procedure D. Yield: 27 mg, 89%.
[a]D +57.0 (c 0.90, MeOH); 1H NMR (500 MHz, CD3OD): d 3.30
(m, 1H, H-5), 3.70–3.74 (m, 2H, H-4, H-6a), 3.78 (dd, J = 1.8,
12.1 Hz, 1H, H-6b), 4.04 (dd, J = 3.2, 8.4 Hz, 1H, H-3), 4.67 (m, 1H,
H-2), 5.14 (s, 2H, CH2OPh), 6.00 (d, J = 1.7 Hz, 1H, H-1), 6.91 (t,
J = 7.3 Hz, 1H, C6H5-H4), 6.96 (d, J = 8.1 Hz, 2H, C6H5-H2, H6),
7.24 (t, J = 7.8 Hz, 2H, C6H5-H3, H5), 8.20 (s, 1H, C2N3H); 13C NMR
(125 MHz, CD3OD): d 62.2 (CH2OPh), 62.5 (C-6), 68.6 (C-4), 70.1
(C-2), 72.5 (C-3), 78.6 (C-5), 88.4 (C-1), 115.8 (2C, C6H5–C2, C6),
122.3 (C6H5–C4), 125.3 (C2N3H–C5), 130.5 (2C, C6H5–C3, C5),
145.4 (C2N3H–C4), 159.7 (C6H5–C1); HR-MS Calcd for
C15H19N3NaO5 [M+Na]+: 360.1172, Found: 360.1171.
4.1.7.24. 1-(a-D-Mannopyranosyl)methyl-4-phenyl-1,2,3-tria-
zole (8n). Prepared from 25n (38 mg, 78 lmol) according to
general procedure D. Yield: 22 mg, 87%.
[a]D +30.6 (c 0.91, MeOH); 1H NMR (500 MHz, CD3OD): d 3.73–
3.75 (m, 2H, H-4, H-6a), 3.79–3.85 (m, 3H, H-2, H-3, H-5), 3.88 (dd,
J = 7.2, 11.5 Hz, 1H, H-6b), 4.25 (dt, J = 4.8, 7.9 Hz, 1H, H-1), 4.73
(dd, J = 8.0, 14.4 Hz, 1H, H-10a), 4.76 (dd, J = 4.5, 14.3 Hz, 1H, H-
10b), 7.33 (t, J = 7.7 Hz, 1H, C6H5-H4), 7.42 (t, J = 7.8 Hz, 2H, C6H5-
H3, H5), 7.81 (d, J = 8.0 Hz, 2H, C6H5-H2, H6), 8.45 (s, 1H, C2N3H);
13C NMR (125 MHz, CD3OD): d 50.9 (C-10), 62.1 (C-6), 69.1 (C-2),
70.0 (C-4), 72.5 (C-3), 74.9 (C-1), 78.5 (C-5), 123.4 (C2N3H–C5),
126.7, 129.3, 129.9, 131.8 (6C, C6H5), 148.8 (C2N3H–C4); HR-MS
Calcd for C15H19NaN3O5 [M+Na]+: 344.1222, Found: 344.1222.
4.1.7.25. 1-(a-D-Mannopyranosyl)methyl-4-(4-methylphenyl)-
1,2,3-triazole (8o). Prepared from 25o (42 mg, 84 lmol)
according to general procedure D. Yield: 25 mg, 87%.
[a]D +33.8 (c 1.12, MeOH); 1H NMR (500 MHz, CD3OD): d 2.35
(PhCH3), 3.72–3.76 (m, 2H, H-4, H-6a), 3.80 (dt, J = 3.2, 7.1 Hz,
1H, H-5), 3.81–3.85 (m, 2H, H-2, H-3), 3.87 (dd, J = 7.1, 11.5 Hz,
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1H, H-6b), 4.24 (dt, J = 5.1, 7.4 Hz, 1H, H-1), 4.72–4.75 (m, 2H, H-
10), 7.24, 7.69 (AA0, BB0 of AA0BB0, J = 8.0 Hz, 4H, C6H4), 8.40 (s, 1H,
C2N3H); 13C NMR (125 MHz, CD3OD): d 21.3 (PhCH3), 50.8 (C-10),
62.0 (C-6), 69.1 (C-2), 69.9 (C-4), 72.4 (C-3), 75.0 (C-1), 78.4 (C-
5), 123.0 (C2N3H–C5), 126.6, 128.9, 130.5, 139.3 (6C, C6H5), 148.9
(C2N3H–C4); HR-MS Calcd for C16H21NaN3O5 [M+Na]+: 358.1379,
Found: 358.1380.
4.1.7.26. 4-(3-Chlorophenyl)-1-(a-D-mannopyranosyl)methyl-
1,2,3-triazole (8p). Prepared from 25p (40 mg, 77 lmol)
according to general procedure D. Yield: 23 mg, 83%.
[a]D +31.5 (c 1.05, MeOH); 1H NMR (500 MHz, CD3OD): d 3.73
(m, 1H, H-4), 3.74 (dd, J = 3.0, 11.5 Hz, 1H, H-6a), 3.79–3.82 (m,
2H, H-3, H-5), 3.83 (dd, J = 3.4, 8.7 Hz, 1H, H-2), 3.89 (dd, J = 7.4,
11.6 Hz, 1H, H-6b), 4.24 (dt, J = 4.7, 7.9 Hz, 1H, H-1), 4.73 (dd,
J = 8.0, 14.4 Hz, 1H, H-10a), 4.77 (dd, J = 4.4, 14.5 Hz, 1H, H-10b),
7.33 (dd, J = 0.9, 8.1 Hz, 1H, C6H4-H6), 7.41 (t, J = 7.9 Hz, 1H,
C6H4–H5), 7.74 (d, J = 7.8 Hz, 1H, C6H4–H4), 7.90 (t, J = 1.6 Hz, 1H,
C6H4-H2), 8.51 (s, 1H, C2N3H); 13C NMR (125 MHz, CD3OD): d
50.9 (C-10), 62.0 (C-6), 69.0 (C-2), 70.0 (C-4), 72.4 (C-3), 74.7 (C-
1), 78.5 (C-5), 124.0 (C2N3H–C5), 124.9, 126.5, 129.1, 131.5,
133.9, 135.9 (6C, C6H4), 147.4 (C2N3H–C4); HR-MS Calcd for
C15H18ClNaN3O5 [M+Na]+: 378.0833, Found: 378.0833.
4.1.7.27. 4-(4-Trifluoromethylphenyl)-1-(a-D-mannopyrano-
syl)methyl-1,2,3-triazole (8q). Prepared from 25q (47 mg,
84 lmol) according to general procedure D. Yield: 28 mg, 86%.
[a]D +32.6 (c 1.03, MeOH); 1H NMR (500 MHz, CD3OD): d 3.73–
3.76 (m, 2H, H-4, H-6a), 3.81–3.86 (m, 3H, H-2, H-3, H-5), 3.89 (dd,
J = 7.5, 11.5 Hz, 1H, H-6b), 4.25 (dt, J = 4.8, 7.9 Hz, 1H, H-1), 4.76
(dd, J = 8.0, 14.5 Hz, 1H, H-10a), 4.79 (dd, J = 4.4, 14.5 Hz, 1H, H-
10b), 7.72, 8.01 (AA0, BB0 of AA0BB0, J = 8.2 Hz, 4H, C6H4), 8.60 (s,
1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 51.0 (C-10), 62.0 (C-6),
69.0 (C-2), 70.0 (C-4), 72.4 (C-3), 74.7 (C-1), 78.6 (C-5), 124.5
(C2N3H–C5), 125.6 (q, J = 271 Hz, CF3), 126.9 (q, J = 3.7 Hz, 2C,
C6H4–C3, C5), 127.0 (2C, C6H4–C2, C6), 130.9 (q, J = 32.4 Hz,
C6H4–C4), 135.7 (C6H4–C1), 147.2 (C2N3H–C4); HR-MS Calcd for
C16H18F3NaN3O5 [M+Na]+: 412.1096, Found: 412.1095.
4.1.7.28. 1-(a-D-Mannopyranosyl)methyl-4-(3-pyridyl)-1,2,3-tri-
azole (8r). Prepared from 25r (44 mg, 90 lmol) according to
general procedure D. Yield: 24 mg, 83%.
[a]D +31.2 (c 0.99, MeOH); 1H NMR (500 MHz, CD3OD): d 3.71–
3.74 (m, 2H, H-4, H-6a), 3.80–3.83 (m, 3H, H-2, H-3, H-5), 3.89 (dd,
J = 7.7, 11.6 Hz, 1H, H-6b), 4.23 (dt, J = 4.6, 8.6 Hz, 1H, H-1), 4.76
(dd, J = 8.4, 14.4 Hz, 1H, H-10a), 4.80 (dd, J = 4.2, 14.4 Hz, 1H, H-
10b), 7.53 (dd, J = 5.0, 7.9 Hz, 1H, C5H4N-H5), 8.28 (d, J = 8.0 Hz,
1H, C5H4N-H6), 8.51 (d, J = 4.8 Hz, 1H, C5H4N-H4), 8.63 (s, 1H,
C2N3H), 9.02 (s, 1H, C5H4N–H2); 13C NMR (125 MHz, CD3OD): d
48.1 (C-10), 60.6 (C-6), 67.2 (C-2), 68.5 (C-4), 70.6 (C-3), 75.1 (C-
1), 76.2 (C-5), 123.2 (C2N3H–C5), 124.5 (C5H4N–C5), 126.82
(C5H4N–C1), 134.3 (C5H4N–C6), 144.4 (C2N3H–C4), 145.7 (C5H4N–
C2), 148.4 (C5H4N–C4); HR-MS Calcd for C14H18NaN4O5 [M+Na]+:
345.1175, Found: 345.1175.
4.1.7.29. 1-(a-D-Mannopyranosyl)methyl-4-phenoxymethyl-
1,2,3-triazole (8s). Prepared from 25s (41 mg, 79 lmol)
according to general procedure D. Yield: 23 mg, 83%.
[a]D +22.8 (c 1.01, MeOH); 1H NMR (500 MHz, CD3OD): d 3.69–
3.76 (m, 3H, H-4, H-5, H-6a), 3.79–3.82 (m, 2H, H-2, H-3), 3.83 (dd,
J = 6.5, 11.5 Hz, 1H, H-6b), 4.19 (dt, J = 5.0, 7.0 Hz, 1H, H-1), 4.69
(dd, J = 7.5, 14.5 Hz, 1H, H-10a), 4.72 (dd, J = 5.0, 14.5 Hz, 1H, H-
10b), 5.15 (s, 2H, CH2OPh), 6.94 (t, J = 7.4 Hz, 1H, C6H5-H4), 7.00
(d, J = 8.1 Hz, 2H, C6H5-H2, H6), 7.27 (m, 2H, C6H5-H3, H5), 8.17
(s, 1H, C2N3H); 13C NMR (125 MHz, CD3OD): d 50.9 (C-10), 62.0
(C-6), 62.3 (CH2OPh), 69.0 (C-2), 69.8 (C-4), 72.4 (C-3), 74.9 (C-1),
78.4 (C-5), 115.9 (2C, C6H5–C2, C6), 122.2 (C6H5–C4), 126.4
(C2N3H–C5), 130.5 (2C, C6H5–C3, C5), 145.0 (C2N3H–C4), 159.8
(C6H5–C1); HR-MS Calcd for C16H21N3NaO5 [M+Na]+: 374.1328,
Found: 374.1328.
4.2. Biological evaluation
4.2.1. Competitive binding assay
A recombinant protein consisting of the CRD of FimH linked
with a thrombin cleavage site to a 6His-tag (FimH-CRD-Th-6His)
was expressed in E. coli strain HM125 and purified by affinity chro-
matography.45 To determine the affinity of the various FimH antag-
onists, an competitive binding assay described previously45 was
applied. Microtiter plates (F96 MaxiSorp, Nunc) were coated with
100 lL/well of a 10 lg/mL solution of FimH-CRD-Th-6His in
20 mM HEPES, 150 mMNaCl and 1 mM CaCl2, pH 7.4 (assay buffer)
overnight at 4 "C. The coating solution was discarded and the wells
were blocked with 150 lL/well of 3% BSA in assay buffer for 2 h at
4 "C. After three washing steps with assay buffer (150 lL/well), a
four-fold serial dilution of the test compound (50 lL/well) in assay
buffer containing 5% DMSO and streptavidin-peroxidase coupled
TM-PAA polymer (50 lL/well of a 0.5 lg/mL solution) were added.
On each individual microtiter plate n-heptyl a-D-mannopyranoside
(1b) was tested in parallel. The plates were incubated for 3 h at
25 "C and 350 rpm and then carefully washed four times with
150 lL/well assay buffer. After the addition of 100 lL/well of
ABTS-substrate, the colorimetric reaction was allowed to develop
for 4 min, then stopped by the addition of 2% aqueous oxalic acid
before the optical density (OD) was measured at 415 nm on a
microplate-reader (Spectramax 190, Molecular Devices, California,
USA). The IC50 values of the compounds tested in duplicates were
calculated with prism software (GraphPad Software, Inc., La Jolla,
USA). The IC50 defines the molar concentration of the test com-
pound that reduces the maximal specific binding of TM-PAA poly-
mer to FimH-CRD by 50%. The relative IC50 (rIC50) is the ratio of the
IC50 of the test compound to the IC50 of 1b.
4.2.2. Aggregometry assay
The aggregometry assay was carried out as previously de-
scribed.46 In short, the percentage of aggregation of E. coli
UTI8959 (UTI89wt) with guinea pig erythrocytes (GPE) was quanti-
tatively determined by measuring the optical density at 740 nm
and 37 "C under stirring at 1000 rpm using an APACT 4004 aggre-
gometer (Endotell AG, Allschwil, Switzerland). GPE were separated
from guinea pig blood (Charles River Laboratories, Sulzfeld, Ger-
many) using Histopaque (density of 1.077 g/mL at 24 "C, Sigma-Al-
drich, Buchs, Switzerland). Prior to the measurements, the cell
densities of E. coli and GPE were adjusted to an OD600 of 4, corre-
sponding to 1.9 # 108 CFU/mL and 2.2 # 106 cells/mL respectively.
For the calibration of the instrument, the aggregation of protein
poor plasma (PPP) using PBS alone was set as 100% and the aggre-
gation of protein rich plasma (PRP) using GPE as 0%. After calibra-
tion, measurements were performed with 250 lL GPE and 50 lL
bacterial suspension and the aggregation monitored over 600 s.
After the aggregation phase of 600 s, 25 lL of antagonist in PBS
were added to each cuvette and disaggregation was monitored
for 1400 s. UTI89 DfimA-H was used as negative control.
4.3. Determination of the pharmacokinetic parameters
4.3.1. Materials
Dimethyl sulfoxide (DMSO) and 1-octanol were purchased from
Sigma-Aldrich (St. Louis MI, USA). PAMPA System Solution, GIT-0
Lipid Solution, and Acceptor Sink Buffer were ordered from pIon
(Woburn MA, USA). Acetonitrile (MeCN) was bought from Acros
Organics (Geel, Belgium).
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4.3.2. LC–MS measurements
Analyses were performed using an Agilent 1100/1200 Series
HPLC System coupled to a 6410 Triple Quadrupole mass detector
(Agilent Technologies, Inc., Santa Clara CA, USA) equippedwith elec-
trospray ionization. The system was controlled with the Agilent
MassHunter Workstation Data Acquisition software (version
B.01.04). The column used was an Atlantis# T3 C18 column (2.1 x
50 m) with a 3 lm particle size (Waters Corp., Milford MA, USA).
Themobile phase consisted of two eluents: solvent A (H2O, contain-
ing 0.1% formic acid, v/v) and solvent B (MeCN, containing 0.1% for-
mic acid, v/v), both delivered at 0.6 mL/min. The gradient was
ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold
at 5% A/95% B for 0.1 min. The system was then brought back to
95% A/5% B, resulting in a total duration of 4 min. MS parameters
such as fragmentor voltage, collision energy and polarity were opti-
mized individually for each compound, and the molecular ion was
followed for each compound in the multiple reaction monitoring
mode. Theconcentrationsof the analyteswerequantifiedby theAgi-
lent Mass Hunter Quantitative Analysis software (version B.01.04).
4.3.3. log D7.4 determination
The in silico prediction tool ALOGPS60 was used to estimate the
log P values. Depending on these values, the compounds were clas-
sified into three categories: hydrophilic compounds (log P below
zero), moderately lipophilic compounds (log P between zero and
one) and lipophilic compounds (log P above one). For each cate-
gory, two different ratios (volume of 1-octanol to volume of buffer)
were defined as experimental parameters:
Compound type log P Ratios (1-octanol:buffer)
Hydrophilic <0 30:140, 40:130
Moderately lipophilic 0–1 70:110, 110:70
Lipophilic >1 3:180, 4:180
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octa-
nol were mixed and shaken vigorously for 5 min to saturate the
phases. The mixture was left until separation of the two phases oc-
curred, and the buffer was retrieved. Stock solutions of the test
compounds were diluted with buffer to a concentration of 1 lM.
For each compound, six determinations, that is, three determina-
tions per 1-octanol : buffer ratio, were performed in different wells
of a 96-well plate. The respective volumes of buffer containing ana-
lyte (1 lM) were pipetted to the wells and covered by saturated 1-
octanol according to the chosen volume ratio. The plate was sealed
with aluminium foil, shaken (1350 rpm, 25 "C, 2 h) on a Heidoph
Titramax 1000 plate-shaker (Heidolph Instruments GmbH & Co.
KG, Schwabach, Germany) and centrifuged (2000 rpm, 25 "C,
5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The
aqueous phase was transferred to a 96-well plate for analysis by li-
quid chromatography-mass spectrometry (LC-MS).
log D7.4 was calculated from the 1-octanol : buffer ratio (o:b),
the initial concentration of the analyte in buffer (1 lM), and the
concentration of the analyte in buffer (cB) with equilibration:
logD7:4 ¼ 1lM " cBcB #
1
o : b
! "
The average of the three log D7.4 values per 1-octanol:buffer ra-
tio was calculated. If the two mean values obtained for a com-
pound did not differ by more than 0.1 unit, the results were
accepted.
4.3.4. Parallel artificial membrane permeation assay (PAMPA)
log Pe was determined in a 96-well format with the PAMPA50
permeation assay. For each compound, measurements were
performed at three pH values (5.0, 6.2 and 7.4) in quadruplicates.
For this purpose, 12 wells of a deep well plate, that is, four wells
per pH-value, were filled with 650 lL PAMPA System Solution.
Samples (150 lL) were withdrawn from each well to determine
the blank spectra by UV-spectroscopy (SpectraMax 190, Molecular
Devices, Silicon Valley Ca, USA). Then, analyte dissolved in DMSO
was added to the remaining PAMPA System Solution to yield
50 lM solutions. To exclude precipitation, the optical density
was measured at 650 nm, with 0.01 being the threshold value.
Solutions exceeding this threshold were filtrated. Afterwards, sam-
ples (150 lL) were withdrawn to determine the reference spectra.
Further 200 lL were transferred to each well of the donor plate of
the PAMPA sandwich (pIon, Woburn MA, USA, P/N 110 163). The
filter membranes at the bottom of the acceptor plate were impreg-
nated with 5 lL of GIT-0 Lipid Solution and 200 lL of Acceptor Sink
Buffer were filled into each acceptor well. The sandwich was
assembled, placed in the GutBox™, and left undisturbed for 16 h.
Then, it was disassembled and samples (150 lL) were transferred
from each donor and acceptor well to UV-plates. Quantification
was performed by both UV-spectroscopy and LC-MS. log Pe-values
were calculated with the aid of the PAMPA Explorer Software
(pIon, version 3.5).
4.3.5. Thermodynamic solubility
Microanalysis tubes (Labo-Tech J. Stofer LTS AG, Muttenz, Swit-
zerland) were charged with 1 mg of solid substance and 250 lL of
phosphate buffer (50 mM, pH 6.5). The samples were briefly sha-
ken by hand, then sonicated for 15 min and vigorously shaken
(600 rpm, 25 "C, 2 h) on a Eppendorf Thermomixer comfort. After-
wards, the samples were left undisturbed for 24 h. After measuring
the pH, the saturated solutions were filtered through a filtration
plate (MultiScreen# HTS, Millipore, Billerica MA, USA) by centrifu-
gation (1500 rpm, 25 "C, 3 min). Prior to concentration determina-
tion by LC-MS, the filtrates were diluted (1:1, 1:10 and 1:100 or, if
the results were outside of the calibration range, 1:1000 and
1:10000). The calibration was based on six values ranging from
0.1 to 10 lg/mL.
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FimH Antagonists: Structure–Activity and Structure–
Property Relationships for Biphenyl a-d-
Mannopyranosides
Lijuan Pang, Simon Kleeb, Katrin Lemme, Said Rabbani, Meike Scharenberg, Adam Zalewski,
Florentina Sch!dler, Oliver Schwardt, and Beat Ernst*[a]
Introduction
Urinary tract infections (UTIs), the most prevalent series of in-
fectious diseases worldwide, affect millions of people and ac-
count for significant morbidity as well as high medical costs.[1]
The primary cause of UTIs are strains of uropathogenic Escheri-
chia coli (UPEC), which make up 70–95% of reported cases.[1a,2]
UTIs are treated with antibiotics; however, recurrent infections
by UPEC with subsequent antibiotic exposure can lead to the
emergence of antimicrobial resistance.[3]
Adhesion to host cells is the initial step of microbial infec-
tion. To gain an initial foothold within the bladder, UPEC strains
encode filamentous surface-adhesive organelles called type 1
pili (fimbriae).[4] They mediate bacterial attachment to uropla-
kin Ia, a glycoprotein located on urothelial cells. This initial
step prevents the clearance of E. coli by the bulk flow of urine
and facilitates the invasion of host cells.[1b,5] A bacterial lectin
known as FimH is located at the tips of type 1 pili. The carbo-
hydrate recognition domain (CRD) of this lectin is responsible
for binding to the complementary carbohydrate epitope of the
host tissue. Blocking this lectin by a carbohydrate or a glycomi-
metic thereof offers a potential therapeutic approach for pre-
vention and/or treatment of UTIs.[6]
More than two decades ago, Sharon and co-workers ex-
plored various mannosides and oligomannosides as potential
antagonists for type 1 pili-mediated bacterial adhesion and ob-
served interactions in the micro- to millimolar range.[7] The first
crystal structure of FimH was solved in 1999,[8] and since then,
numerous crystallographic studies have been reported, greatly
facilitating the design of high-affinity ligands.[9] In summary,
the reported affinities can be rationalized on the basis of the
structure of FimH: First, the binding pocket accommodates the
mannose with the hydroxy groups forming an extended hy-
drogen bond network. Second, the entrance to the binding
site, referred to as the “tyrosine gate”, is formed by three hy-
drophobic amino acids (Tyr48, Tyr137, and Ile52)[9a] and can
host aliphatic and aromatic aglycones.
As a consequence of hydrophobic contacts of the alkyl agly-
cone, n-heptyl a-d-mannopyranoside (1) exhibits nanomolar
affinity.[9b] With aromatic aglycones such as 2–5 (Figure 1), fur-
ther improvements in affinity were observed.[10] To explore the
binding mode and to improve affinity as well as ADME proper-
ties, a series of biphenyl FimH antagonists were synthesized.
Results and Discussion
An unexpected docking mode was discovered upon co-crystal-
lization of biphenyl mannoside 3 with the FimH CRD.[10d]
Whereas the alkyl aglycone of n-butyl a-d-mannopyranoside[9b]
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Urinary tract infections (UTIs) are caused primarily by uropa-
thogenic Escherichia coli (UPEC), which encode filamentous sur-
face-adhesive organelles called type 1 pili. FimH is located at
the tips of these pili. The initial attachment of UPEC to host
cells is mediated by the interaction of the carbohydrate recog-
nition domain (CRD) of FimH with oligomannosides on urothe-
lial cells. Blocking these lectins with carbohydrates or ana-
logues thereof prevents bacterial adhesion to host cells and
therefore offers a potential therapeutic approach for preven-
tion and/or treatment of UTIs. Although numerous FimH an-
tagonists have been developed so far, few of them meet the
requirement for clinical application due to poor pharmacoki-
netics. Additionally, the binding mode of an antagonist to the
CRD of FimH can switch from an in-docking mode to an out-
docking mode, depending on the structure of the antagonist.
In this communication, biphenyl a-d-mannosides were modi-
fied to improve their binding affinity, to explore their binding
mode, and to optimize their pharmacokinetic properties. The
inhibitory potential of the FimH antagonists was measured in
a cell-free competitive binding assay, a cell-based flow cytome-
try assay, and by isothermal titration calorimetry. Furthermore,
pharmacokinetic properties such as logD, solubility, and mem-
brane permeation were analyzed. As a result, a structure–activi-
ty and structure–property relationships were established for
a series of biphenyl a-d-mannosides.
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interacts with both Tyr48 and Tyr137 of the tyrosine gate (in-
docking mode),[10f] the biphenyl aglycone adopts the out-dock-
ing mode; that is, it interacts only with Tyr48 (Figure 2A), prob-
ably due to insufficient flexibility; p–p stacking of the outer ar-
omatic ring of the biphenyl aglycone (ring B) with Tyr48 is ef-
fected by induced fit : a substantial move of Tyr48. Moreover,
further stabilization of the protein–ligand complex by polar in-
teraction between the ester in the meta position of 3 and the
side chain of Arg98 was proposed.[10d]
In silico docking studies with biphenyl derivative 4a[10e] sug-
gested a similar out-docking mode (Figure 2B). A close inspec-
tion revealed empty space between the ortho position of the
aromatic ring adjacent to the anomeric center (ring A) and the
protein surface. Indeed, with an ortho-chloro substituent (!
5a, Figure 1), affinity was substantially improved. Further stud-
ies with FimH antagonists that exhibit enhanced flexibility
(e.g. , compound 6; Figure 2C and Figure 3) indicated a switch
from the out-docking mode to the in-docking mode. However,
whether an optimal p–p stacking within the tyrosine gate can
be realized remains to be determined. Finally, docking studies
also indicated that elongation of the carboxylate-bearing para
substituent enables a polar interaction between the carboxyl-
ate and Arg98 (e.g. , compound 7; Figure 2D and Figure 3).
Starting from antagonist 4, we explored three types of
modifications (Figure 3):
1) For optimizing the van der Waals contact between the
ortho position of ring A and the binding pocket, a series of
substituents — F, CH3, CF3, OCH3, cyclopropyl, and CN —
were introduced as depicted in Scheme 1.
2) To determine whether the out-docking mode reported for
3[10d] results from insufficient flexibility, we increased the
aglycone flexibility by introducing a methylene spacer be-
tween the anomeric oxygen and ring A of the biphenyl
moiety (Scheme 2). This should decrease the conformation-
al constraints to allow an optimized spatial arrangement of
the aglycone in the tyrosine gate (!6, Figure 2C); at the
same time, water solubility
should be improved as
a result of the decreased
stacking tendency derived
from disruption of the sym-
metry of the aglycone.[15]
3) To enable a polar interaction
between the carboxylate
substituent on ring B with
Arg98 of FimH, we extended
the para substituent of 4,
that is, we replaced it with
either a flexible methyl etha-
nolate or a rigid methyl cy-
clopropanecarboxylate
(Scheme 3). Biphenyl a-d-
mannoside 24[10d] shows
a three- to eightfold lower af-
finity for FimH than its coun-
terparts with a methoxycar-
bonyl substituent at the
meta (!3)[10d] or para posi-
tions (!4)[10e] of ring B
(Table 1). Han et al. assigned
the increased affinity of com-
pound 3 to a polar interac-
tion of the ester with Arg98
of FimH.[10d] Because for spa-
tial reasons the ester in the
Figure 1. FimH antagonists : n-heptyl a-d-mannopyranoside (1) is used as
reference compound; the squaric acid derivative 2 and biphenyl derivatives
3–5 exhibit nanomolar affinities.
Figure 2. A) Crystal structure of biphenyl 3 (PDB ID: 3MCY)[10d] bound to the FimH CRD. B–D) In silico docking
studies obtained with flexible docking (Glide software package)[11] to the same FimH CRD structure; top-scored
binding mode of B) 4a, C) 6, and D) 7.
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para-substituted derivative 4 cannot establish a similar in-
teraction with Arg98, the substantial improvement in affini-
ty may result from solvation effects.
Synthesis
Optimization of ortho substituents (Scheme 1)
Mannosylation of phenols 9a–f with mannosyl fluoride 8 and
BF3·OEt2 as promoter yielded a-mannosides 10a–f stereospe-
cifically.[12] Whereas the phenols 9a–d and 9 f are commercially
available, the cyclopropyl derivative 9e was prepared via
tandem carbolithiation/1,3-elimination according to Ocasio
and Scanlan.[13] In a palladium-catalyzed Miyaura–Suzuki cou-
pling[14] of 10a–f with 4-methoxycarbonylphenylboronic acid
(11), biphenyls 12a–f were obtained in good to excellent
yields. Deacetylation using Zempl#n conditions (!13a–f) fol-
lowed by saponification of the methyl esters gave the test
compounds 14a–e. Owing to the instability of the cyano
group under aqueous basic conditions, 14 f was synthesized
by coupling 10 f with 4-carboxyphenylboronic acid pinacol
ester (15) followed by transesterification under Zempl#n condi-
tions to avoid the final saponification with aqueous sodium hy-
droxide.
Increase in aglycone flexibility (Scheme 2)
Benzyl alcohols 16a–c were first mannosylated with donor 8[12]
to yield the benzyl mannosides 17a–c. Subsequent cross-cou-
pling with 4-methoxycarbonylphenylboronic acid (11) afforded
acetates 18a,b and 21. Deacetylation of the mannose moiety
(!19a,b and 22) followed by
saponification of the methyl
esters gave compounds 6, 20,
and 23.
Elongation of the carboxylate-
bearing para substituent
(Scheme 3)
Peracetylated mannose 25 was
treated with 4-iodophenol in the
presence of BF3·Et2O. The result-
ing iodide 26 was transformed
into boronic acid pinacol ester
27, which was coupled with 4-
bromophenylacetic acid methyl
ester (28) and 4-bromophenylcy-
clopropylcarboxylic acid methyl
ester (32) under Miyaura–Suzuki
coupling conditions[14] to yield
biphenyls 29 and 33. Deacetyla-
tion with sodium methoxide (!
30 and 34) followed by saponification of the methyl ester
yielded the sodium salts 31 and 35.
Figure 3. Modifications to the aglycone of FimH antagonists by 1) optimization of the ortho substituent, 2) an in-
crease in the flexibility of the aglycone, and 3) elongation of the carboxylate-bearing para substituent.
Scheme 1. Reagents and conditions: a) BF3·Et2O, CH2Cl2, 0 8C, 3 h (10a–f, 73-
86%); b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 8C, overnight (12a–f, 55–91%);
c) NaOMe, MeOH, RT, 4 h (13a–e, 14 f, 52–73%); d) 1. 0.2n NaOH(aq), MeOH,
RT, overnight; 2. Dowex (Na+), size-exclusion chromatography (P-2 gel)
(14a–e, 15–74%).
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Binding affinity and activity
The biphenyl a-d-mannosides with varying ortho substituents
(5a–b, 13a–f, 14a–f), increased aglycone flexibility (6, 19, 20,
22, 23), and elongated carboxylate-bearing para substituents
(30, 31, 34, 35) were evaluated in vitro by two competitive
assay formats (Table 1). All antagonists were tested in a cell-
free competitive binding assay.[16] Subsequently, the best candi-
dates were investigated in a cell-based flow cytometry assay.[17]
The cell-free competitive binding assay is based on the inter-
action of a biotinylated polyacrylamide glycopolymer as com-
petitor with the isolated CRD of FimH. In contrast, the cell-
based flow cytometry assay involves the infection of human
urinary bladder epithelial carcinoma cells with GFP-labeled
UPECs expressing the complete type 1 pili (see the Experimen-
tal Section below for details). The competitors in the former
assay are thus polymer-bound trimannosides, whereas in the
latter the antagonists compete with more potent high-man-
nose oligosaccharides present on uroplakin Ia, which is located
on the surface of human urinary bladder cells.[18,19] The interac-
tion is further affected by the presence of high- and low-affini-
ty states of the CRD of FimH. Aprikian et al. experimentally
demonstrated that in full-length fimbriae, the pilin domain sta-
bilizes the CRD domain in the low-affinity state, whereas the
CRD domain alone adopts the high-affinity state.[20] Further-
more, it was recently shown that shear stress can induce a con-
formational switch (twist in the b-sandwich fold of the CRD
domain), resulting in improved affinity.[21] Therefore, differing
affinities were expected in the cell-based flow cytometry assay,
in which full-length fimbriae are present, relative to the cell-
free competitive binding assay.
Cell-free competitive binding assays[16]
These assays were performed twice for every com-
pound with each concentration in duplicate. To
ensure comparability between various antagonists,
the reference compound n-heptyl a-d-mannopyrano-
side 1[22] was tested each time in parallel. The affini-
ties are reported relative to 1 as rIC50 in Table 1. A
comparison of the affinities of compounds 4a and
4b with the ortho-substituted analogues 5a, 13a–f
and 5b, 14a–f clearly demonstrates that ortho sub-
stituents on ring A indeed improve binding. However,
the differences between the various substituted
FimH antagonists are small. For a better understand-
ing of these results, a more detailed analysis of the
thermodynamic profile by isothermal titration calo-
rimetry (ITC) was performed (see below). By increas-
ing the flexibility of the aglycone, we expected
a switch from the out-docking mode as present for
antagonists 3 and 4 (Figure 2A,B) to the in-docking
mode (represented by antagonist 6 in Figure 2C).[10f]
However, affinities for all six representatives with in-
creased spacer length between carbohydrate and
aglycone (Table 1: 6—, 19, 20, 22, and 23) were dra-
matically decreased. A similar tendency was observed
Scheme 2. Reagents and conditions: a) BF3·Et2O, CH2Cl2, 0 8C, 3 h (17a–c, 34–
48%); b) 4-methoxycarbonylphenylboronic acid (11), Pd(Cl2)dppf·CH2Cl2,
K3PO4, DMF, 80 8C, overnight (18a,b and 21, 73–94%); c) NaOMe, MeOH, RT,
4 h (19a,b and 22, 47–90%); d) 1. 0.2n NaOH(aq), MeOH, RT, overnight;
2. Dowex (Na+), size-exclusion chromatography (P-2 gel) (6, 20 and 23, 10–
96%).
Scheme 3. Reagents and conditions: a) 4-iodophenol, BF3·Et2O, CH2Cl2, 40 8C, overnight
(70%); b) bis(pinacolato)diborone, Pd(Cl2)dppf·CH2Cl2, KOAc, DMF, MW 120 8C, 2 h (50%);
c) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 8C, overnight (34–56%); d) NaOMe, MeOH, RT, 4 h
(33–95%); e) 1. 0.2n NaOH(aq), MeOH, RT, overnight; 2. Dowex (Na
+), size-exclusion chro-
matography (P-2 gel) (31: 40%; 35 : 23%).
ChemMedChem 2012, 7, 1404 – 1422 " 2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim www.chemmedchem.org 1407
MEDFimH Antagonists
Table 1. Pharmacodynamic parameters of FimH antagonists.
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
1[10e] 73!7.9 1 3.9!1.6
24[10d] 84.9 1.47 n.d.
3[10d] 28.6 0.55 n.d.
4a[10e] 10.4!1.2 0.14 n.d.
4b[10e] 17.1!2.2 0.15 n.d.
5a 4.8!1.2 0.06 n.d.
5b 6.7!2.1 0.09 0.33!0.05
13a 8.0 0.14 n.d.
14a 33.5 0.58 1.54!0.31
13b 23.3 0.40 n.d.
14b 9.2 0.16 1.83!0.14
13c 2.6 0.04 n.d.
14c 8.9 0.15 0.89!0.10
Table 1. (Continued)
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
13d 3.5 0.06 n.d.
14d 4.8 0.08 1.95!0.36
13e 31.7 0.55 n.d.
14e 63.0 1.09 4.85!0.79
13 f 22.5 0.39 n.d.
14 f 33.9 0.58 n.d.
19a 56.1 0.97 n.d.
6 107.9 1.87 n.d.
19b 98.9 1.7 n.d.
20 142.2 2.44 n.d.
22 85.8 1.49 n.d.
23 642.0 11.14 n.d.
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for the biphenyls with an elongated carboxylate-bearing para
substituent (Table 1: 30, 31, 34, and 35). It was previously de-
scribed that the ester of 3 is placed within hydrogen bonding
distance to form a polar interaction with Arg98 and Glu50.[10d]
However, an improvement of affinity provided by a similar
polar interaction between Arg98 and the antagonists 31 and
35 could not be achieved, probably due to the high desolva-
tion penalty of Arg98. Finally, it is important to note that the
free acids (sodium salt) of the antagonists in general showed
slightly lower affinities than their methyl ester counterparts,
with the only exceptions of 13b and 14b (Table 1). However,
because the esters are thought to act as prodrugs and to be
rapidly cleaved after oral application,[10e] the affinities of the
carboxylates are relevant with regard to the therapeutic poten-
tial of the present FimH antagonists.
Cell-based flow cytometry assay[17]
These assays were performed in duplicate/triplicate, and n-
heptyl a-d-mannopyranoside 1 was used as reference com-
pound with an IC50 value of 3.9!1.6 mm. The most potent an-
tagonists 5b and 14c (Table 1) showed respective IC50 values
of 0.33!0.05 and 0.89!0.10 mm. In general, the activities ob-
tained from the flow cytometry assay were ~50-fold lower
than the affinities determined in the target-based competitive
assay (see above).
Isothermal titration calorimetry
Because the biological in vitro evaluation only revealed small
differences between affinities, ITC experiments were carried
out to study the thermodynamic profile of the variously ortho-
substituted biphenyl compounds 5b and 14a–f in binding to
FimH. ITC directly measures the heat of interaction (change in
enthalpy, DH) at a constant temperature on titrating two com-
pounds of known concentration that form an equilibrium com-
plex.[23] It includes contributions from all equilibria that occur
as the interacting molecules go from the free to the bound
state, including those associated with solvent interactions and
macromolecular conformational changes. The noncovalent in-
teraction between a protein and a ligand can be quantified by
the change in free energy (DG), consisting of the change in en-
thalpy (DH) and change in entropy (DS) [Eq. (1)] .[24] The bind-
ing energy under standard conditions (DG8), in which all reac-
tants and products are at a concentration of 1m, can be calcu-
lated from the dissociation constant, KD [Eq. (2)] . With ITC, KD
and DH can be measured directly, whereas DG and the entro-
py term TDS are calculated according to Equations (1) and (2).
DG ¼ DH#TDS ð1Þ
DG ¼ RT lnKD ð2Þ
A favorable enthalpy term DH is associated with hydrogen
bond formation, electrostatic, and dipole–dipole interactions at
the overcompensation of the desolvation penalty.[25] The entro-
py term DS reflects the overall change in the degrees of free-
dom of a system. It can be dissected into translational and
rigid body rotational entropy,[26] solvation entropy,[27] and en-
tropy costs related to conformational changes of protein and
ligand [Eq. (3)] .[28] Whereas the formation of a protein–ligand
complex is always associated with a decrease in translational
and rotational freedom and therefore with entropy costs, the
entropic contribution involving changes in solvation (DSsolv)
and changes in rotational and vibrational entropy due to the
loss of conformational flexibility (DSconf) can differ both in sign
and magnitude.[29]
DS ¼ DSsolv þ DStrans=rot þ DSconf ð3Þ
The FimH CRD was used for the ITC experiments. It was pre-
pared from FimH-CRD-Th-His6 (see Competitive binding assay,
Experimental Section below) by incubation with thrombin, as
described earlier.[16]
The thermodynamic fingerprints of the various biphenyl de-
rivatives (Table 2, Figure 4) reveal a significant improvement in
the enthalpic term (DDH #4.3 to #11.2 kJmol#1) for all substi-
tuted biphenyls (5b, 14a–f) in comparison with the unsubsti-
tuted derivative 4b. The largest enthalpy improvement was
observed for the trifluoromethyl group (14c ; Table 2). Interest-
ingly, these largely improved enthalpic contributions are
mostly compensated by entropic penalties (#TDDS +3.2 to
+7.5 kJmol#1), resulting in only marginally improved KD values.
In the best case, the trifluoromethyl derivative 14c, a fourfold
improvement in KD was measured. Similar, but less pronounced
Table 1. (Continued)
Compd Binding assay Flow cytometry
R IC50 [nm]
[a] rIC50
[b] IC50 [mm]
[a,c]
30 63.2 1.09 n.d.
31 70.5 1.21 n.d.
34 49.5 0.85 n.d.
35 62.5 1.07 n.d.
[a] IC50 values were determined in a cell-free competitive binding assay.
[16]
[b] The rIC50 values were calculated by dividing the IC50 of the compound
of interest by that of reference compound 1; this leads to rIC50 values <1
for derivatives that bind better than reference 1, and rIC50 values >1 for
compounds with lower affinity than 1. [c] The anti-adhesion potential to
human epithelial bladder cells was determined in the flow cytometry
assay;[17] n.d.=not determined.
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effects were observed for most other ortho substituents. This
trend was broken only by the cyclopropyl derivative 14e (DDH
+0.7 kJmol#1, #TDDS #2.4 kJmol#1; Table 2).
The influence of the ortho substituent on binding can be at-
tributed to three factors. First, ortho substituents of appropri-
ate volume establish an improved shape complementarity
within the binding pocket, leading to a better van der Waals
(vdW) contact and therefore an improvement in the enthalpy
term DH. The improvement in enthalpy (DDH) correlates well
with increasing vdW volumes of spherical ortho substituents
(5b, 14a–c ; Figure 5). For non-spherical substituents (OMe,
14d ; cyclopropyl, 14e ; and CN, 14 f), the shape complemen-
tarity is not optimal, leading to only a decreased enthalpy con-
tribution. However, better vdW contacts also lead to decreased
conformational flexibility and therefore an entropic compensa-
tion by a less favorable DSconf value. A second parameter is the
desolvation enthalpy, which depends on the polarity of a spe-
cific ortho substituent and varies
between #2.39 kJmol#1 for CH3
and 19.31 kJmol#1 for CN.[25] Fi-
nally, depending on the surface
area of the ortho substituent,
the entropy of solvation may
change. In summary, the various
effects are superimposed and of
opposing contributions to the
free binding energy DG.
Physicochemical and in vitro
pharmacokinetic characteriza-
tion
To estimate the oral bioavailabil-
ity and renal elimination of acids
4b, 5b, 6, 14a–f, 20, 23, 31, 35,
and the methyl esters 4a, 5a,
13a–f, 19a–b, 22, 30 and 34, several physicochemical parame-
ters (lipophilicity, solubility) as well as permeability through an
artificial membrane and a cell monolayer were determined
(Table 3). The free acids of the antagonists assessed in this
study (4b, 5b, 6, 14a–f, 20, 23, 31, and 35) are generally hy-
drophilic and soluble at pH values >5. All acids showed
logD7.4 values below zero and are therefore thought to under-
go considerable renal clearance,[32] a prerequisite for FimH an-
tagonists to reach their target in the urinary bladder. Permea-
tion studies through an artificial membrane (PAMPA[33]) indicat-
ed for all acids except 14a effective permeation values (logPe)
below #6.7, suggesting low absorption in the small intestine
by passive permeation.[34] However, the high absorption poten-
tial of the fluoro-substituted biphenyl 14a predicted by
Table 2. Binding thermodynamics of FimH antagonists determined by ITC.
Compd R KD [nm] DG8 [kJmol
#1] DH8 [kJmol#1] #TDS8 [kJmol#1] N[a] VvdW [$3][b]
4b H 14.1 #44.8 #47.3 +2.5 1.00 7.2
5b Cl 3.7 #48.1 #55.5 +7.4 1.01 22.4
14a F 9.2 #45.9 #51.6 +5.7 1.00 13.3
14b Me 4.8 #47.5 #56.2 +8.7 1.01 26.7
14c CF3 3.2 #48.5 #58.5 +10.0 1.02 41.4
14d OMe 7.7 #46.3 #52.5 +6.2 1.02 34.8
14e cPr 6.9 #46.6 #46.7 +0.1 1.01 52.5
14 f CN 7.4 #46.4 #55.0 +8.6 1.01 29.7
[a] Molar ratio of protein/ligand. [b] van der Waals volumes (VvdW) of the ortho substituent were calculated with
the Phase volCalc utility.[30]
Figure 4. Enthalpy–entropy compensation, a property often reported for car-
bohydrate–lectin interactions,[31] for ortho-substituted biphenyl a-d-manno-
pyranosides; DDG, DDH, and TDDS values for 5b and 14a–f are plotted rel-
ative to the unsubstituted derivative 4b.
Figure 5. Correlation of DDH (relative to antagonist 4b) with the van der
Waals volumes[30] of ortho substituents.
1410 www.chemmedchem.org " 2012 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2012, 7, 1404 – 1422
MED
Table 3. Physicochemical and in vitro pharmacokinetic parameters of FimH antagonists.
Compd PAMPA logPe [log10
#6 cms#1]/pH[a] Caco-2 Papp [10
#6 cms#1][b] logD7.4
[c] Solubility [mgmL#1]/pH[d]
a!b b!a (b!a)/(a!b)
1 #4.9 7.0!0.6 9.4!0.2 1.3 1.7 >3000/6.5
24 #5.0!0.1/5.0
#4.9!0.1/6.2
#4.7!0.1/7.4
10.0!0.9 19.0!1.2 1.9 2.1!0.1 22!0/3.0
22!1/5.0
21!1/7.4
3 #4.9!0.0/5.0
#4.9!0.0/6.2
#4.9!0.0/7.4
2.2!0.2 17.6!0.4 8.0 2.0!0.0 >150/3.0
>150/5.0
>150/7.4
4a #4.7 1.5!0.0 6.4!0.4 4.3 2.1 14!1/3.0
13!1/5.0
12!1/7.4
4b n.p. n.d. n.d. n.d. <#1.5 >3000/6.6
5a #4.6 5.3!0.6 17.5!1.3 3.3 2.3 16!2/3.0
15!0/5.0
17!2/7.4
5b n.p. 0.2!0.0 0.4!0.0 1.6 #0.8 >3000/6.5
13a #4.8!0.0/5.0
#4.8!0.0/6.2
#4.8!0.0/7.4
5.6!0.7 22.0!0.6 4.0 2.7!0.1 22!1/3.0
24!3/5.0
17!6/7.4
14a #5.8!0.1/5.0
#6.3!0.1/6.2
#7.4!0.1/7.4
0.2!0.1 0.2!0.0 0.8 <#1.5 30!3/3.0
>100/5.0
>100/7.4
13b #4.5!0.1/5.0
#4.5!0.0/6.2
#4.6!0.1/7.4
6.2!1.3 22.7!1.2 3.6 2.4!0.2 7!0/3.0
7!0/5.0
7!0/7.4
14b #8.6!1.7/5.0
#8.8!1.4/6.2
#8.7!1.5/7.4
n.d. n.d. n.d. #0.6!0.1 34!3/3.0
>200/5.0
>200/7.4
13c #4.4!0.0/5.0
#4.4!0.0/6.2
#4.5!0.1/7.4
9.2!0.1 16.9!1.5 1.8 2.8!0.1 17!1/3.0
15!1/5.0
16!1/7.4
14c #8.4!1.3/5.0
#9.3!1.4/6.2
#8.6!1.6/7.4
n.d. n.d. n.d. #0.8!0.1 15!1/3.0
140!6/5.0
>200/7.4
13d #5.4!0.0/5.0
#5.4!0.0/6.2
#5.4!0.0/7.4
4.2!0.7 16.4!1.2 3.9 1.8!0.1 24!0/3.0
24!1/5.0
26!1/7.4
14d #8.5!0.6/5.0
#9.1!0.2/6.2
#9.2!0.4/7.4
n.d. n.d. n.d. <#1.5 127!4/3.0
>200/5.0
>200/7.4
13e #4.5!0.2/5.0
#4.4!0.0/6.2
#4.4!0.1/7.4
6.1!0.6 17.9!1.2 3.0 2.9!0.1 14!2/3.0
13!0/5.0
14!1/7.4
14e #9.3!1.3/5.0
#8.7!1.5/6.2
#8.7!1.5/7.4
n.d. n.d. n.d. #0.8!0.1 31!2/3.0
>200/5.0
>200/7.4
13 f #6.5!0.0/5.0
#6.5!0.1/6.2
#6.3!0.1/7.4
0.9!0.7 18.1!0.6 19.7 1.7!0.0 22!2/3.0
24!1/5.0
23!1/7.4
14 f #8.5!1.7/5.0
#7.3!0.3/6.2
#7.8!1.5/7.4
n.d. n.d. n.d. <#1.5 35!11/3.0
>200/5.0
>200/7.4
19a #4.9!0.0/5.0
#4.9!0.0/6.2
#4.9!0.1/7.4
4.4!0.1 18.8!1.7 4.3 1.9!0.1 103!8/3.0
100!6/5.0
95!5/7.4
6 #8.6!1.6/5.0
#9.3!1.4/6.2
#8.7!1.5/7.4
n.d. n.d. n.d. <#1.5 >130/3.0
>130/5.0
>130/7.4
19b #5.3!0.1/5.0
#5.6!0.1/6.2
#5.1!0.2/7.4
n.d. n.d. n.d. 2.4!0.1 30!0/3.0
29!1/5.0
31!1/7.4
20 #8.6!1.6/5.0
#9.3!1.4/6.2
#10/7.4
n.d. n.d. n.d. #1.2!0.2 >130/3.0
>130/5.0
>130/7.4
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PAMPA could not be confirmed by the colorectal adenocarci-
noma (Caco-2) cell permeation assay. In contrast, the methyl
esters (3, 4a, 5a, 13a–f, 19a–b, 22, 30, and 34) showed
logD7.4 values >1.5, that is, they are more lipophilic and hence
more permeable than the corresponding acids, as shown by
the PAMPA and Caco-2 permeation assay. Despite this high ab-
sorption potential, the ratios between the apparent permeabil-
ity coefficients (Papp) in the basolateral-to-apical (b!a, secreto-
ry) and apical-to-basolateral (a!b, absorptive) directions re-
vealed active efflux processes as an additional issue of all the
assessed compounds. Moreover, the methyl esters must be
readily hydrolyzed after absorption to become more polar and
to be renally eliminated. Rapid metabolic turnover by the
enzyme carboxylesterase was previously shown for the methyl
esters 4a and 5a.[10e]
The different substituents at the ortho position of ring A (5a,
5b, 13a–f, 14a–f ; Table 3) only have a minor influence on the
physicochemical properties. The addition of chloro, fluoro,
methyl, trifluoromethyl, or cyclopropyl substituents slightly in-
creases the lipophilicity of the respective acids and methyl
esters, whereas methoxy and cyano substituents render the
compounds more hydrophilic and less permeable. Moreover,
the substituents at the ortho position have negligible effects
on the low aqueous solubility, which is a major drawback of all
methyl esters.[35] In contrast, the modifications with increased
spacer length between carbohydrate and aglycone (6, 19a–b,
20, 22, and 23 ; Table 3) show higher aqueous solubility. Ex-
tending the spacer and linking it at the ortho or meta positions
of the biaryl moiety disrupts the symmetry of the molecular
structure, leading to increased solubility.[15,36] However, an addi-
tional chloro substituent at the 4-position (19b, 20 ; Table 3) re-
stores the symmetrical character of the structure, which in turn
lowers the solubility of the compound. Disrupted structural
symmetry might also hold true for the enhanced solubility of
the biphenyls with an elongated carboxylate-bearing para sub-
stituent (30, 31, 34, and 35 ; Table 3). The introduction of
a methylene or cyclopropylene group between the biphenyl
and the carboxylate moiety markedly improved the aqueous
solubility of the methyl esters, whereas the absorption poten-
tial was only slightly decreased.
Summary and Conclusions
In this study, we investigated the structure–affinity relationship
for ortho substituents on ring A of the biphenyl aglycone of
the FimH antagonists 13 and 14. The correlation between vdW
volumes of these substituents and the enthalpy term clearly in-
dicates the importance of shape complementary. This interpre-
tation is further supported by the fact that the electronic char-
acter of the substituent [Cl in 5a (Table 2), CF3 in 14c versus
CH3 in 14b] is less important. The correlation of enthalpic im-
provements (DDH) with vdW volumes offers a potent tool for
guiding further structural optimization.
The successful oral application using a prodrug approach
was recently demonstrated with the ester 5a.[10e] A major
drawback of the biphenyl methyl esters is their insufficient sol-
ubility, which is mostly in the range of 15–35 mgmL#1. As ex-
pected,[15] solubility could be substantially improved when the
symmetry of the aglycone was disrupted. Thus, the solubility
of 3 (>150 mgmL#1; Table 3), 19a (100 mgmL#1), and 22 (>
130 mgmL#1) was improved by a factor of ~10. However, for
these more flexible derivatives, the expected optimized fit
leading to improved affinities in the in-docking mode could
not be observed. In fact, the affinities for the members of this
Table 3. (Continued)
Compd PAMPA logPe [log10
#6 cms#1]/pH[a] Caco-2 Papp [10
#6 cms#1][b] logD7.4
[c] Solubility [mgmL#1]/pH[d]
a!b b!a (b!a)/(a!b)
22 #5.1!0.0/5.0
#5.1!0.0/6.2
#5.1!0.0/7.4
n.d. n.d. n.d. 1.7!0.1 >130/3.0
>130/5.0
>130/7.4
23 #7.3!1.8/5.0
#8.1!2.2/6.2
#10/7.4
n.d. n.d. n.d. <#1.5 >130/3.0
>130/5.0
>130/7.4
30 #5.5!0.0/5.0
#5.5!0.0/6.2
#5.4!0.1/7.4
n.d. n.d. n.d. 1.6!0.1 >130/3.0
>130/5.0
>130/7.4
31 #7.7!1.6/5.0
#8.1!1.3/6.2
#10/7.4
n.d. n.d. n.d. <#1.5 >130/3.0
>130/5.0
>130/7.4
34 #5.3!0.1/5.0
#5.6!0.0/6.2
#5.3!0.2/7.4
n.d. n.d. n.d. 2.2!0.1 >130/3.0
>130/5.0
>130/7.4
35 #8.0!1.3/5.0
#8.6!1.6/6.2
#10/7.4
n.d. n.d. n.d. n.d. 63!8/3.0
>130/5.0
>130/7.4
[a] Pe=effective permeation: passive permeation through an artificial membrane was determined by parallel artificial membrane permeation assay
(PAMPA); values represent the mean !SD of quadruplicate measurements taken at three pH values (pH 5.0, 6.2, and 7.4).[33] [b] Papp=apparent permeabili-
ty: permeation through cell monolayers was assessed by a Caco-2 assay in the absorptive (a!b) and secretory (b!a) directions in triplicate;[42] n.p.=no
permeation, n.d.=not determined. [c] Distribution coefficients (logD) were measured by a miniaturized shake-flask procedure at pH 7.4. [d] Kinetic solubili-
ty was measured in a 96-well format using the mSOL Explorer solubility analyzer at three pH values (pH 3.0, 5.0, and 7.4) in triplicate.
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family of compounds are drastically decreased, for example,
compounds 20 or 23 (Table 1).
Finally, the elongation of the ester-bearing para substituent
(Table 1; compounds 31 and 35) did not lead to the expected
additional polar interaction with Arg98. Instead, a five- to sev-
enfold decrease in affinity was observed. Clearly, the desolva-
tion penalty for the guanidinium group could not be matched
by the geometrically possible salt bridge with the carboxylate
of the antagonists 31 and 35.
In summary, our study confirms the earlier selection of the
FimH antagonists 5a for oral and 5b for intravenous applica-
tion. However, the methoxy derivative 13d (Table 1) shows
slightly improved pharmacokinetic properties and therefore
represents an additional candidate for future in vivo studies.
Experimental Section
General methods : NMR spectra were recorded on a Bruker Avance
DMX-500 (500.1 MHz) spectrometer. Assignment of 1H and 13C NMR
spectra was achieved using 2D methods (COSY, HSQC, HMBC).
Chemical shifts are expressed in ppm using residual CHCl3,
CHD2OD, or HDO as references. Optical rotations were measured
with a PerkinElmer Polarimeter 341. Electrospray ionization mass
spectrometry (ESI-MS) data were obtained on a Waters Micromass
ZQ instrument. LC–HRMS analyses were carried out using an Agi-
lent 1100 LC equipped with a photodiode array detector and a Mi-
cromass QTOF I equipped with a 4 GHz digital time converter. Mi-
crowave-assisted reactions were carried out with a CEM Discover
and Explorer. Reactions were monitored by TLC using glass plates
coated with silica gel 60 F254 (Merck) and visualized by UV light
and/or by charring with a molybdate solution (0.02m solution of
ammonium cerium sulfate dihydrate and ammonium molybdate
tetrahydrate in aqueous 10% H2SO4). MPLC separations were car-
ried out on a CombiFlash Companion or Rf from Teledyne Isco
equipped with RediSep normal-phase or RP-18 reversed-phase
flash columns. LC–MS separations were carried out on a Waters
system equipped with sample manager 2767, pump 2525, PDA
2525, and Micromass ZQ. Size-exclusion chromatography was per-
formed on Bio-Gel P-2 Gel (45–90 mm) from Bio-Rad (Reinach,
Switzerland). All compounds used for biological assays are at least
of 98% purity based on analytical HPLC results. Commercially avail-
able reagents were purchased from Fluka, Aldrich, Alfa Aesar or Iris
Biotech (Germany). Solvents were purchased from Sigma–Aldrich
(Buchs, Switzerland) or Acros Organics (Geel, Belgium) and were
dried prior to use where indicated. MeOH was dried by reflux with
sodium methoxide and distilled immediately before use. CH2Cl2
was dried by filtration over Al2O3 (Fluka, type 5016 A basic). Molec-
ular sieves (4 $) were activated in vacuo at 500 8C for 1 h immedi-
ately before use.
General procedure A for the synthesis of mannosides 10a–f and
17a–c : To an ice-cold suspension of 8[12] (200 mg, 0.57 mmol,
1.1 equiv), phenol 9a–f or benzyl alcohol 16a–c (0.52 mmol,
1.0 equiv), and molecular sieves (4 $, 600 mg) in dry CH2Cl2 (5 mL),
BF3·Et2O (0.3 mL, 2.44 mmol, 4.7 equiv) was added dropwise under
argon. The mixture was stirred at 0 8C for 3 h, and then at RT over-
night. The reaction mixture was filtered over Celite, and the filtrate
was diluted with CH2Cl2 (50 mL), extracted with 0.5n NaOH(aq)
(50 mL), H2O (50 mL), and brine (50 mL). The organic layer was
dried over Na2SO4 and concentrated in vacuo. The residue was pu-
rified by MPLC on silica gel (petroleum ether (PE)/EtOAc) to yield
10a–f or 17a–c.
General procedure B for the synthesis of mannosylated biphen-
yls : A Schlenk tube was charged with aryl bromide (1.0 equiv), bor-
onic acid or boronate (1.1 equiv), Pd(dppf)Cl2·CH2Cl2 (0.03 equiv),
K3PO4 (1.5 equiv) and a stirring bar. The tube was closed with
a rubber septum and was evacuated and flushed with argon. This
procedure was repeated once, then anhydrous DMF (2 mL) was
added under a stream of argon. The mixture was degassed in an
ultrasonic bath and flushed with argon for 5 min, and then stirred
at 80 8C overnight. The reaction mixture was cooled to RT, diluted
with EtOAc (50 mL), and washed with H2O (50 mL) and brine
(50 mL). The organic layer was dried over Na2SO4 and concentrated
in vacuo. The residue was purified by MPLC on silica gel (PE/EtOAc)
to afford biphenyls 12a–f, 18a,b, 21, 29 or 33.
General procedure C for deacetylation : To a solution of 12a–f,
18a,b, 21, 29 or 33 (1.0 equiv) in dry MeOH (5 mL) was added
freshly prepared 1m NaOMe/MeOH (0.1 equiv) under argon. The
mixture was stirred at RT until the reaction was complete (moni-
tored by TLC), then neutralized with Amberlyst-15 (H+) ion-ex-
change resin, filtered and concentrated in vacuo. The residue was
purified by MPLC on silica gel (CH2Cl2/MeOH, 10:1–8:1) to afford
13a–f, 19a,b, 22, 30 or 34 as white solids.
General procedure D for saponification : To a solution of 12a–e,
18a,b, 21, 29 or 33 (1.0 equiv) in MeOH (5 mL) was added 1m
NaOMe/MeOH (0.1 equiv) at RT. The reaction mixture was stirred at
RT for 4 h and concentrated. The residue was treated with 0.5m
NaOH(aq) (1 mL) for 24 h at RT. The solution was then adjusted to
pH 3–4 with Amberlyst-15 (H+), and the mixture was filtered and
concentrated. The crude product was transformed into the sodium
salt by passing through a small column of Dowex 50X8 (Na+ form)
ion-exchange resin. After concentration, the residue was purified
by MPLC (RP-18, H2O/MeOH, 1:0–2:1) followed by size-exclusion
chromatography (P-2 gel, H2O) to give 14a–e, 6, 20, 23, 31 or 35
as white solids after final lyophilization from H2O.
4-Bromo-2-fluorophenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10a): Prepared according to general procedure A from
8[12] and 4-bromo-2-fluorophenol (9a). Yield: 220 mg (74%) as
white solid. Rf=0.48 (PE/EtOAc, 2:1) ; [a]
20
D +83.0 (c=0.70, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.30 (dd, J=2.3, 10.1 Hz, 1H, Ar-H),
7.21 (dt, J=1.7, 8.8 Hz, 1H, Ar-H), 7.08 (t, J=8.6 Hz, 1H, Ar-H), 5.54
(dd, J=3.5, 10.0 Hz, 1H, H-3), 5.50 (dd, J=1.8, 3.4 Hz, 1H, H-2),
5.46 (d, J=1.5 Hz, 1H, H-1), 5.36 (t, J=10.0 Hz, 1H, H-4), 4.26 (dd,
J=5.5, 12.2 Hz, 1H, H-6a), 4.17 (ddd, J=2.1, 5.5, 10.0 Hz, 1H, H-5),
4.10 (dd, J=2.2, 12.2 Hz, 1H, H-6b), 2.20, 2.07, 2.05, 2.04 ppm (4 s,
12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.51, 169.95, 169.82,
169.76 (4 CO), 153.28 (d, J=251.4 Hz, Ar-C), 142.64 (d, J=11.1 Hz,
Ar-C), 127.58 (d, J=4.0 Hz, Ar-C), 120.4 (d, J=21.5 Hz, Ar-C), 120.28
(d, J=0.9 Hz, Ar-C), 115.73 (d, J=8.1 Hz, Ar-C), 97.49 (C-1), 69.76 (C-
5), 69.15 (C-2), 68.60 (C-3), 65.76 (C-4), 62.09 (C-6), 20.87, 20.71,
20.69, 20.67 ppm (4 COCH3); elemental analysis calcd (%) for
C20H22BrFO10: C 46.08, H 4.25, found: C 46.11, H 4.26.
4-Bromo-2-methylphenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10b): Prepared according to general procedure A from
8[12] and 4-bromo-2-methylphenol (9b). Yield: 254 mg (86%) as
white solid. Rf=0.60 (PE/EtOAc, 2:1) ; [a]
20
D +61.8 (c=1.00, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.31 (d, J=1.9 Hz, 1H, Ar-H), 7.24
(dd, J=2.3, 8.7 Hz, 1H, Ar-H), 6.97 (d, J=8.8 Hz, 1H, Ar-H), 5.53 (dd,
J=3.4, 10.0 Hz, 1H, H-3), 5.47 (d, J=1.7 Hz, 1H, H-1), 5.45 (dd, J=
2.0, 3.4 Hz, 1H, H-2), 5.37 (t, J=10.0 Hz, 1H, H-4), 4.28 (dd, J=5.6,
12.3 Hz, 1H, H-6a), 4.10–4.03 (m, 2H, H-5, H-6b), 2.27 (s, 3H, CH3),
2.20, 2.06, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.53, 170.04, 169.96, 169.73 (4 CO), 152.96, 133.78,
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129.88, 129.61, 115.81, 115.23 (Ar-C), 95.91 (C-1), 69.39 (C-5), 69.38
(C-2), 68.88 (C-3), 65.76 (C-4), 62.12 (C-6), 20.88, 20.70, 20.68 (4C, 4
COCH3), 16.07 ppm (CH3); elemental analysis calcd (%) for
C21H25BrO10: C 48.76, H 4.87, found: C 48.84, H 4.91.
4-Bromo-2-trifluoromethyl-phenyl 2,3,4,6-tetra-O-acetyl-a-d-
mannopyranoside (10c): Prepared according to general procedure
A from 8[12] and 4-bromo-2-trifluoromethylphenol (9c). Yield:
260 mg (80%) as white solid. Rf=0.50 (PE/EtOAc, 2:1) ; [a]
20
D +64.6
(c=1.00, EtOAc); 1H NMR (500 MHz, CDCl3): d=7.74 (d, J=2.3 Hz,
1H, Ar-H), 7.61 (dd, J=2.4, 8.9 Hz, 1H, Ar-H), 7.15 (d, J=8.9 Hz, 1H,
Ar-H), 5.60 (d, J=1.6 Hz, 1H, H-1), 5.51 (dd, J=3.5, 10.1 Hz, 1H, H-
3), 5.45 (dd, J=2.0, 3.3 Hz, 1H, H-2), 5.39 (t, J=10.1 Hz, 1H, H-4),
4.27 (dd, J=5.3, 12.4 Hz, 1H, H-6a), 4.08–4.00 (m, 2H, H-5, H-6b),
2.21, 2.06, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.41, 169.91, 169.74, 169.62 (4 CO), 152.16 (d, J=
1.7 Hz, Ar-C), 136.07 (Ar-C), 130.35 (t, J=5.3 Hz, Ar-C), 122.30 (d, J=
271.4 Hz, CF3), 121.72 (d, J=31.7 Hz, Ar-C), 117.08, 114.88 (Ar-C),
95.75 (C-1), 69.96 (C-5), 69.02 (C-2), 68.45 (C-3), 65.44 (C-4), 61.95
(C-6), 20.84, 20.70, 20.67, 20.63 ppm (4 COCH3); elemental analysis
calcd (%) for C21H22BrF3O10: C 44.15, H 3.88, found: C 44.10, H 3.88.
4-Bromo-2-methoxyphenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyr-
anoside (10d): Prepared according to general procedure A from
8[12] and 4-bromo-2-methoxyphenol (9d). Yield: 234 mg (77%) as
white solid. Rf=0.32 (PE/acetone, 4:1) ; [a]
20
D +70.3 (c=0.70,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.03–6.95 (m, 3H, Ar-H), 5.58
(dd, J=3.5, 10.0 Hz, 1H, H-3), 5.52 (dd, J=1.8, 3.4 Hz, 1H, H-2),
5.42 (d, J=1.8 Hz, 1H, H-1), 5.34 (t, J=10.0 Hz, 1H, H-4), 4.28–4.24
(m, 2H, H-5, H-6a), 4.10 (m, 1H, H-6b), 3.84 (s, 3H, OCH3), 2.19,
2.07, 2.05, 2.04 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3):
d=170.58, 169.98, 169.89, 169.80 (4 CO), 151.52, 143.91, 123.49,
120.37, 116.69, 115.94 (Ar-C), 97.52 (C-1), 69.45 (C-5), 69.36 (C-2),
68.80 (C-3), 66.06 (C-4), 62.27 (C-6), 56.04 (OCH3), 20.91, 20.73,
20.71, 20.69 ppm (4 COCH3); elemental analysis calcd (%) for
C21H25BrO11: C 47.29, H 4.72, found: C 47.20, H 4.70.
4-Bromo-2-cyclopropylphenyl 2,3,4,6-tetra-O-acetyl-a-d-manno-
pyranoside (10e): Prepared according to general procedure A
from 8[12] and 4-bromo-2-cyclopropylphenol (9e). Yield: 235 mg
(76%) as white solid. Rf=0.30 (PE/EtOAc, 3:1) ; [a]
20
D +64.7 (c=0.40,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.20 (d, J=8.7 Hz, 1H, Ar-H),
7.00–6.69 (m, 2H, Ar-H), 5.58 (d, J=10.1 Hz, 1H, H-3), 5.50 (s, 2H,
H-1, H-2), 5.39 (t, J=10.1 Hz, 1H, H-4), 4.28 (dd, J=5.4, 12.2 Hz, 1H,
H-6a), 4.14–4.08 (m, 2H, H-5, H-6b), 2.21, 2.09, 2.04 (3 s, 12H, 4
OAc), 1.02 (d, J=8.1 Hz, 2H, CH2-cPr), 0.65 ppm (d, J=4.6 Hz, 2H,
CH2-cPr) ;
13C NMR (125 MHz, CDCl3): d=170.54, 170.03, 170.15,
169.75 (4 CO), 153.64, 135.64, 129.11, 128.94, 116.29, 115.79 (Ar-C),
96.15 (C-1), 69.46 (C-5), 69.39 (C-2), 68.93 (C-3), 65.78 (C-4), 62.16
(C-6), 21.07, 20.89, 20.70 (4C, 4COCH3), 9.73, 7.88, 7.82 ppm (cPr);
elemental analysis calcd (%) for C23H27BrFO10: C 50.84, H 5.01,
found: C 50.82, H 5.00.
4-Bromo-2-cyanophenyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (10 f): Prepared according to general procedure A from 8[12]
and 4-bromo-2-cyanophenol (9 f). Yield: 220 mg (73%) as white
solid. Rf=0.51 (PE/EtOAc, 2:3) ; [a]
20
D +54.3 (c=0.60, EtOAc); IR
(KBr): n˜=2232 (s, C'N), 1749 cm#1 (vs, C=O); 1H NMR (500 MHz,
CDCl3): d=7.73 (d, J=2.5 Hz, 1H, Ar-H), 7.66 (dd, J=2.5, 9.0 Hz,
1H, Ar-H), 7.15 (d, J=9.0 Hz, 1H, Ar-H), 5.62 (d, J=1.7 Hz, 1H, H-1),
5.56 (dd, J=3.5, 10.0 Hz, 1H, H-3), 5.51 (dd, J=2.0, 3.4 Hz, 1H, H-
2), 5.41 (t, J=10.0 Hz, 1H, H-4), 4.28 (dd, J=4.9, 12.1 Hz, 1H, H-6a),
4.13–4.08 (m, 2H, H-5, H-6b), 2.21, 2.07, 2.05, 2.04 ppm (4 s, 12H, 4
OAc); 13C NMR (125 MHz, CDCl3): d=169.37, 168.93, 168.71, 168.48
(4CO), 155.18, 136.28, 135.00, 116.12, 114.41, 112.97, 104.62 (Ar-C,
CN), 95.68 (C-1), 69.26 (C-5), 68.02 (C-2), 67.35 (C-3), 64.38 (C-4),
60.85 (C-6), 19.81, 19.67, 19.64, 19.58 ppm (4 COCH3); elemental
analysis calcd (%) for C21H22BrNO10: C 47.74, H 4.02, N 2.65, found:
C 47.78, H 4.29, N 2.67.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-flu-
orobiphenyl-4-carboxylate (12a): Prepared according to general
procedure B from 10a (100 mg, 0.192 mmol), 4-methoxycarbonyl-
phenylboronic acid (11, 38.0 mg, 0.211 mmol), Pd(dppf)Cl2·CH2Cl2
(4.7 mg, 5.8 mmol) and K3PO4 (61.1 mg, 0.288 mmol). Yield: 83 mg
(75%) as white solid. Rf=0.26 (PE/EtOAc, 2:1) ; [a]
20
D +93.0 (c=0.60,
EtOAc); 1H NMR (500 MHz, CDCl3): d=8.03–8.02 (m, 2H, Ar-H),
7.53–7.52 (m, 2H, Ar-H), 7.33 (dd, J=2.1, 11.8 Hz, 1H, Ar-H), 7.27
(dd, J=1.5, 8.9 Hz, 1H, Ar-H), 7.20 (t, J=8.3 Hz, 1H, Ar-H), 5.53 (dd,
J=3.4, 10.0 Hz, 1H, H-3), 5.49–5.47 (m, 2H, H-1, H-2), 5.32 (t, J=
10.0 Hz, 1H, H-4), 4.22 (dd, J=5.4, 12.1 Hz, 1H, H-6a), 4.17 (m, 1H,
H-5), 4.05 (dd, J=1.8, 12.1 Hz, 1H, H-6b), 3.87 (s, 3H, OCH3), 2.15,
2.01, 1.98, 1.97 ppm (4 s, 12H, 4OAc); 13C NMR (125 MHz, CDCl3):
d=170.54, 170.00, 169.86, 169.79, 166.82 (5 CO), 153.50 (d, J=
247.0 Hz, Ar-C), 143.56 (d, J=1.8 Hz, Ar-C), 143.22 (d, J=11.2 Hz,
Ar-C), 136.48 (d, J=6.7 Hz, Ar-C), 130.27, 129.29, 126.75 (5C, Ar-C),
123.16 (d, J=3.4 Hz, Ar-C), 119.32 (Ar-C), 115.64 (d, J=19.4 Hz, Ar-
C), 97.42 (C-1), 69.71 (C-5), 69.26 (C-2), 68.70 (C-3), 65.83 (C-4),
62.10 (C-6), 52.24 (OMe), 20.91, 20.74, 20.72, 20.70 ppm (4 COCH3);
HRMS: m/z : calcd for C28H29FNaO12 [M+Na]
+ : 599.1535, found:
599.1536.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-
methylbiphenyl-4-carboxylate (12b): Prepared according to gen-
eral procedure B from 10b (100 mg, 0.193 mmol), 11 (38.2 mg,
0.212 mmol), Pd(dppf)Cl2·CH2Cl2 (4.7 mg, 5.8 mmol) and K3PO4
(61.5 mg, 0.290 mmol). Yield: 87 mg (79%) as white solid. Rf=0.41
(PE/EtOAc, 1:0.9) ; [a]20D +85.4 (c=0.80, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.09–8.07 (m, 2H, Ar-H), 7.61 (m, 2H, Ar-H), 7.46 (d, J=
1.8 Hz, 1H, Ar-H), 7.40 (dd, J=2.3, 8.5 Hz, 1H, Ar-H), 7.18 (d, J=
8.5 Hz, 1H, Ar-H), 5.61–5.58 (m, 2H, H-1, H-3), 5.50 (dd, J=2.0,
3.5 Hz, 1H, H-2), 5.41 (t, J=10.0 Hz, 1H, H-4), 4.31 (dd, J=5.9,
12.8 Hz, 1H, H-6a), 4.14–4.09 (m, 2H, H-5, H-6b), 3.94 (s, 3H, OCH3),
2.37 (s, 3H, CH3), 2.22, 2.08, 2.05, 2.04 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.55, 170.06, 169.98, 169.75,
167.00 (5 CO), 154.05, 144.94, 134.54, 130.10, 130.02, 128.54,
128.05, 126.66, 125.76, 114.46 (12C, Ar-C), 95.84 (C-1), 69.48 (C-5),
69.37 (C-2), 68.98 (C-3), 65.81 (C-4), 62.13 (C-6), 52.12 (OCH3), 21.06,
20.91, 20.72, 20.70 (4 COCH3), 16.40 ppm (CH3); HRMS: m/z : calcd
for C29H32NaO12 [M+Na]
+ : 595.1786, found: 595.1786; elemental
analysis calcd (%) for C29H32O12: C 60.84, H 5.63, found: C 60.76, H
5.80.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-tri-
fluoromethylbiphenyl-4-carboxylate (12c): Prepared according to
general procedure B from 10c (100 mg, 0.175 mmol), 11 (34.6 mg,
0.193 mmol), Pd(dppf)Cl2·CH2Cl2 (4.3 mg, 5.3 mmol) and K3PO4
(55.7 mg, 0.263 mmol). Yield: 100 mg (91%) as white solid. Rf=0.25
(PE/EtOAc, 2:1) ; [a]20D +43.3 (c=1.00, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.87 (d, J=2.1 Hz, 1H, Ar-H),
7.75 (dd, J=2.2, 8.7 Hz, 1H, Ar-H), 7.63–7.61 (m, 2H, Ar-H), 7.35 (d,
J=8.7 Hz, 1H, Ar-H), 5.70 (d, J=1.7 Hz, 1H, H-1), 5.57 (dd, J=3.5,
10.1 Hz, 1H, H-3), 5.50 (dd, J=2.0, 3.4 Hz, 1H, H-2), 5.43 (t, J=
10.0 Hz, 1H, H-4), 4.30 (dd, J=5.6, 12.8 Hz, 1H, H-6a), 4.11–4.08 (m,
2H, H-5, H-6b), 3.95 (s, 3H, OCH3), 2.24, 2.07, 2.06, 2.05 ppm (4 s,
12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.45, 169.96, 169.78,
169.65, 166.76 (5 CO), 152.94, 143.37, 134.59, 130.34, 129.40,
126.79, 126.14, 115.79 (12C, Ar-C), 95.67 (C-1), 69.91 (C-5), 69.15 (C-
2), 68.56 (C-3), 65.50 (C-4), 61.97 (C-6), 52.25 (OCH3), 20.88, 20.71,
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20.66 ppm (4C, 4 COCH3); HRMS: m/z : calcd for C29H29F3NaO12 [M+
Na]+ : 649.1503, found: 649.1503.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-me-
thoxybiphenyl-4-carboxylate (12d): Prepared according to gener-
al procedure B from 10d (100 mg, 0.188 mmol), 11 (37.1 mg,
0.206 mmol), Pd(dppf)Cl2·CH2Cl2 (4.6 mg, 5.6 mmol) and K3PO4
(59.9 mg, 0.282 mmol). Yield: 91 mg (83%) as white solid. Rf=0.25
(PE/EtOAc, 1:0.9) ; [a]20D +50.7 (c=1.40, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.10–8.08 (m, 2H, Ar-H), 7.62–7.60 (m, 2H, Ar-H), 7.19–
7.13 (m, 3H, Ar-H), 5.64 (dd, J=3.5, 10.0 Hz, 1H, H-3), 5.58 (dd, J=
1.8, 3.5 Hz, 1H, H-2), 5.53 (d, J=1.7 Hz, 1H, H-1), 5.38 (t, J=
10.0 Hz, 1H, H-4), 4.34–4.28 (m, 2H, H-5, H-6a), 4.12 (m, 1H, H-6b),
3.94 (2 s, 6H, 2 OCH3), 2.21, 2.08, 2.05, 2.04 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.61, 170.02, 169.92, 169.83,
166.94 (5 CO), 151.01, 145.06, 144.92, 136.51, 130.13, 128.86,
126.87, 119.72, 119.32, 111.60 (12C, Ar-C), 97.50 (C-1), 69.48 (C-5),
69.43 (C-2), 68.91 (C-3), 66.12 (C-4), 62.29 (C-6), 56.01 (OCH3), 52.18
(CO2CH3), 20.95, 20.76, 20.74, 20.72 ppm (4 COCH3); HRMS: m/z :
calcd for C29H32NaO13 [M+Na]
+ : 611.1735, found: 611.1736.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-cy-
clopropylbiphenyl-4-carboxylate (12e): Prepared according to
general procedure B from 10e (100 mg, 0.184 mmol), 11 (36.4 mg,
0.202 mmol), Pd(dppf)Cl2·CH2Cl2 (4.5 mg, 5.5 mmol) and K3PO4
(58.6 mg, 0.276 mmol). Yield: 60 mg (55%) as white solid. Rf=0.48
(PE/EtOAc, 2:1) ; [a]20D +53.0 (c=0.70, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.08–8.07 (m, 2H, Ar-H), 7.59–7.57 (m, 2H, Ar-H), 7.37
(dd, J=2.4, 8.5 Hz, 1H, Ar-H), 7.19–7.17 (m, 2H, Ar-H), 5.64 (dd, J=
3.5, 10.1 Hz, 1H, H-3), 5.61 (d, J=1.6 Hz, 1H, H-1), 5.54 (dd, J=1.9,
3.4 Hz, 1H, H-2), 5.42 (t, J=10.1 Hz, 1H, H-4), 4.31 (dd, J=5.3,
12.2 Hz, 1H, H-6a), 4.19–4.10 (m, 2H, H-5, H-6b), 3.94 (s, 3H, OCH3),
2.22 (s, 3H, OAc), 2.17 (m, 1H, H-cPr), 2.08–2.05 (m, 9H, 3 OAc),
1.06–1.05 (m, 2H, CH2-cPr), 0.74–0.73 ppm (m, 2H, CH2-cPr) ;
13C NMR (125 MHz, CDCl3): d=170.55, 170.06, 170.02, 169.75,
166.98 (5 CO), 154.76, 145.12, 134.83, 133.56, 130.08, 128.58,
126.71, 125.33, 125.06, 114.84 (12C, Ar-C), 96.04 (C-1), 69.49 (C-5),
69.42 (C-2), 69.02 (C-3), 65.81 (C-4), 62.15 (C-6), 52.12 (OCH3), 20.91,
20.71 (4C, 4 COCH3), 9.78, 7.58 ppm (3C, cPr) ; elemental analysis
calcd (%) for C29H32O12: C 62.20, H 5.72, found: C 62.00, H 5.86.
Methyl 4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)-3’-cya-
nobiphenyl-4-carboxylate (12 f): Prepared according to general
procedure B from 10 f (100 mg, 0.189 mmol), 11 (37.5 mg,
0.208 mmol), Pd(dppf)Cl2·CH2Cl2 (4.6 mg, 5.7 mmol) and K3PO4
(60.2 mg, 0.284 mmol). Yield: 92 mg (84%) as white solid. Rf=0.18
(PE/EtOAc, 2:1) ; [a]20D +61.4 (c=0.80, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.06–8.05 (m, 2H, Ar-H), 7.80 (d, J=2.3 Hz, 1H, Ar-H),
7.72 (dd, J=2.3, 8.8 Hz, 1H, Ar-H), 7.53–7.51 (m, 2H, Ar-H), 7.28 (d,
J=8.8 Hz, 1H, Ar-H), 5.64 (d, J=1.7 Hz, 1H, H-1), 5.55 (dd, J=3.5,
10.0 Hz, 1H, H-3), 5.49 (dd, J=1.9, 3.4 Hz, 1H, H-2), 5.37 (t, J=
10.0 Hz, 1H, H-4), 4.24 (dd, J=5.0, 12.4 Hz, 1H, H-6a), 4.12 (ddd,
J=2.2, 4.9, 10.0 Hz, 1H, H-5), 4.05 (dd, J=2.2, 12.4 Hz, 1H, H-6b),
3.88 (s, 3H, OCH3), 2.16, 2.01, 1.99, 1.98 ppm (4 s, 12H, 4 OAc);
13C NMR (125 MHz, CDCl3): d=170.45, 170.01, 169.78, 169.54,
166.65 (5 CO), 156.84, 142.44, 135.67, 132.36, 129.77, 126.76,
115.99, 115.18, 104.47 (13C, Ar-C, CN), 96.63 (C-1), 70.24 (C-5), 69.17
(C-2), 68.49 (C-3), 65.48 (C-4), 60.85 (C-6), 20.88, 20.73, 20.71,
20.64 ppm (4 COCH3); HRMS: m/z : calcd for C29H29NNaO12 [M+
Na]+ : 606.1582, found: 606.1583.
Methyl 3’-fluoro-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (13a): Prepared according to general procedure C from 12a
(33 mg, 0.057 mmol). Yield: 15 mg (65%). [a]20D +114.3 (c=0.30,
MeOH); 1H NMR (500 MHz, CD3OD): d=7.98–7.97 (m, 2H, Ar-H),
7.63–7.61 (m, 2H, Ar-H), 7.42–7.36 (m, 3H, Ar-H), 5.45 (d, J=1.7 Hz,
1H, H-1), 3.99 (dd, J=1.9, 3.4 Hz, 1H, H-2), 3.82–3.84 (m, 4H, H-3,
OCH3), 3.71–3.56 ppm (m, 4H, H-4, H-5, H-6);
13C NMR (125 MHz,
CD3OD): d=168.34 (CO), 154.75 (d, J=243.8 Hz, Ar-C), 145.6 (2C,
Ar-C), 136.37 (d, J=6.9 Hz, Ar-C), 130.20, 129.20, 127.80, 124.33,
120.33 (7C, Ar-C), 116.00 (d, J=20.0 Hz, Ar-C), 101.40 (C-1), 75.97
(C-5), 72.31 (C-3), 71.82 (C-2), 68.18 (C-4), 62.65 (C-6), 52.65 ppm
(OCH3); HRMS: m/z : calcd for C20H21FNaO8 [M+Na]
+ : 431.1113,
found: 431.1112.
Methyl 4’-(a-d-mannopyranosyloxy)-3’-methylbiphenyl-4-carbox-
ylate (13b): Prepared according to general procedure C from 12b
(31 mg, 0.054 mmol). Yield: 16 mg (73%). [a]20D +110.5 (c=0.35,
MeOH); 1H NMR (500 MHz, CD3OD): d=7.96–7.94 (m, 2H, Ar-H),
7.60–7.58 (m, 2H, Ar-H), 7.40–7.37 (m, 2H, Ar-H), 7.22 (d, J=8.5 Hz,
1H, Ar-H), 5.47 (d, J=1.6 Hz, 1H, H-1), 3.97 (dd, J=1.9, 3.4 Hz, 1H,
H-2), 3.87 (dd, J=3.4, 9.5 Hz, 1H, H-3), 3.82 (s, 3H, OMe), 3.67–3.52
(m, 3H, H-4, H-6), 3.46 (m, 1H, H-5), 2.21 ppm (s, 3H, Me); 13C NMR
(125 MHz, CD3OD): d=168.56 (CO), 156.20, 146.86, 134.70, 131.07,
130.07, 130.54, 129.45, 128.92, 127.63, 126.85, 115.83 (12C, Ar-C),
99.76 (C-1), 75.55 (C-5), 72.64 (C-3), 72.11 (C-2), 68.31 (C-4), 62.68
(C-6), 52.59 ppm (OCH3), 16.54 (CH3); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1370.
Methyl 3’-trifluoromethyl-4’-(a-d-mannopyranosyloxy)biphenyl-
4-carboxylate (13c): Prepared according to general procedure C
from 12c (30 mg, 0.048 mmol). Yield: 14 mg (64%). [a]20D +113.1
(c=0.40, MeOH); 1H NMR (500 MHz, CD3OD): d=8.11–8.10 (m, 2H,
Ar-H), 7.92–7.90 (m, 2H, Ar-H), 7.75–7.73 (m, 2H, Ar-H), 7.63 (d, J=
8.4 Hz, 1H, Ar-H), 5.69 (d, J=1.5 Hz, 1H, H-1), 4.09 (dd, J=1.8,
3.3 Hz, 1H, H-2), 3.98–3.94 (m, 4H, H-3, OMe), 3.79–3.73 (m, 3H, H-
4, H-6), 3.61 ppm (ddd, J=2.3, 5.7, 9.6 Hz, 1H, H-5); 13C NMR
(125 MHz, CD3OD): d=168.29 (CO), 155.54, 145.13, 134.74, 133.45,
131.36, 131.29, 130.32, 127.91, 127.85, 126.44, 117.80 (Ar-C), 100.27
(C-1), 76.13 (C-5), 72.24 (C-3), 71.74 (C-2), 68.09 (C-4), 62.67 ppm (C-
6), 52.69 (OMe); HRMS: m/z : calcd for C21H21F3NaO8 [M+Na]
+ :
481.1081, found: 481.1082.
Methyl 4’-(a-d-mannopyranosyloxy)-3’-methoxybiphenyl-4-car-
boxylate (13d): Prepared according to general procedure C from
12d (32 mg, 0.055 mmol). Yield: 12 mg (52%). [a]20D +133.1 (c=
0.20, MeOH); 1H NMR (500 MHz, CD3OD): d=7.97–7.96 (m, 2H, Ar-
H), 7.63–7.61 (m, 2H, Ar-H), 7.21–7.11 (m, 3H, Ar-H), 5.37 (d, J=
1.7 Hz, 1H, H-1), 4.00 (dd, J=1.8, 3.4 Hz, 1H, H-2), 3.86 (dd, J=3.5,
8.8 Hz, 1H, H-3), 3.82 (s, 6H, 2 CH3), 3.70–3.63 ppm (m, 4H, H-4, H-
5, H-6); 13C NMR (125 MHz, CD3OD): d=168.50 (CO), 152.33, 147.40,
146.83, 136.56, 131.08, 129.76, 127.87, 120.86, 120.10, 112.54 (Ar-C),
101.51 (C-1), 75.66 (C-5), 72.40 (C-2), 72.00 (C-3), 68.34 (C-4), 62.70
(C-6), 56.61 (OMe), 52.63 ppm (OMe); HRMS: m/z : calcd for
C21H24NaO9 [M+Na]
+ : 443.1313, found: 443.1315.
Methyl 3’-cyclopropyl-4’-(a-d-mannopyranosyloxy)biphenyl-4-
carboxylate (13e): Prepared according to general procedure C
from 12e (21 mg, 0.035 mmol). Yield: 10 mg (67%). [a]20D +101.6
(c=0.24, MeOH); 1H NMR (500 MHz, CD3OD): d=8.07–8.05 (m, 2H,
Ar-H), 7.68–7.67 (m, 2H, Ar-H), 7.46 (dd, J=2.4, 8.5 Hz, 1H, Ar-H),
7.33 (d, J=8.5 Hz, 1H, Ar-H), 7.21 (d, J=2.4 Hz, 1H, Ar-H), 5.60 (d,
J=1.7 Hz, 1H, H-1), 4.13 (dd, J=1.9, 3.3 Hz, 1H, H-2), 4.02 (dd, J=
3.4, 9.5 Hz, 1H, H-3), 3.93 (s, 3H, OMe), 3.81–3.74 (m, 3H, H-4, H-6),
3.69 (m, 1H, H-5), 2.19 (m, 1H, H-cPr), 1.01–0.99 (m, 2H, CH2-cPr),
0.76–0.74 ppm (m, 2H, CH2-cPr);
13C NMR (125 MHz, CD3OD): d=
168.54 (CO), 156.92, 146.98, 135.00, 134.59, 131.07, 127.34, 127.67,
126.39, 125.34, 116.29 (12C, Ar-C), 100.14 (C-1), 75.61 (C-5), 72.64
(C-3), 72.14 (C-2), 68.33 (C-4), 62.71 (C-6), 52.60 (OCH3), 10.93,
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8.06 ppm (3C, cPr) ; HRMS: m/z : calcd for C23H26NaO8 [M+Na]
+ :
453.1520, found: 453.1519.
Methyl 3’-cyano-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (13 f): Prepared according to general procedure C from 12 f
(37 mg, 0.063 mmol). Yield: 19 mg (73%). [a]20D +101.1 (c=0.30,
MeOH); 1H NMR (500 MHz, CD3OD): d=8.00–7.99 (m, 2H, Ar-H),
7.90–7.85 (m, 2H, Ar-H), 7.65–7.63 (m, 2H, Ar-H), 7.50 (d, J=8.8 Hz,
1H, Ar-H), 5.63 (s, 1H, H-1), 4.03 (m, 1H, H-2), 3.91 (dd, J=2.8,
9.4 Hz, 1H, H-3), 3.83 (s, 3H, OMe), 3.69–3.60 (m, 3H, H-4, H-6),
3.50 ppm (m, 1H, H-5); 13C NMR (125 MHz, CD3OD): d=168.22
(CO), 159.29, 144.38, 135.61, 134.50, 133.08, 131.31, 130.56, 127.87,
117.36, 116.75, 104.35 (13C, Ar-C, CN), 100.62 (C-1), 76.39 (C-5),
72.27 (C-2), 71.62 (C-3), 68.07 (C-4), 62.64 (C-6), 52.71 ppm (OMe);
HRMS: m/z : calcd for C21H21NNaO8 [M+Na]
+ : 438.1159, found:
438.1162.
Sodium 3’-fluoro-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (14a): Prepared according to general procedure D from 12a
(50 mg, 0.087 mmol). Yield: 21 mg (58%). [a]20D +112.7 (c=0.40,
MeOH); 1H NMR (500 MHz, D2O): d=7.78–7.77 (m, 2H, Ar-H), 7.46–
7.45 (m, 2H, Ar-H), 7.30–7.15 (m, 3H, Ar-H), 5.43 (s, 1H, H-1), 4.07
(s, 1H, H-2), 3.93 (d, J=3.3 Hz, 1H, H-3), 3.68–3.62 ppm (m, 4H, H-
4, H-5, H-6); 13C NMR (125 MHz, D2O): d=175.19 (CO), 153.02 (d,
J=242.6 Hz, Ar-C), 142.52 (d, J=10.8 Hz, Ar-C), 141.23 (Ar-C),
135.53 (d, J=6.4 Hz, Ar-C), 135.07, 129.43, 126.25, 126.01, 122.96,
119.13 (Ar-C), 114.83 (d, J=19.4 Hz, Ar-C), 99.32 (C-1), 73.65 (C-5),
70.23 (C-3), 69.67 (C-2), 66.35 (C-4), 60.52 ppm (C-6); HRMS: m/z :
calcd for C19H19FNaO8 [M+Na]
+ : 417.0956, found: 417.0957.
Sodium 4’-(a-d-mannopyranosyloxy)-3’-methylbiphenyl-4-car-
boxylate (14b): Prepared according to general procedure D from
12b (46 mg, 0.081 mmol). Yield: 5 mg (15%). [a]20D +85.7 (c=0.20,
MeOH); 1H NMR (500 MHz, D2O): d=7.78–7.76 (m, 2H, Ar-H), 7.53–
7.52 (m, 2H, Ar-H), 7.43–7.37 (m, 2H, Ar-H), 7.10 (d, J=8.6 Hz, 1H,
Ar-H), 5.52 (d, J=1.6 Hz, 1H, H-1), 4.07 (dd, J=1.9, 3.4 Hz, 1H, H-2),
3.95 (dd, J=3.5, 9.6 Hz, 1H, H-3), 3.63–3.50 (m, 4H, H-4, H-5, H-6),
2.14 ppm (s, 3H, CH3);
13C NMR (125 MHz, D2O): d=153.33, 142.57,
134.59, 133.97, 129.47, 128.42, 126.25, 125.43, 114.99 (12C, Ar-C),
97.46 (C-1), 73.39 (C-5), 70.54 (C-3), 69.88 (C-2), 66.53 (C-4), 60.60
(C-6), 15.31 ppm (CH3); HRMS: m/z : calcd for C20H22NaO8 [M+Na]
+ :
413.1207, found: 413.1209.
Sodium 3’-trifluoromethyl-4’-(a-d-mannopyranosyloxy)biphenyl-
4-carboxylate (14c): Prepared according to general procedure D
from 12c (45 mg, 0.072 mmol). Yield: 25 mg (74%). [a]20D +94.2
(c=0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.83–7.81(m, 3H, Ar-
H), 7.75 (d, J=8.7 Hz, 1H, Ar-H), 7.57–7.55 (m, 2H, Ar-H), 7.31 (d,
J=8.8 Hz, 1H, Ar-H), 5.64 (s, 1H, H-1), 4.09 (d, J=1.5 Hz, 1H, H-2),
3.94 (dd, J=3.4, 9.7 Hz, 1H, H-3), 3.67–3.60 (m, 3H, H-4, H-6),
3.54 ppm (m, 1H, H-5); 13C NMR (125 MHz, D2O): d=175.25 (CO),
152.40, 141.31, 135.09, 133.53, 131.93, 129.46, 126.34, 125.59,
115.86 (12C, Ar-C), 97.20 (C-1), 73.68 (C-5), 70.19 (C-3), 69.58 (C-2),
66.36 (C-4), 60.55 ppm (C-6); HRMS: m/z : calcd for C20H19F3NaO8
[M+Na]+ : 467.0924, found: 467.0923.
Sodium 4’-(a-d-mannopyranosyloxy)-3’-methoxybiphenyl-4-car-
boxylate (14d): Prepared according to general procedure D from
12d (47 mg, 0.080 mmol). Yield: 10 mg (29%). [a]20D +115.1 (c=
0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.81–7.79 (m, 2H, Ar-H),
7.54–7.53 (m, 2H, Ar-H), 7.19–7.11 (m, 3H, Ar-H), 5.43 (d, J=1.6 Hz,
1H, H-1), 4.10 (dd, J=1.8, 3.5 Hz, 1H, H-2), 3.96 (dd, J=3.5, 9.0 Hz,
1H, H-3), 3.78 (s, 3H, OCH3), 3.70–3.62 ppm (m, 4H, H-4, H-5, H-6);
13C NMR (125 MHz, D2O): d=175.24 (CO), 149.53, 144.24, 142.42,
135.59, 134.75, 129.40, 126.41, 119.86, 118.03, 111.44 (12C, Ar-C),
99.23 (C-1), 73.53 (C-5), 70.32 (C-3), 69.78 (C-2), 66.40 (C-4), 60.54
(C-6), 55.81 ppm (OCH3); HRMS: m/z : calcd for C20H22NaO9 [M+
Na]+ : 429.1156, found: 429.1154.
Sodium 3’-cyclopropyl-4’-(a-d-mannopyranosyloxy)biphenyl-4-
carboxylate (14e): Prepared according to general procedure D
from 12e (28 mg, 0.047 mmol). Yield: 6 mg (26%). [a]20D +149.8
(c=0.20, MeOH); 1H NMR (500 MHz, D2O): d=7.79–7.77 (m, 2H, Ar-
H), 7.48–7.46 (m, 2H, Ar-H), 7.30 (d, J=7.8 Hz, 1H, Ar-H), 7.07–7.05
(m, 2H, Ar-H), 5.52 (s, 1H, H-1), 4.10 (m, 1H, H-2), 3.98 (dd, J=3.4,
9.5 Hz, 1H, H-3), 3.69–3.62 (m, 4H, H-4, H-5, H-6), 1.99 (m, 1H, H-
cPr), 0.86–0.84 (m, 2H, CH2-cPr), 0.58–0.56 ppm (m, 2H, CH2-cPr);
13C NMR (125 MHz, D2O): d=175.34 (CO), 153.82, 142.58, 134.57,
134.34, 133.74, 129.38, 126.26, 125.01, 124.01, 115.47 (12C, Ar-C),
97.88 (C-1), 73.47 (C-5), 70.55 (C-3), 69.93 (C-2), 66.46 (C-4), 60.57
(C-6), 9.16, 7.26, 7.06 ppm (cPr); HRMS: m/z : calcd for C22H24ONaO8
[M+Na]+ : 439.1363, found: 439.1363.
Sodium 3’-cyano-4’-(a-d-mannopyranosyloxy)biphenyl-4-carbox-
ylate (14 f): A two-neck flask was charged with 10 f (150 mg,
0.28 mmol), 4-carboxybenzene boronic acid pinacol ester (15)
(77 mg, 0.31 mmol), Pd(dppf)Cl2· CH2Cl2 (7 mg, 0.008 mmol), K3PO4
(89 mg, 0.42 mmol) and a stirring bar. The flask was evacuated and
flushed with argon, then anhydrous DMF (2 mL) was added under
a stream of argon. The mixture was degassed in an ultrasonic bath
and flushed with argon for 5 min, and then stirred at 80 8C over-
night. The reaction mixture was cooled to RT, diluted with EtOAc
(50 mL), and washed with H2O (50 mL) and brine (50 mL). The or-
ganic layer was dried over Na2SO4 and concentrated in vacuo. The
residue was purified by MPLC on silica gel (CH2Cl2/MeOH, 10:1–8:1)
to afford the biphenyl intermediate (162 mg). The intermediate
was dissolved in dry MeOH (4 mL) and treated with freshly pre-
pared 1m NaOMe/MeOH (28 mL) for 4 h at RT. The reaction mixture
was neutralized with Amberlyst-15 (H+), filtered and concentrated.
The crude product was transformed into the sodium salt by pass-
ing through a small column of Dowex 50X8 (Na+ form) ion-ex-
change resin. After concentration the residue was purified by
MPLC (RP-18, H2O) followed by size-exclusion chromatography (P-2
gel, H2O) to give 14 f (19 mg, 17%) as a white solid after final lyo-
philization from H2O. [a]
20
D +75.3 (c=0.20, MeOH);
1H NMR
(500 MHz, D2O): d=7.86–7.79 (m, 4H, Ar-H), 7.53–7.52 (m, 2H, Ar-
H), 7.31 (d, J=8.9 Hz, 1H, Ar-H), 5.64 (d, J=1.9 Hz, 1H, H-1), 4.11
(dd, J=1.9, 3.4 Hz, 1H, H-2), 4.00 (dd, J=3.5, 9.7 Hz, 1H, H-3),
3.73–3.65 (m, 3H, H-4, H-6), 3.58 ppm (ddd, J=2.4, 5.5, 9.9 Hz, 1H,
H-5); 13C NMR (125 MHz, D2O): d=175.12 (CO), 156.82, 140.37,
134.39, 133.56, 131.83, 129.58, 126.25, 116.82, 115.78, 102.08 (13C,
Ar-C, CN), 98.09 (C-1), 73.97 (C-5), 70.29 (C-3), 69.54 (C-2), 66.36 (C-
4), 60.56 ppm (C-6); HRMS: m/z : calcd for C21H21NNaO8 [M+Na]
+ :
424.1003, found: 424.1003.
3-Bromobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyranoside
(17a): Prepared according to general procedure A from 8[12] and 3-
bromobenzyl alcohol (16a). Yield: 100 mg (34%) as colorless oil.
Rf=0.43 (PE/EtOAc, 2:1) ; [a]
20
D +42.0 (c=1.40, EtOAc);
1H NMR
(500 MHz, CDCl3): d=7.48–7.46, 7.30–7.24 (m, 4H, Ar-H), 5.37 (dd,
1H, J=3.4, 10.1 Hz, H-3), 5.33–5.29 (m, 2H, H-2, H-4), 4.88 (d, 1H,
J=1.3 Hz, H-1), 4.68, 4.54 (A, B of AB, J=12.1 Hz, 2H, CH2Ar), 4.29
(dd, 1H, J=5.2, 12.3 Hz, H-6a), 4.07 (dd, 1H, J=2.3, 12.3 Hz, H-6b),
3.99 (ddd, 1H, J=2.4, 5.2, 9.9 Hz, H-5), 2.15, 2.13, 2.05, 2.00 ppm
(4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.59, 169.98,
169.87, 169.69 (4 CO), 138.49, 131.34, 131.09, 130.24, 126.66, 122.57
(Ar-C), 96.83 (C-1), 69.43, 69.02, 68.90, 68.78 (C-2, C-3, C-5, CH2Ar),
66.03 (C-4), 62.36 (C-6), 20.86, 20.76, 20.68 ppm (4C, COCH3); ESI-
MS: m/z : calcd for C21H25BrNaO10 [M+Na]
+ : 539.05, found: 539.14.
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5-Bromo-2-chlorobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyra-
noside (17b): Prepared according to general procedure A from
8[12] and 5-bromo-2-chlorobenzyl alcohol (16b). Yield: 152 mg
(48%) as a white solid. Rf=0.56 (PE/EtOAc, 2:1) ; [a]
20
D +48.0 (c=
1.50, EtOAc); 1H NMR (500 MHz, CDCl3): d=7.48 (t, J=1.8 Hz, 1H,
Ar-H), 7.38 (s, 1H, Ar-H), 7.35 (d, J=1.8 Hz, 1H, Ar), 5.33 (m, 3H, H-
2, H-3, H-4), 4.88 (d, J=1.5 Hz, 1H, H-1), 4.65, 4.51 (A, B of AB, J=
12.3 Hz, 2H, CH2Ar), 4.30 (dd, J=5.3, 12.3 Hz, 1H, H-6a), 4.09 (dd,
J=2.4, 12.3 Hz, 1H, H-6b), 3.98 (ddd, J=2.4, 5.2, 9.7 Hz, 1H, H-5),
2.16, 2.13, 2.05, 2.01 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz,
CDCl3): d=170.58, 169.98, 169.89, 169.69 (4 CO), 139.77, 135.35,
129.25, 126.85, 122.91 (6C, Ar-C), 96.96 (C-1), 69.33, 68.93, 68.24
(4C, C-2, C-3, C-5, CH2Ar), 65.98 (C-4), 62.38 (C-6), 20.86, 20.77,
20.68 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for C21H24BrClNaO10
[M+Na]+ : 573.01, found: 573.06.
2-Bromobenzyl 2,3,4,6-tetra-O-acetyl-a-d-mannopyranoside
(17c): Prepared according to general procedure A from 8[12] and 2-
bromobenzyl alcohol (16c). Yield: 140 mg (47%) as a white solid.
Rf=0.55 (petrol ether/EtOAc, 2:1) ; [a]
20
D +44.6 (c=2.10, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.57 (dd, J=1.0, 8.0 Hz, 1H, Ar-H),
7.47 (dd, J=1.4, 7.6 Hz, 1H, Ar-H), 7.35 (td, J=1.1, 7.5 Hz, 1H, Ar-
H), 7.20 (td, J=1.7, 7.9 Hz, 1H, Ar-H), 5.41 (dd, J=3.5, 10.0 Hz, 1H,
H-3), 5.35 (dd, J=1.8, 3.5 Hz, 1H, H-2), 5.31 (t, J=9.9 Hz, 1H, H-4),
4.98 (d, J=1.6 Hz, 1H, H-1), 4.83, 4.61 (A, B of AB, J=12.7 Hz, 2H,
CH2Ar), 4.29 (dd, J=5.8, 12.6 Hz, 1H, H-6a), 4.10–4.06 (m, 2H, H-6b,
H-5), 2.17, 2.12, 2.04, 2.00 ppm (4 s, 12H, 4 OAc); 13C NMR
(125 MHz, CDCl3): d=170.64, 170.02, 169.88, 169.72 (4 CO), 135.77,
132.69, 129.58, 129.49, 127.64, 122.96 (Ar-C), 97.33 (C-1), 69.48,
69.30, 69.10, 68.84 (C-2, C-3, C-5, CH2Ar), 66.05 (C-4), 62.35 (C-6),
20.88, 20.76, 20.69 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for
C21H25BrNaO10 [M+Na]
+ : 539.05, found: 539.14.
Methyl 3’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)me-
thyl]biphenyl-4-carboxylate (18a): Prepared according to general
procedure B from 17a (87.0 mg, 0.167 mmol), 11 (33.1 mg,
0.184 mmol), Pd(dppf)Cl2·CH2Cl2 (4.1 mg, 5.0 mmol) and K3PO4
(53.2 mg, 0.251 mmol). Yield: 70 mg (73%) as colorless oil. Rf=0.30
(PE/EtOAc, 2:1) ; [a]20D +41.2 (c=1.00, EtOAc);
1H NMR (500 MHz,
CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.68–7.67 (m, 2H, Ar-H), 7.60–
7.58 (m, 2H, Ar-H), 7.48 (t, J=4.7 Hz, 1H, Ar-H), 7.39 (d, J=7.7 Hz,
1H, Ar-H), 5.41 (dd, J=3.4, 10.0 Hz, 1H, H-3), 5.33–5.30 (m, 2H, H-2,
H-4), 4.94 (d, J=1.5 Hz, 1H, H-1), 4.79, 4.64 (A, B of AB, J=12.0 Hz,
2H, CH2Ar), 4.30 (dd, J=5.0, 12.1 Hz, 1H, H-6a), 4.09–4.03 (m, 2H,
H-6b, H-5), 3.94 (s, 3H, OMe), 2.15, 2.11, 2.04, 2.00 ppm (4 s, 12H, 4
OAc); 13C NMR (125 MHz, CDCl3): d=170.64, 170.03, 169.91, 169.73,
166.94 (5 CO), 145.11, 140.41, 136.97, 130.15, 129.27, 129.09,
127.94, 127.22, 127.11 (12C, Ar-C), 96.76 (C-1), 69.57, 69.09, 68.94,
66.12 (C-2, C-3, C-5, CH2Ar), 62.40 (C-4), 60.38 (C-6), 52.15 (OMe),
20.89, 20.77, 20.69 ppm (4C, 4COCH3); ESI-MS: m/z : calcd for
C29H32NaO12 [M+Na]
+ : 595.18, found: 595.21.
Methyl 3’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)meth-
yl]-4’-chlorobiphenyl-4-carboxylate (18b): Prepared according to
general procedure B from 17b (143 mg, 0.260 mmol), 11 (51.5 mg,
0.286 mmol), Pd(dppf)Cl2·CH2Cl2 (6.4 mg, 7.8 mmol) and K3PO4
(82.8 mg, 0.390 mmol). Yield: 133 mg (84%) as colorless oil. Rf=
0.30 (PE/EtOAc, 2:1) ; [a]20D +45.9 (c=1.20, EtOAc);
1H NMR
(500 MHz, CDCl3): d=8.13–8.11 (m, 2H, Ar-H), 7.65–7.64 (m, 2H, Ar-
H), 7.57 (t, J=1.8 Hz, 1H, Ar-H), 7.47 (s, 1H, Ar-H), 7.37 (s, 1H, Ar-
H), 5.40 (dd, J=3.4, 10.1 Hz, 1H, H-3), 5.33–5.29 (m, 2H, H-2, H-4),
4.93 (d, J=1.4 Hz, 1H, H-1), 4.76, 4.61 (A, B of AB, J=12.1 Hz, 2H,
CH2Ar), 4.31 (dd, J=5.2, 12.3 Hz, 1H, H-6a), 4.11 (dd, J=2.3,
12.3 Hz, 1H, H-6b), 4.03 (ddd, J=2.4, 5.2, 9.9 Hz, 1H, H-5), 3.95 (s,
3H, OMe), 2.16, 2.12, 2.05, 2.00 ppm (4 s, 12H, 4OAc); 13C NMR
(125 MHz, CDCl3): d=170.61, 170.02, 169.90, 169.72, 166.75 (5 CO),
143.68, 142.16, 138.79, 135.11, 130.26, 129.68, 127.14, 125.14 (12C,
Ar-C), 96.85 (C-1), 68.99, 68.89, 68.85, 66.07 (C-2, C-3, C-5, CH2Ar),
62.42 (C-4), 60.39 (C-6), 52.23 (OMe), 20.89, 20.78, 20.71, 20.69 ppm
(4COCH3); ESI-MS: m/z : calcd for C29H31ClNaO12 [M+Na]
+ : 629.14,
found: 629.10.
Methyl 2’-[(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)me-
thyl]biphenyl-4-carboxylate (21): Prepared according to general
procedure B from 17c (115 mg, 0.223 mmol), 11 (44.1 mg,
0.245 mmol), Pd(dppf)Cl2·CH2Cl2 (5.5 mg, 6.7 mmol) and K3PO4
(71.0 mg, 0.335 mmol). Yield: 120 mg (94%) as colorless oil. Rf=
0.41 (PE/EtOAc, 2:1) ; [a]20D +38.3 (c=2.00, EtOAc);
1H NMR
(500 MHz, CDCl3): d=8.11–8.10 (m, 2H, Ar-H), 7.51–7.48 (m, 1H, Ar-
H), 7.45–7.41 (m, 4H, Ar-H), 7.29 (m, 1H, Ar-H), 5.27–5.21 (m, 2H,
H-3, H-4), 5.19 (dd, J=1.9, 3.3 Hz, 1H, H-2), 4.77 (d, J=1.4 Hz, 1H,
H-1), 4.67, 4.34 (A, B of AB, J=11.3 Hz, 2H, CH2Ar), 4.13 (dd, J=5.2,
12.5 Hz, 1H, H-6a), 3.94 (s, 3H, OMe), 3.90 (dd, J=2.2, 12.3 Hz, 1H,
H-6a), 3.52 (ddd, J=2.2, 5.1, 9.3 Hz, 1H, H-5), 2.13, 2.05, 2.04,
1.99 ppm (4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=170.52,
169.95, 169.82, 169.74, 166.77 (5 CO), 145.48, 141.44, 133.46,
129.99, 129.91, 129.58, 129.22, 128.52, 128.21 (12C, Ar-C), 97.20 (C-
1), 69.47 (C-2), 68.98 (C-3), 68.48 (C-5), 68.13 (CH2Ar), 65.88 (C-4),
62.15 (C-6), 52.18 (OMe), 20.85, 20.66, 20.62 ppm (4C, 4COCH3);
ESI-MS: m/z : calcd for C29H32NaO12 [M+Na]
+ : 595.18, found:
595.21.
Methyl 3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carboxyl-
ate (19a): Prepared according to general procedure C from 18a
(24 mg, 0.042 mmol). Yield: 11 mg (65%). Rf=0.40 (CH2Cl2/MeOH,
8:1) ; [a]20D +68.0 (c=0.34, MeOH);
1H NMR (500 MHz, CD3OD): d=
8.11–8.09 (m, 2H, Ar-H), 7.77–7.75 (m, 2H, Ar-H), 7.70 (s, 1H, Ar-H),
7.63 (d, J=7.6 Hz, 1H, Ar-H), 7.49 (t, J=7.6 Hz, 1H, Ar-H), 7.45 (d,
J=7.6 Hz, 1H, Ar-H), 4.90 (d, J=1.8 Hz, 1H, H-1), 4.86, 4.63 (A, B of
AB, J=12.0 Hz, 2H, CH2Ar), 3.94 (s, 3H, OMe), 3.89–3.87 (m, 2H, H-
2, H-3), 3.79–3.73 (m, 2H, H-4, H-6a), 3.68–3.64 ppm (m, 2H, H-5, H-
6b); 13C NMR (125 MHz, CD3OD): d=168.42 (CO), 146.91, 141.31,
139.97, 131.13, 130.20, 129.07, 128.17, 127.91, 127.67 (12C, Ar-C),
100.76 (C-1), 75.02 (C-5), 72.65 (C-3), 72.22 (C-2), 69.73 (CH2Ar),
68.65 (C-4), 62.98 (C-6), 52.66 ppm (OMe); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1361.
Methyl 4’-chloro-3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-
4-carboxylate (19b): Prepared according to general procedure C
from 18b (40 mg, 0.066 mmol). Yield: 26 mg (90%). Rf=0.19
(CH2Cl2/MeOH, 8:1) ; [a]
20
D +101.8 (c=0.50, MeOH);
1H NMR
(500 MHz, CD3OD): d=8.06 (d, J=8.4 Hz, 2H, Ar-H), 7.69 (d, J=
8.4 Hz, 2H, Ar-H), 7.57–7.56 (m, 2H, Ar-H), 7.41 (s, 1H, Ar-H), 4.87 (s,
1H, H-1), 4.80, 4.58 (A, B of AB, J=12.3 Hz, 2H, CH2Ar), 3.91 (s, 3H,
OMe), 3.87–3.83 (m, 2H, H-2, H-3), 3.74–3.57 ppm (m, 4H, H-4, H-5,
H-6); 13C NMR (125 MHz, CD3OD): d=168.74 (CO), 145.78, 143.68,
142.71, 136.55, 131.75, 131.31, 129.02, 128.77, 127.95, 126.63 (12C,
Ar-C), 101.47 (C-1), 75.65 (C-5), 73.16 (C-3), 72.65 (C-2), 69.49
(CH2Ar), 69.13 (C-4), 63.49 (C-6), 53.26 ppm (OMe); HRMS: m/z :
calcd for C21H23ClNaO8 [M+Na]
+ : 461.0974, found: 461.0975.
Methyl 2’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carboxyl-
ate (22): Prepared according to general procedure C from 21
(48 mg, 0.084 mmol). Yield: 16 mg (47%). Rf=0.42 (CH2Cl2/MeOH,
8:1) ; [a]20D +61.9 (c=0.90, MeOH);
1H NMR (500 MHz, CD3OD): d=
8.11–8.09 (m, 2H, Ar-H), 7.57 (m, 1H, Ar-H), 7.51–7.49 (m, 2H, Ar-H),
7.43–7.40 (m, 2H, Ar-H), 7.31 (m, 1H, Ar-H), 4.71 (A of AB, J=
11.4 Hz, 1H, CH2Ar), 4.70 (d, J=1.5 Hz, 1H, H-1), 4.38 (B of AB, J=
11.4 Hz, 1H, CH2Ar), 3.75–3.60 (m, 5H, H-2, H-3, H-4, H-6), 3.95 (s,
3H, OMe), 3.40 ppm (ddd, J=3.0, 5.6, 6.8 Hz, 1H, H-5); 13C NMR
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(125 MHz, CD3OD): d=168.42 (CO), 147.33, 142.66, 136.03, 130.83,
130.53, 130.47, 129.26, 129.15 (12C, Ar-C), 101.14 (C-1), 74.78 (C-5),
72.60 (C-3), 72.18 (C-2), 68.37 (2C, C-4, CH2Ar), 62.71 ppm (C-6),
52.69 (OMe); HRMS: m/z : calcd for C21H24NaO8Na [M+Na]
+ :
427.1363, found: 427.1367.
Sodium 3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carbox-
ylate (6): Prepared according to general procedure D from 18a
(35 mg, 0.061 mmol). Yield: 24 mg (96%). [a]20D +64.5 (c=0.30,
MeOH/H2O 1:1);
1H NMR (500 MHz, D2O): d=7.80–7.78 (m, 2H, Ar-
H), 7.50–7.43 (m, 4H, Ar-H), 7.31–7.24 (m, 2H, Ar-H), 4.82 (s, 1H, H-
1), 4.58, 4.40 (A, B of AB, J=11.5 Hz, 2H, CH2Ar), 3.82 (m, 1H, H-2),
3.75–3.50 ppm (m, 5H, H-3, H-4, H-5, H-6); 13C NMR (125 MHz, D2O):
d=175.14 (CO), 142.69, 140.05, 137.34, 135.01, 129.46, 129.28,
127.92, 126.87, 126.64 (12C, Ar-C), 99.40 (C-1), 72.84 (C-5), 70.51 (C-
3), 70.01 (C-2), 69.29 (CH2Ar), 66.61 (C-4), 60.71 ppm (C-6); HRMS:
m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207, found: 413.1211.
Sodium 4’-chloro-3’-[(a-d-mannopyranosyloxy)methyl]biphenyl-
4-carboxylate (20): Prepared according to general procedure D
from 18b (54 mg, 0.089 mmol). Yield: 4 mg (10%). [a]20D +44.7 (c=
0.30, MeOH); 1H NMR (500 MHz, D2O): d=7.86 (d, J=7.8 Hz, 2H,
Ar-H), 7.58–7.56 (m, 3H, Ar-H), 7.46, 7.34 (2 s, 2H, Ar-H), 4.90 (s, 1H,
H-1), 4.58, 4.50 (A, B of AB, J=12.3 Hz, 2H, CH2Ar), 3.91 (s, 1H, H-
2), 3.78–3.75 (m, 2H, H-3, H-4), 3.71–3.59 ppm (m, 3H, H-5, H-6);
13C NMR (125 MHz, D2O): d=174.76 (CO), 141.82, 141.55, 139.40,
134.37, 129.56, 127.34, 126.74, 126.62, 125.15 (12C, Ar-C), 99.99 (C-
1), 72.96 (C-5), 70.55 (C-3), 70.04 (C-2), 68.72 (CH2Ar), 66.66 (C-4),
60.77 ppm (C-6); HRMS: m/z : calcd for C20H21ClNaO8 [M+Na]
+ :
447.0817, found: 447.0816.
Sodium 2’-[(a-d-mannopyranosyloxy)methyl]biphenyl-4-carbox-
ylate (23): Prepared according to general procedure D from 21
(78 mg, 0.137 mmol). Yield: 26 mg (46%). [a]20D +53.2 (c=0.40,
MeOH); 1H NMR (500 MHz, D2O): d=7.91–7.89 (m, 2H, Ar-H), 7.43–
7.34 (m, 5H, Ar-H), 7.26 (m, 1H, Ar-H), 4.68 (s, 1H, H-1), 4.57, 4.31
(A, B of AB, J=10.8 Hz, 2H, CH2Ar), 3.57 (m, 1H, H-2), 3.46–3.39 (m,
4H, H-3, H-4, H-6), 2.83 ppm (m, 1H, H-5); 13C NMR (125 MHz, D2O):
d=173.20 (CO), 144.48, 141.80, 133.47, 132.43, 130.69, 129.95,
129.27, 128.96, 128.32 (12C, Ar-C), 99.90 (C-1), 72.44 (C-5), 70.33 (C-
3), 69.82 (C-2), 68.14 (CH2Ar), 65.99 (C-4), 60.25 ppm (C-6); HRMS:
m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207, found: 413.1208.
4-(4,4,5,5-Tetramethyl)-1,3,2-dioxaborolan-2-yl)phenyl 2,3,4,6-
tetra-O-acetyl-a-d-mannopyranoside (27): A microwave tube was
charged with 26[37] (240 mg, 0.55 mmol), KOAc (161 mg,
1.65 mmol), bis(pinacolato)diborone (152 mg, 0.60 mmol) and Pd-
(dppf)Cl2·CH2Cl2 (13 mg, 0.017 mmol). The tube was closed, evacu-
ated and flushed with argon. Then anhydrous DMF (1 mL) was
added under a stream of argon. The mixture was degassed in an
ultrasonic bath and flushed with argon for 5 min, and then heated
by microwave irradiation at 120 8C for 2 h. The reaction mixture
was cooled to RT and diluted with CH2Cl2/H2O (100 mL, 1:1). The
organic layer was washed with H2O (50 mL) and brine (50 mL),
dried over Na2SO4 and concentrated. The residue was purified by
MPLC (toluene/EtOAc, 4:1) to afford 27 (120 mg, 50%) as colorless
oil. [a]20D +58.1 (c=0.60, EtOAc);
1H NMR (500 MHz, CDCl3): d=7.76
(d, J=8.6 Hz, 2H, Ar-H), 7.08 (d, J=8.6 Hz, 2H, Ar-H), 5.58–5.55 (m,
2H, H-1, H-3), 5.45 (dd, J=1.9, 3.4 Hz, 1H, H-2), 5.37 (t, J=10.0 Hz,
1H, H-4), 4.28 (dd, J=5.0, 12.0 Hz, 1H. H-6a), 4.05–4.02 (m, 2H, H-
6b, H-5), 2.20, 2.05, 2.03 (3 s, 12H, 4 OAc), 1.33 ppm (s, 12H, 4
CH3);
13C NMR (125 MHz, CDCl3): d=170.55, 169.91, 169.74 (4C, 4
CO), 157.98, 136.62, 136.58, 115.67 (5C, Ar-C), 95.44 (C-1), 83.77 (Ar-
C), 69.37 (C-2), 69.21 (C-5), 68.87 (C-3), 65.92 (C-4), 62.06 (C-6),
24.86, 24.58 (4C, 4 CH3), 20.87, 20.69 ppm (4C, 4COCH3); ESI-MS:
m/z : calcd for C26H35BNaO12 [M+Na]
+ : 573.21, found: 573.32.
Methyl 2-[4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)bi-
phenyl-4-yl]acetate (29): Prepared according to general procedure
B from methyl 2-(4-bromophenyl)acetate (28, 41.2 mg,
0.180 mmol), 27 (109 mg, 0.198 mmol), Pd(dppf)Cl2·CH2Cl2 (4.4 mg,
5.4 mmol) and K3PO4 (57.3 mg, 0.270 mmol). Yield: 35 mg (34%) as
yellow oil. Rf=0.25 (petrol ether/EtOAc 2:1); [a]
20
D +75.09 (c=0.8,
EtOAc); 1H NMR (500 MHz, CDCl3): d=7.52–7.49 (m, 4H, Ar-H),
7.35–7.33 (m, 2H, Ar-H), 7.17–7.14 (m, 2H, Ar-H), 5.60–5.56 (m, 2H,
H-1, H-3), 5.47 (dd, J=1.8, 3.5 Hz, 1H, H-2), 5.38 (t, J=10.0 Hz, 1H,
H-4), 4.29 (dd, J=5.0, 11.9 Hz, 1H, H-6a), 4.15–4.08 (m, 2H, H-6b, H-
5), 3.71 (s, 3H, OMe), 3.66 (s, 2H, ArCH2), 2.21, 2.06, 2.05, 2.03 ppm
(4 s, 12H, 4 OAc); 13C NMR (125 MHz, CDCl3): d=171.99, 170.53,
169.99, 169.95, 169.76 (5 CO), 155.09, 139.26, 135.72, 132.83,
129.73, 128.21, 127.03, 116.82 (12C, Ar-C), 95.87 (C-1), 69.43 (C-2),
69.23 (C-5), 68.91 (C-3), 65.99 (C-4), 62.15 (C-6), 52.11 (OMe), 40.78
(ArCH2), 20.88, 20.71, 20.70, 20.67 ppm (4COCH3); ESI-MS: m/z :
calcd for C29H32NaO12 [M+Na]
+ : 595.18, found: 595.21.
Methyl 2-[4’-(2,3,4,6-tetra-O-acetyl-a-d-mannopyranosyloxy)bi-
phenyl-4-yl]cyclopropanecarboxylate (33): Prepared according to
general procedure B from methyl 1-(4-bromophenyl)cyclopropane-
carboxylate (32, 42.6 mg, 0.167 mmol), 27 (101 mg, 0.184 mmol),
Pd(dppf)Cl2·CH2Cl2 (4.1 mg, 5.0 mmol) and K3PO4 (53.2 mg,
0.251 mmol). Yield: 60 mg (56%) as colorless oil. Rf=0.31 (PE/
EtOAc, 2:1) ; [a]20D +70.2 (c=1.00, EtOAc);
1H NMR (500 MHz, CDCl3):
d=7.54–7.48 (m, 4H, Ar-H), 7.40–7.39 (m, 2H, Ar-H), 7.17–7.14 (m,
2H, Ar-H), 5.59 (dd, J=3.55, 10.1 Hz, 1H, H-3), 5.56 (d, J=1.6 Hz,
1H, H-1), 5.46 (dd, J=1.9, 3.5 Hz, 1H, H-2), 5.38 (t, J=10.0 Hz, 1H,
H-4), 4.29 (dd, J=5.1, 12.0 Hz, 1H, H-6a), 4.15–4.09 (m, 2H, H-6b,
H-5), 3.65 (s, 3H, OMe), 2.21, 2.06, 2.05, 2.03 (4 s, 12H, 4 OAc),
1.64–1.62 (m, 2H, cPr), 1.27–1.16 ppm (m, 2H, cPr); 13C NMR
(125 MHz, CDCl3): d=175.04, 170.53, 169.98, 169.95, 169.75 (5 CO),
155.10, 139.25, 138.43, 135.76, 130.94, 128.24, 126.61, 116.80 (12C,
Ar-C), 95.89 (C-1), 69.44 (C-5), 69.23 (C-2), 68.90 (C-3), 66.00 (C-4),
62.15 (C-6), 52.42 (OMe), 28.67 (cPr), 20.71, 20.68 (4C, 4COCH3),
16.75 ppm (cPr) ; ESI-MS: m/z : calcd for C31H34NaO12 [M+Na]
+ :
621.19, found: 621.26.
Methyl 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]acetate (30):
Prepared according to general procedure C from 29 (30 mg,
0.052 mmol). Yield: 20 mg (95%). Rf=0.25 (CH2Cl2/MeOH, 8:1) ; [a]
20
D
+116.0 (c=0.50, MeOH); 1H NMR (500 MHz, CD3OD): d=7.57–7.53
(m, 4H, Ar-H), 7.34–7.33 (m, 2H, Ar-H), 7.22–7.20 (m, 2H, Ar-H),
5.54 (d, J=1.5 Hz, 1H, H-1), 4.05 (dd, J=1.8, 3.3 Hz, 1H, H-2), 3.95
(dd, J=3.4, 9.5 Hz, 1H, H-3), 3.82–3.74 (m, 3H, H-4, H-6), 3.71 (s,
3H, OMe), 3.66 (s, 2H, ArCH2), 3.65 ppm (ddd, J=2.5, 5.2, 9.7 Hz,
1H, H-5); 13C NMR (125 MHz, CD3OD): d=174.02 (CO), 157.50,
140.77, 136.22, 134.29, 130.81, 129.00, 127.77, 118.13 (12C, Ar-C),
100.23 (C-1), 75.42 (C-5), 72.45 (C-3), 72.03 (C-2), 68.38 (C-4), 62.70
(C-6), 52.49 (OMe), 41.34 ppm (ArCH2); HRMS: m/z : calcd for
C21H24NaO8 [M+Na]
+ : 427.1363, found: 427.1363.
Methyl 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]cyclopropa-
necarboxylate (34): Prepared according to general procedure C
from 33 (38 mg, 0.063 mmol). Yield: 9 mg (33%). Rf=0.33 (CH2Cl2/
MeOH, 8:1) ; [a]20D +108.0 (c=0.30, MeOH);
1H NMR (500 MHz,
CD3OD): d=7.46–7.39 (m, 4H, Ar-H), 7.28–7.26 (m, 2H, Ar-H), 7.10–
7.07 (m, 2H, Ar-H), 5.42 (d, J=1.7 Hz, 1H, H-1), 3.93 (dd, J=1.9,
3.4 Hz, 1H, H-2), 3.82 (dd, J=3.4, 9.4 Hz, 1H, H-3), 3.69–3.61 (m,
3H, H-4, H-6), 3.53 (m, 4H, OMe, H-5), 1.49–1.47 (m, 2H, cPr), 1.14–
1.11 ppm (m, 2H, cPr); 13C NMR (125 MHz, CD3OD): d=157.50,
140.87, 139.51, 136.26, 132.03, 129.04, 127.43, 118.11 (12C, Ar-C),
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100.20 (C-1), 75.43 (C-5), 72.42 (C-3), 72.02 (C-2), 68.34 (C-4), 62.68
(C-6), 52.81 (OMe), 17.20 ppm (2C, cPr) ; HRMS: m/z : calcd for
C23H26NaO8 [M+Na]
+ : 453.1520, found: 453.1523.
Sodium 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]acetate
(31): Prepared according to general procedure D from 29 (59 mg,
0.103 mmol). Yield: 17 mg (40%). [a]20D +94.0 (c=0.20, MeOH/H2O
1:1); 1H NMR (500 MHz, D2O): d=7.61 (d, J=8.6 Hz, 2H, Ar-H), 7.55
(d, J=8.0 Hz, 2H, Ar-H), 7.31 (d, J=8.0 Hz, 2H, Ar-H), 7.19 (d, J=
8.6 Hz, 2H, Ar-H), 5.60 (s, 1H, H-1), 4.13 (m, 1H, H-2), 4.00 (dd, J=
3.2, 8.5 Hz, 1H, H-3), 3.75–3.67 (m, 4H, H-4, H-5, H-6), 3.51 ppm (s,
2H, ArCH2);
13C NMR (125 MHz, D2O): d=154.94, 137.93, 136.29,
135.08, 129.76, 128.07, 126.72, 117.49 (12C, Ar-C), 98.20 (C-1), 73.37
(C-5), 70.40 (C-3), 69.89 (C-2), 66.58 (C-4), 60.65 (C-6), 43.89 ppm
(ArCH2); HRMS: m/z : calcd for C20H22NaO8 [M+Na]
+ : 413.1207,
found: 413.1208.
Sodium 2-[4’-(a-d-mannopyranosyloxy)biphenyl-4-yl]cyclopropa-
necarboxylate (35): Prepared according to general procedure D
from 33 (59 mg, 0.099 mmol). Yield: 10 mg (23%). [a]20D +95.0 (c=
0.20, dioxane/H2O 1:1);
1H NMR (500 MHz, D2O): d=7.62–7.60 (m,
2H, Ar-H), 7.54–7.53 (m, 2H, Ar-H), 7.38–7.19 (m, 4H, Ar-H), 5.60 (s,
1H, H-1), 4.13 (m, 1H, H-2), 4.00 (m, 1H, H-3), 3.75–3.67 (4H, H-4,
H-5, H-6), 1.33 (s, 2H, cPr), 1.01 ppm (s, 2H, cPr) ; 13C NMR
(125 MHz, D2O): d=128.67, 126.10, 124.37, 115.47 (12C, Ar-C), 96.18
(C-1), 71.35 (C-5), 68.38 (C-3), 67.87 (C-2), 64.56 (C-4), 58.62 (C-6),
12.66 ppm (2C, cPr); HRMS: m/z : calcd for C22H24NaO8 [M+Na]
+ :
439.1363, found: 439.1363.
Competitive binding assay
A recombinant protein consisting of the CRD of FimH linked with
a thrombin cleavage site (Th) to a His6-tag (FimH-CRD-Th-His6) was
expressed in E. coli strain HM125 and purified by affinity chroma-
tography.[16] To determine the affinity of the various FimH antago-
nists, a competitive binding assay described previously[16] was ap-
plied. Microtiter plates (F96 MaxiSorp, Nunc) were coated with
a 10 mgmL#1 solution of FimH-CRD-Th-His6 in 20 mm HEPES,
150 mm NaCl, and 1 mm CaCl2, pH 7.4 (assay buffer), 100 mL per
well, overnight at 4 8C. The coating solution was discarded, and the
wells were blocked with 3% BSA in assay buffer (150 mL per well)
for 2 h at 4 8C. After three washing steps with assay buffer (150 mL
per well), a fourfold serial dilution of the test compound (50 mL per
well) in assay buffer containing 5% DMSO and streptavidin-perox-
idase coupled Man-a(1–3)[Man-a(1–6)]-Man-b(1–4)-GlcNAc-b(1–4)-
GlcNAcb polyacrylamide (TM-PAA) polymer (50 mL per well of
a 0.5 mgmL#1 solution) were added. On each individual microtiter
plate, n-heptyl a-d-mannopyranoside (1) was tested in parallel. The
plates were incubated for 3 h at 25 8C and 350 rpm and then care-
fully washed four times with 150 mL per well assay buffer. After the
addition of 100 mL per well of 2,2’-azino-di-(3-ethylbenzthiazoline-
6-sulfonic acid) (ABTS) substrate, the colorimetric reaction was al-
lowed to develop for 4 min and then was stopped by the addition
of 2% aqueous oxalic acid before the optical density (OD) was
measured at 415 nm on a microplate reader (Spectramax 190, Mo-
lecular Devices, CA, USA). The IC50 values of the compounds tested
in duplicate were calculated with Prism software (GraphPad Soft-
ware Inc. , La Jolla, CA, USA). The IC50 defines the molar concentra-
tion of the test compound that decreases the maximal specific
binding of TM-PAA polymer to FimH-CRD by 50%. The relative IC50
(rIC50) is the ratio of the IC50 of the test compound to the IC50 of n-
heptyl a-d-mannopyranoside (1).
Cell-based flow cytometry assay
The assay was performed as described previously.[17] Briefly, 5637
cells (DSMZ, Braunschweig, Germany) were grown to confluence in
24-well plates. Before infection, a serial dilution of test compound
in 5% DMSO, PBS (Sigma–Aldrich) was prepared. GFP-labeled
UTI89 bacteria (200 mL) in RPMI 1640 medium (Invitrogen, Basel,
Switzerland) were pre-incubated with test compound (25 mL) for
10 min at RT. The bacteria–antagonist mixtures were then added
to the monolayers of 5637 cells. The multiplicity of infection (MOI)
was 1:50 (cell/bacteria). To homogenize the infection, plates were
centrifuged at RT for 3 min at 600 g. After an incubation time of
1.5 h at 37 8C, infected cells were washed four times with RPMI
1640 medium and suspended in ice-cold PBS for 5–20 min (treat-
ment with ice-cold PBS results in the detachment of the infected
cells). Cells were then kept in the dark until analysis. Samples were
measured with a CyAn ADP flow cytometer (Beckman–Coulter,
Brea, CA, USA) and analyzed by gating on the eukaryotic cells
based on forward (FSC) and side scatter (SSC), which excludes un-
bound labeled bacteria and debris from analysis. A total of 104
cells were measured per sample. Data were acquired in a linear
mode for the SSC and logarithmic mode for FSC and the green flu-
orescent channel FL1-H (GFP). The mean fluorescence intensity
(MFI) of GFP was counted as a surrogate marker for the adherence
of bacteria. Quantification of adhesion was evaluated with the
FlowJo software 9.0.1 (Tree Star Inc. , Ashland, OR, USA). IC50 values
were determined by plotting the concentration of the antagonist
in a logarithmic mode versus the MFI and by fitting the curve with
Prism software (GraphPad, inhibition curve, variable slope), (n=2–
3, in duplicate/triplicate).
Isothermal titration calorimetry (ITC)
For the ITC experiments, the His tag in FimH-CRD-Th-His6 was
cleaved.[16] Briefly, the protein (1 mg) was incubated with 10 U
thrombin (T-6884, Sigma–Aldrich) in 20 mm Tris·HCl, pH 8.4,
150 mm NaCl and 2.5 mm CaCl2 (cleavage buffer) at 20 8C for 16 h.
The mixture was then applied to a gel filtration column (Bio-Prep
SE100/17, Bio-Rad) attached to an FPLC system. The chromatogra-
phy was run with assay buffer and analyzed by SDS-PAGE. The frac-
tions containing FimH-CRD were pooled and concentrated by ul-
trafiltration (MWCO10, Sartorius AG, Tagelswangen, Switzerland).
The ITC experiments were performed using a VP-ITC instrument
from MicroCal Inc. (GE Healthcare, Northampton, MA, USA). The
measurements were performed at 25 8C. Prior to measurements,
the protein was dialyzed in assay buffer (10 mm HEPES, 150 mm
NaCl, 1 mm CaCl2, pH 7.4 (HBS-Ca). Injections of 3–5 mL ligand solu-
tions (150 mm) were added at an interval of 10 min into the sample
cell solution containing FimH-CRD (8–22 mm, sample cell volume
1.4523 mL) with stirring at 307 rpm. Protein concentration was de-
termined by HPLC-UV against a BSA standard.[38] The quantity c=
Mt(0) KD
#1, where Mt(0) is the initial macromolecule concentration,
is of importance in titration microcalorimetry. The c values ranged
between 300 and 3200. Because the smallest reliable volumes
were injected, sigmoidal curves were obtained. Control experi-
ments injecting ligand solution into buffer without protein showed
that the heat of dilution was small and constant. Baseline correc-
tion and peak integration were accomplished using Origin 7 as de-
scribed by the manufacturer (OriginLab, Northampton, MA, USA).
The first injection was always excluded from data analysis because
it usually suffers from sample loss during the mounting of the sy-
ringe and the equilibration preceding the actual titration. A three-
parameter (N (stoichiometry), KD (dissociation constant) and DH8
(change in enthalpy) nonlinear least-square data fitting was per-
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formed in a Microsoft Excel spreadsheet using the Solver add-in
(Frontline System)[39,40] according to binding isotherms published
by Ziegler and Seelig.[41]
Thermodynamics parameters were calculated from Equation (4).
DG ¼ DH#TDS ¼ RT lnKD ¼ #RT lnKA ð4Þ
where DG, DH, and DS are the changes in free energy, enthalpy,
and entropy of binding, respectively, T is the absolute temperature,
and R is the universal gas constant (8.314 Jmol#1 K#1).
Determination of pharmacokinetic parameters
Materials : Dimethyl sulfoxide (DMSO), 1-octanol, Dulbecco’s modi-
fied Eagle’s medium (DMEM) high glucose, l-glutamine solution,
penicillin–streptomycin solution, Dulbecco’s phosphate-buffered
saline (DPBS), and trypsin–EDTA solution were purchased from
Sigma–Aldrich. MEM nonessential amino acid (MEM-NEAA) solu-
tion, fetal bovine serum (FBS), and DMEM without sodium pyruvate
and phenol red were bought from Invitrogen. PAMPA System Solu-
tion, GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered
from pIon (Woburn, MA, USA). Acetonitrile (MeCN) was bought
from Acros Organics. The Caco-2 cells were kindly provided by
Prof. G. Imanidis, FHNW, Muttenz, Switzerland and originated from
the American Type Culture Collection (Rockville, MD, USA).
Parallel artificial membrane permeation assay (PAMPA)
Values of logPe were determined in a 96-well format with the
PAMPA[33] permeation assay. For each compound, measurements
were performed at three pH values (5.0, 6.2, 7.4) in quadruplicate.
For this purpose, 12 wells of a deep-well plate, i.e. , four wells per
pH value, were filled with 650 mL System Solution. Samples
(150 mL) were withdrawn from each well to determine the blank
spectra by UV spectroscopy (SpectraMax 190). Then, analyte dis-
solved in DMSO was added to the remaining System Solution to
yield 50 mm solutions. To exclude precipitation, the optical density
was measured at 650 nm, with 0.01 being the threshold value. Sol-
utions exceeding this threshold were filtered. Afterward, samples
(150 mL) were withdrawn to determine the reference spectra. Fur-
ther 200 mL were transferred to each well of the donor plate of the
PAMPA sandwich P/N 110 163 (pIon, Woburn MA, USA). The filter
membranes at the bottom of the acceptor plate were impregnated
with 5 mL of GIT-0 Lipid Solution, and 200 mL of Acceptor Sink
Buffer were filled into each acceptor well. The sandwich was as-
sembled, placed in the GutBox, and left undisturbed for 16 h. It
was then disassembled, and samples (150 mL) were transferred
from each donor and acceptor well to UV plates. Quantification
was performed by both UV spectroscopy and LC–MS; logPe values
were calculated with the aid of the PAMPA Explorer Software (pIon,
version 3.5).
Colorectal adenocarcinoma (Caco-2) cell permeation assay
Caco-2 cells were cultivated in tissue culture flasks (BD Biosciences,
Franklin Lakes, NJ, USA) with DMEM high-glucose medium contain-
ing l-glutamine (2 mm), nonessential amino acids (0.1 mm), penicil-
lin (100 UmL#1), streptomycin (100 mgmL#1), and FBS (10%). The
cells were kept at 37 8C in humidified air containing 5% CO2, and
the medium was changed every second day. When ~90% conflu-
ence was reached, the cells were split in a 1:10 ratio and distribut-
ed to new tissue culture flasks. At passage numbers between 60
and 65, they were seeded at a density of 5.3%105 cells per well to
Transwell 6-well plates (Corning Inc. , Corning, NY, USA) with 2.5 mL
culture medium in the basolateral and 1.8 mL in the apical com-
partment. The medium was renewed on alternate days. Permeation
experiments were performed between days 19 and 21 post-seed-
ing. Prior to the experiment, the integrity of the Caco-2 monolay-
ers was evaluated by measuring the transepithelial electrical resist-
ance (TEER) with an Endohm tissue resistance instrument (World
Precision Instruments Inc. , Sarasota, FL, USA). Only wells with TEER
values >300 Wcm2 were used. Experiments were performed in the
apical-to-basolateral (absorptive) and basolateral-to-apical (secreto-
ry) directions in triplicate. Transport medium (DMEM without
sodium pyruvate and phenol red) was withdrawn from the donor
compartments of three wells and replaced by the same volume of
compound stock solutions to reach an initial sample concentration
of 62.5 mm. The Transwell plate was then shaken (250 rpm) in the
incubator. Samples (40 mL) were withdrawn after 15, 30, and
60 min from the donor and acceptor compartments, and their con-
centrations were determined by LC–MS. Apparent permeability co-
efficients (Papp) were calculated according to the equation
Papp ¼ dQdt (
1
A( c0 ð5Þ
where dQ/dt is the permeability rate, A the surface area of the
monolayer, and c0 the initial concentration in the donor compart-
ment.[42] After the experiment, TEER values were assessed again for
each well and results from wells with values <300 Wcm2 were dis-
carded.
logD7.4 determination
The in silico prediction tool ALOGPS[43] was used to estimate the
logP values of the compounds. Depending on these values, the
compounds were classified into three categories: hydrophilic com-
pounds (logP<0), moderately lipophilic compounds (0) logP)1)
and lipophilic compounds (logP>1). For each category, two differ-
ent ratios (volume of 1-octanol to volume of buffer) were defined
as experimental parameters (Table 4).
Equal amounts of phosphate buffer (0.1m, pH 7.4) and 1-octanol
were mixed and shaken vigorously for 5 min to saturate the
phases. The mixture was left until separation of the two phases oc-
curred, and the buffer was retrieved. Stock solutions of the test
compounds were diluted with buffer to a concentration of 1 mm.
For each compound, six determinations, i.e. , three determinations
per 1-octanol/buffer ratio, were performed in different wells of
a 96-well plate. The respective volumes of buffer containing ana-
lyte (1 mm) were pipetted to the wells and covered by saturated 1-
octanol according to the chosen volume ratio. The plate was
sealed with aluminum foil, shaken (1350 rpm, 25 8C, 2 h) on a Hei-
doph Titramax 1000 plate shaker (Heidolph Instruments GmbH &
Co. KG, Schwabach, Germany) and centrifuged (2000 rpm, 25 8C,
Table 4. Compound classification based on estimated logP values.[43]
Compound type logP Ratio (1-octanol)/(buffer)
hydrophilic <0 30:140, 40:130
moderately lipophilic 0–1 70:110, 110:70
lipophilic >1 3:180, 4:180
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5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The
aqueous phase was transferred to a 96-well plate for analysis by
LC–MS.
logD7.4 was calculated from the 1-octanol/buffer ratio (o/b), the ini-
tial concentration of the analyte in buffer (1 mm), and the concen-
tration of the analyte in the aqueous phase (cB) with equation:
logD7:4 ¼ log 1mM# cBcB (
1
o : b
! "
ð6Þ
Solubility
Solubility was determined in a 96-well format using the mSOL Ex-
plorer solubility analyzer (pIon, version 3.4.0.5). For each com-
pound, measurements were performed at three pH values (3.0, 5.0,
7.4) in triplicates. For this purpose, nine wells of a deep-well plate,
that is, three wells per pH value, were filled with 300 mL of an
aqueous universal buffer solution. Aliquots (3 mL) of a compound
stock solution (10–50 mm in DMSO) were added and thoroughly
mixed. The final sample concentration was 0.1–0.5 mm, the residual
DMSO concentration was 1.0% (v/v) in the buffer solutions. After
15 h, the solutions were filtered (0.2 mm 96-well filter plates) using
a vacuum to collect manifold (Whatman Ltd. , Maidstone, UK) to
remove any precipitates. Equal amounts of filtrate and n-propanol
were mixed and transferred to a 96-well plate for UV detection
(190–500 nm). The amount of material dissolved was calculated by
comparison with UV spectra obtained from reference samples,
which were prepared by dissolving compound stock solution in
a 1:1 mixture of buffer and n-propanol (final concentrations 0.017–
0.083 mm).
LC–MS measurements
Analyses were performed using an 1100/1200 Series HPLC System
coupled to a 6410 Triple Quadrupole mass detector (Agilent Tech-
nologies, Inc. , Santa Clara, CA, USA) equipped with electrospray
ionization. The system was controlled with the Agilent MassHunter
Workstation Data Acquisition software (version B.01.04). The
column used was an Atlantis T3 C18 column (2.1%50 mm) with
a 3 mm particle size (Waters Corp., Milford, MA, USA). The mobile
phase consisted of two eluents: solvent A (H2O, containing 0.1%
formic acid, v/v) and solvent B (MeCN, containing 0.1% formic acid,
v/v), both delivered at 0.6 mLmin#1. The gradient was ramped
from 95% A/5% B to 5% A/95% B over 1 min, and then held at
5% A/95% B for 0.1 min. The system was then brought back to
95% A/5% B, resulting in a total duration of 4 min. MS parameters
such as fragmentor voltage, collision energy, and polarity were op-
timized individually for each analyte, and the molecular ion was
followed for each compound in the multiple reaction monitoring
mode. The concentrations of the analytes were quantified by the
Agilent Mass Hunter Quantitative Analysis software (version
B.01.04).
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